<SEC-DOCUMENT>0002023658-24-000002.txt : 20241112
<SEC-HEADER>0002023658-24-000002.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112160219
ACCESSION NUMBER:		0002023658-24-000002
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bicara Therapeutics Inc.
		CENTRAL INDEX KEY:			0002023658
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42271
		FILM NUMBER:		241447816

	BUSINESS ADDRESS:	
		STREET 1:		245 MAIN STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-785-8308

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcax-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c,d:034d45b5fcc840799db4927dd41f8356-->
<html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:bcax="http://www.bicara.com/20240930" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bcax-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0002023658</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-103" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-401">0.1082</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-103" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-552">0.1082</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bcax-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="financialinstitution"><xbrli:measure>bcax:financialInstitution</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bcax:segment</xbrli:measure></xbrli:unit><xbrli:unit id="investor"><xbrli:measure>bcax:investor</xbrli:measure></xbrli:unit><xbrli:unit id="board_member"><xbrli:measure>bcax:board_member</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-13</xbrli:startDate><xbrli:endDate>2024-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-13</xbrli:startDate><xbrli:endDate>2024-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-13</xbrli:startDate><xbrli:endDate>2024-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-13</xbrli:startDate><xbrli:endDate>2024-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bcax:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bcax:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcax:BioconLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:BioconLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:BioconLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsRelativesOfBoardMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-06</xbrli:startDate><xbrli:endDate>2023-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcax:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-05</xbrli:startDate><xbrli:endDate>2024-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementMasterContractServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-24</xbrli:startDate><xbrli:endDate>2020-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BiofusionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BiofusionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementRefundableDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i034d45b5fcc840799db4927dd41f8356_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:28.3pt;text-align:justify;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2024</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ____________ to _______________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-42271</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BICARA THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;padding-left:28.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"/><td style="width:40.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">85-2903745</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">116 Huntington Ave</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 703</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02116</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">617</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">468-4219</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-top:6pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">BCAX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="background-color:#ffffff;color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 8, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">54,415,619</ix:nonFraction> shares of common stock, $0.0001 par value per share outstanding.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_10">PART I</a>:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_10">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_13">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_16">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_19">Condensed Consolidated Statements of Operations and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_19">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a> (Deficit)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_22">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_25">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_28">11</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_67">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_67">23</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_103">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_106">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_109">PART II</a>:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_109">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_109">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_112">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_112">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_115">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_115">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_118">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_118">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_118">89</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_121">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_121">90</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_124">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_124">90</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_127">90</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i034d45b5fcc840799db4927dd41f8356_130">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_130">90</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i034d45b5fcc840799db4927dd41f8356_133">93</a></span></div></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">We are subject to numerous risks and uncertainties, including those further described below in the section entitled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is highly dependent on the success of ficerafusp alfa. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize ficerafusp alfa, or if we experience delays in doing so, our business will be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize ficerafusp alfa and any future product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ficerafusp alfa or any future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of ficerafusp alfa or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to develop product candidates, leverage our potential and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Additionally, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently and in the future may depend on other third-party collaborators for the discovery, development and commercialization of ficerafusp alfa and any of our future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not yet demonstrated an ability to generate revenue, obtain regulatory approval, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the initiation timing, progress, results and cost of ficerafusp alfa, including the Phase 2/3 trial in head and neck squamous cell carcinoma, or HNSCC, and the potential expansion Phase 1 trial in additional HNSCC patient populations, as well as our research and development programs and our current and future preclinical and clinical studies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the ability and the potential to secure pembrolizumab for our clinical trials and successfully manufacture our drug substances and ficerafusp alfa for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the ability of clinical trials to demonstrate safety and efficacy of ficerafusp alfa, and other positive results;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the timing, scope and likelihood of regulatory filings and approvals, for ficerafusp alfa and future product candidates, including the timing of INDs and final FDA approval of ficerafusp alfa or any future product candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our estimates of the number of patients that we will enroll and our ability to initiate, recruit and enroll patients in and conduct and successfully complete our clinical trials at the pace that we project;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to maintain and further develop the specific shipping, storage, handling and administration of ficerafusp alfa at the clinical sites;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to obtain funding for our operations necessary to complete further development and commercialization of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to commercialize ficerafusp alfa, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the pricing and reimbursement of ficerafusp alfa, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the implementation of our business model, and strategic plans for our business, ficerafusp alfa and technology;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering ficerafusp alfa and other product candidate we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">estimates of our future expenses, revenues and capital requirements and our needs for additional financing;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">future agreements with third parties in connection with the development and commercialization of ficerafusp alfa and any other approved product;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the size and growth potential of the markets for ficerafusp alfa and our ability to serve those markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the rate and degree of market acceptance of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">regulatory developments in the U.S., Canada, European Union and other foreign countries;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to produce our products or ficerafusp alfa with advantages in turnaround times or manufacturing cost;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">developments relating to our competitors and our industry; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In some cases, forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Form 10-Q and the documents that we reference in this Form 10-Q and have filed with the SEC as exhibits, of which this Form 10-Q is a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">5</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">PART I - FINANCIAL INFORMATION</span></div><div id="i034d45b5fcc840799db4927dd41f8356_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Item 1. Financial Statements (Unaudited)</span></div><div id="i034d45b5fcc840799db4927dd41f8356_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, in thousands, except shares and per share data)</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:133%">(Unaudited)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">520,758</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">230,440</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Prepaid expenses and other assets </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-34">756</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-35">633</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total current assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">521,514</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">231,073</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">130</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">202</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Right of use asset &#8211; operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-40">414</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-41">613</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Other assets </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">2,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">2,094</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">524,173</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">233,982</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,142</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable &#8211; related party</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-48">431</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,044</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accrued expenses and other current liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">10,410</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">8,053</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accrued expenses and other current liabilities &#8211; related party </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">3,561</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liability &#8211; current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-54">308</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-55">285</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total current liabilities</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">14,481</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">15,085</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liability &#8211; net of current portion</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-58">137</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-59">372</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-61">17</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total liabilities</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">14,618</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">15,474</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Commitments and Contingencies: </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"/></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-65"/></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Seed Series redeemable convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-67">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="f-70">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-73">81,790,144</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized; issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively (liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="f-74">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-75">81,790</ix:nonFraction> as of September&#160;30, 2024, and December&#160;31, 2023, respectively)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-77">81,525</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Series B redeemable convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-79">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="f-82">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85">105,595,101</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively (liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="f-86">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-87">108,235</ix:nonFraction> as of September&#160;30, 2024 and December&#160;31, 2023, respectively);</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-89">121,148</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Series C redeemable convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-90"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-91">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="f-94">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97">119,599,872</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively (liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="f-98">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-99">165,000</ix:nonFraction> as of September&#160;30, 2024 and December&#160;31, 2023, respectively)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-101">164,604</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-103">367,277</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Preferred stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-104"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-105">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-111">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-113">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-114"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-115">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-116">500,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-117">365,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-118">54,424,994</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-119">711,895</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120">54,409,708</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-121">640,386</ix:nonFraction> shares outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-122">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-123">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-124">709,607</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-125">4,250</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-126">200,059</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-127">153,021</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">509,555</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">148,769</ix:nonFraction>)</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">524,173</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">233,982</ix:nonFraction></span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">6</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares and per share data)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating expenses</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Research and development - related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">7,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">13,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">4,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">36,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">13,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">4,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">12,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-143">6,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-144">20,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-145">9,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-146">55,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-147">26,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">20,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">9,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">55,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">26,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Other (expenses) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-153">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">8,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-155">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Change in fair value of Series B preferred stock tranche rights liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:fixed-zero" scale="3" id="f-156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:num-dot-decimal" scale="3" id="f-157">13,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:num-dot-decimal" scale="3" id="f-159">13,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-160">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-161">13,315</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-162">8,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-163">13,343</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">17,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">22,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-166">47,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-167">39,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Income tax expense </span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-168">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-169">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-170">1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-171">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">17,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">22,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">47,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">39,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net Loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-176"><ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-177">1.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-178"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-179">38.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-180"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-181">11.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-182"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-183">70.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Weighted-average number common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-185">10,901,138</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-186"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-187">597,586</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-188"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">4,174,353</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-190"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-191">563,483</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">7</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Seed Series Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Series B Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Common Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Additional Paid in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total Stockholders Deficit</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">December 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-192">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-193">81,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-194">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-196">504,544</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-197">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">101,036</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">98,803</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-201">37,073,162</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-202">37,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-203">10,428</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-204">43</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-205">43</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-206">264</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-207">264</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">7,412</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">7,412</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-210">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-211">81,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-212">37,073,162</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-213">37,185</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-214">514,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-215">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-216">2,538</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-217">108,448</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">105,908</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-219">6,739</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-220">27</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-221">27</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-222">54,035</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-223">352</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-224">352</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">9,288</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">9,288</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">June 30, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-228">81,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-229">37,073,162</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-230">37,185</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-231">575,746</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-232">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">2,917</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">117,736</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">114,817</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-236">39,024,386</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-237">39,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Settlement of Series B preferred stock tranche rights liability, upon issuance of milestone shares</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="bcax:TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" format="ixt:num-dot-decimal" scale="3" id="f-238">8,001</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-239">4,229</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-240">32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-241">32</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-242">519</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-243">519</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">22,845</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">22,845</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">September 30, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-246">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-247">81,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-248">76,097,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-249">85,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-250">579,975</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-251">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">3,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">140,581</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">137,111</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">8</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_704"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.133%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Seed Series Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Series B Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Series C Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Common Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Additional Paid in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total Stockholders Equity (Deficit)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-255">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-256">81,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-257">105,595,101</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-258">121,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-259">119,599,872</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-260">164,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-261">640,386</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-262">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">4,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">153,021</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">148,769</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-266">50</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-267">50</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-268">1,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">1,147</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-270">12,508</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">12,508</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-272">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-273">81,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-274">105,595,101</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-275">121,148</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-276">119,599,872</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-277">164,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-278">640,386</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-279">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-280">5,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-281">165,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-282">160,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-283">349,962</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-284">1,315</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-285">1,315</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-286">33,193</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-287">1,038</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-288">1,038</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">17,049</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-290">17,049</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">June 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">81,790,144</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-292">81,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-293">105,595,101</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-294">121,148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-295">119,599,872</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-296">164,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-297">1,023,541</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-298">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">7,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-300">182,578</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-301">174,776</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock, net of offering cost, expenses and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-302">20,125,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-303">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-304">332,427</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-305">332,429</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock into common stock upon initial public offering</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" sign="-" name="bcax:TemporaryEquitySharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-306">81,790,144</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" sign="-" name="bcax:TemporaryEquityValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-307">81,525</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" sign="-" name="bcax:TemporaryEquitySharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-308">105,595,101</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" sign="-" name="bcax:TemporaryEquityValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-309">121,148</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" sign="-" name="bcax:TemporaryEquitySharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-310">119,599,872</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" sign="-" name="bcax:TemporaryEquityValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">164,604</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-312">33,210,876</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-313">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-314">367,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-315">367,153</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-316">43,232</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-317">199</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-318">199</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-319">7,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-320">2,031</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-321">2,031</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-322">17,481</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">17,481</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-324">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-325">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-326">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-327">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-328">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-329">&#8211;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-330">54,409,708</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-331">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-332">709,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-333">200,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-334">509,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">9</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-335">47,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-336">39,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Change in fair value of Series B preferred stock tranche rights liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:num-dot-decimal" scale="3" id="f-338">13,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-339">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-340">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-341">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-342">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-343">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-344">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-345">280</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-346">855</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-347">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-348">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable and accrued expenses &#8211; related party</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-349">2,374</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-350">11,296</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-351">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-352">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-353">44,719</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-354">37,592</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Investing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-355">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-356">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-357">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-359">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-360">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from issuance on common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-361">333,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from issuance of preferred stock and preferred stock tranche rights, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" format="ixt:num-dot-decimal" scale="3" id="f-364">77,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-365">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-366">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">335,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-368">77,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-369">290,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-370">40,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-371">230,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-372">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-373">520,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-374">44,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Settlement of Series B preferred stock tranche rights, upon issuance of milestone shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:SettlementOfFreestandingFinancialInstrumentLiabilities" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:SettlementOfFreestandingFinancialInstrumentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-376">8,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-378">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Vesting of early exercise stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:VestingOfEarlyExerciseStockOptions" scale="3" id="f-379">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:VestingOfEarlyExerciseStockOptions" scale="3" id="f-380">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Offering costs included in accounts payable and accrued expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="3" id="f-381">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Series B preferred stock tranche rights liability, upon initial issuance of shares </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument" scale="3" id="f-384">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_28"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="i034d45b5fcc840799db4927dd41f8356_31"></div><div style="margin-top:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-385" continuedAt="f-385-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of Business, Organization, and Liquidity</span></ix:nonNumeric></div><ix:continuation id="f-385-1" continuedAt="f-385-2"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bicara Therapeutics Inc. (&#8220;Bicara&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, Bicara will realize significant revenue from product sales.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reverse Stock Split</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company&#8217;s board of directors approved an amendment to the fourth amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#8217;s common stock and redeemable convertible preferred stock on a 9.2435-to-1 basis (the &#8220;Reverse Stock Split&#8221;) which was effected on September 5, 2024. The par value and authorized number of shares of common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Initial Public Offering ("IPO")</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">On September 13, 2024, the Company closed its IPO, pursuant to which it issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-386">17,500,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-387">18.00</ix:nonFraction> per share and the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-388">2,625,000</ix:nonFraction> additional shares of its common stock to the underwriters of the IPO pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="f-389">332.4</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-390">29.8</ix:nonFraction>&#160;million. Immediately prior to the closing of the IPO, the Company&#8217;s outstanding redeemable convertible preferred stock automatically converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-391">33,210,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> shares of common stock. Following the closing of the IPO, <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-392"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-393">no</ix:nonFraction></ix:nonFraction> shares of redeemable convertible preferred stock were authorized or outstanding.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In connection with the closing of its IPO, on September 13, 2024, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-394">500,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-395">0.0001</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-396">10,000,000</ix:nonFraction> shares of preferred stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-397">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically has funded its operations from the issuance of redeemable convertible preferred stock, common stock and through debt financing.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of September&#160;30, 2024, the Company had cash of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-398">520.8</ix:nonFraction> million and an accumulated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-399">200.1</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-385-2">The Company expects that its cash and cash equivalents as of September&#160;30, 2024 of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-400">520.8</ix:nonFraction> million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</ix:continuation> </span></div><div id="i034d45b5fcc840799db4927dd41f8356_34"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-402" continuedAt="f-402-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="f-402-1" continuedAt="f-402-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-403-1">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-404" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2024, condensed consolidated statements of operations, condensed consolidated statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) and condensed consolidated cash flows for the nine months ended September&#160;30, 2024 and 2023 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements, which were previously filed in Form S-1/A on September 11, 2024.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Emerging Growth Company Status</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our IPO or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in total annual gross revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K), or we issue more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-402-2" continuedAt="f-402-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-405" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="f-406" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC&#160;480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore classified the Seed Series, Series&#160;B and Series C convertible preferred stock as mezzanine equity. The convertible preferred stock was recorded outside of stockholders&#8217; deficit because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger or consolidation and sale, lease or transfer of all or substantially all of the Company&#8217;s assets, the convertible preferred stock would have become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would have been distributed in accordance with the corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bcax:StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" id="f-407" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Tranche Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the consolidated financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock issuance as described in Note 6 Redeemable Convertible Preferred Stock to these condensed consolidated financial statements, included tranche rights (&#8220;Series B Tranche Rights&#8221;) to purchasers who participated in the initial Series B Preferred Stock issuance. The Series B Tranche Rights were determined to be a &#8220;freestanding financial instrument&#8221; as defined in the ASC Master Glossary as they are legally detachable and separately exercisable. Management assessed the freestanding financial instrument under </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that such rights should be accounted for as a liability at fair value given they impose an obligation on the Company to issue shares that are contingently redeemable. The Series B Tranche Rights were revalued at each reporting period until settlement, with changes in the fair value recorded in the consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-402-3" continuedAt="f-402-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-408" continuedAt="f-408-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities;</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; defined as inputs other than quoted prices included in Level 1 that are either directly or indirectly observable; and</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-408-1">The carrying amounts of the Company&#8217;s financial assets (which include cash) and liabilities (which include accounts payable) approximate fair value because of the short maturity of these instruments and have been classified as Level 1. The Series B Tranche Rights were classified as Level 3 financial liabilities</ix:continuation> (Refer to Note 3 Fair value measurement to these unaudited condensed consolidated financial statements for more details).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-409" continuedAt="f-409-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-409-1">The Company&#8217;s cash and cash equivalents are held in standard checking accounts and money market funds at <ix:nonFraction unitRef="financialinstitution" contextRef="c-3" decimals="INF" name="bcax:NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" format="ixt-sec:numwordsen" scale="0" id="f-410">two</ix:nonFraction> financial institutions. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-411" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company&#8217;s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance&#160;sheet concentrations of credit risk.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with a term of greater than 12 months regardless of classification. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. The incremental borrowing rate is based on the estimated interest rate for borrowing over a term similar to that of the lease payments at commencement of the lease. The operating lease expense for the operating leases is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components of contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this new standard on January 1, 2022 using the required modified retrospective approach and utilizing the effective date as its date of initial application. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-412-1">Upon adoption, the Company elected, to apply the &#8216;package of practical expedients&#8217; which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, if any, and (iii) not to reassess initial direct costs for any existing leases.</ix:continuation> </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-402-4" continuedAt="f-402-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-413" continuedAt="f-413-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-413-1">The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.</ix:continuation> During the three months ended September&#160;30, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-414">15.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-415">6.9</ix:nonFraction> million, respectively, relating to research and development expenses. During the nine months ended September&#160;30, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-416">43.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-417">20.1</ix:nonFraction> million, respectively, relating to research and development expenses. The Company recorded accrued liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="bcax:AccruedClinicalTrialAndContractManufacturingExpenses" scale="6" id="f-418">9.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="bcax:AccruedClinicalTrialAndContractManufacturingExpenses" scale="6" id="f-419">9.6</ix:nonFraction> million for clinical trial and contract manufacturing expenses as of September&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-420" continuedAt="f-420-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-420-1">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-421" continuedAt="f-421-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors:</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-402-5" continuedAt="f-402-6"><ix:continuation id="f-421-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company's IPO, the grant date fair value of stock awards granted under its 2019 Stock Option and Grant Plan were determined using the fair market value of the Company&#8217;s common stock on the date of grant, as set forth in the applicable plan document. Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as option-pricing method or OPM and probability weighted expected return method or PWERM. The OPM method allowed for the allocation of the Company's equity value among the various equity capital owners and considered a variety of factors, included the illiquid nature of the common stock, recent transactions involving the Company&#8217;s stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. PWERM involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome which included an IPO scenario or continued operation as a private company scenario. Among other factors were the Company's financial position and historical financial performance, the status of clinical developments, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-422" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, of which we have none. Our comprehensive loss equals our net loss for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-423" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share was computed using the two-class method required due to the participating securities, such securities did not participate in net losses and therefore did not impact the Company&#8217;s net loss from continuing operations per share calculations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. Outstanding common stock options, unvested restricted stock awards and redeemable convertible preferred shares are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-402-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-424" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 and 2023, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and restricted stock awards outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-425">7,999,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-426">2,950,707</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seed Series redeemable convertible preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-427">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-428">8,848,387</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-429">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-430">8,232,546</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above reflect the common stock equivalents of the noted instruments.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-431" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-432">one</ix:nonFraction> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-433" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements and Significant Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. As of September&#160;30, 2024, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September&#160;30, 2024</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2023-07,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity report segment information in accordance with&#160;Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its unaudited condensed consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. The standard largely follows the proposed ASU issued in 2023 with several important modifications and clarifications. ASU 2023-09 is effective for public entities for annual periods beginning after December 15, 2024 and for all other business for annual periods beginning after December 15, 2025. Early adoption is permitted, and the Company is evaluating the impact of this guidance on the unaudited condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i034d45b5fcc840799db4927dd41f8356_37"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-434" continuedAt="f-434-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value Measurements</span></ix:nonNumeric></div><ix:continuation id="f-434-1" continuedAt="f-434-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-435" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-436">519,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-439">519,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-440">519,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-443">519,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-444">230,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-447">230,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">230,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-451">230,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the Series B Tranche Rights at the time of issuance and subsequently remeasured them at each reporting period and prior to settlement. The fair value of the Series B Tranche Rights was determined using a contingent forward model, which considered as inputs the estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, probability of achievement and estimated time to tranche closing. The most significant assumptions in the contingent forward model impacting the fair value of the Series B Tranche Rights are the fair value of the Company&#8217;s Series B Preferred Stock, probability of achievement of certain milestones, and time to the tranche closing as of each measurement date. The Company determined the fair value per share of the underlying Series B Preferred Stock by taking into consideration the most recent sales of its preferred units, results obtained from third-party valuations and additional factors the Company deemed relevant.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-452" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the Level 3 Series B Tranche Rights for the nine months ended September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:83.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tranche Rights Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value recognized upon the issuance of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="f-454">642</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-455">13,356</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-456">8,001</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-457">5,997</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="bcax:FreestandingFinancialInstrumentLiabilityCurrent" scale="6" id="f-458">6.0</ix:nonFraction> million tranche rights liability within accrued expenses and other current liabilities on the balance sheet. The tranche rights liability were settled in September and November 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-459" escape="true"><ix:continuation id="f-434-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used in the estimation of the fair value of the Series B Tranche Rights, on the closing dates of Series B financing tranches and as of September 30, 2023:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 2, 2023 <br/>Initial Closing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 8, 2023 Milestone Closing</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred share price</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="0" id="f-460">1.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="0" id="f-461">1.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="0" id="f-462">0.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="0" id="f-463">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="-2" id="f-464">5.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="3" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-465">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="-2" id="f-466">95.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput" scale="-2" id="f-467">100.0</ix:nonFraction>%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i034d45b5fcc840799db4927dd41f8356_40"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-468" continuedAt="f-468-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Accrued Expenses and Other Current Liabilities</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-469" escape="true"><ix:continuation id="f-468-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:67.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcax:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-470">7,448</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcax:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">6,035</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-473">1,742</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-474">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-475">184</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-476">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-477">92</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-478">10,410</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-479">8,053</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i034d45b5fcc840799db4927dd41f8356_46"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Common Stock</span></ix:nonNumeric></div><ix:continuation id="f-480-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-481">500,000,000</ix:nonFraction> shares of Common Stock authorized for issuance, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-482">0.0001</ix:nonFraction> per share, of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-483">54,424,994</ix:nonFraction> shares issued, net of share repurchased and cancellation, and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-484">54,409,708</ix:nonFraction> shares, net were outstanding as of September&#160;30, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-485">711,895</ix:nonFraction> shares issued, net of share repurchased and cancellation, and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-486">640,386</ix:nonFraction> shares, net were outstanding as of December&#160;31, 2023. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-487">5,881,181</ix:nonFraction> shares of Common Stock for issuance to officers, directors, employees and consultants pursuant to the 2019 Stock Option and Grant Plan. As of December&#160;31, 2023, of the <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-488">640,386</ix:nonFraction> shares outstanding, <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-489">87,404</ix:nonFraction> shares relate to the exercises of stock options, <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-490">437,203</ix:nonFraction> shares relate to vesting of RSAs issued under the 2019 Stock Option and Grant Plan, <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-491">115,757</ix:nonFraction> shares of Common Stock are held by Biocon Limited and its affiliates (&#8220;Biocon&#8221;) and were awarded by the Company in 2020 and the remaining balance was issued to an investor.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company completed an IPO. As part of the IPO, the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="f-492">332.4</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-493">29.8</ix:nonFraction>&#160;million from the issuance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-494">20,125,000</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prior to the IPO, the Company held shares of convertible redeemable preferred shares, which consisted of Series A, Series B and Series C of preferred stock. Each tranche was subject to automatic conversion to common stock per the terms of the initial agreement. Prior to the IPO, there were <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-495">81,790,144</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-496">105,595,101</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-497">119,599,872</ix:nonFraction> shares outstanding in Series A, Series B and Series C tranches of preferred stock, respectively. These shares were converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-498">33,210,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> shares of common stock upon completion of the IPO.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i034d45b5fcc840799db4927dd41f8356_49"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><ix:nonNumeric contextRef="c-1" name="bcax:TemporaryEquityDisclosureTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Redeemable Convertible Preferred Stock</span></ix:nonNumeric></div><ix:continuation id="f-499-1" continuedAt="f-499-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;23, 2020, the Company issued to Biocon <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-500">40,000,000</ix:nonFraction> shares of Seed Series Preferred Stock (&#8220;Seed Series&#8221;) with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-501">0.0001</ix:nonFraction> per share and purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-502">1.00</ix:nonFraction> per share, in exchange for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="f-503">40.0</ix:nonFraction> million. On April&#160;26, 2022, the Company authorized for issuance an additional <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-504">50,940,144</ix:nonFraction> shares of Seed Series Preferred Stock with par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-505">0.0001</ix:nonFraction> per share and price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-506">1.00</ix:nonFraction> per share. On March&#160;2, 2023, the Company reduced the total number of its authorized Seed Series Preferred Stock to <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-507">81,790,144</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In March 2022, as part of the first close of the Company&#8217;s Seed Series extension financing, the Company entered into several SAFEs, pursuant to which the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="f-508">5.4</ix:nonFraction> million in exchange for its agreement to issue to certain investors shares of its preferred stock upon the occurrence of the Seed Series extension financing at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-509">1.00</ix:nonFraction> per share. On April&#160;26, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-510">5,350,000</ix:nonFraction> shares of Seed Series Preferred Stock with par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-511">0.0001</ix:nonFraction> per share and a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-512">1.00</ix:nonFraction> per share price to settle the $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="f-513">5.4</ix:nonFraction> million in SAFEs, of which <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-514">4,000,000</ix:nonFraction> shares of Seed Series Preferred Stock were issued to <ix:nonFraction unitRef="investor" contextRef="c-146" decimals="INF" name="bcax:TemporaryEquityNumberOfInvestorsStockIssued" format="ixt-sec:numwordsen" scale="0" id="f-515">two</ix:nonFraction> investors controlled by a board member, who is also a relative of the Chief Executive Officer, and <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-516">350,000</ix:nonFraction> shares of Seed Series Preferred Stock held by relatives of the Chief Executive Officer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, as part of the second close of the Company&#8217;s Seed Series extension financing, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-517">3,000,000</ix:nonFraction> shares of Seed Series Preferred Stock to the <ix:nonFraction unitRef="investor" contextRef="c-150" decimals="INF" name="bcax:TemporaryEquityNumberOfInvestorsStockIssued" format="ixt-sec:numwordsen" scale="0" id="f-518">two</ix:nonFraction> investors controlled by a board member, who is also a relative of the Chief Executive Officer, referred to above increasing their ownership to <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-519">7,000,000</ix:nonFraction> shares of Seed Series Preferred Stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-520">37,073,162</ix:nonFraction> shares of Series B Preferred Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-521">1.025</ix:nonFraction> per share (the &#8220;Initial Series B Closing&#8221;) for proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" scale="6" id="f-522">37.8</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was also obligated to sell up to <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-523">68,521,939</ix:nonFraction> additional shares (the &#8220;Milestone Shares&#8221;) of Series B Preferred Stock to the same purchasers at the same purchase price as the Initial Series B Closing the Series B Tranche Rights. The sale of Milestone Shares (the &#8220;Milestone Closings&#8221;) was contingent upon the Company&#8217;s achievement of certain milestones. In addition, if elected by a purchaser, the Company was obligated to sell Milestone Shares prior to achievement of the milestones (the &#8220;Voluntary Closings&#8221;). The Series B Tranche Rights are considered a freestanding instrument classified as a liability under ASC 480. The initial fair value of the liability was determined to be $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="bcax:FreestandingFinancialInstrumentLiabilityFairValue" scale="6" id="f-524">0.6</ix:nonFraction> million. Refer to Note 3 Fair Value Measurements to these unaudited condensed consolidated financial statements for further details. Share issuances pursuant to exercise of the Series B Tranche Rights under such Milestone Closings occurred on September&#160;8 and November&#160;3, 2023 in the amounts of <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-525">39,024,386</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-526">29,497,553</ix:nonFraction>, respectively, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="f-527">69.9</ix:nonFraction> million. Upon completion of the Milestone Closings, such tranche liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="f-528">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="f-529">6.0</ix:nonFraction> million on September&#160;8, 2023 and November&#160;3, 2023, respectively, were settled to redeemable convertible preferred stock on the unaudited condensed consolidated balance sheets. The Voluntary Closings were not exercised by the purchasers in 2023, and this right has expired.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-530">119,599,872</ix:nonFraction> shares of Series C Preferred Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="f-531">1.3796</ix:nonFraction> per share in exchange for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="f-532">164.6</ix:nonFraction> million. The Company additionally executed various side letters where certain purchasers have the right to tender all owned shares back to the Company for an aggregate purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="INF" name="bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" scale="0" id="f-533">1.00</ix:nonFraction> (the &#8220;Put Option&#8221;). The Put Option has no accounting implications as it is considered immaterial.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Seed Series Preferred Stock, Series B Preferred Stock and Series C Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221;. As of December&#160;31, 2023, the Preferred Stock had the following rights, preferences, and privileges:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock had rights to convert the shares of Preferred Stock into shares of Common Stock (the &#8220;Conversion Rights&#8221;) at the applicable original issue price (&#8220;Conversion Price&#8221;) with a conversion ratio (&#8220;Conversion Ratio&#8221;) of 9.2435:1. All outstanding shares of the Preferred Stock were converted automatically into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-534">33,210,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock immediately prior to the closing of the sale of shares of Common Stock to the public on September 13, 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-499-2" continuedAt="f-499-3"><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Liquidation Preference</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B and Series C Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the shareholders of outstanding Series B Preferred Stock and Series C Preferred Stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders and in case of a Deemed Liquidation Event (defined as a merger or consolidation in which the Company is a constituent party, or the sale, lease, transfer, exclusive license or other disposition by the Company of all or substantially all the assets), the holders of the Series B and Series C Preferred Stock shall be entitled to be paid out of the consideration payable to stockholders or out of the available proceeds of the Company, before the Seed Series and common stockholders, an amount per share (the &#8220;Liquidation Amount&#8221;) equal to the greater of: (a) the applicable original issue price, plus any dividends declared but unpaid, or (b) such amount per share amount as would have been payable on the conversion of all Series B Preferred Stock and Series C Preferred Stock (as applicable) into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If the amount to be paid as Liquidation Amount is insufficient, then all Series B and Series C preferred stockholders shall share the assets available for distribution in proportion of their shareholding. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seed Series Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Seed Series preferred stockholders shall have priority over the common stockholders, with a liquidation preference equal to the greater of (a) the Seed Series original issue price, plus any dividends declared but unpaid thereon, or (b) such amount per share as would have been payable on the conversion of all shares of Seed Series Preferred Stock into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, and after the payment of all preferential amounts required to be paid to the holders of the Series B Preferred Stock and Series C Preferred Stock, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Seed Series Preferred Stock the full amount to which they shall be entitled, the holders of shares of Seed Series Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares of Seed Series Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Preferred Stock is not redeemable except in the event of a Deemed Liquidation Event. As redemption by the holders is not within the control of the Company, all the outstanding convertible preferred stock is classified as temporary equity in the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B and Series C Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The holders of then outstanding shares of Series B Preferred Stock and Series C Preferred Stock shall be entitled to receive, only when, as and if declared by the board of directors of the Company, dividends at the rate of eight percent (<ix:nonFraction unitRef="number" contextRef="c-13" decimals="2" name="bcax:TemporaryEquityDividendRatePercentage" scale="-2" id="f-535"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="2" name="bcax:TemporaryEquityDividendRatePercentage" scale="-2" id="f-536">8</ix:nonFraction></ix:nonFraction>%) of the applicable original issue price for each share of Series B Preferred Stock or Series C Preferred Stock, prior and in preference to any declaration or payment of any other dividend on shares of Seed Series Preferred Stock or Common Stock (other than dividends on shares of Common Stock payable in shares of Common Stock) during the same calendar year. The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company unless the holders of the Series B Preferred Stock and Series C Preferred Stock then outstanding first receive a dividend on each outstanding share of Series B Preferred Stock or Series C Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seed Series Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company shall not declare, pay or set aside any dividends on shares of Common Stock unless the holders of the Seed Series Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-499-3" continuedAt="f-499-4"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock have the same voting rights as the holders of the Common Stock, on an as-converted basis. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the board of directors of the Company was comprised of <ix:nonFraction unitRef="board_member" contextRef="c-4" decimals="INF" name="bcax:NumberOfMembersBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="f-537">ten</ix:nonFraction> members. The election of directors is determined as following:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">The holders of record of the shares of Seed Series Preferred Stock, exclusively and as a separate class, shall be entitled to elect <ix:nonFraction unitRef="board_member" contextRef="c-9" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" format="ixt-sec:numwordsen" scale="0" id="f-538">one</ix:nonFraction> (<ix:nonFraction unitRef="board_member" contextRef="c-9" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" id="f-539">1</ix:nonFraction>) director of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect <ix:nonFraction unitRef="board_member" contextRef="c-12" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" format="ixt-sec:numwordsen" scale="0" id="f-540">three</ix:nonFraction> (<ix:nonFraction unitRef="board_member" contextRef="c-12" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" scale="0" id="f-541">3</ix:nonFraction>) directors of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The holders of record of the shares of Series C Preferred Stock, exclusively and as a separate class, shall be entitled to elect <ix:nonFraction unitRef="board_member" contextRef="c-14" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" format="ixt-sec:numwordsen" scale="0" id="f-542">one</ix:nonFraction> (<ix:nonFraction unitRef="board_member" contextRef="c-14" decimals="INF" name="bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" scale="0" id="f-543">1</ix:nonFraction>) director of the Company </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The holders of record of the shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-544">0.0001</ix:nonFraction> par value per share, of the Company, exclusively and as a separate class, shall be entitled to elect <ix:nonFraction unitRef="board_member" contextRef="c-4" decimals="INF" name="bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" format="ixt-sec:numwordsen" scale="0" id="f-545">one</ix:nonFraction> (<ix:nonFraction unitRef="board_member" contextRef="c-4" decimals="INF" name="bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" scale="0" id="f-546">1</ix:nonFraction>) director of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The holders of record of the shares of Common Stock and the Preferred Stock, voting together as a single class on an as converted basis, shall be entitled to elect the balance of the total number of directors of the Company.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">Any director elected as above may be removed without cause by, and only by, the affirmative vote of the holders of the class or series of capital stock entitled to elect such director or directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time when shares of Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative vote of at least <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" scale="-2" id="f-547">65</ix:nonFraction>% of the outstanding Preferred Stock holders, including at least one holder of Series C Preferred Stock who does not hold shares of any other class or series of Preferred Stock: 1) liquidate, dissolve or wind-up the business and affairs of the Company, or effect any merger or consolidation or any other Deemed Liquidation Event; 2) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Company in a manner that adversely affects the powers, preferences or rights of the Preferred Stock; 3) create, issue, or reclassify any capital stock unless the same ranks junior to the Preferred Stock with respect to its rights, preferences and privileges; 4) cause or permit any of its subsidiaries to, without approval of the board of directors, sell, issue, sponsor, create or distribute any digital tokens, cryptocurrency or other blockchain-based assets; 5) purchase or redeem or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than as expressed with the Preferred Stock agreements; 6) create, issue, or authorize the issuance of any debt security or create any lien or security interest or incur other indebtedness for borrowed money; 7) create, or hold capital stock in, any subsidiary that is not wholly owned by the Company, or permit any subsidiary to create or issue any shares, or sell, transfer or otherwise dispose of any capital stock; 8) create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation plan; or 9) increase or decrease the authorized number of directors constituting the board of directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional protective provisions for certain classes of shares include the following:</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For so long as at least <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" format="ixt:num-dot-decimal" scale="0" id="f-548">52,797,551</ix:nonFraction> shares of Series B Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" scale="-2" id="f-549">60</ix:nonFraction>% of the Series B holders: a) waive or otherwise forego any adjustment in the Series B Conversion Price; b) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series B Preferred Stock with respect to its rights, preferences and privileges; or c) amend, modify, change or waive the liquidation amount applicable to the Series B Preferred Stock. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><ix:continuation id="f-499-4" continuedAt="f-499-5"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Preferred Stock</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-499-5"> - For so long as at least <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" format="ixt:num-dot-decimal" scale="0" id="f-550">71,759,924</ix:nonFraction> shares of Series C Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least <ix:nonFraction unitRef="number" contextRef="c-165" decimals="2" name="bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" scale="-2" id="f-551">60</ix:nonFraction>% of the Series C holders: a) waive or otherwise forego any adjustment in the Series C Conversion Price; b) effect the conversion of the Series C Preferred Stock to Common Stock in a Qualified IPO; c) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series C Preferred Stock with respect to its rights, preferences and privileges; or d) amend, modify, change or waive the liquidation amount applicable to the Series C Preferred Stock.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">22</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_52"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-553" continuedAt="f-553-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Stock-Based Compensation</span></ix:nonNumeric></div><ix:continuation id="f-553-1" continuedAt="f-553-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option and Grant Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the board of directors adopted, and the Company&#8217;s shareholders approved, the 2019 Stock Option and Grant Plan (the &#8220;2019 Plan&#8221;) under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are awards that are authorized to be issued:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock Options including Incentive Stock Options (&#8220;ISO&#8221;) or Non-Qualified Stock Options (&#8220;NQSO&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted Stock Awards (&#8220;RSA&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unrestricted Stock Awards (&#8220;URSA&#8221;); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted Stock Units (&#8220;RSU&#8221;)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2019 Plan, as amended, the Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-554">8,856,245</ix:nonFraction> shares of Common Stock. For the period ended September&#160;30, 2024, the Company has issued RSAs, ISOs and NQSOs under the 2019 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2019 Plan. Equity awards granted to employees and non-employees generally vest over a <ix:nonNumeric contextRef="c-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-555">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Certain options provide for early vesting. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSAs were issued under individual RSA agreements (the &#8220;Award Agreements&#8221;). The Award Agreements dictate vesting terms and once vested, the recipients&#8217; restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided in the respective Award Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than <ix:nonNumeric contextRef="c-166" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-556">10</ix:nonNumeric> years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In 2024, in connection with the Company's IPO, the board of directors adopted, and the Company's shareholders approved the 2024 Stock Option and Grant Plan (the "2024 Plan") under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2024 Plan, the Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-557">2,453,616</ix:nonFraction> shares of Common Stock, plus on January 1, and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by <ix:nonFraction unitRef="number" contextRef="c-168" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" scale="-2" id="f-558">5</ix:nonFraction>% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through September&#160;30, 2024, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-559">174,707</ix:nonFraction> ISOs and NQSOs under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a <ix:nonNumeric contextRef="c-168" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-560">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Certain options provide for early vesting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than <ix:nonNumeric contextRef="c-168" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-561">10</ix:nonNumeric> years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-553-2" continuedAt="f-553-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-562" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of operations as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-563">1,469</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-564">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-565">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-566">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-567">2,031</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-568">519</ix:nonFraction></span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-569">3,172</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-570">924</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-571">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-572">210</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-573">4,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-574">1,134</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-575" escape="true"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-576">47,199</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-178" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-577">4.07</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-578">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-179" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-579">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-580">40,252</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-179" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-581">4.07</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchased/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-582">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-179" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-583">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-584">6,947</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-585">4.07</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-586">0.1</ix:nonFraction> million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted average period of <ix:nonNumeric contextRef="c-179" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-587">0.1</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-553-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-588" continuedAt="f-588-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic <br/>Value (1)<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-589">4,850,669</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-590">4.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-591">3,652,807</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-592">9.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-593">393,216</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-594">3.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-595">117,494</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-596">4.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-597">7,992,766</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-598">6.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-599">9.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-600">133,789</ix:nonFraction></span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-601">897,774</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-602">4.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-603">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-604">16,951</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-605">7,992,766</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-606">9.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-588-1" continuedAt="f-588-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:continuation id="f-588-2">The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on September&#160;30, 2024 for the options that were in the money.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the nine months ended September&#160;30, 2024 and 2023, was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-607">6.99</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-608">2.77</ix:nonFraction>, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-609">7,094,992</ix:nonFraction> unvested stock options outstanding as of September&#160;30, 2024. As of September&#160;30, 2024, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-610">37.0</ix:nonFraction> million related to unvested stock options are expected to be recognized as expense over a weighted average period of <ix:nonNumeric contextRef="c-181" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-611">3.3</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">On September 5, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-612">507,383</ix:nonFraction> shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-613">1,014,766</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-614">1</ix:nonFraction>% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date and no stock-based compensation expense was recognized during the three months ended September 30, 2024.</span></div></ix:continuation><div id="i034d45b5fcc840799db4927dd41f8356_55"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-615" continuedAt="f-615-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Income Taxes</span></ix:nonNumeric></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-616" escape="true"><ix:continuation id="f-615-1">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</ix:continuation></ix:nonNumeric> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i034d45b5fcc840799db4927dd41f8356_58"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-617" continuedAt="f-617-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Significant Agreements &#8211; Related Parties</span></ix:nonNumeric></div><ix:continuation id="f-617-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a master services agreement on December 15, 2020 (the &#8220;Master Services Agreement&#8221;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company did <ix:nonFraction unitRef="usd" contextRef="c-184" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-618"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-619"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-620"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-621">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> incur any expenses under the Master Services Agreement during the three and nine months ended September&#160;30, 2024 and 2023. As of September&#160;30, 2024 and December&#160;31, 2023, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-622">0.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-623">1.6</ix:nonFraction> million, respectively, which were classified in accrued expenses-related party on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;23, 2019, the Company entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#8220;BBL&#8221;) formerly Biocon Biologics India Limited, which is valid for <ix:nonNumeric contextRef="c-190" name="bcax:RelatedPartyAgreementTerm" format="ixt-sec:duryear" id="f-624">5</ix:nonNumeric> years unless earlier terminated by one of the parties. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023 and a manufacturing agreement on December 15, 2023 (the &#8220;BBL Agreements&#8221;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended September&#160;30, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-625">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-626">0.7</ix:nonFraction> million research and development expenses, respectively, under the BBL Agreements. For the nine months ended September&#160;30, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-627">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-628">0.7</ix:nonFraction> million research and development expenses, respectively, under the BBL Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-629">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-630">1.7</ix:nonFraction> million, respectively, which were classified in accrued expenses-related party on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company additionally entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#8220;Syngene&#8221;), on July 17, 2019, as amended on May 18, 2022 and on August 1, 2022, along with a master contract services agreement on July&#160;24, 2020 (the &#8220;Syngene Agreements&#8221;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The manufacturing agreement is valid for <ix:nonNumeric contextRef="c-197" name="bcax:RelatedPartyAgreementTerm" format="ixt-sec:duryear" id="f-631">6</ix:nonNumeric> years unless earlier terminated by one of the parties, while the master contract services agreement carried a term of <ix:nonNumeric contextRef="c-198" name="bcax:RelatedPartyAgreementTerm" format="ixt-sec:duryear" id="f-632">2</ix:nonNumeric> years. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-633">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-634">1.6</ix:nonFraction> million of research and development expenses, respectively, under the Syngene Agreements. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-635">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-636">5.8</ix:nonFraction> million of research and development expenses, respectively, under the Syngene Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-637">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-638">2.9</ix:nonFraction> million, respectively, relating to these incurred costs, of which $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-639">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-640">1.0</ix:nonFraction> million, respectively, were classified in accounts payable-related party and $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-641">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-642">1.9</ix:nonFraction> million, respectively, were classified in accrued expenses-related party on the balance sheets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company entered into a master service agreement with a wholly-owned subsidiary of Biocon, Biofusion Therapeutics Limited (&#8220;Biofusion&#8221;) (the &#8220;Biofusion Agreement&#8221;), which was terminated upon acquisition of Biofusion by Syngene on August 2, 2022. Pursuant to the terms of the Biofusion Agreement, Biofusion provided research and development services. As of December&#160;31, 2022, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-643">7.7</ix:nonFraction> million in connection with services provided by Biofusion, which were classified in accrued expenses-related party on the balance sheet, of which $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-644">4.1</ix:nonFraction> million were incurred in 2022. The Company paid the full amount on March 21, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a full recourse promissory note (the &#8220;Promissory Note&#8221;) with our Chief Financial Officer (&#8220;CFO&#8221;), pursuant to which the Company loaned $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="f-645">274</ix:nonFraction> thousand, plus interest accruing at rate of <ix:nonFraction unitRef="number" contextRef="c-207" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-646">0.86</ix:nonFraction>% per annum (or if higher, the applicable federal rate as of the date of the Promissory Note), due by the earliest to occur of (i) December 31, 2025, (ii) the date of certain transfers of the collateral pledged under the Promissory Note, (iii) upon the day prior to the date a change in the Company&#8217;s or the CFO&#8217;s status would cause the loan to be deemed prohibited under applicable law, (iv) upon the date prior to the Company&#8217;s filing of a registration statement for an initial public offering or a change of control, (v) upon acceleration of the Promissory Note in accordance with its terms or (vi) the date three months following the CFO&#8217;s termination of employment with the Company. As part of the Promissory Note, the CFO pledged <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="bcax:DebtInstrumentCollateralPledgedShares" format="ixt:num-dot-decimal" scale="0" id="f-647">616,320</ix:nonFraction> shares of restricted Common Stock as collateral under the terms of a security agreement. There has been immaterial interest income from the Promissory Note. The CFO repaid the full amount in June 2024. As of December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-648">68</ix:nonFraction> thousand within prepaid expenses and other assets, and $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-649">68</ix:nonFraction> thousand within other assets on the balance sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">26</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_61"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-650" continuedAt="f-650-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Significant Agreements</span></ix:nonNumeric></div><ix:continuation id="f-650-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#8220;IQVIA), which was amended in December 2023 to include global clinical trials Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#8220;SOWs&#8221;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-651">1.8</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-652">1.0</ix:nonFraction> million was a refundable deposit and $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-653">0.8</ix:nonFraction> million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#8220;ATP&#8221;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:OtherCommitment" scale="6" id="f-654">0.9</ix:nonFraction> million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of December&#160;31, 2023, the refundable deposit balance was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="bcax:OtherCommitmentLiabilityRefundableDepositAmount" scale="6" id="f-655">1.9</ix:nonFraction> million. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-656">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-657">2.1</ix:nonFraction> million in expenses. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-658">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-659">5.3</ix:nonFraction> million in expenses, respectively and paid $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="bcax:PaymentsForOtherCommitments" scale="6" id="f-660">13.3</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="bcax:PaymentsForOtherCommitments" scale="6" id="f-661">8.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to IQVIA. As of September&#160;30, 2024 and December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-662">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-663">1.6</ix:nonFraction> million classified in accounts payable, respectively and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-664">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-665">4.7</ix:nonFraction> million classified in accrued expenses and other current liabilities on the balance sheets.</span></div></ix:continuation><div id="i034d45b5fcc840799db4927dd41f8356_43"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-666" continuedAt="f-666-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Commitments and Contingencies</span></ix:nonNumeric></div><ix:continuation id="f-666-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have contingency reserves established for any litigation liabilities as of September&#160;30, 2024, and December&#160;31, 2023.</span></div></ix:continuation><div id="i034d45b5fcc840799db4927dd41f8356_64"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-667" continuedAt="f-667-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Subsequent Events</span></ix:nonNumeric></div><ix:continuation id="f-667-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October, 2024, the Company amended its original lease agreement to lease an additional <ix:nonFraction unitRef="sqft" contextRef="c-220" decimals="INF" name="bcax:LesseeOperatingLeaseAreaOfProperty" format="ixt:num-dot-decimal" scale="0" id="f-668">4,744</ix:nonFraction> square feet of office space (the "Amended Lease") in order to expand the Company's headquarters. The base rent under the Amended Lease is approximately $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-669">0.3</ix:nonFraction>&#160;million per year. The Amended Lease did not extend the original lease end date under the original lease term.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. (&#8220;Y-Trap&#8221;) naming as defendants us and Biocon LTD. (&#8220;Biocon&#8221;), captioned Y-Trap, Inc. v. Biocon LTD. and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). The complaint alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. We intend to vigorously defend against this litigation.</span></div></ix:continuation><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">27</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_676"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">should</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">read</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">discussion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and analysis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as of and for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> months ended September 30, 2024 and 2023</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, and related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">notes and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">information</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">included</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in the previously filed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prospectus and in conjunction</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">audited</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements. This discussion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">analysis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">parts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">contain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">forward-looking</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">based upon our current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plans</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">expectations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">involve</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">risks,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">uncertainties</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">assumptions,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">regarding our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plans,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">objectives,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">expectations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">intentions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and beliefs.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our actual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of events</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">differ materially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">anticipated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">forward-looking</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">result</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">various</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">factors,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">including those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">set</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">forth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">section</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Risk</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Factors&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">should</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">carefully read</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Risk</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Factors&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">section</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">to gain an understanding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">important</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">factors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">could cause</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">actual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">to differ</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">materially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">from our forward-looking</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Please also see the section titled &#8220;Special</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note Regarding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statements.&#8221;</span></div><div id="i034d45b5fcc840799db4927dd41f8356_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical-stage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biopharmaceutical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to bringing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transformative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bifunctional therapies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solid</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumors.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lead</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a bifunctional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antibody</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combines two</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinically</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">validated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targets,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epidermal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receptor,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monoclonal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antibody with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">domain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">binds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transforming</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beta,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF-&#946;. Through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dual-targeting mechanism,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exert</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-tumor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by simultaneously</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">blocking</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both cancer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cell-intrinsic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">survival</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proliferation,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunosuppressive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF-&#946;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">signaling</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">microenvironment,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TME.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%">-</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#946;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inhibitor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TME through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">binding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cells,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we believe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lead</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to durable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and an increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in overall</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">survival,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OS,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reducing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">systemic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF-&#946; inhibition. Ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">head</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neck</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cell</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carcinoma,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HNSCC, where</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there remains</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unmet</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">need.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intend</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pivotal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2/3</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in combination with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pembrolizumab</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-line</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapy</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recurrent/metastatic,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HNSCC</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excluding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-positive oropharyngeal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cell</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carcinoma,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or OPSCC,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%"> late in the fourth quarter of 2024 or early in the first quarter of 2025. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other sources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and negative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flows</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operations.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alf</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, raising</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">building</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hiring</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and providing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funded</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through private</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">placements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our redeemable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt financing.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had raised</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate net</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$686.5 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d had cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and cash equivalents</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$520.8 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses in each year since our inception. Our net losses were $47.0 million and $39.5 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $200.1 million. We expect our expenses and operating losses will increase substantially as we:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">utilize</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">raw</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we decide</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">so, build</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and maintain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a commercial-scale</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">good manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practice,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or cGMP, manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facility;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercial,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and operational</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add quality</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quality</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">groups</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operations;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expand,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforce,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defend</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portfolio</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtained</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and provide</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of third-party</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our patent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portfolio;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approvals</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we successfully</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complete</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establish</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa or any future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalties</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other payments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or collaboration</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with being</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fluctuate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter-to-quarter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and year-to-year,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depending</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing of our planned</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%">, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing and research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon our current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we believe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fund</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the first half of 2029. Without</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have sufficient</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to meet</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next twelve</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unless</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and until</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we successfully complete</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which will not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ever.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any of our future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to incur</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales, marketing,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and distribution.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we can generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ever,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to finance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt financings</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements. See</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resource</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be unable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional funds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">failure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when needed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would have a negative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">force</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delay,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limit,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prefer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and market ourselves.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_73"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Operations</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the future,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any approved</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do not expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to occur for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ever.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depend on the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eventual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursue.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fail</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complete</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of or to obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any future product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position would be adversely</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_76"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development&#8212;Related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Party)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have primarily consisted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">external</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">internal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bifunctional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antibody</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to treat</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solid</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumors,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as sponsored</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consultants</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our scientific</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advisors;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">salaries,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bonuses,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for employees</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engaged</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">functions;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laboratory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supplies,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reagents;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of developing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and validating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use in our future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alf</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and infrastructure resources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">across</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">breadth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">toward</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifying and developing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an evaluation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progress</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to completion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of specific</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tasks</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our vendors,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and third-party</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service providers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we continue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to pursue. Due</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unpredictable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with certainty</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duration</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and pre-clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of product candidates.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timelines</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can vary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we pursue,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unpredictable nature</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">make</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determinations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to which programs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to pursue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and how</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">much</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to direct</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to each</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program on an ongoing basis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in response</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results, regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ongoing assessments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to each</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">central</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">model.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">later stages</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have higher</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in earlier</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stages,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duration</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">later-stage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a result,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to (i)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advance ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">late-stage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, (ii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa for other potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expand our manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timely</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and successful completion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">positive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receipt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of marketing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approvals</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from applicable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with third</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">updates, and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continued</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tolerability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and efficacy</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profile</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of any product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of any of these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variables</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in preclinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mean</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authority</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delay</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planned</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">start</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beyond</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we experience</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in enrollment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in any of our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planned</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to expend significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to complete</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">never</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do, drug commercialization</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">takes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and millions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of dollars in development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Administrative</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses consist</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel-related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">salaries, bonuses, benefits, and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation charges</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individuals in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive, legal,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance, human</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facility</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">functions.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal fees relating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and corporate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matters,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees for auditing, accounting, tax and consulting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">office</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depreciation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which include</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and maintenance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of facilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and utilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to audit, accounting,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax-related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with maintaining</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our Nasdaq and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC, requirements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">director</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">officer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">premiums,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and investor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earned</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">invest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> both </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our IPO in 2024 and from sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Series</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B and C redeemable convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of Series</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">tranche</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">liability</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holder</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">puttable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the holder,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sheets</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tranche</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B Tranche Right</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">details.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not material</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2024 and 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earned</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credits,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our uncertainty</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of realizing a benefit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">items.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_79"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the three months ended September 30, 2024 and 2023</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Research and development&#8212;related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Research and development</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,554&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,668&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,886&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,628&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,530&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,098&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(20,628)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(9,530)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(11,098)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other income (expenses)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Change in fair value of Series B preferred stock tranche rights liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(13,328)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,328&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total other income (expenses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(13,315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss before income taxes </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17,481)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(22,845)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,364&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17,481)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(22,845)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development&#8212;Related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Party)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $8.9 million from $6.9&#160;million for the three months ended September 30, 2023, to $15.9&#160;million for the three months ended September 30, 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended September 30, 2024 and 2023. (in thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">448&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">452&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and process</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,339&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,512&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,827&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:-1pt;text-indent:-5.76pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,864&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,939&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,925&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the three months ended September 30, 2024, compared to the three months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.3 million in increased manufacturing cost, driven by an increase in drug substance batch manufacturing in connection with our Phase 1/1b and our pivotal Phase 2/3 clinical trial; </span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.8 million in increased clinical operation and development cost, driven by costs associated with our pivotal Phase 2/3 clinical trial design and continued patient enrollment in our Phase 1/1b dose expansion cohorts; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.8 million in increased personnel and other related costs including stock-based compensation, driven by an increase in the size of our workforce to support clinical development, manufacturing and research and increased professional service expenses as we continue to build out our clinical operations and development functions.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below summarizes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by program</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Direct external program expenses:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BCA 300</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">37&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(37)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Internal and unallocated expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Personnel related costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,860&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,197&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,663&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,864&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,939&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,925&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses by program for the three months ended September 30, 2024, compared to the three months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $7.3 million in increased costs for our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program, driven by manufacturing costs and clinical operation and development costs associated with our pivotal Phase 2/3 clinical trial design and continued patient enrollment in our Phase 1/1b dose expansion cohorts; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.7 million in increased personnel cost, driven by an increase in the size of our workforce to support clinical development, manufacturing and research and increased professional service expenses as we continue to build out our clinical operations and development functions.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $2.2 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.6 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2023</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> three</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024. The following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">table</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">summarizes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2024 and 2023 (in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:9pt;padding-right:-1pt;text-indent:-7.2pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,312&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,539&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,773&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT, office</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">582&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">397&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">185&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:22pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses for the three months ended September 30, 2024, compared to the three months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.8 million in increased personnel related costs, including stock-based compensation, primarily driven by an increase in the size of our workforce and due to a higher number and value of stock options granted;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.2 million in increased professional service expenses, including legal, accounting and other expenses as we continue to build out our general and administrative functions to support advancing our clinical studies and operating a publicly traded company; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.2 million in increased information technology expenses and related miscellaneous expenses.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended September 30, 2024 and 2023 was $3.1 million and $0.1 million, respectively. The increase was primarily due to significant increase in cash equivalents, as a result of proceeds from the IPO, Series B and Series C financings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of Series B preferred stock tranche rights liability</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of Series B preferred stock tranche rights liability for the three months ended September 30, 2024 and 2023 was none and $13.3 million, respectively. The change in fair value in 2023 was due to meeting the milestone in the third quarter of 2023.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the nine months ended September 30, 2024 and 2023</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Research and development&#8212;related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Research and development</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">36,336&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,544&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22,792&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,752&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26,202&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29,550&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other (expenses) income</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Change in fair value of Series B preferred stock tranche rights liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(13,356)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,356&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(13,343)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47,037&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39,545&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,492&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47,038&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39,545&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,493&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development&#8212;Related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Party)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $23.7 million from $20.1&#160;million for the nine months ended September 30, 2023, to $43.7&#160;million for the nine months ended September 30, 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,780&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,690&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">90&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and process</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,113&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,606&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,507&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:-1pt;text-indent:-6.48pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based compensation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">43,736&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,055&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23,681&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $12.6 million in increased manufacturing cost, driven by an increase in drug substance batch manufacturing in connection with our Phase 1/1b and our pivotal Phase 2/3 clinical trial; </span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $6.5 million in increased clinical operation and development cost, driven by costs associated with our pivotal Phase 2/3 clinical trial design and continued patient enrollment in our Phase 1/1b dose expansion cohorts; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.5 million in increased personnel and other related costs including stock-based compensation, driven by an increase in the size of our workforce to support clinical development, manufacturing and research and increased professional service expenses as we continue to build out our clinical operations and development functions.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below summarizes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by program</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Direct external program expenses:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">36,939</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,773</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,166</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCA 300</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">702&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1.4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(702)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCA 400/600</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Internal and unallocated expenses:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1.4pt 2px 1pt;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Personnel related costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,102</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">154&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1.4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">132</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">43,736</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,055</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3pt 2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23,681</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses by program for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $20.2 million in increased costs for our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program, driven by manufacturing costs and clinical operation and development costs associated with our pivotal Phase 2/3 clinical trial design and continued patient enrollment in our Phase 1/1b dose expansion cohorts; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.1 million in increased personnel cost, driven by an increase in the size of our workforce to support clinical development, manufacturing and research and increased professional service expenses as we continue to build out our clinical operations and development functions; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by approximately $0.7 million in decreased costs for our BCA 300 program, which was paused in 2023.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $5.9 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.1 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2023</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> nine</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024. The following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">table</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">summarizes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2024 and 2023 (in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:9pt;padding-right:-1pt;text-indent:-6.48pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,127&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,977&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,150&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT, office</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,426&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,363&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">63&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:22pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.2 million in increased personnel related costs, including stock-based compensation, primarily driven by an increase in the size of our workforce and related number and value of stock options granted;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.7 million in increased professional service expenses, including legal, accounting and other expenses as we continue to build out our general and administrative functions to support advancing our clinical studies and operating a publicly traded company; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.1 million in increased information technology expenses and related miscellaneous expenses.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the nine months ended September 30, 2024 and 2023 was $8.7 million and $0.1 million, respectively. The increase was primarily due to significant increase in cash equivalents, as a result of proceeds from the IPO, Series B and Series C financings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of Series B preferred stock tranche rights liability</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of Series B preferred stock tranche rights liability for the nine months ended September 30, 2024 and 2023 was none and $13.4 million, respectively. The change in fair value in 2023 was due to the meeting of the milestone in the third quarter of 2023.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_82"></div><div style="margin-top:12pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Resources</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018, we have not generated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any sources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have incurred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and negative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flows</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to incur</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we advance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to pursue.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our inception</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in December</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 through</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate net</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$686.5</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fr</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">om</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our redeemable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in private</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">placements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and debt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company completed an initial public offering, or IPO. As part of the offering, the Company received net proceeds of $332.4 million after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8&#160;million from the issuance of 20,125,000 shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $520.8 million, which based upon our current operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fund</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the first half of 2029.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecast</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a forward-looking statement</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involves</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainties,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and actual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costly,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progress</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertain.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">need to raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future.</span></div><div style="margin-top:12pt;padding-right:-1pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depend on many</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not limited</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to:</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.4pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">type,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progress,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expansions,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.25em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates and commercial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs, timing,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of regulatory review</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of establishing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and maintaining</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.35pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtaining,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintaining,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtained</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements);</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">systems</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hire</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfy</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with hiring</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and consultants</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as our clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of establishing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or securing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and marketing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.35pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieve</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptance,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third- party</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and adequate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any approved</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with any products</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or technologies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-license</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or acquire.</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such time,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ever,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we can generate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our cost</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">structure,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we expect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to finance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financings,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially including collaborations, licenses,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other similar arrangements.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we may be unable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to raise additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or convertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt securities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ownership interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diluted,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other preferences</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if available,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involve</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covenants</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limiting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restricting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific actions,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurring</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenditures,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or declaring</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividends.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relinquish</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuable rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technologies,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">streams,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">raise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have a negative</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and strategies.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to raise additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financings</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when needed,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to delay,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limit,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or terminate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our current</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prefer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such product candidates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ourselves.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_85"></div><div style="margin-top:10pt;padding-right:-1pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of the Nine Months Ended September 30, 2024 and 2023</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">table</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">summary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flow</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2024 and 2023 (in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:66.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(44,719)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(37,592)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by (used in) investing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by financing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">335,006&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77,794&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:22pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and cash</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">290,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Activities</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, net cash used in operating activities was $44.7 million resulting from our net loss of $47.0 million and decreases in our operating assets and liabilities of $2.1 million, partially offset by non-cash charges of $4.5 million, consisting of stock-based compensation expense, depreciation and non-cash lease expense. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, net cash used in operating activities was $37.6 million resulting from our net loss of $39.5 million and net outflows in our operating assets and liabilities of $12.6 million, partially offset by non-cash charges of $14.5 million. Non-cash charges consisted of stock-based compensation expense, depreciation and changes in fair value of Series B preferred stock tranche rights liability.</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was insignificant for the nine months ended September 30, 2024 and net cash spent was $0.2 million for the nine months ended September 30, 2023, due to purchases of new equipment for the Company's new office space. </span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $335.0 million during the nine months ended September 30, 2024, consisting of $333.5 million in net proceeds from issuance of common stock in its IPO and $1.5 million in proceeds from the exercise of stock options. Offering costs of $1.1 million remain in accounts payable and accrued expenses as of September 30, 2024 and will be offset against net financing fees received upon payment.</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $77.8 million during the nine months ended September 30, 2023, consisting of $77.7 million in net proceeds from the issuance of preferred stock and preferred stock tranche rights, in connection with Series B financing and $0.1 million in proceeds from the exercise of stock options.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_88"></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sheet Arrangements</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we do not currently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have, any off-balance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sheet arrangements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as defined</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rules</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_91"></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Polices</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Estimates</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analysis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prepared</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with generally</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accepted accounting principles</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP. The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preparation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us to make estimates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of assets,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and expenses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the disclosure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">notes. We base our estimates and assumptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on historical experience</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other factors that we believe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be reasonable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our estimates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and judgments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on an ongoing basis.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">known</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trends</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we believe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are reasonable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which form</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">about</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying values</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not readily</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apparent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differ</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:3.35pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Summary of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policies&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appearing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the previously filed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> Form </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we believe that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">most</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">critical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">understanding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and evaluating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our financial condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations.</span></div><div style="margin-top:10pt;padding-right:268.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:10pt;padding-right:3.35pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">W</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">require</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">estimat</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">resultin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fro</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">obligation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">unde</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">contract</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">wit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">vendor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">and consultants</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">connectio</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">wit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">conductin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">researc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">developmen</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">Th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">financia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">term</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">these contract</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">subjec</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">negotiations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">whic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">var</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fro</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">contrac</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">contrac</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ma</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">resul</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">paymen</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">flow</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">tha</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">do no</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">matc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">period</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ove</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">whic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">material</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">service</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">provide</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">unde</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">suc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">contracts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">W</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">reflec</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">researc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">and developmen</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">consolidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">financia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">statement</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">b</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">matchin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">thos</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">wit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">perio</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">which service</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">effort</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expended</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">W</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">accoun</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fo</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">thes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">accordin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">progres</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">clinica</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">studie</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">as measure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">b</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">timin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">variou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">aspect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">stud</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">relate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">W</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">determin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">accrua</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">estimate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">through revie</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">underlyin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">contract</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">alon</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">wit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">preparatio</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">financia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">model</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">takin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">int</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">accoun</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">discussion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">with researc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">othe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ke</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">personne</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">progres</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">studies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">othe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">service</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">bein</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">conducted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">Durin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">course o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">study</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">w</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">adjus</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">rat</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expens</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">recognitio</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">actua</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">result</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">diffe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fro</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">estimates.</span></div><div style="margin-top:10pt;padding-right:3.4pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">Althoug</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">w</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">no</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expec</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">estimate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">b</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">materiall</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">differen</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fro</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">amount</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">actuall</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">our estimate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">statu</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">timin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">service</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">performe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">diffe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">fro</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">actua</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">statu</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">timin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">services performed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">coul</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">resul</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">u</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">reportin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">amount</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">tha</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">hig</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">lo</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">particula</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">period</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">T</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">there hav</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">bee</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">materia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">difference</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">betwee</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">ou</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">estimate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">suc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">th</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">amount</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">actuall</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.01em;line-height:120%">incurred.</span></div><div style="margin-top:10pt;padding-right:358.6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B Tranche Rights</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permit</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holder</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">puttable</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the holder,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingently</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sheets</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any change</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations.</span></div><div style="margin-top:10pt;padding-right:3.2pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tranche</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B Tranche</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchasers</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who participated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B convertible</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tranche</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;freestanding</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instrument&#8221;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Master</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glossary</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as they</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were legally</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">detachable</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and separately</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessed the freestanding</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instrument</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distinguishing</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that such</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a liability</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imposed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a contingent</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Company</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would be contingently</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B Tranche</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were revalued</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlement,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with changes</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value recorded</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations.</span></div><div style="margin-top:10pt;padding-right:352.75pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuation</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">absence</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">active</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock prior to September 2024,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we utilized</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approaches</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and assumptions</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consistent</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certified</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountants&#8217;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Accounting Practice</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guide:</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privately-Held</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issued</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we considered</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was determined</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our board of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variety</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including:</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuations</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specialists;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stage</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategy,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the status</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our business and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">industry;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">projections;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and financial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">levels</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of publicly</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">traded</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">life</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sciences</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and biotechnology</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sectors,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as recently</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mergers</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and acquisitions</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of peer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lack</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of marketability</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party investors,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferences</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privileges</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relative</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock; the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likelihood</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieving</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public offering</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevailing</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trends</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and developments</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our industry;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hiring</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of key personnel</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and external</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affecting</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">life</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sciences</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and biotechnology</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">industry</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sectors.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key assumptions</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underlying</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">used could result</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in different</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:358.05pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Methodologies</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuations</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prepared</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guidelines</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AICPA Practice</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aid, which prescribes</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approaches</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of an enterprise,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost, market and income</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approaches,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and various</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocating</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of an enterprise to its capital structure</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specifically</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock.</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuations</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prepared</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> (i) </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back-solve</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to calculate</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option-pricing</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPM,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocate</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value and (ii) probability weighted expected return method or PWERM.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back-solve</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derives</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the implied</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">type</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contemporaneous</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involving</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">type of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">used</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back-solve</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculate</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our company</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we had recently completed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financings</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimating</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AICPA</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:-0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Practice</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aid. The</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPM</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allows</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a company&#8217;s</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital owners</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders).</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OPM uses</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders&#8217;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferences, participation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividend</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policy,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">how</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidity</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event shall</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be distributed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classes</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a future</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date.</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PWERM method involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome. The common stock per share value determined using this approach was ultimately based upon probability-weighted per share values resulting from the various future scenarios, which included an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPO</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scenario or continued operation as a private company scenario.</span></div><div style="margin-top:10pt;padding-right:346.4pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of equity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">awards recognized</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requisite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">awards</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(usually</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vesting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">awards</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">model</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognize forfeitures</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as they</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occur.</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">model</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use of subjective</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk-free interest</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volatility,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected dividend yield, and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underlying</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can materially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ultimately</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">how much</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inputs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subjective</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8221; </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our unaudited condensed consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerning certain of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">used</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applying</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">model</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to determine</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the estimated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30, 2024, and 2023, respectively. Stock-based</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tota</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">led</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> September</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, respectively. </span></div><div id="i034d45b5fcc840799db4927dd41f8356_97"></div><div style="margin-top:10pt;padding-right:163.6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Company and Smaller</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reporting Company Status</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualify</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company,&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jumpstart</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Startups</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2012.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of specified</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other requirements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include:</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being permitted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">only</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of audited</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in addition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to any required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interim financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">correspondingly</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Management&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Analysis</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-Q;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">about</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our executive compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hold</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advisory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">votes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholder</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">golden</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parachute</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an exemption from the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auditor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attestation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement in the assessment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our internal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting pursuant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarbanes-Oxley</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act; and (v)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an exemption</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oversight</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">communication</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">critical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">audit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matters</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auditor&#8217;s report</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exemptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">longer an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cease</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earliest of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">last</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.235</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more; (ii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">last</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fifth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our IPO; (iii)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on which we have issued</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 billion</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in nonconvertible</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previous</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three years;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">large</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rules</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC. We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may choose</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exemptions.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elected</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">avail</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ourselves</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this exemption</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be subject</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to new or revised accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standards</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">election,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be comparable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to those of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comply</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revised</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pronouncements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company effective</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dates.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">choose</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">early</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adopt</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new or revised</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standards</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whenever</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such early adoption</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permitted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies.</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a &#8220;smaller</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as defined</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act of 1934, as amended. We may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be a smaller</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even after</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no longer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an emerging</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth company. We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scaled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smaller</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be able</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scaled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">so</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our shares</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock held</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-affiliates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">less</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$250.0</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">last</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter, or our annual</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">less</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$100.0 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">most</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market value</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by non-affiliates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">less</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$700.0 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">last business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day of our second</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_100"></div><div style="margin-top:10pt;padding-right:303.5pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">description</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recently</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pronouncements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our financial position</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosed</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policie</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in this</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_103"></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is not applicable as we are electing scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_106"></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Item 4. Controls and Procedures</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Principal Executive Officer (our Chief Executive Officer) and Principal Financial Officer (our Chief Financial Officer, Treasurer), has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Principal Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">34</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:3.65pt;padding-right:3.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i034d45b5fcc840799db4927dd41f8356_112"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may become involved in litigation or other legal proceedings. On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. (&#8220;Y-Trap&#8221;) naming as defendants us and Biocon LTD. (&#8220;Biocon&#8221;), captioned Y-Trap, Inc. v. Biocon LTD. and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). The complaint alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. We intend to vigorously defend against this litigation.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_115"></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as the other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all or part of your investment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in December 2018, and our operations to date have been limited to pre-commercial activities. We have not yet demonstrated an ability to generate revenue, obtain regulatory approval, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have no products approved for commercial sale and have not generated any revenue from product sales to date. We will continue to incur significant research and development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net losses totaled $52.0 million and $37.8 million for the years ended December 31, 2023 and 2022, respectively, and $47.0 million for the nine months ended September 30, 2024. As of September 30, 2024, we have not yet generated revenues. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">advance ficerafusp alfa through clinical development; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seek regulatory approvals for ficerafusp alfa and any future our product candidates that successfully complete clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">hire additional clinical, quality control, medical, scientific and other technical personnel to support the clinical development of ficerafusp alfa and any future product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">experience an increase in headcount as we expand our research and development organization and market development and pre-commercial planning activities; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">undertake any pre-commercial or commercial activities to establish sales, marketing and distribution capabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">advancing any future product candidates into clinical development; seek to identify, acquire and develop additional product candidates, including through business development efforts to invest in or in-license other technologies or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">make any payments due under our license agreements and any potential milestones, royalties or other payments due under any future in-license or collaboration agreements; and   </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">make milestone, royalty, interest or other payments due under any future financing or other arrangements with third parties. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biopharmaceutical product development entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and become commercially viable, and therefore any investment in us is highly speculative. Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or the FDA, Health Canada, the European Medicines Agency, or the EMA, or other comparable regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, ficerafusp alfa. Even if ficerafusp alfa or any future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of ficerafusp alfa, continue to develop and deploy our bifunctional approach, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or in-licensing product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023 and September 30, 2024, we had $230.4 million and $520.8 million of cash and cash equivalents, respectively. Based upon our current operating plan, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. In addition, based upon our current operating plan, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop ficerafusp alfa. Our future capital requirements will depend on many factors, including but not limited to: </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of clinical trials required for regulatory approval of ficerafusp alfa or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of manufacturing clinical and commercial supplies of ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effectiveness of our approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expenses to attract, hire and retain skilled personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs of operating as a public company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effect of macroeconomic trends including inflation and rising interest rates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">addressing any potential supply chain interruptions or delays;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the extent to which we acquire or invest in business, products and technologies.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to predict the timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for ficerafusp alfa, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash and cash equivalents, the net proceeds from our initial public offering, short-term investments, or any future equity or debt financings and upfront and milestone and royalties payments, if any, received under any future licenses or collaborations. In the future, if we raise additional capital through the sale of equity or convertible debt securities or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties in the future, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions and changes in financial regulations and policies can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Business Operations and Industry </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business is highly dependent on the success of ficerafusp alfa. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize ficerafusp alfa, or if we experience delays in doing so, our business will be materially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, as an organization, we have not completed the development of any product candidates and ficerafusp alfa remains in clinical or preclinical development. Our future success and ability to generate revenue from ficerafusp alfa is dependent on our ability to successfully develop and commercialize ficerafusp alfa or any of our future product candidates. If any of our product candidates encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may not have the financial resources to continue development of ficerafusp alfa if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, ficerafusp alfa, including:     </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">     </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA, Health Canada, EMA or other comparable regulatory authorities that ficerafusp alfa is safe and effective;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension, termination, or hold, of a clinical trial once commenced; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">conditions imposed by the FDA, Health Canada, the EMA or other comparable regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays or failures in reaching agreement on acceptable terms with clinical trial sites or contract research organizations, or CROs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">poor effectiveness of ficerafusp alfa during clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from our clinical trials;     </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">higher than anticipated clinical trial or manufacturing costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unfavorable FDA, Health Canada, EMA or other comparable regulatory authority inspection and review of our clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">failure of our CROs, clinical trial sites, or investigators to comply with regulatory requirements or the clinical trial protocol or otherwise meet their contractual obligations in a timely manner, or at all;   </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our therapies in particular; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">varying interpretations of data by the FDA, Health Canada, EMA and other comparable regulatory authorities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. ficerafusp alfa or any future product candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA, Health Canada, the EMA or other regulatory approval or discovering, developing and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our competitors may obtain FDA, Health Canada, the EMA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights that </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limit our ability to develop or commercialize ficerafusp alfa. Our competitors may also develop drugs or discovery platforms that are more effective, more convenient, more widely used or less costly than ficerafusp alfa or, in the case of drugs, have a better safety profile than ficerafusp alfa. These competitors may also be more successful than us in manufacturing and marketing their products and have significantly greater financial resources and expertise in research and development. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. In addition, numerous compounds are in clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience. More specifically, we expect to compete with commercially available therapies for the treatment of head and neck squamous cell carcinoma, or HNSCC, including pembrolizumab (marketed as Keytruda by Merck &amp; Co); the combination of pembrolizumab, platinum chemotherapy and 5-fluorouracil; and the combination of cetuximab (marketed as Erbitux by Eli Lilly in the US and by Merck KGaA outside of the US), platinum chemotherapy and 5-fluorouracil. In addition, there are numerous companies that are developing new treatments for HNSCC, including Merck &amp; Co, Pfizer Inc., Genmab A/S, Exelixis, Inc., Merus N.V., Iovance Biotherapeutics, Inc., Kura Oncology, Inc. and ALX Oncology Holdings, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, ficerafusp alfa and any future product candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render ficerafusp alfa obsolete, less competitive or uneconomical. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize ficerafusp alfa. Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a greater likelihood of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our lead program, ficerafusp alfa, is initially being developed in HNSCC. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding patients with HPV-positive oropharyngeal squamous cell carcinoma, or OPSCC, and, more generally, we seek to bring transformative bifunctional therapies to patients with solid tumors. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for disorders of the brain and nervous system, our business, financial condition and results of operations could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may seek to grow our business through acquisitions or investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or other strategic alliances. The failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and patients&#8217; needs, competitive technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. Potential and completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">issues maintaining uniform standards, procedures, controls and policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversion of management&#8217;s attention from our core business and disruption of ongoing operations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse effects on existing business relationships with suppliers, sales agents, health care facilities, surgeons and other health care providers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">risks associated with entering new markets in which we have limited or no experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential losses related to investments in other companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential loss of key employees of acquired businesses; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">increased legal and accounting compliance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not know if we will be able to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business, product or technology into our business or retain any key personnel, suppliers, sales agent, health care facilities, physicians or other health care providers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, technologies or products and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are exposed to the risk of employee fraud or other illegal activity by our current and any future employees, independent contractors, consultants, contract manufacturing organizations, or CMOs, and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that fails to comply with FDA, Health Canada, the EMA or other regulations, provide true, complete and accurate information to the FDA, Health Canada, EMA and other comparable regulatory authorities, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S., our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We, our collaborators and our service providers are subject to a variety of privacy and data security laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to significant fines and other penalties and otherwise harm our business and operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The legislative and regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, several jurisdictions, including those in which we operate or collect personal information, have established their own data security and privacy frameworks with which we must comply. In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information, could apply to our operations or the operations of our collaborators and service providers. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and impose requirements regarding the privacy and security of individually identifiable health information, including mandatory contractual terms, for covered entities, or certain healthcare providers, health plans and healthcare clearinghouses, and their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information. While pharmaceutical and biotechnology companies are typically not directly regulated by HIPAA, our business may be indirectly impacted by HIPAA in our interactions with providers, payors, and others that have HIPAA compliance obligations. If we are unable to properly protect the privacy and security of protected health information, we could be found to have violated these privacy and security laws and/or breached certain contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant civil and criminal penalties. U.S. Department of Health &amp; Human Services, or HHS, enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the state level, numerous states have or are in the process of enacting or considering comprehensive data privacy and security laws, rules and regulations while other states have focused on more narrow aspects of privacy. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. In the state of Washington, for example, the My Health My Data Act, which has a private right of action that further increases the relevant compliance risk, requires regulated entities to obtain consent to collect health-related information and grants consumers certain rights, including to request deletion of their information. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states have passed laws that regulate biometric data specifically. Although many of the existing state privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be broader in scope. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we may likely become subject, if enacted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we conduct clinical trials in the European Economic Area, or the EEA, and/or the United Kingdom, or the U.K., we will be subject to additional, more stringent privacy laws in other jurisdictions, such as the General Data Protection Regulation, or the EU GDPR, as well as other national data protection legislation in force in relevant European Union, or EU, member states. The EU GDPR imposes strict regulations and establishes a series of requirements regarding the collection, transfer, storage and processing of personal data. Following the U.K.&#8217;s withdrawal from the EU on January 31, 2020 and the end of the transitional arrangements agreed between the U.K. and EU as of January 1, 2021, the EU GDPR has been incorporated into U.K. domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 and amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019, or the U.K. GDPR, and, together with the EU GDPR, the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including strict requirements relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the processing of personal data, where required strict requirements relating to obtaining consent of individuals, disclosures about how personal information is to be used, limitations on retention of information, implementing safeguards to protect the security and confidentiality of personal data, where required providing notification of data breaches, maintaining records of processing activities, documenting data protection impact assessments where there is high risk processing and taking certain measures when engaging third-party processors. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA or the U.K., including the United States (see below), and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million GBP) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Non-compliance could also result in the imposition of orders to stop data processing activities, which could have a material adverse effect on our business, financial position and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When subject to GDPR, we will be required to put in place mechanisms to ensure compliance, including as implemented by national laws of EU Member States which may partially deviate from the EU GDPR and impose different and more restrictive obligations from country to country. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European and U.K. activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#8217;s data protection regime, which is independent from but, currently, aligned to the EU&#8217;s data protection regime. The European Commission, or the EC, has adopted an adequacy decision in respect of transfers of personal data to the U.K. for a four-year period (until June 27, 2025). Similarly, the U.K. has determined that it considers all of the EEA to be adequate for the purposes of data protection. This ensures that data flows between the U.K. and the EEA remain unaffected. The U.K. Government has also introduced a Data Protection and Digital Information Bill (or the UK Bill) into the UK legislative process with the intention for this bill to reform the U.K.&#8217;s data protection regime which will likely have the effect of further altering the similarities between the U.K. and EU data protection regime. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we will be required to implement adequate safeguards to enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., in compliance with the GDPR. In some cases, we may rely upon the EC&#8217;s approved standard contractual clauses to legitimize transfers of personal data out of the EEA from controllers or processors established outside the EEA (and not subject to the GDPR). The U.K. is not subject to the EC&#8217;s standard contractual clauses but has published its own transfer mechanism, the International Data Transfer Addendum/Agreement, which enables transfers from the U.K. Changes with respect to any of these matters may lead to additional costs and increase our overall risk exposure. The EU and U.S. have adopted its adequacy decision for the EU U.S. Data Privacy Framework, or the Framework, which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and the U.S. is comparable to that offered in the EU. Moreover, the U.K. Government adopted the Data Protection (Adequacy) Regulations 2023, also referred to as the &#8220;UK-U.S. Data Bridge&#8221;, which, since 12 October 2023 allows companies to transfer personal data from the U.K. to the U.S. on the basis of the Framework. This provides a further avenue to ensuring transfers to the U.S. are carried out in line with GDPR. However, the long-term validity of the Framework remains uncertain and it has already been challenged before European courts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by us to comply with any applicable federal, state or foreign laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, injunctions, penalties or judgments. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to protect the confidentiality of our proprietary information, the value of ficerafusp alfa could be adversely affected. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets and/or confidential know-how, unpatented know-how and/or other proprietary information. We may rely on other proprietary rights, including protection of trade secrets, confidential know-how, unpatented know-how and/or other proprietary information to protect ficerafusp alfa, especially where patent protection is believed to be of limited value. However, trade secrets and/or confidential know-how are difficult to maintain as confidential. To maintain the confidentiality of this type of information, it is our policy to enter into confidentiality agreements with our employees, consultants, advisors, collaborators, contractors (including CROs), and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual(s) or made known to the individual by us during the course of the individual&#8217;s relationship or work with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms, intentionally or unintentionally. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants, contractors or others use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us or a current or future licensor is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. The disclosure of our trade secrets could impair our competitive position and may materially harm our business, financial condition and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements and theft of trade secret claims may vary from jurisdiction to jurisdiction. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. As such, adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. Such persons may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, such persons could limit our use of our trade secrets and/or confidential know-how. Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some know-how to prevent others from obtaining patent rights covering such know-how.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The use of new and evolving technologies, such as artificial intelligence, or AI, in our operations may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm and liability. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may integrate AI into our operations, and this innovation presents risks and challenges that could affect its adoption, and therefore our business. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#8217;s Artificial Intelligence Act, or the AI Act&#8212;the world&#8217;s first comprehensive AI law &#8212; is anticipated to enter into force in 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes significant obligations on providers and deployers of high risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. If we deploy AI systems that are governed by the AI Act, we may be required to adopt higher standards of data quality, transparency, and human oversight, and adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our products and services to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Discovery and Development of ficerafusp alfa or Future Product Candidates </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business is dependent on our ability to advance ficerafusp alfa and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are early in our development efforts as ficerafusp alfa remains in clinical development. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual regulatory approval and commercialization of our current products or future product candidates we develop, which may never occur. Our current product candidate, ficerafusp alfa, and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the U.S., Canada and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The clinical and commercial success of ficerafusp alfa and any future product candidates will depend on several factors, including the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">      </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">timely and successful completion of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our plans to successfully submit new Investigational New Drug, or IND, applications with the FDA for ficerafusp alfa and any future product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to complete preclinical studies for ficerafusp alfa or any future product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successful enrollment in, and completion of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish agreements with third-party manufacturers on a timely and cost-efficient manner;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether we are required by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successfully launching commercial sales of our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">entry into collaborations to further the development of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintaining a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our compliance with any post-approval requirements imposed on our products, such as post-marketing studies, a Risk Evaluation and Mitigation Strategy, or REMS, or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost prohibitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competing effectively with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">enforcing and defending intellectual property rights and claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These factors, many of which are beyond our control, could cause us to fall behind our competitors, experience significant delays or an inability to obtain regulatory approvals or commercialize ficerafusp alfa or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that ficerafusp alfa or any future product candidates we develop will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of ficerafusp alfa or any future product candidate, we may not be able to continue our business operations or achieve profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize ficerafusp alfa and any future product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent in humans and have a favorable risk-benefit profile. Clinical trials are expensive and can take many years to complete, with a highly uncertain outcome. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We cannot be certain the ongoing and planned preclinical studies or clinical trials for ficerafusp alfa or any other future product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">results from preclinical studies or clinical trials may not be predictive of results from later clinical trials of any product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or other regulatory authorities, Institutional Review Boards, or IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements on us, before permitting us to initiate a clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinical trials of any product candidate may fail to show safety, purity or potency, or may produce negative or inconclusive results, which may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of patients required for clinical trials may be larger than we anticipate, or we may have difficulty in recruiting and enrolling patients to participate in clinical trials, including as a result of the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications and clinical trial subjects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any of our product candidates could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical development or receive regulatory approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the supply, quality or timeliness of delivery of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may need to change the manufacturing site and potentially the CMO for our product candidates from those that are able to produce clinical supply for our clinical trials to those with the capacity and ability to perform commercial manufacturing and/or the production of clinical material for our later stage clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We could encounter delays if a clinical trial is suspended or terminated by us, or by the IRBs of the institutions in which such trials are being conducted, ethics committees or the Data and Safety Monitoring Board, or the DSMB, for such trial or by the FDA, Health Canada, the EMA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, Health Canada, the EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. The FDA, Health Canada, the EMA or other regulatory authorities may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Further, the FDA, Health Canada, the EMA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials. For example, we are conducting and may in the future conduct additional &#8220;open-label&#8221; clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical trials often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. For example, in our ongoing Phase 1/1b trial, objective response rate as determined using RECIST 1.1 criteria is assessed by the trial investigators who may be aware of the trial treatment, patient history or other information that could impact their choices in applying the rules and conventions of RECIST 1.1. The published literature demonstrates a consistent decrease in response rate when investigator assessed response rates are verified by independent radiology review. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or other compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing ficerafusp alfa or any future product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any such events would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preclinical development is uncertain. Any preclinical programs we pursue may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The risk of failure for product candidates still in the discovery or preclinical stage is high. In addition, any one or more of our product candidates that have not yet entered the clinic may never advance into clinical development. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of ficerafusp alfa or any future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA, Health Canada, the EMA or other regulatory authorities allowing clinical trials to begin. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">an inability to generate sufficient preclinical or other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> data to support the initiation of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays in reaching a consensus with regulatory agencies on trial design; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or foreign regulatory authorities not permitting the reliance on preclinical or other data from published scientific literature.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are currently conducting, and may in the future conduct, clinical trials for ficerafusp alfa or any future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently conducting, and may in the future conduct, clinical trials for ficerafusp alfa or any future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We are currently conducting clinical trials in the U.S. and Canada, and we expect to continue to conduct trials internationally in the future. The acceptance of data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA, Health Canada, the EMA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice, (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice, or GCP, regulations, and (iii) the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, Health Canada, the EMA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA, Health Canada, the EMA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in ficerafusp alfa or any future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to (i) test safety, (ii) study pharmacokinetics and pharmacodynamics and (iii) understand the side effects of product candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biological products proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, ficerafusp alfa or any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, third parties, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could delay or prevent regulatory approval of, or limit commercial prospects for, the particular product candidate. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to disclose. If regulatory authorities disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Ficerafusp alfa or any future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most biological products, use of ficerafusp alfa or any future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. There have been serious adverse side effects reported in response to product therapeutics and bispecifics in oncology. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EGFR-targeted drugs have been observed to cause side effects, predominantly related to skin toxicity and rash, and TGF-b inhibitors have been shown to have side effects primarily related to bleeding. While we have observed these side effects during our studies, the severity of these has been minimal but additional or more severe treatment-related side effects may emerge at a later time in our trials. In addition to any potential side effects caused by the product or product candidate, the administration process or related procedures also can cause adverse side effects. If unacceptable adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated. Additionally, we may be required to repeat or conduct additional clinical trials or nonclinical studies for our product candidates beyond those that we currently contemplate. There can be no assurance that ficerafusp alfa or any future product candidates will not demonstrate unacceptable toxicities in later testing that may render it unsafe or intolerable. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our trials are conducted or the DSMB could suspend or terminate our clinical trials or the FDA, Health Canada, the EMA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although ficerafusp alfa and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Antibody therapeutics and bispecifics and their method of action of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that ficerafusp alfa is safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If ficerafusp alfa or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we intend to pursue our product candidates in combination with other therapies and may develop future product candidates in combination with other therapies, which exposes us to additional risks relating to undesirable side effects or other properties. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we successfully advance our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of treatment outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory authorities may limit, suspend, or withdraw their approval of the product or may refuse to approve supplemental applications for such product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be required to recall a product or change the way such product is administered to patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our reputation may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues, which would materially harm our business. In addition, if one or more of our product candidates or our antibody therapeutic development approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would also materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">As an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the trial results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for biologics license application, or BLA, submission and FDA approval of ficerafusp alfa or any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or our collaborators encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the nature and size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number and location of participating and available clinical sites or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays in, inability, or failure to add new clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the design of the trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the availability of competing commercially available therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents for participation in our clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product candidates. It is also likely that we may compete with competitors developing product candidates in the same therapeutic areas for clinical trial sites. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delays of difficulties in patient enrollment may result in increased costs or may affect the timing, outcome or completion of clinical trials, which would adversely affect our ability to advance the development of the product candidates we develop. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We plan to develop, or engage third parties to develop, companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third-party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may terminate their relationship with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and our third-party collaborators may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third- party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of our related product candidates. Further, if any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third-party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Dependence on and Work with Third Parties </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct monitor and manage data for our preclinical studies and clinical trials. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the competent authorities of the member states of the EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, Health Canada, the EMA or comparable foreign regulatory authorities, who may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with the product candidate produced under FDA&#8217;s current good manufacturing practice, or cGMP, regulations or similar foreign regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, these principal investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently and in the future may depend on other third-party collaborators for the discovery, development and commercialization of ficerafusp alfa and any of our future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into collaborations with MSD International GmbH, or MSDIG, and MSD International Business GmbH, or MSDIB, and collectively with MSDIG, MSD and Biocon Ltd, or Biocon. In the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop. Our current and potential future collaborations involving our product candidates may pose various risks to us, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other intellectual property proceedings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaboration agreements may restrict our right to independently pursue new product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the mutual termination of the Contract Transfer and License Agreement with Biocon could delay the commercialization of ficerafusp alfa.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For future collaborations, if we enter into such collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above, among others, could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently have established collaborations and may seek to establish future collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The advancement of our product candidates and development programs and the potential commercialization of ficerafusp alfa and any of our future product candidates will require substantial additional cash to fund expenses. We currently collaborate with pharmaceutical and biotechnology companies with respect to development and potential commercialization of ficerafusp alfa, and we may also do so with any future product candidates. These relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA, Health Canada, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently rely on third-party suppliers and other third parties for production of our product candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates. Moreover, we intend to rely on third parties to produce commercial supplies of any approved product candidate and our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities following inspection of their facilities and procedures to manufacture our product candidates, fail to provide us with sufficient quantities of a product candidate or fail to do so at acceptable timing, quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on and expect to continue to rely on third-party CMOs for the supply of cGMP-grade clinical trial materials and commercial quantities of our product candidates and products, if approved. Reliance on third-party providers may expose us to more risk than if we were to manufacture product candidates ourselves. The facilities used by our CMOs to manufacture our product candidates must be approved by the FDA foreign regulatory authorities pursuant to inspections that will be conducted after we submit our Biologics License Application, or BLA, to the FDA, or similar applications to foreign regulatory authorities. We have limited control over the manufacturing process of, and beyond contractual terms, we are completely dependent on our CMOs for compliance with cGMP or similar foreign requirements for the manufacture of our product candidates. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities, or are unable to do so in a timely manner, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities or may result in delay of our ability to obtain marketing authorization, if any, of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, Health Canada, the EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our CMOs and other third parties for the manufacture, filling, storage and distribution of our product candidates means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our CMOs to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials, and will rely on our existing and future collaborators to purchase from third-party suppliers the materials necessary to develop and produce our product candidates for future clinical trials and, upon approval, our products for commercialization. There are a limited number of suppliers for raw materials that we use to manufacture our product candidates and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. Apart from contractual measures, we do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers or manufacturers paid by our collaborators. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of an product candidate to complete the clinical trial or have secured resupply capacity, any significant delay in the supply of an product candidate, or the raw material components thereof, for a planned or an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the manufacturing of our product candidates is expensive and time-consuming, and generally requires more complex processes than those associated with small-molecule drugs. If we are successful in obtaining regulatory approval for any of our product candidates, we might have limited quantities of such product candidates available to us in connection with a potential commercial launch, and these supplies may be further limited by our ongoing clinical development activities. If our manufacturers, collaborators or we are unable to purchase or produce sufficient quantities of raw materials or of our product candidates after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates could be delayed or there could be a shortage in supply, which in either case, would impair our ability to generate revenues from the sale of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturers and other subcontractors to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the course of completing their contractual obligations to us, we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The operations of our suppliers, many of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently rely on and engage third-party manufacturers to provide all of the drug substance and the final drug product formulation of all of our product candidates that are being used in our clinical trials and preclinical studies. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we primarily rely on one manufacturer, WuXi Biologics (Hong Kong) Limited, or WuXi Bio, for the production of product necessary to complete our ongoing clinical trials. If a replacement manufacturer became necessary in the future, we may incur added costs and delays in identifying and qualifying another manufacturer. We currently do not have any long-term supply agreements in place, though we intend to enter into such agreements as well as evaluate additional product manufacturing sources in the future. As a result of our dependence on ex-U.S. suppliers, we are subject to risks associated with doing business abroad, including:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">geopolitical tensions, political unrest, terrorism, labor disputes and economic instability resulting in the disruption of trade from foreign countries in which our products are manufactured, particularly China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the imposition of new laws and regulations, including those relating to labor conditions, safety standards, information and data transfer, imports, duties, taxes, and other charges on imports, as well as trade restrictions and restrictions on currency exchange or the transfer of funds, particularly new or increased tariffs imposed on imports from countries where our suppliers operate, including China, pursuant to our master supply agreement with WuXi Bio; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">greater challenges and increased costs with enforcing and periodically auditing or reviewing our suppliers&#8217; and manufacturers&#8217; compliance with cGMPs or status acceptable to the FDA, Health Canada, the EMA or comparable foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reduced protection for intellectual property rights, including trade secret protection, in some countries, particularly China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disruptions in operations due to global, regional, or local epidemics, pandemics, public health crises or other emergencies or natural disasters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disruptions or delays in shipments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in local economic conditions in countries where our manufacturers or suppliers are located.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If enacted, legislation known as the BIOSECURE Act, which was introduced by Congress, would prohibit U.S. federal agencies from entering into or renewing a contract with any company that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; in the performance of that government contract. It would also prohibit recipients of loan or grant funding from U.S. federal agencies from using loan or grant funds to procure, obtain or use any biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern.&#8221; This legislation would have the effect of restricting the ability of biopharmaceutical companies that enter into contracts with or receive funding from U.S. federal agencies from purchasing services or equipment from certain Chinese biotechnology companies, including those that are specifically named in the proposed BIOSECURE Act. The most recent version of the BIOSECURE Act introduced in the House of Representatives names WuXi Bio as a &#8220;biotechnology company of concern.&#8221; The most recent version of the BIOSECURE Act introduced in the House of Representatives also includes a grace period that would restrict the applicability of the BIOSECURE Act&#8217;s prohibitions to existing contractual arrangements with named &#8220;biotechnology companies of concern&#8221; until 2032. If approved in this form, the BIOSECURE Act would likely not prevent us from sourcing drug product from WuXi Bio for use in clinical development. However, depending on the final language of the BIOSECURE Act, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing U.S. federal government business or government reimbursement for our products in the future if we enter long-term commercial arrangements with WuXi Bio or other suppliers or partners identified as &#8220;biotechnology companies of concern&#8221; that extend beyond this grace period. Additionally, the legislation could adversely impact WuXi Bio&#8217;s operations or financial position, which, in turn, could impact its and ability to supply us with product in the future. We may also face additional manufacturing and supply-chain risks due to the evolving regulatory and legal requirements in China, or due to the deterioration of the geo-political relationship between China and the U.S., including but not limited to potential sanctions imposed by the U.S. government on WuXi Bio, or other companies in China on whom we might rely, or any of the other countries in which our products are manufactured or marketed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These and other factors beyond our control could interrupt our suppliers&#8217; production, influence the ability of our suppliers to export our clinical supplies cost-effectively or at all and inhibit our supplier&#8217; ability to procure certain materials, any of which could delay our clinical trials or otherwise harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may need to maintain licenses for drug substances from third parties to develop and commercialize some of our product candidates, which could increase our development costs and delay our ability to commercialize those product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should we decide to use any cell line and raw materials in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those drug substances from those third parties. If we are unable to gain or continue to access rights to these drug substances prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate drug substances, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired drug substances on commercially reasonable terms or develop suitable alternate drug substances, we may not be able to commercialize product candidates from these programs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Government Regulation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval (or maintain approval) may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, the Oncology Center of Excellence within the FDA has advanced Project Optimus, which is an initiative to reform the dose optimization and dose selection paradigm in oncology drug development to emphasize selection of an optimal dose, which is a dose or doses that maximizes not only the efficacy of a drug but the safety and tolerability as well. This shift from the prior approach, which generally determined the maximum tolerated dose, has required and will require us to continue to spend additional time and resources to further explore a product candidate&#8217;s dose-response relationship to facilitate optimum dose selection in a target population. Other recent Oncology Center of Excellence initiatives have included Project FrontRunner, a new initiative with a goal of developing a framework for identifying candidate drugs for initial clinical development in the earlier advanced setting rather than for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options; Project Equity, which is an initiative to ensure that the data submitted to the FDA for approval of oncology medical products adequately reflects the demographic representation of patients for whom the medical products are intended; and Project Confirm, which is an initiative to promote the transparency of outcomes related to accelerated approvals for oncology indications and provide a framework to foster discussion, research and innovation in approval and post-marketing processes, with the goal to enhance the balance. We are considering these and other policy changes as they relate to our programs. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not obtained regulatory approval for any product candidate. Neither we nor any future collaborator is permitted to market any biological product in the U.S. until we or the future collaborator receives regulatory approval of a BLA, from the FDA. It is possible that ficerafusp alfa or any future product candidates will not obtain regulatory approval from the FDA, Health Canada, the EMA or comparable foreign regulatory authorities. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ficerafusp alfa and any future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities that a product candidate has an acceptable risk-benefit profile in the proposed indication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities that the facility in which a product candidate is manufactured meets standards designed to assure that the product candidate continues to be safe, pure, and potent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA, Health Canada, the EMA or regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.           </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, Health Canada, the EMA or any other regulatory authority. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we request, may grant approval contingent on the performance of costly clinical trials or other post-marketing requirements, or may approve a product candidate with a label that does not include the labeling claims we believe are necessary or desirable for the successful commercialization of such product candidates. Even if we obtain regulatory approval for our product candidates, we will be required to submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process and the FDA or comparable foreign regulatory authority may refuse to approve such applications or supplements. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may change their policies, promulgate additional regulations, revise existing regulations or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for biological products or modifications to approved biological products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trials must be conducted in accordance with GCP requirements, which are regulations and guidelines enforced by the FDA, Health Canada, the EMA and comparable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical committees at the trial sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or trial protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the clinical trial operations or trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unforeseen adverse side effects or the emergence of undue risks to trial subjects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the trial design necessary to demonstrate efficacy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ficerafusp alfa may not appear to offer benefits over current therapies; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the quality or stability of ficerafusp alfa may fall below acceptable standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We intend to develop our product candidates in part in combination with other therapies and may develop our future product candidates in combination with other therapies, which exposes us to additional regulatory risks. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to develop our product candidates in part in combination with other therapies, including ficerafusp alfa in combination with pembrolizumab as a treatment for HNSCC and SCAC, and may develop ficerafusp alfa and any future product candidates in combination with one or more currently approved cancer therapies. These combinations have not been previously tested in the clinic and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any of these approved therapeutics. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for testing or commercial use with any of our approved products. The other therapies we may use in combination with our product candidates may also be supplanted in the market by newer, safer or more efficacious products or combinations of products. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA, Health Canada, the EMA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of cancer diseases, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also evaluate ficerafusp alfa or any future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the FDA, Health Canada, the EMA or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the biological products we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any such product candidate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if we receive marketing approval of ficerafusp alfa, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any marketing approvals that we may receive for ficerafusp alfa or any future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, Health Canada, the EMA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, tracking and tracing event and deviation reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP, for any clinical trials that we may conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers&#8217; manufacturing processes or facilities, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">suspension of, or imposition of restrictions on, the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Warning letters or untitled letters, or holds on clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved biologics licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">permanent injunctions and consent decrees including the imposition of civil or criminal penalties.      </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the nature of biological products manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials and other components required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product or product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development and commercialization timelines and our business, financial condition, results of operations and prospects and could adversely affect our ability to meet our supply obligations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, an approved product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm&#8217;s product communication is consistent with the FDA-required labeling for that product, and those factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">While we intend to seek designations for our potential product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our potential product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities and priority review. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, there can be no assurance that we will successfully obtain such designations for any potential product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our potential product candidates, there can be no assurance that we will realize their intended benefits. For example, we may seek fast-track designation for some of our potential product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy nonclinical or clinical data demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for fast-track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a fast-track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast-track designation if it believes that the designation is no longer supported by data from our clinical development program. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, we may seek a breakthrough therapy designation for some of our potential product candidates. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our potential product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our potential product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we may also seek approval of potential product candidates under the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life threatening disease or condition and generally provides a meaningful advantage over available therapies upon a determination that the potential future product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the Agency, that all advertising and promotional materials intended for dissemination or publication be submitted to the Agency for review. There can be no assurance that FDA would allow any of the potential future product candidates we may develop to proceed on an accelerated approval pathway, and even if FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review, or approval will be granted on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for the product candidates that we may develop. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to obtain or maintain orphan drug designations for our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. For example, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than 200,000 individuals in the U.S. but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. We may not be able to obtain orphan drug designation for any indications for our product candidates, and we may not be able to maintain such designations if granted. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same biologic for the same indications for seven years. Even if we are able to obtain orphan drug designation or orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if, among other things, the FDA concludes that the later drug is clinically superior, if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Even if we receive orphan drug designation or orphan drug exclusivity for any of our product candidates, there is no guarantee that we will enjoy the benefits of such designations or exclusivity periods. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decision of the U.S. Court of Appeals for the 11th Circuit in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Catalyst Pharms., Inc. v. Becerra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, 14 F.4th 1299 (11th Cir. 2021) has created uncertainty regarding the scope of orphan drug exclusivity. Although the FDA subsequently announced that it intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Catalyst</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> order and continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, it is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">While we may seek accelerated approval for some of our product candidates, we may not be able to obtain it as the sufficiency of our clinical trial results for accelerated approval are subject to the FDA&#8217;s discretion. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We plan to seek approval for ficerafusp alfa under the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. For more information, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business&#8212;Government Regulation&#8212;Review and Approval for Licensing Biologics in the U.S.&#8212;Expedited Review Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. There can be no assurance that the FDA would allow any of the product candidates we may develop to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover, even if we received accelerated approval, any </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Commercialization </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The commercial success of ficerafusp alfa or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ficerafusp alfa and any future product candidates may not be commercially successful. Even if ficerafusp alfa or any future product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, or the medical community. The commercial success of ficerafusp alfa or any future product candidates will depend significantly on the broad adoption and use of the resulting product by these individuals and organizations for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">demonstration of clinical efficacy and safety, including as compared to anymore established products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the indications for which ficerafusp alfa or any future product candidates are approved, if any;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential product liability claims;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing of market introduction of our products as well as availability, safety and efficacy of competitive drugs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effectiveness of our or any current or future collaborators&#8217; sales and marketing strategies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unfavorable publicity relating to the product.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If ficerafusp alfa or any future product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The market opportunities for ficerafusp alfa or any future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the U.S. and any other jurisdiction for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, even if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. The number of patients who receive second- and third-line treatment is significantly smaller than the number of patients who receive first-line treatment, and the prognosis of patients who receive second- or third-line treatment is often poorer than that of patients who receive first-line treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may initially seek approval for any other product candidates we develop as second- or third-line therapies. If we do so, for those products that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The number of patients who have the types of cancer or autoimmune diseases we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for ficerafusp alfa or any future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If approved, our product candidates that are regulated as biological products, or biologics, may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, established an abbreviated pathway for the approval of biosimilar and interchangeable biologics with an FDA-licensed reference biologic product. Under the BPCIA, a reference biological product is granted 12 years of non-patent data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not rely on the reference product or sponsor&#8217;s data and is not submitted as a biosimilar application. Certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12-year exclusivity period. The law is complex and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that any of the product candidates we develop that is approved in the U.S. as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidate to be a reference product for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing pressure. It is also possible that payors will give reimbursement preference to biosimilars over reference biological products, even absent a determination of interchangeability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Laws and regulations outside the United States differ, including the length and extent of patent and exclusivity protection and pathways for competition to enter the market. Other countries may have significantly shorter or longer periods of exclusivity. In addition, other countries may have different standards in determining similarity to a reference product. Any market entry of competing products to our product candidates in these other regions could adversely affect our business in those regions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that we do not receive any anticipated periods of regulatory exclusivity for our product candidates it could adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in other jurisdictions. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may enter into agreements with third parties to sell, distribute and/or market ficerafusp alfa if we obtain regulatory approval, which may adversely affect our ability to generate revenues. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the development stage of ficerafusp alfa, we have no experience in sales, marketing and distribution of biotech products. However, if ficerafusp alfa obtains marketing approval, we might intend to develop sales and marketing capacity, either alone or with partners, or rely upon the sales and marketing capabilities of our partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Outsourcing sales, distribution and marketing may subject us to a variety of risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to exercise direct control over sales, distribution and marketing activities and personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential failure or inability of contracted sales personnel to successfully market our products to physicians; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential disputes with third parties concerning distribution, sales and marketing expenses, calculation of royalties, and sales and marketing strategies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to partner with a third party that has adequate sales, marketing, and distribution capabilities, we may have difficulty commercializing our ficerafusp alfa which would adversely affect our business, financial condition, and ability to generate product revenues. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Off-label use or misuse of ficerafusp alfa may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If ficerafusp alfa is approved by the FDA, we may only promote or market ficerafusp alfa in a manner consistent with its FDA-approved labeling. We will train our marketing and sales force against promoting ficerafusp alfa for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using ficerafusp alfa off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate. Furthermore, the use of ficerafusp alfa for indications other than those approved by the FDA may not effectively treat such conditions. Any such off-label use of ficerafusp alfa could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use ficerafusp alfa for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to export and import controls, economic sanctions and anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery laws, including the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and waste. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of ficerafusp alfa or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Intellectual Property </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to compete may decline if we do not adequately protect our proprietary rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success depends, in part, on obtaining and maintaining patents and other forms of intellectual property rights for ficerafusp alfa, including ficerafusp alfa and any future product candidates, methods used to produce, purify, and manufacture those product candidates, and methods of utilizing the product candidates, including methods for treating patients, among other aspects of ficerafusp alfa or on licensing-in such rights. Failure to protect or to obtain, maintain, or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our strategy depends in part on our ability to identify and seek patent protection for our discoveries. The patent prosecution process is time-consuming and expensive, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our current or future licensors, licensees, or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change in the future. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, the issuance, scope, validity, enforceability, and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; current and future patent rights are highly uncertain. We cannot predict whether additional patents protecting ficerafusp alfa will issue in the U.S. or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications may not result in patents being issued which protect ficerafusp alfa or other technology, in whole or in part, or which effectively prevent others from commercializing competitive products and technology. The patent examination process may require us or our current or future licensors, licensees or collaborators to narrow the scope of the claims of our or our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, or have issued and even if such patents cover a product candidate, and/or other technologies, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, litigation, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability, scope, inventorship, or ownership of such patents, which may result in the patent claims being narrowed, invalidated, held unenforceable, or unavailable to us. Our and our current and future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issue from such application(s), and then only to the extent the issued claims cover the technology in the relevant jurisdiction. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries. As such, we cannot be certain that we or our licensors were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the U.S. and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, changes in, or different interpretations of, patent laws in the U.S. and other countries may permit others to use our discoveries or to develop and commercialize ficerafusp alfa without providing any notice or compensation to us or may limit the scope of patent protection that we or our licensors are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filing, prosecuting and defending patents on ficerafusp alfa in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. could be less extensive than those in the U.S., assuming that rights are obtained in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. As such, we will not file for patent protection in all national and regional jurisdictions in the world where such protection may be available. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, competitors may use our and our existing or future licensors&#8217;, licensees&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our existing or future licensors, licensees or collaborators have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with ficerafusp alfa or other technologies, and our and our existing or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, and the requirements for patentability differ, in varying degrees, from country to country, and the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Such issues may make it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">own or license. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, proceedings to enforce our patent rights and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful, while the damages and other remedies we may be ordered to pay such third parties may be significant. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Issued patents covering ficerafusp alfa and related technology could be found invalid or unenforceable if challenged in court or before a patent office. We may become involved in lawsuits involving our intellectual property, including patents, to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued patents may be challenged, narrowed, invalidated, circumvented, or otherwise encumbered by a third party. We may from time to time need to resort or become a party to litigation (or other adversarial proceeding) to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties in the U.S. and in other jurisdictions. For example, in October 2024, a complaint was filed in federal court, which among other things, alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. As enforcement of intellectual property rights is difficult, unpredictable and expensive, we may fail in enforcing our rights&#8212;in which case our competitors may be permitted to use our product without being enjoined, required to pay us any license fees, or compensate us for lost profits or reasonable royalty. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize technology covered by our patents we seek to enforce, such as those covering ficerafusp alfa and related methods, among other technologies, and then compete directly with us, without payment to us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we were to initiate legal proceedings against a third party to enforce a patent covering ficerafusp alfa or other technology, the defendant could counterclaim that our patent is invalid and/or unenforceable, which is commonplace in patent litigation in the U.S. and other foreign jurisdictions. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements for patentability, for example, lack of utility, novelty, obviousness, non-enablement or lack of written description or as constituting unpatentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone substantively involved in prosecution of the patent withheld but-for material information from the USPTO or engaged in affirmatively egregious misconduct, during prosecution, with a specific intent to deceive the USPTO. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on ficerafusp alfa or other technology. Such a loss of patent protection could have a material adverse impact on our business. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Patents and other intellectual property rights also will not protect ficerafusp alfa if competitors design around our protected technology without infringing our patents or other intellectual property rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if such litigation (or other adversarial proceedings or disputes) is resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings and the legal costs associated with them, could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unsuccessful in defending against any claims by competitors or others that we are infringing upon their intellectual property rights, our business could be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success will depend, in part, on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or other proprietary rights that could limit our ability to make, use, sell, offer for sale or import a product candidate, a future approved product, or impair our competitive position. We are aware of third party issued patents and/or pending patent applications, including in the U.S., that could be alleged as covering ficerafusp alfa, irrespective of the merits of any such allegation, for example in August 2024, we received a letter alleging ficerafusp alfa infringes certain third party patents. For example, in October 2024, a complaint was filed in federal court, which among other things, alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover a product candidate and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that if such patents or patent applications were asserted against us, we would have counterclaims and defenses against such claims, including non-infringement, the affirmative defense of safe harbor designed to protect activity undertaken to obtain federal regulatory approval of a drug, including under 35 U.S.C. &#167; 271(e) and similar foreign exceptions to infringement, and defenses concerning patent invalidity and/or unenforceability. However, if such counterclaims and defenses were not successful and such patents were successfully asserted against us such that they are found to be valid and enforceable, and infringed, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize ficerafusp alfa. We could also be required to pay substantial damages. We cannot assure you that we will ultimately prevail if any of this third-party intellectual property is asserted against us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the biotechnology industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties&#8217; patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These lawsuits (or other proceedings) would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if the breadth or strength of protection provided by our or our present or future licensors&#8217;, collaborators&#8217; or partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize ficerafusp alfa or any future product candidates. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third party intellectual property right holders, including our competitors, may actively bring infringement claims against us. We may not be able to successfully settle, license on commercially acceptable terms or otherwise resolve such potential infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing any approved products. If we fail in any such dispute, in addition to being forced to potentially pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing our product candidates that are held to be infringing or be forced to redesign our product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The biotechnology industry has produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing ficerafusp alfa to market and be precluded from manufacturing or selling ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is also possible that in our evaluation of third-party intellectual property, we failed to identify relevant patents or applications. We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of ficerafusp alfa in any jurisdiction. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market ficerafusp alfa. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to claim broad coverage in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover ficerafusp alfa or related technology. We cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently party to intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to our clinical product candidate and related methods. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be unsuccessful in licensing or acquiring third-party intellectual property that may be required to develop and commercialize ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have rights, through patents that we have in-licensed or own, to the intellectual property to develop ficerafusp alfa. Because our programs may involve additional product candidates, that may require the use of intellectual property or proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. We may be unable to acquire or in-license any third-party intellectual property or proprietary rights or to do so on commercially reasonable terms. For example, we sometimes collaborate with public or private academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the strategic collaboration. Regardless of such option, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us, and the institution may license such intellectual property rights to third parties, potentially blocking our ability to pursue our development and commercialization plans. The same situation may occur with a present or future development partner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The licensing and acquisition of third-party intellectual property and proprietary rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property and proprietary rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size and greater capital resources and development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property and proprietary rights to us. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to successfully acquire or in-license rights to required third-party intellectual property and proprietary rights or maintain our intellectual property and proprietary rights, we may have to cease development of the relevant the relevant program, product or product candidate, which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution and post grant or issuance. We employ reputable law firms and other professionals to help us comply. Additionally, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or patent applications. We rely on our outside counsel or our agents to pay these fees when due. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from third parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. If we or our existing or future licensors fail to maintain the patents and patent applications covering ficerafusp alfa, our competitors might be able to enter the market, which would have an adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering ficerafusp alfa, our business may be materially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patents typically have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date, not including potential patent term extensions or adjustments that may be available in the U.S., and under comparable laws applicable outside the U.S., where certain conditions are met. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering ficerafusp alfa are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including biosimilar medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, causing our revenue from applicable products to be reduced, possibly materially, and potentially harming our ability to recover our investment in such product or obtain a reasonable return on that investment. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending upon the timing, duration, and conditions of FDA marketing approval of ficerafusp alfa, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at other biotechnology or pharmaceutical companies, universities, and/or research institutions and the like, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to ficerafusp alfa, are rightfully owned by their former or concurrent employer. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize ficerafusp alfa. Such a license may not be available on commercially reasonable terms or at all. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Healthcare, Insurance and Legal Matters </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face an inherent risk of product liability exposure related to the testing of ficerafusp alfa in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">decreased demand for any product candidate we may develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">withdrawal of trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">significant time and costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">substantial monetary awards to trial subjects or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the inability to commercialize any product candidates that we may develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for ficerafusp alfa, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The successful commercialization of ficerafusp alfa or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs including but not limited to Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as ficerafusp alfa or any future product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For more information, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business&#8212;Government Regulation&#8212;Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221; </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would be subject to ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to be in violation of any applicable obligations thereunder. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for ficerafusp alfa or any future product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that changes in these rules and regulations are likely. For products administered under the supervision of a physician (including products administered in the clinical setting), obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the administration of the product, or the treatment or procedure in which the product is used, may not be available, which may impact physician utilization. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of ficerafusp alfa or any future product candidates, if approved in these jurisdictions. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, increasing efforts by governmental and other third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare and Medicaid beneficiaries, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidate may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, and plan to market, sell and distribute </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any products for which we obtain regulatory approval. For more information, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business&#8212;Government Regulation&#8212; Other U.S. Healthcare Laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be noncompliant with applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. We plan to implement a corporate compliance program designed to identify, prevent and mitigate risk through the implementation of policies and procedures, training, and auditing and monitoring. We expect to devote resources to implement, maintain, administer and expand the compliance program as necessary. We cannot be certain, however, that our compliance program will ensure compliance with the various complex laws and regulations to which we are subject now or in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to obtain coverage for and commercialize ficerafusp alfa, if approved, or any future product candidates and may adversely affect the prices we may set. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and biologics and affect our ability to profitably sell ficerafusp alfa or any future product candidates for which we obtain regulatory approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For more information, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business&#8212;Government Regulation&#8212;Current and Future U.S. Healthcare Reform Legislation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for ficerafusp alfa and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that these existing laws and other federal and state healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our potential products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize ficerafusp alfa or any future product candidates, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to comply with laws and regulations related to the protection of research subjects could result in fines, penalties, and litigation, and have a material adverse effect upon our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may be subject to regulation under international, federal, state, and local laws and regulations relating to the protection of research subjects. Federally funded human-subject research in the U.S., including the collection of identifiable human biospecimens, is governed by 45 CFR Part 46, also known as the Health and Human Services Policy for Protection of Human Research Subjects or the &#8220;Common Rule.&#8221; Use of biospecimens in certain other research is subject to FDA regulations for the Protection of Human Subjects and Institutional Review Boards at 21 CFR Parts 50 and 56. Research funded by the National Institutes of Health, or NIH, may be subject to grant or contract requirements, as well as NIH Certificates of Confidentiality. When collecting specimens for research in the U.S., our company and its collection sites are responsible for ensuring that specimens are collected in accordance with these regulations. In addition, other countries have their own regulations around the ethical collection of human specimens for research. While we believe that we are in compliance with these laws, we may not be aware of all such laws or may fail to properly audit and identify gaps in compliance. Similarly, we may find errors in our product candidates and processes and may fail to properly match the compliance requirements of our researchers to the compliance requirements of our suppliers. Failure of our company or our suppliers to comply with international, federal, state, and local laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties, and/or other enforcement actions which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Manufacturing of Our Product Candidates </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. In addition, we may need a different CMO for manufacturing ficerafusp alfa or any future product candidates for commercial supply needs. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause ficerafusp alfa or any future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of ficerafusp alfa and jeopardize our ability to commence sales and generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of manufacturing product therapeutics and bispecifics, including ficerafusp alfa, is complex, time-consuming, highly regulated and subject to several risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, natural disasters, power failures and numerous other factors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.          </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task and involves additional risks, including cost overruns, process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of sufficient quantity of raw materials. Even if we obtain regulatory approval for any of our product candidates, manufacturers may not be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause ficerafusp alfa to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Employee Matters and Managing Growth </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to develop product candidates, leverage our potential and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Additionally, we will need to grow the size of our organization, and we may experience difficulties in managing this growth. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. The loss of services of any of these individuals could delay or prevent the successful development of ficerafusp alfa, completion of our planned clinical trials or the commercialization of ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success also depends upon the continued contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of dual-action biologics and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our scientists, would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As our development plans and strategies develop, and as we continue operating as a public company, we expect to need additional managerial, operational, marketing, sales, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for ficerafusp alfa and any other future product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future financial performance and our ability to advance development of and, if approved, commercialize ficerafusp alfa and any future product candidates we develop, will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ficerafusp alfa or any future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize ficerafusp alfa or any future product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Ownership of Our Common Stock </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The price of our stock may be volatile, and you could lose all or part of your investment. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the commencement, enrollment, completion or results of our current or future preclinical and clinical trials for ficerafusp alfa;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any delay in identifying and advancing a clinical candidate for our other programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any delay in our regulatory filings for ficerafusp alfa and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval or potential accelerated approval of ficerafusp alfa or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in laws or regulations applicable to ficerafusp alfa, including but not limited to clinical trial requirements for approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse developments concerning our manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to establish collaborations, if needed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our failure to commercialize ficerafusp alfa, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unanticipated serious safety concerns related to ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our cash position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">publication of research reports about us or our industry, or ficerafusp alfa in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in the structure of the healthcare payment systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our quarterly and annual operating results may fluctuate significantly, due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to ficerafusp alfa or any future product candidates, which may change from time to time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and status of enrollment for clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of manufacturing ficerafusp alfa, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and success or failure of preclinical studies and clinical trials for ficerafusp alfa or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and success or failure of preclinical studies and clinical trials for ficerafusp alfa or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing of receipt of approvals for ficerafusp alfa from regulatory authorities in the U.S. and internationally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">coverage and reimbursement policies with respect to ficerafusp alfa, if approved, and potential future drugs that compete with our products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the level of demand for ficerafusp alfa, if approved, may vary significantly over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our executive officers, directors, principal stockholders and their respective affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the beneficial ownership of our common stock as of September 30, 2024, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own a significant percentage of our common stock. These stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. In addition, certain of our principal stockholders, including RA Capital and TPG LSA, have designated certain members of our board of directors. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Future sales of our common stock in the public market could cause our common stock price to fall. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our fifth amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">require the approval of not less than two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our third amended and restated certificate of incorporation or amended and restated bylaws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#8217;s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other General Risks </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of the 2024 presidential election in the United States, military conflict, including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions imposed by the U.S. and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our drug candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. For example, there has been proposed U.S. legislation that may restrict the ability of U.S. biopharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Natural disasters or public health crises could severely disrupt our operations, and have a material adverse impact on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, public health crisis or other event occurred that prevented us from conducting our clinical trials, releasing clinical trial results or delaying our ability to obtain regulatory approval for ficerafusp alfa, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents or breaches, which could adversely affect our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Despite the implementation of security measures, our information technology systems and data and those of our current or future CROs or other contractors and consultants are vulnerable to compromise or damage from computer hacking, computer viruses, social engineering (e.g., phishing attacks) and malware (e.g., ransomware malicious software), fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in frequency and sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#8220;hacktivists,&#8221; nation states, and others. As a result of a continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. Further, as a company with an increasingly global presence, our systems are subject to frequent attacks, which are becoming more commonplace in the industry, including attempted hacking, phishing attempts, such as cyber-related threats involving spoofed or manipulated electronic communications, which increasingly represent considerable risk. Due to the nature of some of the attacks described herein, there is a risk that an attack may remain undetected for a period of time. Even if identified, we may be unable to adequately investigate or remediate cybersecurity incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. While we continue to make investments to improve the protection of data and information technology, including in the hiring of IT personnel, periodic cyber security awareness trainings, and improvements to IT infrastructure and controls, and conduct regular testing of our systems, there can be no assurance that our efforts will prevent service interruptions or cybersecurity incidents or breaches. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and certain of our service providers are from time to time subject to cyberattack attempts or incidents and cybersecurity incidents. Any cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. Although to our knowledge we have not experienced any significant cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We could be subject to cybersecurity incident or breach notification requirements, regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties, result in substantial costs and distract management. Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price and shareholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a cybersecurity breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for research and development of ficerafusp alfa and other third parties for the manufacture of ficerafusp alfa and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm our business. Any security compromise affecting us, our collaborators or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. To the extent that any disruption or cybersecurity incident or breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of ficerafusp alfa could be delayed, result in substantial costs and distract management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are eligible to be treated as an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in this Quarterly Report on Form 10-Q and our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements in this Quarterly Report on Form 10-Q. We could be an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in total annual gross revenue. (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by non-affiliates exceeds $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of our initial public offering. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section 404;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; disclosure in this Quarterly Report on Form 10-Q;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In this Quarterly Report on Form 10-Q, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even after we no longer qualify as an emerging growth company, we could still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this Quarterly Report on Form 10-Q and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a public company, we will incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to the fifth anniversary of our initial public offering. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have started the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting beginning with the Form 10-Q for the nine months ending September 30, 2024. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following our initial public offering. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, we had approximately $80.4 million of federal net operating losses, or NOLs. Federal NOLs generated in taxable years since inception, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of our taxable income. As of December 31, 2023, we had approximately $75.6 million of state NOLs. Of the state NOLs, some are of indefinite life, but most are of definite life with various expiration dates, beginning in 2039. As of December 31, 2023, we had approximately $1.3 million of federal research and development tax credit carryforwards. Federal tax credit carryforwards expire at various dates, beginning in 2040. As of December 31, 2023, we had approximately $0.3 million of state research and development tax credit carryforwards. The state tax credits, which have various carryforward rules, begin to expire in 2035. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by &#8220;5 percent shareholders&#8221; over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its pre-ownership change NOLs equal to the value of the corporation immediately before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). We may have experienced ownership changes in the past and may experience ownership changes as a result of our acquisitions of assets and/or subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by federal or state taxing authorities or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our ability to use our pre-change NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), including with respect to net operating losses and research and development tax credits, could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may become involved in securities class action litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.                                                  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i034d45b5fcc840799db4927dd41f8356_118"></div><div style="margin-top:10pt;padding-right:2.3pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period between July 1, 2024 and September 30, 2024, we issued to certain of our employees and officers options to purchase an aggregate of 3,240,096 shares of our common stock under our 2019 Stock Option and Grant Plan (the "2019 Plan") at a weighted-average exercise price of $9.24 per share. During this period, 43,244 shares of common stock were issued upon the exercise of options pursuant to the 2019 Plan. We deemed these issuances to be exempt from registration under the Securities Act either in reliance on Rule 701 of the Securities Act as sales and offers under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701, or in reliance on Section 4(a)(2), as transaction by an issuer not involving a public offering. On September 13, 2024, we filed a registration statement on Form S-8 under the Securities Act to register all of the shares of our common stock subject to outstanding options and all shares of our common stock otherwise issuable pursuant to our equity compensation plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, the SEC declared effective our registration statement on Form S-1 (File No. 333-281722), as amended, filed in connection with our IPO, or the Registration Statement. Pursuant to the Registration Statement, we registered the offer and sale of 20,125,000 shares of our common stock with a proposed maximum aggregate offering price of approximately $362,000,000. Morgan Stanley &amp; Co. LLC, TD Securities (USA) LLC, Cantor Fitzgerald &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated acted as representatives of the underwriters for the offering. On September 16, 2024, we issued and sold 20,125,000 shares of our common stock at a price to the public of $18.00 per share, including the exercise in full by the underwriters of their option to purchase 2,626,000 shares of Common Stock. Upon completion of the IPO on September 16, 2024, we received net proceeds of approximately $336.9 million, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us of $4.5 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are holding a significant portion of the balance of the net proceeds in money market funds. There has been no material change in the planned proceeds from our IPO, as described in our final prospectus filed with the SEC on September 13, 2024 pursuant to Rule 424(b) under the Securities Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offering terminated after the sale of all securities registered pursuant to the Registration Statement. There has been no material change in the expected use of the net proceeds from our IPO as described in the final prospectus dated September 12, 2024 and filed with the SEC on September 13, 2024, pursuant to Rule 424(b)(4) (File No. 333-281722) of the Securities Act.</span></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Repurchases of Equity Securities</span></div><div style="padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_121"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_124"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_127"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director and Officer Trading Plans and Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or &#8220;officers,&#8221; as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, <ix:nonNumeric contextRef="c-23" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-670"><ix:nonNumeric contextRef="c-23" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-671">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-23" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-672"><ix:nonNumeric contextRef="c-23" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-673">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.</span></div><div id="i034d45b5fcc840799db4927dd41f8356_130"></div><div style="margin-top:10pt;padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Item 6. Exhibits.</span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex31.htm">Fifth Amended and Restated Certificate of Certificate of Incorporation of the Registrant ((incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K (File No. 001-42271) filed on September 16, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex32.htm">Third Amended and Restated Bylaws of the Registrant ((incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Form 8-K (File No. 001-42271) filed on September 16, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex41.htm">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex102.htm">10.1#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex102.htm">2024 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex103.htm">10.2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex103.htm">#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex103.htm">2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex104.htm">10.3</a>#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex104.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524205393/d821336dex105.htm">10.4#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524205393/d821336dex105.htm">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524205393/d821336dex106.htm">10.5#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524205393/d821336dex106.htm">Form of Executive Employment Agreement (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex107.htm">10.6#</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000119312524214674/d821336dex107.htm">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-281722) filed on September 11, 2024).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="leaseagreement.htm">10.7*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">Office </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">Lease Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm"> by and between Columbia</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm"> Prop</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">erty</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm"> Trust</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm"> and the Registra</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">nt, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm"> October 1, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="leaseagreement.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit311.htm">31.1*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit312.htm">31.2*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit321.htm">32.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321.htm">Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">92</span></div></div></div><div id="i034d45b5fcc840799db4927dd41f8356_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:3.65pt;padding-right:3.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Bicara Therapeutics Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date: November 12, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Claire Mazumdar</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Claire Mazumdar</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date: November 12, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Ivan Hyep</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ivan Hyep</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">93</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>leaseagreement.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ief2666b6fc32450ca7039fc21ca1aa9c_1"></div><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FIRST AMENDMENT TO OFFICE LEASE AGREEMENT</font></div><div style="margin-top:4.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS&#160;&#160;&#160;&#160;FIRST&#160;&#160;&#160;&#160;AMENDMENT&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;OFFICE&#160;&#160;&#160;&#160;LEASE&#160;&#160;&#160;&#160;AGREEMENT&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(this</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:28.411%"><div style="margin-top:1.85pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) is made as of</font></div><div style="margin-top:0.15pt;padding-left:6pt"><font><br></font></div></div><div style="display:inline-block;max-width:7.382%;min-width:6.882%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.411%"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 24, 2024</font></div><div style="margin-top:1.85pt;padding-left:6pt"><font><br></font></div></div><div style="display:inline-block;max-width:7.382%;min-width:6.882%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.414%"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and</font></div></div></div><div style="padding-left:153.2pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"></div><div style="padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLUMBIA REIT &#8211; 116 HUNTINGTON, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited liability company (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;).</font></div><div style="margin-top:13.2pt;padding-left:0.07pt;padding-right:0.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R-1. Landlord and Tenant entered into that certain Office Lease Agreement dated as of August 16, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to which Landlord is leasing to Tenant and Tenant is leasing from Landlord certain office space (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) deemed to contain 4,617 square feet of rentable area located on a portion of the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor of the Building. The Building is located at 116 Huntington Avenue, Boston, Massachusetts 02116.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R-2.  Landlord and Tenant desire to amend the Lease to (i) provide for the addition to the Existing Premises of certain additional space deemed to contain 4,744 square feet of rentable area located on a portion of the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor of the Building, as depicted on the diagram attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) otherwise amend the Lease, subject to and in accordance with the terms and conditions set forth in this Amendment.</font></div><div style="margin-top:12.05pt;padding-left:5.95pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R-3.  Except as otherwise defined in this Amendment, all terms and phrases used in this Amendment that are defined in the Lease shall have the same meaning as set forth in the Lease. In the event of any conflict between the Lease and this Amendment, the terms of this Amendment shall control. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as used herein, shall be deemed to refer to the Existing Lease as amended by this Amendment.</font></div><div style="margin-top:12pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">COVENANTS</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the sum of Ten Dollars ($10.00) cash in hand paid, the mutual covenants hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The foregoing Recitals are true and correct and are incorporated herein by this reference&#58;</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.95pt;text-decoration:underline">Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Description</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord and Tenant hereby agree to add the Expansion Space to the Existing Premises as of the Expansion Space Commencement Date (defined below). As of the Expansion Space Commencement Date, the entire Premises shall be deemed to contain 9,361 rentable square feet comprised of a portion of the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor of the Building (i.e., the Existing Premises and the Expansion Space). Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Expansion Space upon the terms and conditions of this </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendment. On the Expansion Space Commencement Date, the Expansion Space shall become part of the Premises and, except as otherwise provided below, be subject to all the terms and</font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><div id="ief2666b6fc32450ca7039fc21ca1aa9c_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:6pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conditions of the Lease. From and after the Expansion Space Commencement Date, the Existing Premises, together with the Expansion Space, shall be collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:13.8pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt;text-decoration:underline">Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for Landlord&#8217;s Work (hereinafter defined </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), the Expansion Space will be delivered to Tenant and are being leased &#8220;AS IS&#8221; and &#8220;WITH ALL FAULTS,&#8221; and Landlord makes no representation or warranty of any kind, expressed or implied, with respect to the condition of the Expansion Space (including habitability, suitability, or fitness for a particular purpose). TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, LANDLORD HEREBY DISCLAIMS, AND TENANT WAIVES THE BENEFIT OF, ANY AND ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF HABITABILITY, SUITABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Landlord</font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is under no obligation to make any Alterations, repairs, or the like in or to the Expansion Space (except for Landlord&#8217;s Work), the Existing Premises, the Building, or any systems serving the same on account of this Amendment.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">FF&#38;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Expansion Space contains certain fixtures (including so-called trade fixtures), furniture, and equipment (the &#8220;FF&#38;E&#8221;), as more specifically described on Exhibit C annexed hereto and made a part hereof. Landlord has made no representations or warranties whatsoever as to the condition of the FF&#38;E. Tenant has examined the FF&#38;E and accepts same in its &#8220;as-is&#8221; condition in all respects. Tenant shall neither sell nor transfer any portion of the FF&#38;E. Tenant shall repair and maintain the FF&#38;E throughout the Lease Term, at its sole cost and expense. Tenant shall neither replace any of the FF&#38;E nor add any improvements to the FF&#38;E, without Landlord&#8217;s prior written approval. Tenant shall make all approved replacements and improvements at its sole cost and expense. Upon the expiration or sooner termination of this Lease, Tenant shall return the FF&#38;E, and all replacements and improvements thereto, if any, to Landlord in good order and condition (normal wear and tear excepted). Tenant shall be solely responsible and liable for any damage done to all or any portion of the FF&#38;E by Tenant, its agents, employees, contractors, invitees, or licensees.</font></div><div style="margin-top:13.75pt;padding-left:5.95pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.05pt;text-decoration:underline">Expansion Space Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Expansion Space Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be October 1, 2024. Notwithstanding the foregoing, Tenant shall not have any right to commence beneficial use of the Expansion Space unless the same are vacant and delivered to Tenant by Landlord. The Term for the Expansion Space shall commence on the Expansion Space Commencement Date and continue through the Expiration Date such that the Lease for all the Premises (i.e., as expanded pursuant to this Amendment) shall expire on the Expiration Date. From and after the Expansion Space Commencement Date (subject to the Expansion Space Abatement Period, defined below), Tenant shall pay Base Rent and additional rent for the Expansion Space in equal monthly installments in advance on the first day of each month during the Lease Term without setoff, deduction, or demand, and otherwise in accordance with the terms of the Lease.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Access Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Move In Period means the period commencing on September 1, 2024 and continuing through September 30, 2024&#59; provided that no access to the Expansion Space shall be permitted unless Tenant shall deliver to Landlord written evidence specifying that Tenant is then carrying all insurance required by the Lease. Provided no Event of Default by </font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tenant has occurred under the Lease, Tenant shall have the right to install in the Expansion Space, during the Move In Period only, Tenant&#8217;s Cabling and other furniture, furnishings,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">inventory, equipment, or trade fixtures, subject to all applicable terms and conditions of the Lease. Any and all activity by Tenant or any Agent of Tenant prior to the Expansion Space Commencement Date shall be coordinated with Landlord and its general contractor to ensure that such activity does not, to more than a de minimis extent, interfere with Landlord&#8217;s Work. If Landlord determines that any such interference is occurring to more than a de minimis extent, then Landlord shall have the right to require the removal of the offending party from the Expansion Space (with Tenant having no right to assert that the Expansion Space Commencement Date or Tenant&#8217;s other obligations are affected thereby). Notwithstanding anything in this Lease to the contrary&#58; (a) Landlord shall have no responsibility with respect to any items placed in the Expansion Space by Tenant or any Agent of Tenant prior to the Expansion Space Commencement Date&#59; and (b) all of the provisions of the Lease (including all insurance, indemnity and utility provisions) shall apply during the Move In Period, except that during such period (i) Tenant shall not be obligated to pay Base Rent and (ii) Landlord shall not be obligated to provide any utility, service or other item in excess of those customarily provided to or for the benefit of a premises in order for Landlord to perform its building standard initial improvement work thereto.</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.95pt;text-decoration:underline">Monetary Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Expansion Space Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Base Rent payable with respect to the Expansion Space during the Term shall be as follows&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.45pt"><font><br></font></div><div style="padding-left:14.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.625%"><tr><td style="width:1.0%"></td><td style="width:20.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:5.05pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">Start Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:5.05pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.33pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">End Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rate Per Rentable Square Foot</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:5.05pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.23pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">Annually*</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:5.05pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.33pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">Monthly</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">October 1, 2024**</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">September 30, 2025</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$64.00</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.23pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$303,615.96</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$25,301.33</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-right:-2.33pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">October 1, 2025</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-right:-2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">February 28, 2026</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-right:-2.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$64.00</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$303,615.96</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">$25,301.33</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*Based on twelve (12) calendar months.</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.75pt">**Subject to abatement during the Abatement Period as set forth below.</font></div></td></tr></table></div><div style="margin-top:12.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt;text-decoration:underline">Expansion Space Abatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, provided no Event of Default by Tenant has occurred under the Lease, Landlord grants to Tenant an abatement of the Base Rent otherwise payable hereunder for the Expansion Space during the month of October of 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Expansion Space Abatement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Concurrently with Tenant&#8217;s execution of this Amendment, Tenant shall pay an amount equal to one (1) monthly installment of Base Rent payable for the Expansion Space, which amount shall be credited toward the monthly installment of Base Rent payable after expiration of the Expansion Space Abatement Period.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Operating Charges Base Year for the Expansion Space shall be calendar year 2025. The Real Estate Taxes Base Year for the Expansion Space shall be July 1, 2024 through June 30, 2025 (i.e., the City of Boston Fiscal Year 2025). From and after October 1, 2025, Tenant shall pay as additional rent for the Expansion Space, Tenant's </font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proportionate Share of the amount by which (i) Operating Charges for each calendar year falling entirely or partly within the Lease Term exceed the Operating Charges Base Amount (i.e., the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:6pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Operating Charges incurred during the Operating Charges Base Year for the Expansion Space), and (ii) the Real Estate Taxes for each calendar year falling entirely or partly within the Lease Term exceed the Real Estate Taxes Base Amount (i.e., the Real Estate Taxes incurred during the Real Estate Taxes Base Year for the Expansion Space). Tenant&#8217;s Proportionate Share for the Expansion Space shall be 1.74% for each of Operating Charges and Real Estate Taxes. With respect to the Existing Premises, Tenant shall continue to pay all items of Base Rent and additional rent in accordance with the terms of the Existing Lease.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt;text-decoration:underline">Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Concurrently with Tenant&#8217;s execution of this Amendment, Tenant shall pay an amount equal to one (1) monthly installment of Base Rent payable for the Expansion Space, which amount shall be credited toward the monthly installment of Base Rent payable for the Expansion Space following the end of the Expansion Space Abatement Period.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.05pt;text-decoration:underline">Renewal Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord hereby grants to Tenant the conditional right, exercisable at Tenant&#8217;s option, to renew the Lease Term, with respect to all of the Premises, for one (1) term of three (3) years (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Renewal Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If exercised, and if the conditions applicable thereto have been satisfied, the Renewal Term shall commence immediately following the Expiration Date. The right of renewal herein granted to Tenant shall be subject to, and shall be exercised in accordance with, the following terms and conditions&#58;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt">Tenant shall exercise its right of renewal with respect to the Renewal Term by giving Landlord written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Renewal Option Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of such election not earlier than fifteen (15) months nor later than twelve (12) months prior to the expiration of the then-current Lease Term. The parties shall then have thirty (30) days after Landlord&#8217;s timely receipt of such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in which to agree on the annual base rent, escalation factor and additional rent which shall be payable during the Renewal Term. The parties shall attempt in good faith to agree upon an annual base rent payable for the first year of the Renewal Term and an escalation factor for which would equal one hundred percent (100%) of the applicable fair market rent taking into account all relevant factors&#59; provided, however that consideration shall be given to the savings to Tenant resulting from its remaining in the Premises (e.g., no moving or related costs), and no consideration shall be given to (and the fair market rent so determined shall not be reduced on account of) &#8220;downtime&#8221; that may be associated with this or comparable transactions. If during the Negotiation Period the parties agree on such annual base rent, escalation factor and additional rent, then they shall promptly execute an amendment to the Lease stating the terms so agreed upon. If during the Negotiation Period the parties are unable, for any reason whatsoever, to agree on such annual base rent, escalation factor and additional rent payable, then within five (5) business days after the last day of the Negotiation Period, the parties shall each appoint a real estate broker who shall be licensed in Massachusetts and who specializes in the field of commercial office space leasing in the Building&#8217;s submarket, has at least ten (10) years of experience and is recognized within the field as being reputable and ethical. Such two individuals shall each determine, within ten (10) business days after their appointment, such annual base rent, escalation factor and additional rent. If such individuals do not agree on such items, then the two individuals shall, within five (5) business days, render separate written reports of their determinations and together appoint a third similarly qualified individual. The third individual shall, within ten (10) business days after his or her appointment, </font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">select either Landlord&#8217;s broker&#8217;s determination or Tenant&#8217;s broker&#8217;s determination (this being the third broker&#8217;s sole function) as being closest to the applicable fair market annual base rent,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">escalation factor and additional rent and shall notify the parties of such selection. The third broker&#8217;s decision shall be final and conclusive, and binding on Landlord and Tenant. Landlord and Tenant shall each bear the cost of its broker and shall share equally the cost of the third broker. Upon determination of the annual base rent, escalation factor and concessions payable pursuant to this Section, the parties shall promptly execute an amendment to the Lease stating the rent and additional terms so determined.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt">If the Renewal Option Notice is not given timely, then Tenant&#8217;s right of renewal with respect to the Renewal Term shall lapse and be of no further force or effect.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.75pt">If an Event of Default by Tenant exists on the date Tenant sends its Renewal Option Notice or any time thereafter until the Renewal Term is to commence, then, at Landlord&#8217;s election, the Renewal Term shall not commence and the term of this Lease shall expire at the expiration of the Lease Term.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.07pt">If at any time fifty percent (50%) or more of the square feet of rentable area of the entire Premises has been subleased or assigned, or if the Lease has been terminated with respect to such portion of the Premises, then Tenant&#8217;s rights pursuant to this Section shall lapse and be of no further force or effect.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.75pt">Tenant&#8217;s right of renewal under this Section may be exercised only by Tenant and may not be exercised by or for the benefit of any other transferee, sublessee, or assignee of Tenant.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.08pt">The Renewal Term may be exercised only with respect to all of the then- current Premises.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Simultaneously with Tenant&#8217;s execution of this Amendment, Tenant shall deposit with Landlord the amount of $25,301.33 and such amount shall be added to the security deposit held by Landlord under the Lease and the same shall be subject to all terms and conditions of the Lease applicable to the security deposit. Based on the foregoing, the Security Deposit Amount is hereby revised to be $125,301.33.</font></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Brokerage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord and Tenant each warrant to the other that in connection with this Amendment it has not employed or dealt with any broker, agent, or finder, other than Cushman &#38; Wakefield U.S., Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Landlord&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Cresa (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tenant&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Landlord&#8217;s Broker and Tenant&#8217;s Broker are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; It is understood that Landlord shall pay Landlord's Broker and Tenant's Broker pursuant to separate agreements between Landlord and the Brokers. Tenant shall indemnify and hold Landlord harmless from and against any claim for brokerage or other commissions asserted by any broker, agent or finder employed by Tenant or with whom Tenant has dealt, other than the Brokers. Landlord shall indemnify and hold Tenant harmless from and against any claim for brokerage or other commissions asserted by Landlord's Broker and Tenant's Broker and any other broker, agent or finder employed by Landlord or with whom Landlord has dealt. Tenant's and Landlord's indemnities set forth in this Section shall survive the expiration or earlier termination of the Lease Term.</font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.95pt;text-decoration:underline">Ratification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise expressly modified by the terms of this</font></div><div><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:4pt;padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendment, the Lease shall remain unchanged and continue in full force and effect. All terms, covenants and conditions of the Lease not expressly modified herein are hereby confirmed and ratified and remain in full force and effect, and as further amended hereby, constitute valid and binding obligations of Tenant enforceable according to the terms thereof. Nothing contained herein shall be deemed to waive any sums due from Tenant to Landlord or from Landlord to Tenant, or any default or event which, with the passage of time or delivery of notice, or both, would constitute an Event of Default under the Lease as of the date hereof. Tenant acknowledges Landlord is not in default in the performance of any of its obligations under the Lease and Tenant is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute a default by Landlord under the Lease. Tenant has no claims, defenses or set offs of any kind to the performance of Tenant's obligations and duties under the Lease.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.05pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Tenant and the person executing and delivering this Amendment on Tenant&#8217;s behalf each represents and warrants that such person is duly authorized to so act&#59; that Tenant is duly organized, is qualified to do business in the jurisdiction in which the Building is located, is in good standing under the Laws of Delaware and the Laws of the jurisdiction in which the Building is located, and has the power and authority to enter into this Amendment, and that all action required to authorize Tenant and such person to enter into this Amendment has been duly taken.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment shall not be effective and binding unless and until fully executed and delivered by each of the parties hereto.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.05pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment may be executed in multiple counterparts, each of which shall be an original, but all of which shall constitute one and the same Amendment. Signatures transmitted by facsimile machine, electronically or signatures transmitted via e-mail in a &#8220;PDF&#8221; format may be used in place of original signatures on this Amendment. Each party intends to be bound by such party&#8217;s facsimile or &#8220;PDF&#8221; format or DocuSign or other electronic signature on this Amendment, is aware that the other parties are relying on such party&#8217;s facsimile or &#8220;PDF&#8221; format or DocuSign or other electronic signature, and hereby waives any defenses to the enforcement of this Amendment based upon the form of signature.</font></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment contains and embodies the entire agreement of the parties hereto with respect to the amendment of the Lease, and supersedes and revokes all negotiations, arrangements, letters of intent, representations, inducements, or other agreements, oral or in writing. No representations, inducements, or agreements, oral or in writing, between the parties not contained in this Amendment shall be of any force or effect. If any part of this Amendment is illegal or unenforceable, such part or parts of this Amendment shall be of no force or effect, and this Amendment shall be treated as if such part or parts had not been inserted. Except as otherwise provided herein, the terms and conditions of this Amendment shall inure to the benefit of and be binding upon the parties hereto and their respective successors or assigns&#59; provided however, the foregoing shall not be deemed to amend the assignment and subletting provisions in the Lease. Landlord and Tenant each hereby covenant and agree that each provision of this Amendment has been jointly and mutually negotiated and authorized by both </font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Landlord and Tenant, and in the event of any dispute arising out of any provision of this Amendment, Landlord and Tenant do hereby waive any claim of authorship against the other</font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.815%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><div id="ief2666b6fc32450ca7039fc21ca1aa9c_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">party.</font></div><div><font><br></font></div><div style="margin-top:11.95pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#91;Signature page follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:3.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><div id="ief2666b6fc32450ca7039fc21ca1aa9c_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have caused this Amendment to be executed under seal as of the Effective Date.</font></div><div style="margin-top:11.95pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:13.8pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLUMBIA REIT &#8211; 116 HUNTINGTON, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="margin-top:13.8pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;Chaperone Portfolio Mezz B LLC,</font></div><div style="padding-left:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company, its sole member</font></div><div><font><br></font></div><div style="padding-left:78pt;padding-right:144.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;Columbia Property Trust Operating Partnership, L.P., a Delaware limited partnership, its sole member</font></div><div><font><br></font></div><div style="padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;Columbia Property Trust, Inc.,</font></div><div style="padding-left:114pt"><img alt="image_4.jpg" src="image_4.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:108px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Maryland corporation, its general partner</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:114pt;padding-right:185.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:212%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:212%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:212%"> Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:212%;text-decoration:underline"> Maria Blake&#160;&#160;&#160;&#160;</font></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><div id="ief2666b6fc32450ca7039fc21ca1aa9c_13"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.246%"><div style="margin-top:2.3pt;text-align:right"><img alt="image_5.jpg" src="image_5.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:205px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="margin-top:1.45pt;padding-left:13.45pt"><font><br></font></div></div><div style="display:inline-block;max-width:7.507%;min-width:6.507%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.247%"><div style="padding-left:13.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vice President</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div style="padding-left:6pt"><img alt="image_6.jpg" src="image_6.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:119px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;SEAL&#93;</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ryan Cohlhepp</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Operating Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.05pt"><font><br></font></div><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:120%">&#91;SIGNATURE PAGE TO FIRST AMENDMENT TO OFFICE LEASE AGREEMENT - BICARA&#93;</font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><div id="ief2666b6fc32450ca7039fc21ca1aa9c_16"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:10.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PLAN SHOWING THE EXPANSION SPACE</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.05pt"><img alt="image_7.jpg" src="image_7.jpg" style="height:405px;margin-bottom:5pt;vertical-align:text-bottom;width:614px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;padding-left:179.45pt;padding-right:179.25pt;text-indent:29.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:318%">EXHIBIT B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:318%;text-decoration:underline">WORK AGREEMENT</font></div><div style="padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.05pt;text-decoration:underline">Landlord&#8217;s Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord, through its designated contractor, shall, combine the Existing Premises and the Expansion Space by creating an opening between such spaces in the area identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as &#8220;New Openings&#8221; and otherwise in accordance with Landlord&#8217;s plans and specifications therefor and using Landlord&#8217;s Building standard practices, materials, items, and finishes (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Landlord&#8217;s Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Tenant hereby acknowledges and agrees that the performance of Landlord's Work shall occur during the Move In Period and that the same shall not give rise to a claim by Tenant for any damages, set off or abatement of rent on account thereof. The parties shall use their commercially reasonable efforts to cooperate with one another in connection with the performance of Landlord's Work (including, without limitation, the scheduling, staging and moving of any of Tenant's furniture, furnishings and equipment necessary for Landlord's designated contractor to perform Landlord's Work (which moving of furniture, furnishings and equipment shall be Tenant's responsibility to do at Tenant's cost) and providing access to and from the Expansion Space by contractors, subcontractors, deliverymen and agents). Without limiting the generality of Paragraph, Tenant hereby grants Landlord, its agents, employees and contractors access to the Expansion Space at any time and from time to time to perform Landlord's Work specified above.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.05pt;text-decoration:underline">Possession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord&#8217;s Work shall be deemed substantially complete as reasonably determined by Landlord or Landlord&#8217;s architect in its professional judgment and notwithstanding items of work and that can be completed after the Expansion Space is occupied without causing substantial interference with Tenant&#8217;s use of the Expansion Space. With respect to any defect or incomplete work that is described in a written notice given by Tenant to Landlord not later than the date of substantial completion of Landlord&#8217;s Work, if Landlord confirms the same are in fact defects or incomplete items, then Landlord will correct and complete the same. At Landlord&#8217;s request, Tenant shall accompany Landlord to prepare the punch list on or before the date of substantial completion of Landlord&#8217;s Work.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.9pt"><font><br></font></div><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B-1</font></div><div style="text-align:center"><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;padding-left:193.92pt;padding-right:193.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:318%">EXHIBIT C </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:318%;text-decoration:underline">FF&#38;E</font></div><div style="padding-left:6.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.910%"><tr><td style="width:1.0%"></td><td style="width:27.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Item</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Quantity</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Main Area</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Grey two&#8208;seater sofa</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Coffee table &#8208; round, large</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Coffee table &#8208; round, small</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Box of carpet tiles</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">2</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">19</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Two&#8208;drawer filing cabinets</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">20</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">White metal with grey top</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Desktop monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">4</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">HP, LG</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stone top coffee table &#8208;</font></div><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">round</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Credenza</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Printer</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Brother</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">iPad Minis</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">4</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.67pt;padding-right:1.57pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Mounted outside conference rooms&#59; for conference reservation system</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large planters</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">2</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:2.42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:142%">Put Patients First Room (Large Conference Room)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">17</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">6</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">2</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Poly webcam&#47;speaker + tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Conference table</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">6</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Pushed together to make 1 large table</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Credenza</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Server equipment in one side&#59; cabinet is temperature controlled</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Kitchen</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Kitchen&#8208;Aid Double Door Fridge + Drawer Freezer</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.95pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Microwave</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Dishwashers</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">2</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Stacked</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Trash cans and recycling bins</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">4</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.45pt">Bar&#8208;height chairs</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.45pt">8</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:1.9pt"><font><br></font></div><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C-1</font></div><div style="text-align:center"><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.910%"><tr><td style="width:1.0%"></td><td style="width:27.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Water cooler</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Filing cabinet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">&#126;5.5' tall, empty, silver</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Fixture&#58; hanging lightbulbs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">10</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Edison bulb style</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large kitchen table</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.50pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:13.40pt">Inspired to Cure Room (Smaller Conference</font></div><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.35pt">Room)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Round table</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">6</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:44.12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Large whiteboard, mounted</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.85pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large planter</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Empty</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Poly webcam&#47;speaker + tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Fixture&#58; hanging lightbulbs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">10</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Edison bulb style</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Be Bold Room (Smaller Conference Room)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Conference table</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">6</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Whiteboard, mounted</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Round coffee table</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Poly webcam&#47;speaker + tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:2.42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:142%">Embrace Change Room (Smallest Conference Room)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Round table, small</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">3</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Whiteboard, mounted</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:13.40pt">Poly webcam&#47;speaker +</font></div><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.35pt">tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:2.42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:142%">Drive to Success Room (Smallest Conference Room)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Whiteboard, mounted</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Poly webcam&#47;speaker + tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">3</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Conference table</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="margin-top:3.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C-2</font></div><div style="text-align:center"><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.910%"><tr><td style="width:1.0%"></td><td style="width:27.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.540%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:12.40pt">Be Respectful Room</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">TV&#47;Computer Monitors</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Large, Sony, mounted</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Whiteboard, mounted</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Poly webcam&#47;speaker + tablet</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.8pt;padding-right:-2.63pt"><font><br></font></div><div style="padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Mounted&#59; on table</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Black rolling chairs</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.4pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">6</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.72pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Conference table</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.62pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">1</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.6pt;padding-left:2.67pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:12.40pt">Rectangular</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:8.95pt">Docusign Envelope ID&#58; C176A656-82B8-46C5-9B39-048B6B0D0A1E</font></div></td></tr></table><img alt="image_3.jpg" src="image_3.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:360px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.457%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Docusign Envelope ID&#58; 058972C8-7131-455E-A10E-A71A63AB872E</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C-3</font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.825%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;4126-2912-5458  v3 </font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9c42080657f448339653129f1280032c_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Claire Mazumdar, Ph.D., certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">I have reviewed this Quarterly Report on Form 10-Q of Bicara Therapeutics Inc.&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Claire Mazumdar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claire Mazumdar, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8a9e040a6b24405e99eb8b507a05b173_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Ivan Hyep, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">I have reviewed this Quarterly Report on Form 10-Q of Bicara Therapeutics Inc.&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5217e9b8cdf34723b55522d7ed6a43cf_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Bicara Therapeutics Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Claire Mazumdar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claire Mazumdar, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bcax-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bcax="http://www.bicara.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bicara.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.bicara.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidity" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity">
        <link:definition>9952156 - Disclosure - Description of Business, Organization, and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.bicara.com/role/FairValueMeasurements">
        <link:definition>9952158 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.bicara.com/role/CommonStock">
        <link:definition>9952160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>9952161 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.bicara.com/role/StockBasedCompensation">
        <link:definition>9952162 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.bicara.com/role/IncomeTaxes">
        <link:definition>9952163 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsRelatedParties" roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedParties">
        <link:definition>9952164 - Disclosure - Significant Agreements &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreements" roleURI="http://www.bicara.com/role/SignificantAgreements">
        <link:definition>9952165 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.bicara.com/role/CommitmentsandContingencies">
        <link:definition>9952166 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.bicara.com/role/SubsequentEvents">
        <link:definition>9952167 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.bicara.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.bicara.com/role/StockBasedCompensationTables">
        <link:definition>9954475 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails">
        <link:definition>9954476 - Disclosure - Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails">
        <link:definition>9954477 - Disclosure - Description of Business, Organization, and Liquidity - Initial Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails">
        <link:definition>9954478 - Disclosure - Description of Business, Organization, and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954479 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails" roleURI="http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails">
        <link:definition>9954481 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails" roleURI="http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails">
        <link:definition>9954482 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954483 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails" roleURI="http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails">
        <link:definition>9954484 - Disclosure - Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954485 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.bicara.com/role/CommonStockDetails">
        <link:definition>9954486 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>9954487 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockConversionRightsDetails" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails">
        <link:definition>9954488 - Disclosure - Redeemable Convertible Preferred Stock - Conversion Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockDividendsDetails" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails">
        <link:definition>9954489 - Disclosure - Redeemable Convertible Preferred Stock - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockVotingRightsDetails" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails">
        <link:definition>9954490 - Disclosure - Redeemable Convertible Preferred Stock - Voting Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockProtectiveProvisionsDetails" roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails">
        <link:definition>9954491 - Disclosure - Redeemable Convertible Preferred Stock - Protective Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954492 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails">
        <link:definition>9954493 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSAAwardActivityDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails">
        <link:definition>9954494 - Disclosure - Stock-Based Compensation - RSA Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails">
        <link:definition>9954495 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsRelatedPartiesDetails" roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails">
        <link:definition>9954496 - Disclosure - Significant Agreements &#8211; Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsDetails" roleURI="http://www.bicara.com/role/SignificantAgreementsDetails">
        <link:definition>9954497 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.bicara.com/role/SubsequentEventsDetails">
        <link:definition>9954498 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" abstract="true" name="SeedSeriesRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SeriesBRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SeriesCRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesCRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" abstract="false" name="FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" abstract="false" name="TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_TemporaryEquityValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" abstract="false" name="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" abstract="false" name="SettlementOfFreestandingFinancialInstrumentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_VestingOfEarlyExerciseStockOptions" abstract="false" name="VestingOfEarlyExerciseStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" abstract="false" name="LiabilityUponIssuanceOfFreestandingFinancialInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_TemporaryEquityDisclosureTextBlock" abstract="false" name="TemporaryEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" abstract="false" name="StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" abstract="false" name="NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_AccruedClinicalTrialAndContractManufacturingExpenses" abstract="false" name="AccruedClinicalTrialAndContractManufacturingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_FreestandingFinancialInstrumentLiabilityCurrent" abstract="false" name="FreestandingFinancialInstrumentLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_MeasurementInputProbabilityOfAchievementMember" abstract="true" name="MeasurementInputProbabilityOfAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" abstract="false" name="FreestandingFinancialInstrumentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="bcax_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_A2019StockOptionAndGrantPlanMember" abstract="true" name="A2019StockOptionAndGrantPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_BioconLimitedMember" abstract="true" name="BioconLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" abstract="true" name="SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_TwoInvestorsMember" abstract="true" name="TwoInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_TwoInvestorsRelativesOfBoardMemberMember" abstract="true" name="TwoInvestorsRelativesOfBoardMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_TemporaryEquityNumberOfInvestorsStockIssued" abstract="false" name="TemporaryEquityNumberOfInvestorsStockIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_FreestandingFinancialInstrumentLiabilityFairValue" abstract="false" name="FreestandingFinancialInstrumentLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcax_TemporaryEquityDividendRatePercentage" abstract="false" name="TemporaryEquityDividendRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcax_NumberOfMembersBoardOfDirectors" abstract="false" name="NumberOfMembersBoardOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" abstract="false" name="TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" abstract="false" name="CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" abstract="false" name="TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" abstract="false" name="TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_A2024StockOptionAndGrantPlanMember" abstract="true" name="A2024StockOptionAndGrantPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonQualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_MasterServicesAgreementMember" abstract="true" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_BBLAgreementsMember" abstract="true" name="BBLAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SyngeneAgreementManufacturingMember" abstract="true" name="SyngeneAgreementManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SyngeneAgreementMasterContractServicesMember" abstract="true" name="SyngeneAgreementMasterContractServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SyngeneAgreementsMember" abstract="true" name="SyngeneAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_BiofusionAgreementMember" abstract="true" name="BiofusionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_PromissoryNoteMember" abstract="true" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_RelatedPartyAgreementTerm" abstract="false" name="RelatedPartyAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcax_DebtInstrumentCollateralPledgedShares" abstract="false" name="DebtInstrumentCollateralPledgedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_IQVIARDSIncMember" abstract="true" name="IQVIARDSIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementMember" abstract="true" name="MasterClinicalContractServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" abstract="true" name="MasterClinicalContractServicesAgreementRefundableDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" abstract="true" name="MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" abstract="true" name="MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_OtherCommitmentLiabilityRefundableDepositAmount" abstract="false" name="OtherCommitmentLiabilityRefundableDepositAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_PaymentsForOtherCommitments" abstract="false" name="PaymentsForOtherCommitments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_LesseeOperatingLeaseAreaOfProperty" abstract="false" name="LesseeOperatingLeaseAreaOfProperty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bcax-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_96b371a1-a69e-4b9b-b7c9-573f4864a343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_906f5ce4-2d56-44c1-b1ef-6f4d93c4c8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96b371a1-a69e-4b9b-b7c9-573f4864a343" xlink:to="loc_us-gaap_Liabilities_906f5ce4-2d56-44c1-b1ef-6f4d93c4c8aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2d2a6009-8a91-489c-9688-aee765b0189d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96b371a1-a69e-4b9b-b7c9-573f4864a343" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2d2a6009-8a91-489c-9688-aee765b0189d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_761a4693-633a-4b17-80db-eeb8d3ce90d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96b371a1-a69e-4b9b-b7c9-573f4864a343" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_761a4693-633a-4b17-80db-eeb8d3ce90d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_875035dd-8468-417b-abf1-458ba76fe82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96b371a1-a69e-4b9b-b7c9-573f4864a343" xlink:to="loc_us-gaap_StockholdersEquity_875035dd-8468-417b-abf1-458ba76fe82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbd6e336-6591-4426-9424-a99af46336c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_aa39123b-ac7c-4821-a7cd-5bdd55ea3e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd6e336-6591-4426-9424-a99af46336c4" xlink:to="loc_us-gaap_AccountsPayableCurrent_aa39123b-ac7c-4821-a7cd-5bdd55ea3e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_432d355e-ced0-4887-85e3-bf42f5703d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd6e336-6591-4426-9424-a99af46336c4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_432d355e-ced0-4887-85e3-bf42f5703d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_927047f0-46e0-4214-9d85-37477cd894ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd6e336-6591-4426-9424-a99af46336c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_927047f0-46e0-4214-9d85-37477cd894ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18ca5397-cec1-45fe-ba24-fa207d147ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e724f46-41c7-4bb3-a6ca-1709b9a8c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18ca5397-cec1-45fe-ba24-fa207d147ff2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e724f46-41c7-4bb3-a6ca-1709b9a8c18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bbf7fe71-4ed4-4c28-97a6-f85c8ec4ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18ca5397-cec1-45fe-ba24-fa207d147ff2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bbf7fe71-4ed4-4c28-97a6-f85c8ec4ae67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5b89a20c-6d95-42c3-b8b2-d79c9fe98faa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f7fe2a21-d182-4686-b82d-5cfd32bcae68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5b89a20c-6d95-42c3-b8b2-d79c9fe98faa" xlink:to="loc_us-gaap_LiabilitiesCurrent_f7fe2a21-d182-4686-b82d-5cfd32bcae68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ea81b5f-e571-48f7-9aa4-55c2bfcb4c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5b89a20c-6d95-42c3-b8b2-d79c9fe98faa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ea81b5f-e571-48f7-9aa4-55c2bfcb4c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c0b204f9-64c3-4e6c-88b3-61b0901880f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5b89a20c-6d95-42c3-b8b2-d79c9fe98faa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c0b204f9-64c3-4e6c-88b3-61b0901880f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_68148948-e67e-40ac-af9f-054e279ce5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d714c43-6fd7-4dce-837f-26b8969065dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68148948-e67e-40ac-af9f-054e279ce5bf" xlink:to="loc_us-gaap_AssetsCurrent_0d714c43-6fd7-4dce-837f-26b8969065dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0d83eeed-f70d-4f3f-b9c3-443d5e4dc209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68148948-e67e-40ac-af9f-054e279ce5bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0d83eeed-f70d-4f3f-b9c3-443d5e4dc209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2ac4a05-dfca-4a05-b471-1cb6df39735e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68148948-e67e-40ac-af9f-054e279ce5bf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2ac4a05-dfca-4a05-b471-1cb6df39735e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_acd910ba-7c56-4038-a268-18c1dc8b9251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68148948-e67e-40ac-af9f-054e279ce5bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_acd910ba-7c56-4038-a268-18c1dc8b9251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cb9d694-a783-4152-af56-78bc05897642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_524ffb64-0dfe-4f18-b65b-fbf2d3e80e07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cb9d694-a783-4152-af56-78bc05897642" xlink:to="loc_us-gaap_PreferredStockValue_524ffb64-0dfe-4f18-b65b-fbf2d3e80e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5fb3e7bf-4797-48ec-9d2d-1ad3dc1b0095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cb9d694-a783-4152-af56-78bc05897642" xlink:to="loc_us-gaap_CommonStockValue_5fb3e7bf-4797-48ec-9d2d-1ad3dc1b0095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a30b6dfc-337a-4a31-9566-10d4001012d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cb9d694-a783-4152-af56-78bc05897642" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a30b6dfc-337a-4a31-9566-10d4001012d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2a0738f-396b-47f9-9dbb-4fac923f03a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cb9d694-a783-4152-af56-78bc05897642" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2a0738f-396b-47f9-9dbb-4fac923f03a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1bbcf715-b41d-47fa-835b-1a6bcd483971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_552d01fa-f0e7-446e-aab0-db066acadfba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1bbcf715-b41d-47fa-835b-1a6bcd483971" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_552d01fa-f0e7-446e-aab0-db066acadfba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c9921ee-b05e-41a0-8b9f-7d91b8c34e01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1bbcf715-b41d-47fa-835b-1a6bcd483971" xlink:to="loc_us-gaap_OperatingIncomeLoss_7c9921ee-b05e-41a0-8b9f-7d91b8c34e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_afd457ef-6796-4227-89a9-5e7baa00817a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_79955608-dd76-4a59-9bff-d54b5a729b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_afd457ef-6796-4227-89a9-5e7baa00817a" xlink:to="loc_us-gaap_OperatingExpenses_79955608-dd76-4a59-9bff-d54b5a729b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b6afa3a4-db4c-4367-ac70-782c01dc5dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f73684f3-bc80-471a-ae49-44a7411502df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b6afa3a4-db4c-4367-ac70-782c01dc5dc1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f73684f3-bc80-471a-ae49-44a7411502df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3f9a3b79-1d3e-4841-86f4-5cf969aa7316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b6afa3a4-db4c-4367-ac70-782c01dc5dc1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3f9a3b79-1d3e-4841-86f4-5cf969aa7316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_72a21ca1-6349-4b39-88e0-3d6406dbbf83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_24c8a45c-1257-4b27-8896-831855d6e391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_72a21ca1-6349-4b39-88e0-3d6406dbbf83" xlink:to="loc_us-gaap_InvestmentIncomeInterest_24c8a45c-1257-4b27-8896-831855d6e391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_8032f522-55d8-4a15-9b71-914c2c08ac8b" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_72a21ca1-6349-4b39-88e0-3d6406dbbf83" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_8032f522-55d8-4a15-9b71-914c2c08ac8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d9f3a96-672c-48ca-b80d-022898f3e4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae1cbcb6-1ae9-4dba-a769-9c2f266eb7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6d9f3a96-672c-48ca-b80d-022898f3e4fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae1cbcb6-1ae9-4dba-a769-9c2f266eb7b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_db09c4d0-b0ab-4f13-8ddb-e9f96da8d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6d9f3a96-672c-48ca-b80d-022898f3e4fc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_db09c4d0-b0ab-4f13-8ddb-e9f96da8d0ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e45d7f3-8cbb-4bec-97a1-19b86e4a377e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0aace713-dc5d-430f-8a71-d56a0057c146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e45d7f3-8cbb-4bec-97a1-19b86e4a377e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0aace713-dc5d-430f-8a71-d56a0057c146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_c852384c-1b9c-4b68-b553-1bde014d2031" xlink:href="bcax-20240930.xsd#bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e45d7f3-8cbb-4bec-97a1-19b86e4a377e" xlink:to="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_c852384c-1b9c-4b68-b553-1bde014d2031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_76d15fb7-4d48-4a22-922e-3ff60b95ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e45d7f3-8cbb-4bec-97a1-19b86e4a377e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_76d15fb7-4d48-4a22-922e-3ff60b95ed98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd016bb-ebf2-49a3-82b1-6034ced8d896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8501bde-b1b5-45d0-a50c-52554aa146ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd016bb-ebf2-49a3-82b1-6034ced8d896" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8501bde-b1b5-45d0-a50c-52554aa146ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2312dc4-4a56-4b75-af2d-e26b3a71fca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd016bb-ebf2-49a3-82b1-6034ced8d896" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2312dc4-4a56-4b75-af2d-e26b3a71fca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a7bf1b0-db95-4423-a278-733eb91f685d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd016bb-ebf2-49a3-82b1-6034ced8d896" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a7bf1b0-db95-4423-a278-733eb91f685d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf5c1711-b00a-413e-aa83-6d7129475206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_NetIncomeLoss_cf5c1711-b00a-413e-aa83-6d7129475206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_925feccb-3ad5-4638-b92a-f025a043317a" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_925feccb-3ad5-4638-b92a-f025a043317a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3cac7eee-3858-4a34-b6d6-1a2d3d912a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_ShareBasedCompensation_3cac7eee-3858-4a34-b6d6-1a2d3d912a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2c820830-90b3-4782-a0da-7ec5af74263d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_Depreciation_2c820830-90b3-4782-a0da-7ec5af74263d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c6c18514-2c49-451a-9808-d500114dabc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c6c18514-2c49-451a-9808-d500114dabc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ea6bc003-3d28-4ea3-8a7b-bdcf637865b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ea6bc003-3d28-4ea3-8a7b-bdcf637865b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ca526809-ce66-4e2b-913d-0f482fa6b855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ca526809-ce66-4e2b-913d-0f482fa6b855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b1b411ff-877a-4530-9810-e48e4c0f15cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a4afa5-72cd-4238-ae81-08debdbd0526" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b1b411ff-877a-4530-9810-e48e4c0f15cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a836fc8c-6057-48d7-9521-4a3ba77b13a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a2fa18c-cc9f-48f4-9618-a372cfeb3ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a836fc8c-6057-48d7-9521-4a3ba77b13a4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a2fa18c-cc9f-48f4-9618-a372cfeb3ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f48b3c83-63d6-4f29-9d60-950589f8fb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a836fc8c-6057-48d7-9521-4a3ba77b13a4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f48b3c83-63d6-4f29-9d60-950589f8fb04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ed3c0056-557a-4ad8-b557-68dec180424e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_f600265b-b567-4a86-91f1-dce602e896b2" xlink:href="bcax-20240930.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed3c0056-557a-4ad8-b557-68dec180424e" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_f600265b-b567-4a86-91f1-dce602e896b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ddeba77-ec5d-4715-a524-38f341734f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed3c0056-557a-4ad8-b557-68dec180424e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ddeba77-ec5d-4715-a524-38f341734f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a620cd91-3fa9-4a59-973c-ea1e3eadd072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed3c0056-557a-4ad8-b557-68dec180424e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a620cd91-3fa9-4a59-973c-ea1e3eadd072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0ccc9e85-5a13-4b09-80b9-6aa261d1fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed3c0056-557a-4ad8-b557-68dec180424e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0ccc9e85-5a13-4b09-80b9-6aa261d1fc04" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bcax-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fc52bd11-b7ed-45d8-a988-677f326f68cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:to="loc_us-gaap_RelatedPartyDomain_fc52bd11-b7ed-45d8-a988-677f326f68cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:to="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_bcd55e9e-8e48-4bf7-a66c-1748ad9f2775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:to="loc_us-gaap_NonrelatedPartyMember_bcd55e9e-8e48-4bf7-a66c-1748ad9f2775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5f250c2e-4d71-49fe-b269-521bef577011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:to="loc_us-gaap_RelatedPartyMember_5f250c2e-4d71-49fe-b269-521bef577011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_654019b6-3f93-4a27-adf7-8dd0803a8d48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:to="loc_us-gaap_ClassOfStockDomain_654019b6-3f93-4a27-adf7-8dd0803a8d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:to="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8ca48ebd-9fd9-4ea9-98a6-669433004174" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8ca48ebd-9fd9-4ea9-98a6-669433004174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ded87fb0-7374-492f-9511-05f7ff9f2808" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ded87fb0-7374-492f-9511-05f7ff9f2808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_9537cdef-e301-4b55-aa1c-2b9c28825515" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_9537cdef-e301-4b55-aa1c-2b9c28825515" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89938bf0-d294-4d70-8e78-f98ac64401bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89938bf0-d294-4d70-8e78-f98ac64401bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6ae6379-24dc-46e1-b23a-7534cf623e39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6ae6379-24dc-46e1-b23a-7534cf623e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e76e8ce6-8651-4a35-80d4-2f84325746da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_AssetsCurrent_e76e8ce6-8651-4a35-80d4-2f84325746da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_741e2803-6871-4bcf-b5a8-f73e3b8e0626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_741e2803-6871-4bcf-b5a8-f73e3b8e0626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66b70146-e476-4a60-9f02-2bfd3d75d792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66b70146-e476-4a60-9f02-2bfd3d75d792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1fb9213e-7aae-4993-bf50-db063987e6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1fb9213e-7aae-4993-bf50-db063987e6e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eec5389c-4feb-4a08-81f5-46044b91f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_Assets_eec5389c-4feb-4a08-81f5-46044b91f0fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fbf0fc63-feaa-40e7-b79d-b6596c7b3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_AccountsPayableCurrent_fbf0fc63-feaa-40e7-b79d-b6596c7b3e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c97c420f-a48e-4124-a2f8-a487a736398f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c97c420f-a48e-4124-a2f8-a487a736398f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e280676c-6001-4a6b-8be5-ceb2c70736fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e280676c-6001-4a6b-8be5-ceb2c70736fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1a08fde8-994d-4997-9edc-30f9f0724992" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_LiabilitiesCurrent_1a08fde8-994d-4997-9edc-30f9f0724992" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d8f10d9-37d3-48a4-9dd4-bef84ec0ba31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d8f10d9-37d3-48a4-9dd4-bef84ec0ba31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b1d2186d-ee00-4098-8c7f-0abbdd4eb9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b1d2186d-ee00-4098-8c7f-0abbdd4eb9bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_75862023-a758-475a-8373-07f8167ce1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_Liabilities_75862023-a758-475a-8373-07f8167ce1b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_717a4875-fd82-4f65-85f9-f4715dec1361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_717a4875-fd82-4f65-85f9-f4715dec1361" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_37ed71ba-ff65-41a9-baa1-43e6138c8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_37ed71ba-ff65-41a9-baa1-43e6138c8c66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_433bef29-e9ff-46bb-8fb7-0de075ca9361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_PreferredStockValue_433bef29-e9ff-46bb-8fb7-0de075ca9361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f838cd0a-a44c-4744-b7ee-6b72cdb58d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_CommonStockValue_f838cd0a-a44c-4744-b7ee-6b72cdb58d9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_db951d02-6305-4204-9599-0bb5f20b9b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_AdditionalPaidInCapital_db951d02-6305-4204-9599-0bb5f20b9b63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683c7c75-473e-4398-8200-f922a54397b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683c7c75-473e-4398-8200-f922a54397b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e6665af-6c47-4a46-a21d-456ed283e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_StockholdersEquity_4e6665af-6c47-4a46-a21d-456ed283e8a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3fb9c7-eef5-4a5b-9bd0-b1745012cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3fb9c7-eef5-4a5b-9bd0-b1745012cf27" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4dbc7460-b125-4e33-8718-496ebf267e3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:to="loc_us-gaap_ClassOfStockDomain_4dbc7460-b125-4e33-8718-496ebf267e3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:to="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8228ebad-5c78-4180-b464-66953dcbe8d0" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8228ebad-5c78-4180-b464-66953dcbe8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_0e3996f1-16df-41c4-bd3c-b87873eb8b03" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_0e3996f1-16df-41c4-bd3c-b87873eb8b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_adbbcb62-770f-48d9-9b2b-300f3635cf18" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_adbbcb62-770f-48d9-9b2b-300f3635cf18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_a5b8b87a-7b57-4d2f-a313-e3083f1ce1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_a5b8b87a-7b57-4d2f-a313-e3083f1ce1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_c5357712-64a7-44e3-a770-b73efea5246b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_c5357712-64a7-44e3-a770-b73efea5246b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_766d37ee-496e-451a-88a9-7161e9d3a289" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_766d37ee-496e-451a-88a9-7161e9d3a289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a4d4f9cb-b901-4ce2-bd44-2727c07d5cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a4d4f9cb-b901-4ce2-bd44-2727c07d5cca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_03798139-3071-4121-9711-16dd327d4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_03798139-3071-4121-9711-16dd327d4ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1785225c-a7d2-4ee9-8f63-2358fa8197e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1785225c-a7d2-4ee9-8f63-2358fa8197e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ed34531c-52ac-4190-86d9-817c5502419f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ed34531c-52ac-4190-86d9-817c5502419f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8c51f5bf-7c5c-46df-b32d-c97d4fd77ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8c51f5bf-7c5c-46df-b32d-c97d4fd77ae3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_70284b28-fdc3-4927-a710-fe65b359a9af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_70284b28-fdc3-4927-a710-fe65b359a9af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d390a9fd-5652-4e0e-a83d-d813563b3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d390a9fd-5652-4e0e-a83d-d813563b3e6a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0de82796-33fb-420c-8ec9-6d5d2ca80e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0de82796-33fb-420c-8ec9-6d5d2ca80e0d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6633a224-57d8-4e4b-a01a-4b97ce5de4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesIssued_6633a224-57d8-4e4b-a01a-4b97ce5de4ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d0e79bb2-9936-45f8-8bab-96f3081848d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d0e79bb2-9936-45f8-8bab-96f3081848d8" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_943846a3-3cca-4106-bb09-39ddfdc64e82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:to="loc_us-gaap_RelatedPartyDomain_943846a3-3cca-4106-bb09-39ddfdc64e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:to="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d8f0e9b4-9b14-4816-868f-80a22a3f05de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:to="loc_us-gaap_RelatedPartyMember_d8f0e9b4-9b14-4816-868f-80a22a3f05de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_d32b94c5-1323-4207-aa9c-d5cab155af37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:to="loc_us-gaap_NonrelatedPartyMember_d32b94c5-1323-4207-aa9c-d5cab155af37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5af6b321-f700-45a3-a714-3e89fe3665bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5af6b321-f700-45a3-a714-3e89fe3665bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_af4e7896-fdbf-4afe-bdd6-60659edda8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_af4e7896-fdbf-4afe-bdd6-60659edda8b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9cc7c866-3ece-4fbe-b8ca-7febca0e7494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_OperatingExpenses_9cc7c866-3ece-4fbe-b8ca-7febca0e7494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_797c066a-e989-4305-8250-49992ebaeaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_OperatingIncomeLoss_797c066a-e989-4305-8250-49992ebaeaf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e55a8ddc-ef1b-40b3-a79f-628cfcb6fa18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e55a8ddc-ef1b-40b3-a79f-628cfcb6fa18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_1d706853-4332-44fd-91da-6673bcf1d77a" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_1d706853-4332-44fd-91da-6673bcf1d77a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_57cff915-2c68-4145-8a1c-235adf7cd301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_57cff915-2c68-4145-8a1c-235adf7cd301" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79c2d329-17e9-42be-b946-f7fa518591e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79c2d329-17e9-42be-b946-f7fa518591e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41d5b649-b5c9-45af-923e-25420e8cbb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41d5b649-b5c9-45af-923e-25420e8cbb02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bef4a4e5-d082-447e-893a-2c5db4a2ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_NetIncomeLoss_bef4a4e5-d082-447e-893a-2c5db4a2ba2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c797b2a-a009-49a7-a647-69a5bc25aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_EarningsPerShareBasic_9c797b2a-a009-49a7-a647-69a5bc25aa11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_48dc716d-f4d4-4fc6-82ca-0de42173a255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_EarningsPerShareDiluted_48dc716d-f4d4-4fc6-82ca-0de42173a255" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_121c0643-c413-4ba4-bfe8-edb1de431a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_121c0643-c413-4ba4-bfe8-edb1de431a20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aee7e022-028b-4469-b3dc-c4cedbf40335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aee7e022-028b-4469-b3dc-c4cedbf40335" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:to="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeb6a966-b5bd-44ed-9a5f-505f00f0b444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:to="loc_us-gaap_EquityComponentDomain_eeb6a966-b5bd-44ed-9a5f-505f00f0b444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:to="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_41b030cc-8760-47e0-9677-6321ab28f118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_CommonStockMember_41b030cc-8760-47e0-9677-6321ab28f118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_73a13359-746a-4cdd-98c5-978bbadb9c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_73a13359-746a-4cdd-98c5-978bbadb9c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a19dcaf5-87cc-496e-a908-6028449f989c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_RetainedEarningsMember_a19dcaf5-87cc-496e-a908-6028449f989c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:to="loc_us-gaap_ClassOfStockDomain_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:to="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_bb26346a-caa9-4789-9ab3-f2a2d6da5c00" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_bb26346a-caa9-4789-9ab3-f2a2d6da5c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_8cd71f6e-1c0b-425c-9243-ee19de043d3e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_8cd71f6e-1c0b-425c-9243-ee19de043d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_635e7abf-c962-4880-9d60-a03129ff205a" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_635e7abf-c962-4880-9d60-a03129ff205a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f4e2a1dd-0685-41f7-8e72-dfc35730c142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f4e2a1dd-0685-41f7-8e72-dfc35730c142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28489cc8-4a04-4ac9-825d-da07c7a038ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28489cc8-4a04-4ac9-825d-da07c7a038ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_70668a46-3cfe-4354-8b59-80d0266b9302" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_70668a46-3cfe-4354-8b59-80d0266b9302" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_91757add-77fa-4364-8286-1961daa79462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_91757add-77fa-4364-8286-1961daa79462" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_c71d6ba1-3563-46a0-8ed3-b98f951e5b7b" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_c71d6ba1-3563-46a0-8ed3-b98f951e5b7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_c901883f-5163-4092-9cad-11f0a38a2d5c" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_c901883f-5163-4092-9cad-11f0a38a2d5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_506f825b-f484-47c5-9f58-bc96c5c48e80" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_506f825b-f484-47c5-9f58-bc96c5c48e80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_db772092-5cbf-4406-b9a1-fc4b745638a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_cc2bbe66-6ab6-4963-a350-e68f6cce8414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b4e76808-0479-443f-a0f1-562356170b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b4e76808-0479-443f-a0f1-562356170b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84c8fdf5-0e07-40c3-bc5b-1c4d0e60dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockholdersEquity_84c8fdf5-0e07-40c3-bc5b-1c4d0e60dbc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_55a61dce-2d26-46a4-970d-e868ffdda23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_55a61dce-2d26-46a4-970d-e868ffdda23d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1287c1cd-ac7b-455d-b9d3-4d8d7a7ee757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1287c1cd-ac7b-455d-b9d3-4d8d7a7ee757" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_88af44a2-a07a-4fbf-84c4-3045acf584f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_88af44a2-a07a-4fbf-84c4-3045acf584f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a052ddd5-820e-4acd-8181-1288fd201ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a052ddd5-820e-4acd-8181-1288fd201ce4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23606bf8-9f0e-4f1c-9ebd-488fd18c2b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23606bf8-9f0e-4f1c-9ebd-488fd18c2b7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bbebc3c7-9e8f-4a67-a23a-3183007b1b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bbebc3c7-9e8f-4a67-a23a-3183007b1b3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_484f5f04-c81d-4e7e-8deb-898829ac9b82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_484f5f04-c81d-4e7e-8deb-898829ac9b82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08015919-cbf1-4bac-a49a-8c3bf2201cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08015919-cbf1-4bac-a49a-8c3bf2201cb5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d80acf92-5447-491d-a86b-7beeef4c99a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_NetIncomeLoss_d80acf92-5447-491d-a86b-7beeef4c99a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02209e8a-a128-4036-8141-ab6a4e91b4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aef90bc5-8cba-4bda-837a-72d66fb3853b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_af5dfde1-340f-465d-b352-76acdc09ce65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:to="loc_us-gaap_RelatedPartyDomain_af5dfde1-340f-465d-b352-76acdc09ce65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:to="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9fd9a369-3b9a-4bf8-b730-bead69ef0d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:to="loc_us-gaap_NonrelatedPartyMember_9fd9a369-3b9a-4bf8-b730-bead69ef0d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_65d721a9-f4e1-472f-8779-f671efbfa9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:to="loc_us-gaap_RelatedPartyMember_65d721a9-f4e1-472f-8779-f671efbfa9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04619934-1e98-4f00-a0d9-7b97fd648ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_NetIncomeLoss_04619934-1e98-4f00-a0d9-7b97fd648ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_534fe3e6-9ccf-478c-a1b1-9db93ee0a99d" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_534fe3e6-9ccf-478c-a1b1-9db93ee0a99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_752b2202-80d7-4fe4-b6de-7ec2840a753b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_ShareBasedCompensation_752b2202-80d7-4fe4-b6de-7ec2840a753b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_be4d4de7-0014-4d0d-8ab7-f2399f5f20b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_Depreciation_be4d4de7-0014-4d0d-8ab7-f2399f5f20b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d04cfd96-7c01-45f7-b667-b2f847451610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d04cfd96-7c01-45f7-b667-b2f847451610" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d252a95-dd0b-4568-98ac-43304554652f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d252a95-dd0b-4568-98ac-43304554652f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c9e095f2-0d17-4226-a3a6-2fd1c4398abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c9e095f2-0d17-4226-a3a6-2fd1c4398abd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8019dabf-0b8e-4114-8a10-9321fad1378c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8019dabf-0b8e-4114-8a10-9321fad1378c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7266c2c-3a9a-4097-97fb-975b389e1ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7266c2c-3a9a-4097-97fb-975b389e1ce6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c5b8d5d-04ce-421c-9bf6-87cdf7a399ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c5b8d5d-04ce-421c-9bf6-87cdf7a399ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_392877b1-8c6f-487b-bf68-72db0a87140f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_392877b1-8c6f-487b-bf68-72db0a87140f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf7da128-b4fb-4ef5-ae56-e4a8c2f2249e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf7da128-b4fb-4ef5-ae56-e4a8c2f2249e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f653320-ce81-4ff4-b917-0bc4d6f88651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f653320-ce81-4ff4-b917-0bc4d6f88651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_f5d838b4-1182-48b9-a3e4-b62965e37cee" xlink:href="bcax-20240930.xsd#bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_f5d838b4-1182-48b9-a3e4-b62965e37cee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3478c5b7-b4b5-4bc1-8bba-111aa4ff8957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3478c5b7-b4b5-4bc1-8bba-111aa4ff8957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ad7dfa-a30c-4bf8-9939-94b0b6641463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ad7dfa-a30c-4bf8-9939-94b0b6641463" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64e67b31-1c6a-4f17-abee-38a81205bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64e67b31-1c6a-4f17-abee-38a81205bf5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb2b9ba1-4aea-46ec-a9be-53abede14863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb2b9ba1-4aea-46ec-a9be-53abede14863" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddb4d19-9891-43e8-8f79-870c86f98c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0b59f23b-b1d2-41be-90e5-8c8ac6ac2287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0b59f23b-b1d2-41be-90e5-8c8ac6ac2287" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_81f7422a-8df1-4661-aba0-e56559fff3c8" xlink:href="bcax-20240930.xsd#bcax_SettlementOfFreestandingFinancialInstrumentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_81f7422a-8df1-4661-aba0-e56559fff3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dd9b8265-54d2-4e6f-b6a4-0e1526ee85de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dd9b8265-54d2-4e6f-b6a4-0e1526ee85de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions_fc8ba6d2-15f6-4296-aef5-4e55b2a764be" xlink:href="bcax-20240930.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_VestingOfEarlyExerciseStockOptions_fc8ba6d2-15f6-4296-aef5-4e55b2a764be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_fa746a2b-1685-45e2-920b-1477e4dabe70" xlink:href="bcax-20240930.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_fa746a2b-1685-45e2-920b-1477e4dabe70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_87d708c2-72dc-49b2-91a1-6e8036f57c02" xlink:href="bcax-20240930.xsd#bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_87d708c2-72dc-49b2-91a1-6e8036f57c02" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e23384cf-d726-45d5-a4b3-71fab42de3a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e23384cf-d726-45d5-a4b3-71fab42de3a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b3b58f2a-7678-44ad-8ee0-feee76168c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:to="loc_us-gaap_IPOMember_b3b58f2a-7678-44ad-8ee0-feee76168c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0698d9a0-9cc4-498f-865a-c5bb8e2cc977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0698d9a0-9cc4-498f-865a-c5bb8e2cc977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2938ce67-cfa6-4cf7-8b29-e8a8bade2922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2938ce67-cfa6-4cf7-8b29-e8a8bade2922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c9b965f7-648d-4f29-89b6-7be07901e2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c9b965f7-648d-4f29-89b6-7be07901e2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2672a430-ce90-433f-b2c0-02446b0bc713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2672a430-ce90-433f-b2c0-02446b0bc713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d746ba4-bc8d-4c77-967c-75c2cd98ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d746ba4-bc8d-4c77-967c-75c2cd98ddba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3b2d7d8b-51b7-4fad-809c-afa1eaeffe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3b2d7d8b-51b7-4fad-809c-afa1eaeffe36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bd2086e6-e7a3-4d73-ae2e-c3bab472c973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bd2086e6-e7a3-4d73-ae2e-c3bab472c973" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_afc23654-3343-49ee-bc0f-2994d7637200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_afc23654-3343-49ee-bc0f-2994d7637200" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9825ee80-0357-41eb-9e60-972443eb6f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9825ee80-0357-41eb-9e60-972443eb6f43" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_194afa06-7fc1-4a5c-b151-4f6562569f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_194afa06-7fc1-4a5c-b151-4f6562569f92" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_449e34fb-dac1-42fe-b573-d0913e19b9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_449e34fb-dac1-42fe-b573-d0913e19b9c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13a9176d-9574-46cb-ba6d-01997f3339e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13a9176d-9574-46cb-ba6d-01997f3339e6" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f020b15-7102-47ce-8dc0-d8cf7d4b2018_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f020b15-7102-47ce-8dc0-d8cf7d4b2018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_75c2781f-4298-4fe6-8a0b-83871cd5021f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_us-gaap_StockCompensationPlanMember_75c2781f-4298-4fe6-8a0b-83871cd5021f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0859ae71-aace-4564-9120-5071aa4b2fd9" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0859ae71-aace-4564-9120-5071aa4b2fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ba8a8670-797a-44ce-a302-c4b5b16e7bcc" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ba8a8670-797a-44ce-a302-c4b5b16e7bcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_489b13c6-34fa-4239-a3f7-2651e2a765b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_489b13c6-34fa-4239-a3f7-2651e2a765b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e32114c-98f8-4f8b-a9c5-a1b34a36b504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e32114c-98f8-4f8b-a9c5-a1b34a36b504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0fcd18c3-2cd5-4c4f-8123-8a0d2f72647f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0fcd18c3-2cd5-4c4f-8123-8a0d2f72647f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a3560cc8-5837-458c-92a6-c3203ba5f704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a3560cc8-5837-458c-92a6-c3203ba5f704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_36bf1c04-2bfc-4820-a876-829e35e99936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_36bf1c04-2bfc-4820-a876-829e35e99936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_53dd7f37-7f76-4a0b-937b-6807a38352f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_53dd7f37-7f76-4a0b-937b-6807a38352f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c2ba59ec-7e5a-448d-9e5f-047598ab6aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c2ba59ec-7e5a-448d-9e5f-047598ab6aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b465751d-6775-4f8e-add8-de427078fdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b465751d-6775-4f8e-add8-de427078fdfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_58d9e0c2-e429-43c3-b578-f26560f819c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_58d9e0c2-e429-43c3-b578-f26560f819c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7aeab703-32c2-45d7-9a6d-ef634615ce54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7aeab703-32c2-45d7-9a6d-ef634615ce54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_aa4c7c79-910b-4bd9-8fdd-4af5df0bb049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_aa4c7c79-910b-4bd9-8fdd-4af5df0bb049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7dbd1a0d-89a6-4a41-9f77-ff560706672f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7dbd1a0d-89a6-4a41-9f77-ff560706672f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ab922d1b-b5f4-42b0-93ec-c4243904b653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ab922d1b-b5f4-42b0-93ec-c4243904b653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MeasurementInputProbabilityOfAchievementMember_a63b3cfd-b24c-45c1-9481-e4df7ae7f8b4" xlink:href="bcax-20240930.xsd#bcax_MeasurementInputProbabilityOfAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_bcax_MeasurementInputProbabilityOfAchievementMember_a63b3cfd-b24c-45c1-9481-e4df7ae7f8b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_c1035475-bd4f-40d4-b500-ede20350e21c" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:to="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_c1035475-bd4f-40d4-b500-ede20350e21c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4840e8eb-f78d-4762-9aae-bb95baacd23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:to="loc_us-gaap_RelatedPartyDomain_4840e8eb-f78d-4762-9aae-bb95baacd23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:to="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_cac7415d-cdd7-49b3-bbbc-33dac91965e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:to="loc_us-gaap_NonrelatedPartyMember_cac7415d-cdd7-49b3-bbbc-33dac91965e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_be16407b-9928-4abc-bdc7-2ec50cd80811" xlink:href="bcax-20240930.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_be16407b-9928-4abc-bdc7-2ec50cd80811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1679baef-5272-4c72-b14f-e38ec25fd0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1679baef-5272-4c72-b14f-e38ec25fd0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0e97c3ad-5d36-4149-92fd-6b4e2887e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0e97c3ad-5d36-4149-92fd-6b4e2887e1ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ae2666be-3168-4765-a828-04f422c8b6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ae2666be-3168-4765-a828-04f422c8b6c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_08d0da49-bb58-4489-bc3e-4c0cb1d7a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_08d0da49-bb58-4489-bc3e-4c0cb1d7a3d4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CommonStockDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_81796bb5-f629-41b1-9f2c-1b09bd8ae762_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:to="loc_us-gaap_ClassOfStockDomain_81796bb5-f629-41b1-9f2c-1b09bd8ae762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:to="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0f540c6d-663a-41b4-894b-4dcff67e78e0" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0f540c6d-663a-41b4-894b-4dcff67e78e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_2831c6cf-28db-45ba-bee8-8a7c8c383050" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_2831c6cf-28db-45ba-bee8-8a7c8c383050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_577436c0-ef0a-4c4e-a632-0d215a45f309" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_577436c0-ef0a-4c4e-a632-0d215a45f309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99c32f99-e71c-41c7-b987-1d2ec87dfb79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99c32f99-e71c-41c7-b987-1d2ec87dfb79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16f675fc-0e4d-496c-b826-420c174df919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:to="loc_us-gaap_RestrictedStockMember_16f675fc-0e4d-496c-b826-420c174df919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_76fb6ec9-c601-419d-9a99-cb3569b4d441_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_76fb6ec9-c601-419d-9a99-cb3569b4d441_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f6895913-742e-4b23-ab26-d365f6df2912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:to="loc_us-gaap_IPOMember_f6895913-742e-4b23-ab26-d365f6df2912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_101ae848-5358-4028-997e-470c760a3afd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:to="loc_us-gaap_EquityComponentDomain_101ae848-5358-4028-997e-470c760a3afd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:to="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_43b7d62a-549f-423b-ae4c-4a7aa91d838f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:to="loc_us-gaap_CommonStockMember_43b7d62a-549f-423b-ae4c-4a7aa91d838f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85aff99f-fee7-4cb6-bf71-33e726419434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:to="loc_us-gaap_PlanNameDomain_85aff99f-fee7-4cb6-bf71-33e726419434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:to="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2019StockOptionAndGrantPlanMember_0c4c14a6-d0ab-41aa-b753-8dcf336f42f5" xlink:href="bcax-20240930.xsd#bcax_A2019StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:to="loc_bcax_A2019StockOptionAndGrantPlanMember_0c4c14a6-d0ab-41aa-b753-8dcf336f42f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8e33721f-b1f8-4f1b-919a-2042ad50fc72_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:to="loc_dei_EntityDomain_8e33721f-b1f8-4f1b-919a-2042ad50fc72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:to="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BioconLimitedMember_35b622e0-0844-4d8b-8000-5a50751db03d" xlink:href="bcax-20240930.xsd#bcax_BioconLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:to="loc_bcax_BioconLimitedMember_35b622e0-0844-4d8b-8000-5a50751db03d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bc8ef100-3ad6-4611-8d3c-8df958e84539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bc8ef100-3ad6-4611-8d3c-8df958e84539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9909506d-d794-442e-96ea-cef0f43b70c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9909506d-d794-442e-96ea-cef0f43b70c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_76eb0641-5d03-4c89-aa32-7904eb32227a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesIssued_76eb0641-5d03-4c89-aa32-7904eb32227a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bd00cb7f-3ae4-4154-9032-25f382c938fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bd00cb7f-3ae4-4154-9032-25f382c938fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b6564e3-b37e-4697-b68c-516abb3219f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b6564e3-b37e-4697-b68c-516abb3219f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a06ab9e-c453-4932-b493-9427afe6dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a06ab9e-c453-4932-b493-9427afe6dd57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3bad3bb4-f56f-4aab-8915-2ac78b9776b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3bad3bb4-f56f-4aab-8915-2ac78b9776b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_deaa148c-8c09-4ffe-b1d6-ea9f09ee6255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_deaa148c-8c09-4ffe-b1d6-ea9f09ee6255" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0601db1f-0102-4cd0-88dc-36c9902c19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0601db1f-0102-4cd0-88dc-36c9902c19f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b9f6e5a-e123-488b-9855-e7e860f10931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b9f6e5a-e123-488b-9855-e7e860f10931" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a910403d-4055-4d93-8bab-8a19e60e833f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a910403d-4055-4d93-8bab-8a19e60e833f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2f8bf01c-5be6-4147-810b-4572855128f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2f8bf01c-5be6-4147-810b-4572855128f5" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7256b0f-9765-4695-9812-1565d21392b9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7256b0f-9765-4695-9812-1565d21392b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BioconLimitedMember_8a610880-4bee-4d40-97b0-6432d9c8a71c" xlink:href="bcax-20240930.xsd#bcax_BioconLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:to="loc_bcax_BioconLimitedMember_8a610880-4bee-4d40-97b0-6432d9c8a71c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:to="loc_us-gaap_ClassOfStockDomain_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:to="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_1bfb4b93-364e-490e-8b82-3cfc266d777f" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_1bfb4b93-364e-490e-8b82-3cfc266d777f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_a7ee3500-f4a7-4b5c-bf2c-5e20ddb7292e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_a7ee3500-f4a7-4b5c-bf2c-5e20ddb7292e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_4edeb847-a307-4548-af5d-6604de797c2f" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_4edeb847-a307-4548-af5d-6604de797c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bc81139f-2ba9-4dd9-af6c-9187291010a7" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bc81139f-2ba9-4dd9-af6c-9187291010a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsMember_644031f5-b1da-47d5-bdd2-ef78823e1a27" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:to="loc_bcax_TwoInvestorsMember_644031f5-b1da-47d5-bdd2-ef78823e1a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember_487d60cd-2b4e-45fa-b35c-2bebcc820ea0" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsRelativesOfBoardMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:to="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember_487d60cd-2b4e-45fa-b35c-2bebcc820ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_59db5ec9-04dc-4bf5-bac8-8af88833e7a1" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_59db5ec9-04dc-4bf5-bac8-8af88833e7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0e94f852-f416-470e-84ac-7a4acb60b549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0e94f852-f416-470e-84ac-7a4acb60b549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_a6b18afb-62b6-49c3-9ec6-49efc9562043" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_a6b18afb-62b6-49c3-9ec6-49efc9562043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_9b3e2521-686e-40db-903b-c307c2b999dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_9b3e2521-686e-40db-903b-c307c2b999dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_f7482dd5-5c9d-453c-93a5-baff2624b2e1" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_f7482dd5-5c9d-453c-93a5-baff2624b2e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_e8186308-97ea-476c-a049-3d2b632daebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_e8186308-97ea-476c-a049-3d2b632daebc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ef4954db-14bb-484f-8f80-8d86d9f40c21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ef4954db-14bb-484f-8f80-8d86d9f40c21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued_ef69d0c0-8ae2-443b-bdc6-57285d502a12" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityNumberOfInvestorsStockIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued_ef69d0c0-8ae2-443b-bdc6-57285d502a12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c1ea4207-ffe0-4a5f-870d-8704de3e2102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c1ea4207-ffe0-4a5f-870d-8704de3e2102" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue_4dc8465a-364c-4a05-9ed7-a71c23ffced3" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue_4dc8465a-364c-4a05-9ed7-a71c23ffced3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_d6b043c1-4148-4650-a0dc-d3db6bc89c2a" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_d6b043c1-4148-4650-a0dc-d3db6bc89c2a" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ffbc62bc-768c-40a1-890f-54307e6e3a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:to="loc_us-gaap_ClassOfStockDomain_ffbc62bc-768c-40a1-890f-54307e6e3a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:to="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_fb0eab05-0467-45e0-9f92-0fea731fc63e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_fb0eab05-0467-45e0-9f92-0fea731fc63e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bbf013aa-2f3b-4c68-bd0c-73626f30d356" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bbf013aa-2f3b-4c68-bd0c-73626f30d356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityDividendRatePercentage_1e7141ec-78c7-47a9-a372-f6721700495c" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:to="loc_bcax_TemporaryEquityDividendRatePercentage_1e7141ec-78c7-47a9-a372-f6721700495c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockVotingRightsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_67458477-a505-40e1-adb3-ea4e57c11edd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:to="loc_us-gaap_ClassOfStockDomain_67458477-a505-40e1-adb3-ea4e57c11edd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:to="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_b1f16c34-5cff-4a01-b3c0-11708ff2c54b" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_b1f16c34-5cff-4a01-b3c0-11708ff2c54b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_31493863-b9fb-41f7-afcb-3503110dc9ee" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_31493863-b9fb-41f7-afcb-3503110dc9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_d78f6a7b-fd6e-48d9-bc1a-efecf561f1fa" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_d78f6a7b-fd6e-48d9-bc1a-efecf561f1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_NumberOfMembersBoardOfDirectors_6acc1467-acbd-48be-90d8-b09e901ec195" xlink:href="bcax-20240930.xsd#bcax_NumberOfMembersBoardOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_NumberOfMembersBoardOfDirectors_6acc1467-acbd-48be-90d8-b09e901ec195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_0d2df0fb-709f-42f4-bb27-1729fb87db65" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_0d2df0fb-709f-42f4-bb27-1729fb87db65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a923d89-d70c-4e61-a8be-df4083657b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a923d89-d70c-4e61-a8be-df4083657b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_4678938c-49f7-4e6c-ad1d-98c9a56d392b" xlink:href="bcax-20240930.xsd#bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_4678938c-49f7-4e6c-ad1d-98c9a56d392b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockProtectiveProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6e379d33-56ba-4232-a486-2b248ffe15fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:to="loc_us-gaap_ClassOfStockDomain_6e379d33-56ba-4232-a486-2b248ffe15fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:to="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_38615578-466a-44bc-9428-64df9e6aba19" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_38615578-466a-44bc-9428-64df9e6aba19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_3cebdce5-72a9-4f52-9056-f5ea8e0a3aa3" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_3cebdce5-72a9-4f52-9056-f5ea8e0a3aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_bf6f6619-8153-49e0-84fc-4a3e2600720f" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:to="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_bf6f6619-8153-49e0-84fc-4a3e2600720f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_f7b6f2cd-6f9b-4b71-9f39-31c0633d2aa6" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:to="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_f7b6f2cd-6f9b-4b71-9f39-31c0633d2aa6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:to="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f3d5b505-55b5-4d6a-8ed8-b9d512850e50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:to="loc_us-gaap_PlanNameDomain_f3d5b505-55b5-4d6a-8ed8-b9d512850e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:to="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2019StockOptionAndGrantPlanMember_9e66d49e-8bab-4dfa-8435-5a22be22c8dd" xlink:href="bcax-20240930.xsd#bcax_A2019StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:to="loc_bcax_A2019StockOptionAndGrantPlanMember_9e66d49e-8bab-4dfa-8435-5a22be22c8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember_f762f28f-f497-4225-a9db-f66703aa0e18" xlink:href="bcax-20240930.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:to="loc_bcax_A2024StockOptionAndGrantPlanMember_f762f28f-f497-4225-a9db-f66703aa0e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:to="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_beb5576f-3bb7-4858-94e8-b28343d73a34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_beb5576f-3bb7-4858-94e8-b28343d73a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_039a08ad-d489-4263-bc9d-a6e040713919" xlink:href="bcax-20240930.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_039a08ad-d489-4263-bc9d-a6e040713919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c61de3e4-f9fe-4d2d-85f9-af57c1701bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_RestrictedStockMember_c61de3e4-f9fe-4d2d-85f9-af57c1701bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0af28a30-8b70-4fff-8aae-2963644680fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0af28a30-8b70-4fff-8aae-2963644680fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0f15bb76-1b25-48fb-b792-346ba16d494c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_EmployeeStockMember_0f15bb76-1b25-48fb-b792-346ba16d494c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_eb603de1-8f05-4ae2-8371-fa825f03648c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_eb603de1-8f05-4ae2-8371-fa825f03648c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a9aa0753-db72-4edc-8ed1-f10c08c25434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a9aa0753-db72-4edc-8ed1-f10c08c25434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_000ddcf2-28ad-4402-a113-ceed5b3870b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_000ddcf2-28ad-4402-a113-ceed5b3870b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_d285e47c-d464-4b4f-bf9a-3bf1c3d1da09" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_d285e47c-d464-4b4f-bf9a-3bf1c3d1da09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_42081bc6-979f-4e89-ab6d-c035b758a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_42081bc6-979f-4e89-ab6d-c035b758a78c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1b166f25-cee3-4590-840a-f045baa4341e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1b166f25-cee3-4590-840a-f045baa4341e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e67e5ce9-9814-4f57-8af7-1f97717d9c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e67e5ce9-9814-4f57-8af7-1f97717d9c11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b01a6e51-a9f6-4aaf-ab43-db4173d01a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b01a6e51-a9f6-4aaf-ab43-db4173d01a86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0b28d3fc-86ef-4281-8736-d2790046dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0b28d3fc-86ef-4281-8736-d2790046dc77" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a51b0467-de0e-47be-bddb-2f8165f66d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a51b0467-de0e-47be-bddb-2f8165f66d55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96540d9b-5867-4f49-9abd-20baad94c82b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96540d9b-5867-4f49-9abd-20baad94c82b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_a282e8fb-1371-4314-8089-fd00cc4a9192" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_a282e8fb-1371-4314-8089-fd00cc4a9192" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c3e90503-55cc-4d30-8940-bbcc19f42754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c3e90503-55cc-4d30-8940-bbcc19f42754" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c2523c8-1092-484a-bed7-f819ec53eb95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c2523c8-1092-484a-bed7-f819ec53eb95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4bed86cd-cc45-4b27-9677-4977123b8811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4bed86cd-cc45-4b27-9677-4977123b8811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f541138-fbc8-4bfa-8237-25a434a13a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f541138-fbc8-4bfa-8237-25a434a13a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77ff33ee-73d7-4fdf-835b-7797cb85b13e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77ff33ee-73d7-4fdf-835b-7797cb85b13e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationRSAAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:to="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d919b44a-4e12-46b0-ad6c-003bda57100d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d919b44a-4e12-46b0-ad6c-003bda57100d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f0bd7081-1157-4a74-a494-fc4c37408aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:to="loc_us-gaap_RestrictedStockMember_f0bd7081-1157-4a74-a494-fc4c37408aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cf098a3-e9d4-4ad6-b30a-7a87eb47ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cf098a3-e9d4-4ad6-b30a-7a87eb47ddf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_828e5379-8a29-42c6-b1f7-cc2116c14cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_828e5379-8a29-42c6-b1f7-cc2116c14cd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66720906-36d9-43eb-8535-3a2d054a6c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66720906-36d9-43eb-8535-3a2d054a6c17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_481fd8bc-1ebd-4aa7-a232-7b98fe5ebc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_481fd8bc-1ebd-4aa7-a232-7b98fe5ebc3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea88e913-f3e8-4448-8b21-2cc25a0731a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f9a5293-a793-4d3f-9412-ee7bf3079490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f9a5293-a793-4d3f-9412-ee7bf3079490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_864bdf45-978d-406b-9a20-ca709b4e22c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_864bdf45-978d-406b-9a20-ca709b4e22c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2ab3808e-d4a8-4d40-b371-0b4987ebb846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2ab3808e-d4a8-4d40-b371-0b4987ebb846" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a2ad1a0d-80eb-4eaa-be84-e23239fa46e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a2ad1a0d-80eb-4eaa-be84-e23239fa46e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3cc26455-94a8-48ca-997e-12866dc7ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreementsRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_29611a5d-39bb-49cb-b0a3-bd06e451f339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_29611a5d-39bb-49cb-b0a3-bd06e451f339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember_0550c88c-b551-4907-a264-ad0005472765" xlink:href="bcax-20240930.xsd#bcax_MasterServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_MasterServicesAgreementMember_0550c88c-b551-4907-a264-ad0005472765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember_699b5440-e99d-4f04-a2c7-39c6d053a729" xlink:href="bcax-20240930.xsd#bcax_BBLAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_BBLAgreementsMember_699b5440-e99d-4f04-a2c7-39c6d053a729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementManufacturingMember_2e70a9f2-13ae-4f0d-a774-1025504d8174" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementManufacturingMember_2e70a9f2-13ae-4f0d-a774-1025504d8174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementMasterContractServicesMember_e94de7f2-aa5e-4093-b6b0-58bbf4edc327" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementMasterContractServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementMasterContractServicesMember_e94de7f2-aa5e-4093-b6b0-58bbf4edc327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember_e31f7e34-812d-44e8-83c7-3a3fdd896f2a" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementsMember_e31f7e34-812d-44e8-83c7-3a3fdd896f2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BiofusionAgreementMember_b111e87b-e036-462b-ada4-b1749ce66446" xlink:href="bcax-20240930.xsd#bcax_BiofusionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_BiofusionAgreementMember_b111e87b-e036-462b-ada4-b1749ce66446" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PromissoryNoteMember_7196a5b2-5c6c-468b-9eb8-cc2934f97bac" xlink:href="bcax-20240930.xsd#bcax_PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_PromissoryNoteMember_7196a5b2-5c6c-468b-9eb8-cc2934f97bac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bb12a301-529a-4095-8f37-7e5cdfa20020_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:to="loc_us-gaap_RelatedPartyDomain_bb12a301-529a-4095-8f37-7e5cdfa20020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:to="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b8fd0be5-2463-4dbf-8703-224b9aed2362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:to="loc_us-gaap_RelatedPartyMember_b8fd0be5-2463-4dbf-8703-224b9aed2362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_e097bf52-3346-4911-a0aa-01e7c046432a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:to="loc_srt_ChiefFinancialOfficerMember_e097bf52-3346-4911-a0aa-01e7c046432a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6cfaab20-4dba-415b-a3b8-abe864bab162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6cfaab20-4dba-415b-a3b8-abe864bab162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2a47f84c-317e-44a1-aaaf-5cfee3052e40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2a47f84c-317e-44a1-aaaf-5cfee3052e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RelatedPartyAgreementTerm_d2a7fc87-5482-4876-8e0b-d9ae7c18978f" xlink:href="bcax-20240930.xsd#bcax_RelatedPartyAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_bcax_RelatedPartyAgreementTerm_d2a7fc87-5482-4876-8e0b-d9ae7c18978f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8bbc514b-868f-4cd6-80cb-fb31f0a46f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_LiabilitiesCurrent_8bbc514b-868f-4cd6-80cb-fb31f0a46f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8a564e04-7463-4edb-8eb1-fe55fed013ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_AccountsPayableCurrent_8a564e04-7463-4edb-8eb1-fe55fed013ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2dd66583-f044-48ad-abcf-d040f22f60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2dd66583-f044-48ad-abcf-d040f22f60cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ececfbb6-17d3-4051-8baa-b7fcd29381b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ececfbb6-17d3-4051-8baa-b7fcd29381b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DebtInstrumentCollateralPledgedShares_28f67799-a9e3-40ff-b88d-cac0e714b074" xlink:href="bcax-20240930.xsd#bcax_DebtInstrumentCollateralPledgedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_bcax_DebtInstrumentCollateralPledgedShares_28f67799-a9e3-40ff-b88d-cac0e714b074" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eccf8223-b802-4479-885d-cc38a0e7f8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eccf8223-b802-4479-885d-cc38a0e7f8e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83f5f272-3815-4a89-b8eb-e8a83aebf0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83f5f272-3815-4a89-b8eb-e8a83aebf0f6" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:to="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06a201bb-90c0-4385-8cd9-90a034d8e163_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06a201bb-90c0-4385-8cd9-90a034d8e163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember_f8c21734-e4a3-4bf0-a0ce-9ccff875b236" xlink:href="bcax-20240930.xsd#bcax_IQVIARDSIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:to="loc_bcax_IQVIARDSIncMember_f8c21734-e4a3-4bf0-a0ce-9ccff875b236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:to="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_5fae5b22-1ad4-4736-9f18-99fc3d7a6571_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:to="loc_us-gaap_OtherCommitmentsDomain_5fae5b22-1ad4-4736-9f18-99fc3d7a6571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember_ebdc33b0-b312-4af7-93b5-b1342176e327" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementMember_ebdc33b0-b312-4af7-93b5-b1342176e327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_40ff9c77-1468-4617-ac5e-567da0309b74" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_40ff9c77-1468-4617-ac5e-567da0309b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_91fe4a53-fc43-4d34-8627-e318785c0945" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_91fe4a53-fc43-4d34-8627-e318785c0945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_ecf5a8a8-6fd3-4667-a8d2-0b188a089ed0" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_ecf5a8a8-6fd3-4667-a8d2-0b188a089ed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_ae47edd1-93e5-49c2-8023-5141ea686d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_OtherCommitment_ae47edd1-93e5-49c2-8023-5141ea686d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_b04b12b2-c8ca-4698-aef5-25d992726a61" xlink:href="bcax-20240930.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_b04b12b2-c8ca-4698-aef5-25d992726a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_49dbad07-00ea-40af-80e0-cd719c86e204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_OperatingExpenses_49dbad07-00ea-40af-80e0-cd719c86e204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments_370311c0-8a93-460c-b1aa-252f21b0d271" xlink:href="bcax-20240930.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_bcax_PaymentsForOtherCommitments_370311c0-8a93-460c-b1aa-252f21b0d271" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_49c4af8a-23a2-44c6-9833-f7598e8d0946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_AccountsPayableCurrent_49c4af8a-23a2-44c6-9833-f7598e8d0946" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b33d8c8-1300-46d8-bee4-046e3e8671b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b33d8c8-1300-46d8-bee4-046e3e8671b7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:to="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3f41d4f2-c48c-4f85-b007-67ef0c85da40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3f41d4f2-c48c-4f85-b007-67ef0c85da40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3a75aded-4b66-4517-8840-4122045404c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:to="loc_us-gaap_SubsequentEventMember_3a75aded-4b66-4517-8840-4122045404c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LesseeOperatingLeaseAreaOfProperty_4fb17a4c-6072-47c0-933f-023805f62db4" xlink:href="bcax-20240930.xsd#bcax_LesseeOperatingLeaseAreaOfProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:to="loc_bcax_LesseeOperatingLeaseAreaOfProperty_4fb17a4c-6072-47c0-933f-023805f62db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d91b20fe-9889-4d26-942c-a33328826692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d91b20fe-9889-4d26-942c-a33328826692" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_46bc705a-5e46-4135-98c3-c1e275a22759" xlink:href="bcax-20240930.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_46bc705a-5e46-4135-98c3-c1e275a22759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bcax-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bcax_PaymentsForOtherCommitments_36688f6c-f99d-4df7-ab6b-748b9d0699d5_terseLabel_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid</link:label>
    <link:label id="lab_bcax_PaymentsForOtherCommitments_label_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Other Commitments</link:label>
    <link:label id="lab_bcax_PaymentsForOtherCommitments_documentation_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Other Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments" xlink:href="bcax-20240930.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_PaymentsForOtherCommitments" xlink:to="lab_bcax_PaymentsForOtherCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bca932a8-0167-4a36-a96d-a5bb30287109_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_de85a420-9509-4504-8d59-af059833f5da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Agreements &#8211; Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_655b7211-af77-43ce-a2e3-3263679550f0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e07cab08-f048-4842-a552-f399f6499360_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9cb0d706-98c5-4bf5-8e0d-89563b79f1fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ab9b12fc-3cdb-4f59-ad25-9d88d81c94cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_07eaa09d-9161-4eff-ac48-4a52d351dc4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8d61410a-6a5a-40b3-a445-26aa88ce6f39_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f572bcf4-d9d4-4180-b4c1-59c2ddb767aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c6bf7a34-b573-43aa-940c-6a5ed38f869f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_577cefe9-d77c-4c27-ace4-3f334c601b49_terseLabel_en-US" xlink:label="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of Series B preferred stock tranche rights, upon issuance of milestone shares</link:label>
    <link:label id="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_label_en-US" xlink:label="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Freestanding Financial Instrument Liabilities</link:label>
    <link:label id="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_documentation_en-US" xlink:label="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Freestanding Financial Instrument Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:href="bcax-20240930.xsd#bcax_SettlementOfFreestandingFinancialInstrumentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:to="lab_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c573ea7f-5162-48db-b688-3a827194b25d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a9c7c441-f74e-4603-b629-620d4a6632d7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_90c820eb-2f74-440c-9652-f7bde8364e67_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dd6956e5-c13b-4e4a-a5c6-90a9462fd054_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability &#8211; net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2847ccb-76b5-48a4-b934-5b9270957cb9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ef7c05a-bdce-407c-8940-7efea560fa04_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1b12eed9-9a6d-4a1b-b83d-d63b2ff4e545_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_752e2428-8e8a-41d2-b324-abd5c7afb25f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7d9a68b8-1728-480e-9ce3-9acfc14d375b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6df82bd5-1fc4-4295-a1f2-54af231bf240_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MeasurementInputProbabilityOfAchievementMember_91c455df-759d-406d-a401-4b71e5386ec8_terseLabel_en-US" xlink:label="lab_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of achievement</link:label>
    <link:label id="lab_bcax_MeasurementInputProbabilityOfAchievementMember_label_en-US" xlink:label="lab_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability of Achievement [Member]</link:label>
    <link:label id="lab_bcax_MeasurementInputProbabilityOfAchievementMember_documentation_en-US" xlink:label="lab_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability of Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:href="bcax-20240930.xsd#bcax_MeasurementInputProbabilityOfAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:to="lab_bcax_MeasurementInputProbabilityOfAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_e6c38d39-9b9f-4ee4-b05d-6c4044b3e427_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d07281eb-2a26-45f5-8a2c-549f310bf215_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_4507d1f7-0694-461a-b388-3d0059957e35_terseLabel_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercise stock options</link:label>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_label_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of Early Exercise Stock Options</link:label>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_documentation_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting of Early Exercise Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions" xlink:href="bcax-20240930.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_VestingOfEarlyExerciseStockOptions" xlink:to="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_95945d00-f247-4e08-89c4-68305e44eb18_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds included within Cash and cash equivalent</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c0771be-2904-45a3-aad2-2a5a6990f039_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_c52cbf27-3549-43e0-a551-b5bfcd222bd0_terseLabel_en-US" xlink:label="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value recognized upon the issuance of preferred stock tranche rights</link:label>
    <link:label id="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_label_en-US" xlink:label="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Upon Issuance Of Freestanding Financial Instrument</link:label>
    <link:label id="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_documentation_en-US" xlink:label="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Upon Issuance Of Freestanding Financial Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:href="bcax-20240930.xsd#bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:to="lab_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42a05e85-1680-4de4-9f1c-75c16e7e3c07_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f572547f-062e-438b-9430-6d09ddde2300_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c345e48b-a3ef-4101-8865-53bab0da529a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_98c20f67-54a8-4c28-9089-f1ff5ca74c05_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_35b89a37-43f8-4e0a-ae48-9cce24be486b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9e7bf607-eda8-4ded-bbe3-32bb2aa895fd_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9db4d90-9dc1-4052-91b3-f8827c4c8c82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f9824e5f-e770-49c3-9182-4cd7e1e09223_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fc6bd21c-4fa2-4794-b83f-fac6efffdbb5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fcdcb0a8-7328-4b71-93b4-6d60d22536f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46d7140f-5dd8-46bb-9ae0-f007e82329bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_DebtInstrumentCollateralPledgedShares_d6e11a64-b63f-4cc5-b15b-22e8c520f63f_terseLabel_en-US" xlink:label="lab_bcax_DebtInstrumentCollateralPledgedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares pledged as collateral (in shares)</link:label>
    <link:label id="lab_bcax_DebtInstrumentCollateralPledgedShares_label_en-US" xlink:label="lab_bcax_DebtInstrumentCollateralPledgedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Collateral Pledged, Shares</link:label>
    <link:label id="lab_bcax_DebtInstrumentCollateralPledgedShares_documentation_en-US" xlink:label="lab_bcax_DebtInstrumentCollateralPledgedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Collateral Pledged, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DebtInstrumentCollateralPledgedShares" xlink:href="bcax-20240930.xsd#bcax_DebtInstrumentCollateralPledgedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_DebtInstrumentCollateralPledgedShares" xlink:to="lab_bcax_DebtInstrumentCollateralPledgedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_517bfab5-6435-474a-8d1b-8d80c29afbe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_491e97f4-1ba4-4037-8d16-46a2858cbba5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_53312655-5f9b-40b7-9bdd-685f7f332b03_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b5bc9d10-02f6-48c5-8477-3b8ac9cc57e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_PromissoryNoteMember_c0870ee7-82d5-45b6-8242-8ff3dc328911_terseLabel_en-US" xlink:label="lab_bcax_PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory Note</link:label>
    <link:label id="lab_bcax_PromissoryNoteMember_label_en-US" xlink:label="lab_bcax_PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory Note [Member]</link:label>
    <link:label id="lab_bcax_PromissoryNoteMember_documentation_en-US" xlink:label="lab_bcax_PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PromissoryNoteMember" xlink:href="bcax-20240930.xsd#bcax_PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_PromissoryNoteMember" xlink:to="lab_bcax_PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b0fec51-4a8e-4a35-b7b0-e53008ff129c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62858c3a-e60a-48de-b85e-97b82ba943fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_464434bc-33af-4155-9cbc-a8f9b6e46672_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_45c93c9a-5844-482c-9b72-4059c198e21f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_61511e76-27c1-4eb5-95e7-86c7b7b6ce79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_37e9f8b0-d906-454a-9c33-5cd33deef361_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8fd3be4d-f0aa-4a86-b201-dbf0fa7beacb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual base rental expense under lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_213f5438-aaa0-4e6c-bcba-c0ef9e26fa51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0edfeb07-cd84-4927-aee1-3fa8532209df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_676534a4-a1bd-4a91-8245-afc663e23e44_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e648acc7-439b-4970-970b-71153f79b96e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4eb003c1-ab4e-486b-b64c-cf55498b5575_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1a14b724-709d-4993-b336-6f041a6827c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_A2019StockOptionAndGrantPlanMember_75b02d8a-086d-4529-b1b6-a71c47732b5a_terseLabel_en-US" xlink:label="lab_bcax_A2019StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Stock Option And Grant Plan</link:label>
    <link:label id="lab_bcax_A2019StockOptionAndGrantPlanMember_label_en-US" xlink:label="lab_bcax_A2019StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Stock Option And Grant Plan [Member]</link:label>
    <link:label id="lab_bcax_A2019StockOptionAndGrantPlanMember_documentation_en-US" xlink:label="lab_bcax_A2019StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Stock Option And Grant Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2019StockOptionAndGrantPlanMember" xlink:href="bcax-20240930.xsd#bcax_A2019StockOptionAndGrantPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_A2019StockOptionAndGrantPlanMember" xlink:to="lab_bcax_A2019StockOptionAndGrantPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_RelatedPartyAgreementTerm_8e80acb7-7749-455b-b66d-438e95ae6bc5_terseLabel_en-US" xlink:label="lab_bcax_RelatedPartyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party agreement, term</link:label>
    <link:label id="lab_bcax_RelatedPartyAgreementTerm_label_en-US" xlink:label="lab_bcax_RelatedPartyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Agreement, Term</link:label>
    <link:label id="lab_bcax_RelatedPartyAgreementTerm_documentation_en-US" xlink:label="lab_bcax_RelatedPartyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RelatedPartyAgreementTerm" xlink:href="bcax-20240930.xsd#bcax_RelatedPartyAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_RelatedPartyAgreementTerm" xlink:to="lab_bcax_RelatedPartyAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_929b6dc1-e4ba-4dfe-828d-c7514ece589c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ef279d34-d26e-4368-977f-c12e319f236b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_633080a2-0866-429f-84cb-cd67bbec4079_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ba872b2b-29f8-4a79-a750-7bbfb5b1481a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price. Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2e0ba4a0-2c8f-44cd-b714-123ed6215bb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_e78f6172-d7b4-4973-a32c-9ce6cc10249c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial payment amount</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a9b58828-6e85-4d8b-a2db-63825f3d529d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a262ee0-7a84-474a-aa10-25ccf5a6ce8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39f6628d-3624-45ff-b74e-713a257e4057_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1cbf6ebf-99be-4ffd-afba-aa890ff5e011_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability &#8211; current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ae4b5a33-3d61-48be-a04b-26791e25243b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_ee24712e-aa05-4dc6-ad03-47a784a3ece5_terseLabel_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="bcax-20240930.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_99b1f47d-424b-40d1-b17a-6c880e169c4f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_93f33e13-457a-4867-a9a3-fde0cbb1f080_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6ccb4d91-3c91-42e7-a5c7-543fafcab78d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89e8602d-ea3d-4e70-a86c-3ddd0c82976c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_aa8ee922-9253-4f57-a5e8-b259577590f4_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ddc57e2-8cc0-4c9d-a74f-533a39fa6266_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9244a049-02c2-40b6-a2a6-6cbe0330d7f2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b15a4c85-1222-43a6-a174-8cffc15974d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_46809049-7259-4a4e-b0be-e4db3ae35751_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ccaad83-a2f5-4fe2-b7db-7893c1cdd694_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_48aa1d41-48cf-4ee1-9f6d-22d991007b2c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f6b1695e-b480-4d92-90d6-3c6a9933397c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ed1df430-c9e6-470c-92aa-316f1eacda93_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_20d14520-f4cc-4e83-bd2f-0dede5728b56_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_09d17360-4913-418a-afc3-240f7fcff087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_8f70c381-33f5-4b3b-82fa-c8f2b93a34c2_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_label_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:to="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ed0ac1c-5ce0-42d3-80df-3f1bbbe1ff31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_658415a8-58d6-49f7-9576-c8b797834bb2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d11aa846-5060-423a-b983-edeed7f351a9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_86e6619f-8d89-4532-82ff-7947bd20a647_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_38454a0d-4a78-45fe-bd9b-a0ae252d4c07_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock and preferred stock tranche rights, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2d409820-a59e-4839-bc2d-b05cca4ab5da_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_506c32b2-b95c-4fe3-8a3f-75e8d097e26e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5c53cc87-2084-4e8a-8dab-e80117a082c6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_01ee8e3c-5bb3-41c5-a4c5-7e6047d210b6_terseLabel_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="bcax-20240930.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_0501213c-5483-4afb-88cb-74eef183b2b7_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_967712e8-9fab-44fa-8061-95d69c73349f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_3d426674-678f-490c-ada4-97bc2263abc0_terseLabel_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase in future issuance reserved share</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_label_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_documentation_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:to="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c6d8f081-47da-44db-bb51-de1fabee82f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37056cbd-ab55-4cff-9558-69386735ef3b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_5d59ebbe-540f-49eb-9df6-ac90386300eb_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from issuance</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_label_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Gross</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:to="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_106a9854-4729-40b8-86a4-72a0d64a626e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c68b8ef2-ca13-4f4c-8676-87161ddddf1a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6870d910-6760-46aa-aa27-d017ad498213_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IQVIARDSIncMember_0a57a3c3-f919-49cd-98e6-54ed0bd0521c_terseLabel_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc</link:label>
    <link:label id="lab_bcax_IQVIARDSIncMember_label_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc [Member]</link:label>
    <link:label id="lab_bcax_IQVIARDSIncMember_documentation_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember" xlink:href="bcax-20240930.xsd#bcax_IQVIARDSIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IQVIARDSIncMember" xlink:to="lab_bcax_IQVIARDSIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SyngeneAgreementsMember_2bf82cca-dc26-4d53-887a-aa483288f69b_terseLabel_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syngene Agreements</link:label>
    <link:label id="lab_bcax_SyngeneAgreementsMember_label_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syngene Agreements [Member]</link:label>
    <link:label id="lab_bcax_SyngeneAgreementsMember_documentation_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syngene Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SyngeneAgreementsMember" xlink:to="lab_bcax_SyngeneAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f2164cad-8ced-4893-822b-d66f19f5cc7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_33ac59fe-f618-4504-87ea-6e9e89a285a2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04d5e5ff-3fec-48f5-b506-935db67c0873_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_821de505-bd56-4dd7-b1c9-5f0a3c21d381_terseLabel_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock, Milestone Shares</link:label>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_label_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock, Milestone Shares [Member]</link:label>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_documentation_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock, Milestone Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:to="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_277be4a5-5f02-40b8-ad5b-57d236457232_terseLabel_en-US" xlink:label="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seed Series Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seed Series Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seed Series Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:to="lab_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d30f9ae2-9b50-416e-a33c-b4024ff3c806_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44abc62-f9bf-41e9-bb56-d0daa427b5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49063184-9c3a-408b-b53b-ba675d8d704b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_39e43202-584f-4de1-af69-3e10aa77696b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember_a891a51c-1fc2-4f28-8912-adfd939a54c9_terseLabel_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_bcax_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_bf8d20ed-2883-4929-945d-e4b62fdceb7d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_52c5701d-c03c-4c5a-a1f6-d9196322fcef_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e98205e2-1ae1-45ae-87c3-0db62ecdd431_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_22035e8e-dc08-441e-a451-960dee9600a3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4ca6e089-6e3c-4a53-b357-55121442391c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_324de62a-0cff-4087-9474-1996d705f02e_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment</link:label>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_label_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:to="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_263777a6-d319-41b0-8d2d-66d4439e7072_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Pronouncements Issued and Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4e9ab759-7b3b-4101-ac79-08b71543e2b8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ed7332f7-9bc3-42c6-815d-d3d56492e393_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_bb70c6a2-25a0-498e-a13a-54e662e317d8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c76ecf8c-a6c6-4fc3-adff-c305c78ff0b7_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_faa23151-ae79-4558-be6e-dae5dd9cf8f2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d8998b74-7530-4b84-ae96-5dac49b71678_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_503cb173-fabf-483a-827a-57654692ed6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fa8a8ec3-2510-47d1-b299-a239d9047f38_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cde75ceb-5052-4cd1-8363-ad5a8838e0d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_16161165-bd3c-4676-bdc7-e25b32a45d1e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a9f069b5-ca8a-496b-b746-980cc77de3e0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_44a1b53f-bf3e-4c15-962b-4a6576099e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2d897ece-5b12-4718-87e2-5f7015287771_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_82b9be50-2bd6-4eea-b3d7-42390a027a87_terseLabel_en-US" xlink:label="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock and preferred stock tranche rights, net</link:label>
    <link:label id="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_label_en-US" xlink:label="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability</link:label>
    <link:label id="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_documentation_en-US" xlink:label="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:href="bcax-20240930.xsd#bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:to="lab_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9cc3b1d1-dd2e-41a6-9071-8f0f75732cbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityDividendRatePercentage_f059ce45-7704-4b55-99fd-0d6fb0243cc5_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_bcax_TemporaryEquityDividendRatePercentage_label_en-US" xlink:label="lab_bcax_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:label id="lab_bcax_TemporaryEquityDividendRatePercentage_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityDividendRatePercentage" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityDividendRatePercentage" xlink:to="lab_bcax_TemporaryEquityDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d99b5ef0-7b28-41ef-93ff-6b538b87f4e9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expenses) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc45c154-1fa8-4646-aea9-4b4258e035dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock_7001399d-eb4c-4d3c-97be-8054fcbbb54e_terseLabel_en-US" xlink:label="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Tranche Rights</link:label>
    <link:label id="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Freestanding Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Freestanding Financial Instruments, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:href="bcax-20240930.xsd#bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:to="lab_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aa42ceae-e93b-4178-8982-2aa350285502_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adc1588a-f1d6-4623-8e91-67aa0a96e891_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized share-based compensation cost, period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7fb25532-e98a-452e-8b2c-947b9ee53f94_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6698b13b-3797-424d-94ff-122ac51e8bbd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0d40041a-48ff-4785-aeb2-5172d9cdfa7f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0e376022-c469-4c45-a5d2-8d0ccd5fe38a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cfb9e1c4-3b45-4a52-b9d0-122ea8239b78_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_42b1be99-ce7a-447b-ae94-eb2cd7f88ce6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus and payroll related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_754e422b-655e-4e2a-bd4e-fbf73b51e344_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_009f393a-57b6-4b4e-ab16-485d97e90fb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ba90f7d7-5ad5-4bcf-ba48-c5ef2f9a28e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_4c71e6b8-d89a-4a7d-a413-b3c8da6ec48c_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33d6787a-c9a0-466b-951e-c7dbdfd623ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_244c5bbd-3d01-4c4e-99e2-1b574341c018_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a3d31413-2b69-4bf5-b078-de76803290e9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3f96b3b3-8b11-46f5-8485-3d0eec09b620_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSA Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_a312fc6b-ab3c-4696-b454-e5682e09d433_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_44862c0d-3230-4965-9c3a-d3c5d94b12e3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember_cf0d5c6e-56e9-4039-a73d-dcfcbcea8840_terseLabel_en-US" xlink:label="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Investors, Relatives Of Board Member</link:label>
    <link:label id="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember_label_en-US" xlink:label="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Investors, Relatives Of Board Member [Member]</link:label>
    <link:label id="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember_documentation_en-US" xlink:label="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Investors, Relatives Of Board Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsRelativesOfBoardMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:to="lab_bcax_TwoInvestorsRelativesOfBoardMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_02a28680-8a7e-4e6f-b167-87f9f4520d60_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_b700747b-a215-4663-80b3-2f824bc51aa1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8279ccf7-f481-497b-bc4d-a300189abead_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bd3d533b-e152-43e2-ae67-c27de83ad430_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_df844e54-192e-43eb-ab36-b34f48aa753b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_59441535-1a39-4a36-a0aa-a9c4ebccd95a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_132e4d2b-676d-46f4-aab1-0524aa3dfd5e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember_d2aa29c6-8520-423a-88b9-faad3ddafff6_terseLabel_en-US" xlink:label="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lab_bcax_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_ca1a7f48-f8d3-4430-9bc7-4859a6475afa_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f74b877f-b49f-4825-83b9-2851b8039a88_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da7a623d-5961-49d3-8a05-ec9bb1ad97b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_900d68c3-b88e-4abc-bf08-94b00e8a97e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0a408b8b-fb30-4b11-8479-5ea00a480f6f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4deab229-a6fd-4161-b641-af6bd1cb7c2b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of September 30, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SyngeneAgreementMasterContractServicesMember_3fe844da-1a66-4c24-8cb8-c2cc7fe1f1be_terseLabel_en-US" xlink:label="lab_bcax_SyngeneAgreementMasterContractServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Master Contract Services</link:label>
    <link:label id="lab_bcax_SyngeneAgreementMasterContractServicesMember_label_en-US" xlink:label="lab_bcax_SyngeneAgreementMasterContractServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Master Contract Services [Member]</link:label>
    <link:label id="lab_bcax_SyngeneAgreementMasterContractServicesMember_documentation_en-US" xlink:label="lab_bcax_SyngeneAgreementMasterContractServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Master Contract Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementMasterContractServicesMember" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementMasterContractServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SyngeneAgreementMasterContractServicesMember" xlink:to="lab_bcax_SyngeneAgreementMasterContractServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_BioconLimitedMember_f5014bbe-5f20-481b-ae04-2af6c7e9c006_terseLabel_en-US" xlink:label="lab_bcax_BioconLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biocon Limited</link:label>
    <link:label id="lab_bcax_BioconLimitedMember_label_en-US" xlink:label="lab_bcax_BioconLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biocon Limited [Member]</link:label>
    <link:label id="lab_bcax_BioconLimitedMember_documentation_en-US" xlink:label="lab_bcax_BioconLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biocon Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BioconLimitedMember" xlink:href="bcax-20240930.xsd#bcax_BioconLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_BioconLimitedMember" xlink:to="lab_bcax_BioconLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_402c6895-3128-4652-81c4-ce58ef1f71bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f06855e-ef23-48cf-81f1-40b90236d720_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7145cae7-a32b-407b-893f-46262f4dd76b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset &#8211; operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_39d943d9-f67c-4ecd-858b-e37e4fd85161_negatedTerseLabel_en-US" xlink:label="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of Series B preferred stock tranche rights liability</link:label>
    <link:label id="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_71fcd11d-5856-4781-a7ff-d604518a365b_terseLabel_en-US" xlink:label="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of Series B preferred stock tranche rights liability</link:label>
    <link:label id="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_label_en-US" xlink:label="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability</link:label>
    <link:label id="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_documentation_en-US" xlink:label="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:to="lab_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75a1cd74-89e6-455d-acfd-fee7c970b01d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f98e7f5b-e9b3-4531-a5f8-9f208c2eecee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_4eae21ed-b904-4639-a326-ea8431744dd5_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of Series B preferred stock tranche rights liability, upon issuance of milestone shares</link:label>
    <link:label id="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_label_en-US" xlink:label="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Settlement Of Liability, Freestanding Financial Instrument Liability</link:label>
    <link:label id="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_documentation_en-US" xlink:label="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Settlement Of Liability, Freestanding Financial Instrument Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:to="lab_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_03fd2782-2a94-4eec-b280-683d3acf98a7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_dc065759-6bce-41a8-b5c7-89d967a7007a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e021fb00-5192-4d07-91ab-91a83c038758_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f00acad2-6d3c-4a5b-9725-95edc18642e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13a20e20-7c22-4ac2-951e-80f786a7bd3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2a105d19-6151-419b-b83a-d6ed308575e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_6bb650de-d7e1-4347-9131-2a2ecdf911e6_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum amount of shares required for protective provisions (in shares)</link:label>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_label_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Protective Provision, Shares Outstanding, Minimum Amount Required</link:label>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Protective Provision, Shares Outstanding, Minimum Amount Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:to="lab_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2ef17dff-151c-4544-9984-02d5235fcdf2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_5a985e3a-a7e7-4585-b91e-8b42268a1ea8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Agreements</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_1492301c-1e68-4084-95a9-784b7ced946e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_3ee12c6c-bb3f-4b85-bfd4-f290ff1c26d7_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label id="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:to="lab_bcax_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue_ac272d3d-f080-4e32-80eb-3872e6c904c6_terseLabel_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial fair value of liability</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue_label_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument Liability, Fair Value</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue_documentation_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument Liability, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:to="lab_bcax_FreestandingFinancialInstrumentLiabilityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued_384659c1-fa74-4238-9b2c-e6105eb6e86b_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investors</link:label>
    <link:label id="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued_label_en-US" xlink:label="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Number of Investors, Stock Issued</link:label>
    <link:label id="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Number of Investors, Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityNumberOfInvestorsStockIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:to="lab_bcax_TemporaryEquityNumberOfInvestorsStockIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_191deea3-d93e-4077-ad89-07ac994b6cf8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_18646eb7-fda2-44d0-84a8-97d17c061db5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share, Exercisable and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_478771d3-7b72-4f45-aebb-303752e267a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_975a4125-daf5-427d-a8a5-11d6496c4559_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_894a50ee-411b-4e1e-824c-570009acafbe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0e80a3ba-76e2-41e6-aebe-98b4316e6760_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds included within cash and cash equivalent</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ef8afd15-2208-4fb9-abed-fc04cee54ca0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityDisclosureTextBlock_e35ba090-a08c-44f1-8c41-31e7f4814800_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_bcax_TemporaryEquityDisclosureTextBlock_label_en-US" xlink:label="lab_bcax_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_bcax_TemporaryEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityDisclosureTextBlock" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityDisclosureTextBlock" xlink:to="lab_bcax_TemporaryEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0b8c694a-c38a-4a50-bc32-1f105b126e92_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b803f967-580b-41d0-b1bd-67a4a4fcd25a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses_09133988-e84f-4c32-ad81-0e1ba1763a07_terseLabel_en-US" xlink:label="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial and contract manufacturing expense</link:label>
    <link:label id="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses_label_en-US" xlink:label="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial And Contract Manufacturing Expenses</link:label>
    <link:label id="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses_documentation_en-US" xlink:label="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial And Contract Manufacturing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:href="bcax-20240930.xsd#bcax_AccruedClinicalTrialAndContractManufacturingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:to="lab_bcax_AccruedClinicalTrialAndContractManufacturingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0e6b672-d3cd-4f09-a1da-ca109a0f45c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterServicesAgreementMember_5073745f-08e5-4815-acda-deab7e0d1041_terseLabel_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Services Agreement</link:label>
    <link:label id="lab_bcax_MasterServicesAgreementMember_label_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Services Agreement [Member]</link:label>
    <link:label id="lab_bcax_MasterServicesAgreementMember_documentation_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember" xlink:href="bcax-20240930.xsd#bcax_MasterServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterServicesAgreementMember" xlink:to="lab_bcax_MasterServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent_b86d89c2-7344-4b48-af52-c9c3d28fe079_terseLabel_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche rights liability</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent_label_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument, Liability, Current</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent_documentation_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:to="lab_bcax_FreestandingFinancialInstrumentLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4911eb56-6f6e-49aa-b7cc-d108edd8b7ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Rights Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_5c0a3856-d3ac-4891-a7a4-a25b0453a612_terseLabel_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable deposit amount</link:label>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_label_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, Liability, Refundable Deposit, Amount</link:label>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_documentation_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commitment, Liability, Refundable Deposit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:href="bcax-20240930.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:to="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d11fd98c-e168-46b1-b72d-811e0f6ba19f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_02704b8e-4109-4065-8035-7e1b7bd7de09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_7f505d77-7197-4a07-ac4e-3e941c6515a2_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fa429131-53e4-4944-8091-6f1f65b7613a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_3329fe9b-1e12-42ea-af5d-99f6163da0a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54d47c02-fb6d-4b65-ae12-346983420131_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_43cb6c0f-6dad-4ad1-8b76-520ce6937128_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Equity</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_f2f59010-ccba-47f9-9826-50e9c2b2f9d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_271042c8-3896-40c1-8371-2297a41d7b72_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price for put option (in usd per share)</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_label_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share, Put Option</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share, Put Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:to="lab_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4dd9bad3-ce51-40d1-962b-b0b456b20501_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split ratio, common stock and redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c1ca9c69-a95b-455e-9c19-901aee7287b3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_de39d85d-33f8-41a4-8eef-c7df03caa2f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Fair Value of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e11dcc4c-362f-494c-9fe5-852bb66faeaa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering cost, expenses and discount (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0e0de8d7-ea22-40fe-9514-c79ecf7402c5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_06763bb1-d6ea-41f3-a09a-7f8bd162eefd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_20a74116-cd99-40da-83cf-2a081cf98255_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_af9515a8-3864-4e63-8d39-2320691aae91_terseLabel_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_label_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument, Liability, Measurement Input</link:label>
    <link:label id="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Freestanding Financial Instrument, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:to="lab_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1e6acfbb-8ed5-4756-babe-232528dd0791_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_c661e05d-6217-46e5-8bbf-d65c59cdf32b_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affirmative vote, percentage</link:label>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_label_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Protective Provision, Affirmative Vote, Percentage</link:label>
    <link:label id="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Protective Provision, Affirmative Vote, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:to="lab_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_LesseeOperatingLeaseAreaOfProperty_c576284e-1af7-4a12-b50b-8dc8fd75d4e4_terseLabel_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of property (in square feet)</link:label>
    <link:label id="lab_bcax_LesseeOperatingLeaseAreaOfProperty_label_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Property</link:label>
    <link:label id="lab_bcax_LesseeOperatingLeaseAreaOfProperty_documentation_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:href="bcax-20240930.xsd#bcax_LesseeOperatingLeaseAreaOfProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:to="lab_bcax_LesseeOperatingLeaseAreaOfProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_1a3baa6e-95a5-4d91-b65c-b1022f24ede1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d1caa193-7bde-4330-b55a-5ab5ea63aeba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_27c89bb3-635e-4b25-a5b2-764f07976eca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4976e5a7-f5d4-4bdb-8a24-0d7b545d2cb6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_27f66f08-3c6d-4393-a664-5a3f0df22c13_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_71fcb68f-faee-4cb1-a19c-9e72277df2a5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_d9a61267-833d-415f-bdb3-5fbcd4f0a2ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_ead64d05-4aab-4a9a-9024-dfd2825fb83b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5dcd9111-45bb-488e-8500-7d56fc147048_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in the fair value of preferred stock tranche rights</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_565fb723-d82a-40b4-a61a-fdf894c9e7ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_7546bc41-3dc6-4f07-8fc8-edc7443e5cd7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_4c73dab9-94d7-48ff-b044-c5cc4b3da691_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6735514f-5516-48ec-87c0-49a04e4d36dd_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a7015516-1f54-4120-9dc6-0b88d2a834b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_924c3254-b1e7-4113-8d50-c1e2778a5226_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SyngeneAgreementManufacturingMember_db4a8552-767e-460c-8a7e-2ac10d003085_terseLabel_en-US" xlink:label="lab_bcax_SyngeneAgreementManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Manufacturing</link:label>
    <link:label id="lab_bcax_SyngeneAgreementManufacturingMember_label_en-US" xlink:label="lab_bcax_SyngeneAgreementManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Manufacturing [Member]</link:label>
    <link:label id="lab_bcax_SyngeneAgreementManufacturingMember_documentation_en-US" xlink:label="lab_bcax_SyngeneAgreementManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syngene Agreement, Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementManufacturingMember" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SyngeneAgreementManufacturingMember" xlink:to="lab_bcax_SyngeneAgreementManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d28266c3-8609-4ac8-9834-fba1b8a7e1bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_a7bd8817-49e0-456c-95c8-e9abef73b365_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8815d132-54a7-4df4-b2be-61f184fe0d8d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_5b6c8140-ba68-43c9-a4e1-1c090a5c2f90_terseLabel_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Stock Option and Grant Plan</link:label>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_label_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Stock Option and Grant Plan [Member]</link:label>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_documentation_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Stock Option and Grant Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember" xlink:href="bcax-20240930.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_A2024StockOptionAndGrantPlanMember" xlink:to="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b681fac3-1bc7-4151-9225-cce5b63b4c47_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e3fb4ee5-15ab-46af-b141-043b04f90a67_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b605f95c-99b7-4bcc-b7fe-e15b3adeabe7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_297a3c0e-ac6c-47eb-b2bd-a57a2cbf7670_terseLabel_en-US" xlink:label="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors entitled to be elected, common stock</link:label>
    <link:label id="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_label_en-US" xlink:label="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Directors Entitled To Be Elected</link:label>
    <link:label id="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_documentation_en-US" xlink:label="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Directors Entitled To Be Elected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:href="bcax-20240930.xsd#bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:to="lab_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b1895c74-93e1-46da-b26c-b9afc786ab0c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0a10e40d-ed98-463f-8046-1418c40e7b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9630164f-29f2-4dc2-9f6a-ceccda2378f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used in Estimation of Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d2d4e540-9d93-4770-a68d-07ed3ccc707a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_421ff780-853a-48e2-a2d2-ae4489c3fbd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_7734fba6-efa3-4672-97b8-5cae8ef4d296_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_88151762-12c6-478c-a473-7d59e84036f8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_1bacff41-6e82-4049-b580-8bc68ca6b5ed_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d32d301a-c0b7-4b81-85f5-6b3d071baaa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_87a95753-de27-49d1-989c-c64955cf6eee_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_621811d3-8666-4798-9f18-6c327a70f84c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_53cbcd75-8576-4713-8e0d-dacc3de467e3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d662de86-c314-4b86-824c-65558d415953_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_78e885cc-1468-43e1-80a1-fa2bffa71f5e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_736596aa-230a-462b-bd4f-075fafedbe7e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_18c3f873-bcfb-496c-a7bc-1c2bd8108a3c_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f30e8b0d-4ae8-4482-9f9b-cd18389fb9aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7c825a77-1f65-47aa-9490-066e870ce5cb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld_eaa43bd4-3ef4-4dcf-87f9-98da24391d64_terseLabel_en-US" xlink:label="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions where cash and cash equivalents are held</link:label>
    <link:label id="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld_label_en-US" xlink:label="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions, Cash And Cash Equivalents Held</link:label>
    <link:label id="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld_documentation_en-US" xlink:label="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions, Cash And Cash Equivalents Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:href="bcax-20240930.xsd#bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:to="lab_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a0afe512-96dd-44a4-9b76-53cfb572462d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_36f576f8-b54a-4f4b-918a-0c64ffcd6f3a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_684a7c97-98a4-44dc-bc0f-dd3f58a8d191_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cabdba9c-0336-479e-9687-aaa21031c77c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_c59952b0-6e0a-4e4b-9a93-4acf3e374a78_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82f1d252-86e2-41f8-a154-52094fbd80b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fd68fea4-4721-4003-8f05-498ef74f50a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_764d1f12-980e-4bf2-ab0a-d385c2aa28bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note loan amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_dae1bb92-a020-46b0-9aa2-2d6692d5fcc1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering cost, expenses and discount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3c2868ab-86b6-43ab-89aa-5c8430662bf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlement of preferred stock tranche rights</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5436075c-80b8-4d63-830d-18d5684c922d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_658c0b75-8043-4d8c-925c-7fa74eb66f78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ede2771f-630c-4b5f-8190-648f78c5dc08_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_da148f04-a2c9-48da-965b-83f6e426da3a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1860f21b-2dda-45d5-8ecd-8767c37e15f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value, 500,000,000 and 365,000,000 shares authorized; 54,424,994 and 711,895 shares issued and 54,409,708 and 640,386 shares outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_08f35329-8f5b-40a7-8e10-73703025db51_terseLabel_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_label_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options [Member]</link:label>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="bcax-20240930.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:to="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_72e5f3ed-417e-494e-93d8-0e8e49907fe2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_BiofusionAgreementMember_6c5eedd7-744d-4029-af33-b3b7c9f91c7b_terseLabel_en-US" xlink:label="lab_bcax_BiofusionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biofusion Agreement</link:label>
    <link:label id="lab_bcax_BiofusionAgreementMember_label_en-US" xlink:label="lab_bcax_BiofusionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biofusion Agreement [Member]</link:label>
    <link:label id="lab_bcax_BiofusionAgreementMember_documentation_en-US" xlink:label="lab_bcax_BiofusionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biofusion Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BiofusionAgreementMember" xlink:href="bcax-20240930.xsd#bcax_BiofusionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_BiofusionAgreementMember" xlink:to="lab_bcax_BiofusionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_967ccbf8-709b-464b-a269-424be0f55db2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TwoInvestorsMember_493b2da7-6e4b-4ca5-9e76-652fc4e62f76_terseLabel_en-US" xlink:label="lab_bcax_TwoInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Investors</link:label>
    <link:label id="lab_bcax_TwoInvestorsMember_label_en-US" xlink:label="lab_bcax_TwoInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Investors [Member]</link:label>
    <link:label id="lab_bcax_TwoInvestorsMember_documentation_en-US" xlink:label="lab_bcax_TwoInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsMember" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TwoInvestorsMember" xlink:to="lab_bcax_TwoInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a440838a-9678-498a-a95e-37708c94c11f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9110fc89-43ae-4add-93de-0d6f4f214704_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_NumberOfMembersBoardOfDirectors_36b477e6-1eb9-4a6f-ad1c-cb8e92770544_terseLabel_en-US" xlink:label="lab_bcax_NumberOfMembersBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of members on board of directors</link:label>
    <link:label id="lab_bcax_NumberOfMembersBoardOfDirectors_label_en-US" xlink:label="lab_bcax_NumberOfMembersBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Members, Board Of Directors</link:label>
    <link:label id="lab_bcax_NumberOfMembersBoardOfDirectors_documentation_en-US" xlink:label="lab_bcax_NumberOfMembersBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Members, Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_NumberOfMembersBoardOfDirectors" xlink:href="bcax-20240930.xsd#bcax_NumberOfMembersBoardOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_NumberOfMembersBoardOfDirectors" xlink:to="lab_bcax_NumberOfMembersBoardOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_db9e6e7a-724c-41ce-9817-1d94ea00cce7_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options and restricted stock awards outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d191236-7ba9-4c84-8255-8294a43ae1fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ebf2bae9-7d5c-462f-a8db-5cad184b9981_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0d483324-2078-41ff-9b23-89fa61b620e3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_35d72193-3e8a-4176-9db3-6bd61b81f2a2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_31728830-46a4-41a0-86fe-577fe91426d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance on common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_00bba2b0-3457-4b52-867f-8c513e6ba48f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_f57f7d8b-26da-4152-b8b2-78705a34545e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_79514c61-8199-40a2-9942-5be595f08a86_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d66b450f-b94b-46d7-93c4-6859efbe0c19_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6207c5ef-011f-4209-b073-71cac4ea4500_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_15c0854b-e9fb-43b3-9691-c43a53bcf532_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8f6c40ac-1743-4bd9-8e0f-994e1b9cc9b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_701b0b9b-20a6-4697-9d62-f9ab72843b98_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c70e7b46-2a93-4d3d-8824-cc79e1ee2ee0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7d33b538-3056-4a41-b455-8a0ae1f507c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1d4ddd0a-6617-4aea-a650-f180282da08c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_f1ba2cf2-6b2c-403f-8fbe-a10cb1680254_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b02b33fa-e03d-40b2-9db1-aae5a1d09b8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8812fe53-e487-4d60-a100-96a562bb2927_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cb97716b-8be1-4116-8b77-aa514fcb8616_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c1456a0a-4d6c-4bc7-a7fb-696cc495bdcc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5f31f845-f946-4ac9-bc73-01912e4cfcb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_161d2e2d-998d-4258-9e7d-29ea46a7fe55_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business, Organization, and Liquidity</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a22cd000-0b89-4362-a5be-1d2b799f6329_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_43edd51a-21a7-497c-b7fa-09e51025253a_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors entitled to be elected, preferred stock</link:label>
    <link:label id="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_label_en-US" xlink:label="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Voting Rights, Number Of Directors Entitled To Be Elected</link:label>
    <link:label id="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Voting Rights, Number Of Directors Entitled To Be Elected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:to="lab_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad47de4d-4e3b-4145-b1c9-29d4aea8e291_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1de60aaf-541a-46af-9490-a869c0c8ade7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_36c34da8-cffd-4363-b5e5-bcdd66ebb79d_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1ae75863-d0a3-4954-8889-5b799acd0847_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_599f226a-1c79-46f7-8122-b29f4108c780_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_42fd3162-112d-4199-8f39-560981f778d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4279360d-8885-4c8a-838e-b9fd5ef546aa_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_289d3a73-fc46-45a7-b155-0a897108dbd2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_35077f18-a405-4a88-bc93-c25c1c98b9bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1d6ba1d8-074b-4dd5-b7e3-ddaaa8971924_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69ef4ab0-9e32-4b2b-96ac-105c41c882a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f5ebab94-f638-414a-ba4f-f8436254535c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1e548ead-89f6-4c6c-a8f3-4dbd7bb7920e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchased/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_aa7fb3c7-24b2-4af5-8dcf-98eba27d3b38_terseLabel_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e51d5bb7-4221-4583-ae1b-7bd882ac8084_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_53a89899-a5b4-4d89-89e0-a08e8688db72_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_850429a5-876c-4f6e-9c4a-c6e4f612e69c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9ece87d8-99c5-4ca6-bd58-8e40b711ebb4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b282430d-6350-435c-b572-96cdd24460e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3dcc8b61-c2fd-4ad6-bc2d-ccb018ede898_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_92524e17-dcac-4c47-b6de-53f55ff7c6e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_94ed0da6-9048-43b7-bbc6-51951268e270_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_016b8df0-c514-4473-bb51-7afb22fd5d6b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7264a682-5616-4d9f-a453-569da1ce5e09_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e4a92809-40fc-45c3-a890-342b71e06884_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_afc60273-4f36-4eb7-813f-f7c8fa23aa26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ec728d88-93be-4b79-b281-bcfca9d44d84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value recognized upon the issuance of preferred stock tranche rights</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_c20fe66e-4bf4-46e5-b896-8df078393ded_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred share price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c74fda49-9120-479b-a567-45490b0ccde0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8bad1526-0ded-47fc-b871-97873348afbe_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ff904b9a-e3ae-4a69-b1d1-bf57e4cd2d45_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_BBLAgreementsMember_f43daaf2-a1f4-4bea-a5f3-cf758e75c6b9_terseLabel_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BBL Agreements</link:label>
    <link:label id="lab_bcax_BBLAgreementsMember_label_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BBL Agreements [Member]</link:label>
    <link:label id="lab_bcax_BBLAgreementsMember_documentation_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BBL Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember" xlink:href="bcax-20240930.xsd#bcax_BBLAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_BBLAgreementsMember" xlink:to="lab_bcax_BBLAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e11815a-2cce-4feb-8f22-e30752a8796e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_96c3ed98-0276-42b8-98b2-92edf601694e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_aad671ca-2bd0-4f72-99c5-2d8f105084bc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9aa12c27-77a4-49b7-bf1a-854edbda0801_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance on common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62ffc4dd-6d89-4f8f-b15e-6bbccbf488bc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_22b3bd79-2739-4d24-853d-3a3719cda571_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_98111e96-56bb-42e7-a746-7ac3ed3c337a_terseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount (in shares)</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_29aec272-8d45-4909-b9e7-57f51e4baabb_verboseLabel_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9ad31b02-e903-483a-ac02-7f1670ce1408_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_26d221ad-93e8-4f3c-8187-ffd8726b2345_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ac01bea1-f5fc-45cd-b397-b728c7c59b7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a7011710-423f-4956-b555-641e02253634_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_347b4c73-3c20-43da-a73b-bafc0168624e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bcax-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9669c62b-4993-48ca-beb3-f8aea931c094,g:9302ae0f-8c8b-4a71-b701-48f760cfb72c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bicara.com/role/Cover" xlink:type="simple" xlink:href="bcax-20240930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e8a81fa0-42ae-4a04-ac8b-ebafc0b1dc45" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentType_e8a81fa0-42ae-4a04-ac8b-ebafc0b1dc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5a756517-b00d-449d-a74e-cecac2eb5bfe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentQuarterlyReport_5a756517-b00d-449d-a74e-cecac2eb5bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_44fe7c27-59be-4974-85df-0f7b5a065393" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentPeriodEndDate_44fe7c27-59be-4974-85df-0f7b5a065393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1384c6d1-1870-4f32-8a7f-aef3bb391792" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentTransitionReport_1384c6d1-1870-4f32-8a7f-aef3bb391792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4f85cd53-adda-4b14-991e-85b25c0d4fc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityFileNumber_4f85cd53-adda-4b14-991e-85b25c0d4fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_649391fd-8759-4c7a-adf9-bd6d21e5c27f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityRegistrantName_649391fd-8759-4c7a-adf9-bd6d21e5c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7fc929e6-006c-4682-89a3-327888c74933" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7fc929e6-006c-4682-89a3-327888c74933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d2ebc519-8b6b-48d3-a236-0b38d82b90e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityTaxIdentificationNumber_d2ebc519-8b6b-48d3-a236-0b38d82b90e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c9a460f7-5767-4ad4-9a9d-4e0028726458" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityAddressAddressLine1_c9a460f7-5767-4ad4-9a9d-4e0028726458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_658335b6-0f8e-4234-97a4-162bbef08cd3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityAddressAddressLine2_658335b6-0f8e-4234-97a4-162bbef08cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e2e098f7-a602-4e21-b7d3-8ba53574941e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityAddressCityOrTown_e2e098f7-a602-4e21-b7d3-8ba53574941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0815302d-f969-40b4-b6d9-50c62e668e05" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityAddressStateOrProvince_0815302d-f969-40b4-b6d9-50c62e668e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b8e98248-4f7e-42d8-9927-77ea9a878c15" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityAddressPostalZipCode_b8e98248-4f7e-42d8-9927-77ea9a878c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0e6ead88-7155-49b8-8357-c81d90377061" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_CityAreaCode_0e6ead88-7155-49b8-8357-c81d90377061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_05bccf95-6396-4495-af09-3b0ec1d9bf10" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_LocalPhoneNumber_05bccf95-6396-4495-af09-3b0ec1d9bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ce722a11-5851-49d2-af70-e405ad2e06d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_Security12bTitle_ce722a11-5851-49d2-af70-e405ad2e06d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_02b0cd66-e598-4c66-9172-7acaa8cf0026" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_TradingSymbol_02b0cd66-e598-4c66-9172-7acaa8cf0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b661d955-dcc5-4044-8e50-b98981607c04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_SecurityExchangeName_b661d955-dcc5-4044-8e50-b98981607c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_23303a3e-1603-4016-bef2-ed9aff8e0e2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityCurrentReportingStatus_23303a3e-1603-4016-bef2-ed9aff8e0e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8d16ad5c-c2a3-4608-ad35-989e68d27eec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityInteractiveDataCurrent_8d16ad5c-c2a3-4608-ad35-989e68d27eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_35431672-c407-491e-81b7-913185dc2373" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityFilerCategory_35431672-c407-491e-81b7-913185dc2373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_51b70aac-9f76-4ec3-8751-76de7fe56eb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntitySmallBusiness_51b70aac-9f76-4ec3-8751-76de7fe56eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dcc8c599-975f-4363-aeaf-19c1d641b0d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityEmergingGrowthCompany_dcc8c599-975f-4363-aeaf-19c1d641b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_0a0bd913-20d3-484f-bf97-bf643187bdb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityExTransitionPeriod_0a0bd913-20d3-484f-bf97-bf643187bdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d7d71972-c608-4deb-bdef-48e010211719" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityShellCompany_d7d71972-c608-4deb-bdef-48e010211719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a5cb0440-eae3-422b-a71e-0f5244cd0c3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a5cb0440-eae3-422b-a71e-0f5244cd0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4c9b1e0e-a3ad-4c89-893d-c9d47428ebbe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_EntityCentralIndexKey_4c9b1e0e-a3ad-4c89-893d-c9d47428ebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c22a133f-ecfa-4433-bdf8-1d28f618b567" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_CurrentFiscalYearEndDate_c22a133f-ecfa-4433-bdf8-1d28f618b567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_82692281-83e1-4982-b87f-cc1a1c4d2e14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentFiscalYearFocus_82692281-83e1-4982-b87f-cc1a1c4d2e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_829cc3c6-a4c2-4f93-a3cd-858df0a62952" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_DocumentFiscalPeriodFocus_829cc3c6-a4c2-4f93-a3cd-858df0a62952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7c044996-60e0-41ff-963d-868afc3bd211" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e80d2b80-b5d9-4584-a975-4c070fd30b16" xlink:to="loc_dei_AmendmentFlag_7c044996-60e0-41ff-963d-868afc3bd211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_df077e95-36ab-4b47-b93b-5eee105a5c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_df077e95-36ab-4b47-b93b-5eee105a5c18" xlink:to="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc52bd11-b7ed-45d8-a988-677f326f68cc" xlink:to="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_bcd55e9e-8e48-4bf7-a66c-1748ad9f2775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:to="loc_us-gaap_NonrelatedPartyMember_bcd55e9e-8e48-4bf7-a66c-1748ad9f2775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5f250c2e-4d71-49fe-b269-521bef577011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bc42377f-5941-4bde-b72f-b43a6e2829f8" xlink:to="loc_us-gaap_RelatedPartyMember_5f250c2e-4d71-49fe-b269-521bef577011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654019b6-3f93-4a27-adf7-8dd0803a8d48" xlink:to="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8ca48ebd-9fd9-4ea9-98a6-669433004174" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8ca48ebd-9fd9-4ea9-98a6-669433004174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ded87fb0-7374-492f-9511-05f7ff9f2808" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ded87fb0-7374-492f-9511-05f7ff9f2808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_9537cdef-e301-4b55-aa1c-2b9c28825515" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_674e6091-a1d3-4df4-9c25-c03721c031e2" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_9537cdef-e301-4b55-aa1c-2b9c28825515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98f200f3-0ffd-4c04-a4ba-e8103e7a540d" xlink:to="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89938bf0-d294-4d70-8e78-f98ac64401bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89938bf0-d294-4d70-8e78-f98ac64401bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6ae6379-24dc-46e1-b23a-7534cf623e39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6ae6379-24dc-46e1-b23a-7534cf623e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e76e8ce6-8651-4a35-80d4-2f84325746da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9e5259a0-1e4c-429d-94b9-fbe785868e44" xlink:to="loc_us-gaap_AssetsCurrent_e76e8ce6-8651-4a35-80d4-2f84325746da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_741e2803-6871-4bcf-b5a8-f73e3b8e0626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_741e2803-6871-4bcf-b5a8-f73e3b8e0626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66b70146-e476-4a60-9f02-2bfd3d75d792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66b70146-e476-4a60-9f02-2bfd3d75d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1fb9213e-7aae-4993-bf50-db063987e6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1fb9213e-7aae-4993-bf50-db063987e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eec5389c-4feb-4a08-81f5-46044b91f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb7ac6d3-e5b1-46d7-9b4f-5c504110d9e4" xlink:to="loc_us-gaap_Assets_eec5389c-4feb-4a08-81f5-46044b91f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fbf0fc63-feaa-40e7-b79d-b6596c7b3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_AccountsPayableCurrent_fbf0fc63-feaa-40e7-b79d-b6596c7b3e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c97c420f-a48e-4124-a2f8-a487a736398f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c97c420f-a48e-4124-a2f8-a487a736398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e280676c-6001-4a6b-8be5-ceb2c70736fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e280676c-6001-4a6b-8be5-ceb2c70736fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1a08fde8-994d-4997-9edc-30f9f0724992" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204ca8f8-5d45-4113-babd-0a0211da13a6" xlink:to="loc_us-gaap_LiabilitiesCurrent_1a08fde8-994d-4997-9edc-30f9f0724992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d8f10d9-37d3-48a4-9dd4-bef84ec0ba31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d8f10d9-37d3-48a4-9dd4-bef84ec0ba31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b1d2186d-ee00-4098-8c7f-0abbdd4eb9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b1d2186d-ee00-4098-8c7f-0abbdd4eb9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_75862023-a758-475a-8373-07f8167ce1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_Liabilities_75862023-a758-475a-8373-07f8167ce1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_717a4875-fd82-4f65-85f9-f4715dec1361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_717a4875-fd82-4f65-85f9-f4715dec1361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_37ed71ba-ff65-41a9-baa1-43e6138c8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_37ed71ba-ff65-41a9-baa1-43e6138c8c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d57d3c-a23b-405c-b152-66ed014fb9aa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_433bef29-e9ff-46bb-8fb7-0de075ca9361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_PreferredStockValue_433bef29-e9ff-46bb-8fb7-0de075ca9361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f838cd0a-a44c-4744-b7ee-6b72cdb58d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_CommonStockValue_f838cd0a-a44c-4744-b7ee-6b72cdb58d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_db951d02-6305-4204-9599-0bb5f20b9b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_AdditionalPaidInCapital_db951d02-6305-4204-9599-0bb5f20b9b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683c7c75-473e-4398-8200-f922a54397b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683c7c75-473e-4398-8200-f922a54397b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e6665af-6c47-4a46-a21d-456ed283e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_77f68fdf-773b-402b-adf0-945a33a2f117" xlink:to="loc_us-gaap_StockholdersEquity_4e6665af-6c47-4a46-a21d-456ed283e8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3fb9c7-eef5-4a5b-9bd0-b1745012cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f9b25589-192d-4bfd-b664-220c5ba43ec7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3fb9c7-eef5-4a5b-9bd0-b1745012cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dd8d1e9e-232c-4472-a3d9-10ef769b1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd8d1e9e-232c-4472-a3d9-10ef769b1fa8" xlink:to="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4dbc7460-b125-4e33-8718-496ebf267e3c" xlink:to="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8228ebad-5c78-4180-b464-66953dcbe8d0" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_8228ebad-5c78-4180-b464-66953dcbe8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_0e3996f1-16df-41c4-bd3c-b87873eb8b03" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_0e3996f1-16df-41c4-bd3c-b87873eb8b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_adbbcb62-770f-48d9-9b2b-300f3635cf18" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_21a2da17-5af8-4680-96b1-bd9dcd071441" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_adbbcb62-770f-48d9-9b2b-300f3635cf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d89f62d-0d0c-4bdd-b4ba-d7f2dee4acc3" xlink:to="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_a5b8b87a-7b57-4d2f-a313-e3083f1ce1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_a5b8b87a-7b57-4d2f-a313-e3083f1ce1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_c5357712-64a7-44e3-a770-b73efea5246b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_c5357712-64a7-44e3-a770-b73efea5246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_766d37ee-496e-451a-88a9-7161e9d3a289" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_766d37ee-496e-451a-88a9-7161e9d3a289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a4d4f9cb-b901-4ce2-bd44-2727c07d5cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a4d4f9cb-b901-4ce2-bd44-2727c07d5cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_03798139-3071-4121-9711-16dd327d4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_03798139-3071-4121-9711-16dd327d4ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1785225c-a7d2-4ee9-8f63-2358fa8197e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1785225c-a7d2-4ee9-8f63-2358fa8197e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ed34531c-52ac-4190-86d9-817c5502419f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ed34531c-52ac-4190-86d9-817c5502419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8c51f5bf-7c5c-46df-b32d-c97d4fd77ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8c51f5bf-7c5c-46df-b32d-c97d4fd77ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_70284b28-fdc3-4927-a710-fe65b359a9af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_70284b28-fdc3-4927-a710-fe65b359a9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d390a9fd-5652-4e0e-a83d-d813563b3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d390a9fd-5652-4e0e-a83d-d813563b3e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0de82796-33fb-420c-8ec9-6d5d2ca80e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0de82796-33fb-420c-8ec9-6d5d2ca80e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6633a224-57d8-4e4b-a01a-4b97ce5de4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesIssued_6633a224-57d8-4e4b-a01a-4b97ce5de4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d0e79bb2-9936-45f8-8bab-96f3081848d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a697cf78-03dc-4ab4-a063-2344a36f3008" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d0e79bb2-9936-45f8-8bab-96f3081848d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c0058714-ee4b-4b5d-a386-fd83f5fe4485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c0058714-ee4b-4b5d-a386-fd83f5fe4485" xlink:to="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943846a3-3cca-4106-bb09-39ddfdc64e82" xlink:to="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d8f0e9b4-9b14-4816-868f-80a22a3f05de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:to="loc_us-gaap_RelatedPartyMember_d8f0e9b4-9b14-4816-868f-80a22a3f05de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_d32b94c5-1323-4207-aa9c-d5cab155af37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_93f1b2e1-13d3-4376-b483-33ac2d84b4a6" xlink:to="loc_us-gaap_NonrelatedPartyMember_d32b94c5-1323-4207-aa9c-d5cab155af37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36591768-b82d-4248-bbba-cb86eece22fb" xlink:to="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5af6b321-f700-45a3-a714-3e89fe3665bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5af6b321-f700-45a3-a714-3e89fe3665bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_af4e7896-fdbf-4afe-bdd6-60659edda8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_af4e7896-fdbf-4afe-bdd6-60659edda8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9cc7c866-3ece-4fbe-b8ca-7febca0e7494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e9c336f5-1e62-4c1d-9c80-6e19b671675e" xlink:to="loc_us-gaap_OperatingExpenses_9cc7c866-3ece-4fbe-b8ca-7febca0e7494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_797c066a-e989-4305-8250-49992ebaeaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_OperatingIncomeLoss_797c066a-e989-4305-8250-49992ebaeaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e55a8ddc-ef1b-40b3-a79f-628cfcb6fa18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e55a8ddc-ef1b-40b3-a79f-628cfcb6fa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_1d706853-4332-44fd-91da-6673bcf1d77a" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_1d706853-4332-44fd-91da-6673bcf1d77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_57cff915-2c68-4145-8a1c-235adf7cd301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b19e650f-4ec1-4bc2-bdbf-3a3e6c434a26" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_57cff915-2c68-4145-8a1c-235adf7cd301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79c2d329-17e9-42be-b946-f7fa518591e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79c2d329-17e9-42be-b946-f7fa518591e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41d5b649-b5c9-45af-923e-25420e8cbb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41d5b649-b5c9-45af-923e-25420e8cbb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bef4a4e5-d082-447e-893a-2c5db4a2ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_NetIncomeLoss_bef4a4e5-d082-447e-893a-2c5db4a2ba2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c797b2a-a009-49a7-a647-69a5bc25aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_EarningsPerShareBasic_9c797b2a-a009-49a7-a647-69a5bc25aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_48dc716d-f4d4-4fc6-82ca-0de42173a255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_EarningsPerShareDiluted_48dc716d-f4d4-4fc6-82ca-0de42173a255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_121c0643-c413-4ba4-bfe8-edb1de431a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_121c0643-c413-4ba4-bfe8-edb1de431a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aee7e022-028b-4469-b3dc-c4cedbf40335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea1ef201-6b4f-4f77-ab7e-60ee1610b661" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aee7e022-028b-4469-b3dc-c4cedbf40335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0cef126e-7d11-4d09-a220-2d9e4bda2411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0cef126e-7d11-4d09-a220-2d9e4bda2411" xlink:to="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeb6a966-b5bd-44ed-9a5f-505f00f0b444" xlink:to="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_41b030cc-8760-47e0-9677-6321ab28f118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_CommonStockMember_41b030cc-8760-47e0-9677-6321ab28f118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_73a13359-746a-4cdd-98c5-978bbadb9c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_73a13359-746a-4cdd-98c5-978bbadb9c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a19dcaf5-87cc-496e-a908-6028449f989c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ae9c86-add0-4ded-b620-4ef3426bebe5" xlink:to="loc_us-gaap_RetainedEarningsMember_a19dcaf5-87cc-496e-a908-6028449f989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7bb2f6aa-9441-4af2-b7f6-c21cab6c5a83" xlink:to="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_bb26346a-caa9-4789-9ab3-f2a2d6da5c00" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_bb26346a-caa9-4789-9ab3-f2a2d6da5c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_8cd71f6e-1c0b-425c-9243-ee19de043d3e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_8cd71f6e-1c0b-425c-9243-ee19de043d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_635e7abf-c962-4880-9d60-a03129ff205a" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d3d00601-26be-4b00-8104-b7f3bfa90284" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_635e7abf-c962-4880-9d60-a03129ff205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25fea0c6-6cfd-4e49-b593-5f8560468b2a" xlink:to="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f4e2a1dd-0685-41f7-8e72-dfc35730c142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f4e2a1dd-0685-41f7-8e72-dfc35730c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28489cc8-4a04-4ac9-825d-da07c7a038ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28489cc8-4a04-4ac9-825d-da07c7a038ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_70668a46-3cfe-4354-8b59-80d0266b9302" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_70668a46-3cfe-4354-8b59-80d0266b9302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_91757add-77fa-4364-8286-1961daa79462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_91757add-77fa-4364-8286-1961daa79462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_c71d6ba1-3563-46a0-8ed3-b98f951e5b7b" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability_c71d6ba1-3563-46a0-8ed3-b98f951e5b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_c901883f-5163-4092-9cad-11f0a38a2d5c" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities_c901883f-5163-4092-9cad-11f0a38a2d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_506f825b-f484-47c5-9f58-bc96c5c48e80" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_bcax_TemporaryEquityValueConversionOfConvertibleSecurities_506f825b-f484-47c5-9f58-bc96c5c48e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_db772092-5cbf-4406-b9a1-fc4b745638a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_db772092-5cbf-4406-b9a1-fc4b745638a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_cc2bbe66-6ab6-4963-a350-e68f6cce8414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3015704c-0471-4733-998f-df352633c5f8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_cc2bbe66-6ab6-4963-a350-e68f6cce8414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86cd34-d967-4148-ad48-5cbf00e12884" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b4e76808-0479-443f-a0f1-562356170b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b4e76808-0479-443f-a0f1-562356170b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84c8fdf5-0e07-40c3-bc5b-1c4d0e60dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockholdersEquity_84c8fdf5-0e07-40c3-bc5b-1c4d0e60dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_55a61dce-2d26-46a4-970d-e868ffdda23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_55a61dce-2d26-46a4-970d-e868ffdda23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1287c1cd-ac7b-455d-b9d3-4d8d7a7ee757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1287c1cd-ac7b-455d-b9d3-4d8d7a7ee757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_88af44a2-a07a-4fbf-84c4-3045acf584f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_88af44a2-a07a-4fbf-84c4-3045acf584f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a052ddd5-820e-4acd-8181-1288fd201ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a052ddd5-820e-4acd-8181-1288fd201ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23606bf8-9f0e-4f1c-9ebd-488fd18c2b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23606bf8-9f0e-4f1c-9ebd-488fd18c2b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bbebc3c7-9e8f-4a67-a23a-3183007b1b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bbebc3c7-9e8f-4a67-a23a-3183007b1b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_484f5f04-c81d-4e7e-8deb-898829ac9b82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_484f5f04-c81d-4e7e-8deb-898829ac9b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08015919-cbf1-4bac-a49a-8c3bf2201cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08015919-cbf1-4bac-a49a-8c3bf2201cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d80acf92-5447-491d-a86b-7beeef4c99a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_NetIncomeLoss_d80acf92-5447-491d-a86b-7beeef4c99a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02209e8a-a128-4036-8141-ab6a4e91b4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02209e8a-a128-4036-8141-ab6a4e91b4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aef90bc5-8cba-4bda-837a-72d66fb3853b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31d89173-1bbd-4f70-9978-d15a52545847" xlink:to="loc_us-gaap_StockholdersEquity_aef90bc5-8cba-4bda-837a-72d66fb3853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_be8ba47c-1e40-45e8-9b4b-2cfbe7b69607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_be8ba47c-1e40-45e8-9b4b-2cfbe7b69607" xlink:to="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_af5dfde1-340f-465d-b352-76acdc09ce65" xlink:to="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9fd9a369-3b9a-4bf8-b730-bead69ef0d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:to="loc_us-gaap_NonrelatedPartyMember_9fd9a369-3b9a-4bf8-b730-bead69ef0d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_65d721a9-f4e1-472f-8779-f671efbfa9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a3a24c79-4b63-41f2-8ad3-cc09c93f0e4c" xlink:to="loc_us-gaap_RelatedPartyMember_65d721a9-f4e1-472f-8779-f671efbfa9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddf10bd9-216c-4f33-81bb-aa7e0d777c44" xlink:to="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04619934-1e98-4f00-a0d9-7b97fd648ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_NetIncomeLoss_04619934-1e98-4f00-a0d9-7b97fd648ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_534fe3e6-9ccf-478c-a1b1-9db93ee0a99d" xlink:href="bcax-20240930.xsd#bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability_534fe3e6-9ccf-478c-a1b1-9db93ee0a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_752b2202-80d7-4fe4-b6de-7ec2840a753b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_ShareBasedCompensation_752b2202-80d7-4fe4-b6de-7ec2840a753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_be4d4de7-0014-4d0d-8ab7-f2399f5f20b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_Depreciation_be4d4de7-0014-4d0d-8ab7-f2399f5f20b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d04cfd96-7c01-45f7-b667-b2f847451610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c543636a-0930-49d4-b109-d533d67c5a10" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d04cfd96-7c01-45f7-b667-b2f847451610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d252a95-dd0b-4568-98ac-43304554652f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d252a95-dd0b-4568-98ac-43304554652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c9e095f2-0d17-4226-a3a6-2fd1c4398abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c9e095f2-0d17-4226-a3a6-2fd1c4398abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8019dabf-0b8e-4114-8a10-9321fad1378c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7556350-ad5c-4194-95dc-dde6114bb3d2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8019dabf-0b8e-4114-8a10-9321fad1378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7266c2c-3a9a-4097-97fb-975b389e1ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97762019-398b-4f16-8602-921e2f639bc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7266c2c-3a9a-4097-97fb-975b389e1ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c5b8d5d-04ce-421c-9bf6-87cdf7a399ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c5b8d5d-04ce-421c-9bf6-87cdf7a399ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_392877b1-8c6f-487b-bf68-72db0a87140f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_392877b1-8c6f-487b-bf68-72db0a87140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf7da128-b4fb-4ef5-ae56-e4a8c2f2249e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f879886-4124-40c6-8cf3-065ee910b87b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf7da128-b4fb-4ef5-ae56-e4a8c2f2249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f653320-ce81-4ff4-b917-0bc4d6f88651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f653320-ce81-4ff4-b917-0bc4d6f88651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_f5d838b4-1182-48b9-a3e4-b62965e37cee" xlink:href="bcax-20240930.xsd#bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability_f5d838b4-1182-48b9-a3e4-b62965e37cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3478c5b7-b4b5-4bc1-8bba-111aa4ff8957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3478c5b7-b4b5-4bc1-8bba-111aa4ff8957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ad7dfa-a30c-4bf8-9939-94b0b6641463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50c2403f-d6f6-4445-83a8-769add3f3e18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ad7dfa-a30c-4bf8-9939-94b0b6641463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64e67b31-1c6a-4f17-abee-38a81205bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64e67b31-1c6a-4f17-abee-38a81205bf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb2b9ba1-4aea-46ec-a9be-53abede14863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb2b9ba1-4aea-46ec-a9be-53abede14863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddb4d19-9891-43e8-8f79-870c86f98c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddb4d19-9891-43e8-8f79-870c86f98c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0b59f23b-b1d2-41be-90e5-8c8ac6ac2287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0b59f23b-b1d2-41be-90e5-8c8ac6ac2287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_feb85d57-ab56-4f1e-9165-414bbc4b8668" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_81f7422a-8df1-4661-aba0-e56559fff3c8" xlink:href="bcax-20240930.xsd#bcax_SettlementOfFreestandingFinancialInstrumentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities_81f7422a-8df1-4661-aba0-e56559fff3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dd9b8265-54d2-4e6f-b6a4-0e1526ee85de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dd9b8265-54d2-4e6f-b6a4-0e1526ee85de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions_fc8ba6d2-15f6-4296-aef5-4e55b2a764be" xlink:href="bcax-20240930.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_VestingOfEarlyExerciseStockOptions_fc8ba6d2-15f6-4296-aef5-4e55b2a764be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_fa746a2b-1685-45e2-920b-1477e4dabe70" xlink:href="bcax-20240930.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_fa746a2b-1685-45e2-920b-1477e4dabe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_87d708c2-72dc-49b2-91a1-6e8036f57c02" xlink:href="bcax-20240930.xsd#bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_287a51c0-b0b4-49ef-988b-0eae83c02111" xlink:to="loc_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument_87d708c2-72dc-49b2-91a1-6e8036f57c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity" xlink:type="simple" xlink:href="bcax-20240930.xsd#DescriptionofBusinessOrganizationandLiquidity"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d36b8695-b904-4620-876d-135c81d4a871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bfc1a53d-e05b-464d-ad4b-f48ec15c5183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d36b8695-b904-4620-876d-135c81d4a871" xlink:to="loc_us-gaap_NatureOfOperations_bfc1a53d-e05b-464d-ad4b-f48ec15c5183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df00bfe3-4025-4904-9cf7-f3fad4d70007" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_02a5dd08-27ad-41f8-963d-d91eb96ac6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df00bfe3-4025-4904-9cf7-f3fad4d70007" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_02a5dd08-27ad-41f8-963d-d91eb96ac6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d62be6b2-4925-4efe-9439-69c5aa98b9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_294f2120-760e-41f1-96c5-c59474733d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d62be6b2-4925-4efe-9439-69c5aa98b9fa" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_294f2120-760e-41f1-96c5-c59474733d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="bcax-20240930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_535627bc-ed8d-4068-8de3-10127e5dd656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_90108461-51f0-485a-95b7-39d765d0ddb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_535627bc-ed8d-4068-8de3-10127e5dd656" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_90108461-51f0-485a-95b7-39d765d0ddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CommonStock" xlink:type="simple" xlink:href="bcax-20240930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_91185bac-6425-4ffb-bf03-714c5952d508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f63be6d-734a-406c-a3dc-957e8316e781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91185bac-6425-4ffb-bf03-714c5952d508" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f63be6d-734a-406c-a3dc-957e8316e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_e211d565-5e4c-4768-aaa8-34089a507c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityDisclosureTextBlock_8ccd7f50-f71e-4df9-8c2c-12a4f84ed72d" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_e211d565-5e4c-4768-aaa8-34089a507c39" xlink:to="loc_bcax_TemporaryEquityDisclosureTextBlock_8ccd7f50-f71e-4df9-8c2c-12a4f84ed72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7658fbe-f07b-4d03-9be2-e5d22f1f57ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eb9d32e0-8976-431a-9dec-006cad1ea75f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7658fbe-f07b-4d03-9be2-e5d22f1f57ed" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eb9d32e0-8976-431a-9dec-006cad1ea75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bcax-20240930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_be5c75ac-e090-49c2-9107-a335c8547ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d4d49f60-c9f1-4394-9073-41279ed37cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be5c75ac-e090-49c2-9107-a335c8547ecb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d4d49f60-c9f1-4394-9073-41279ed37cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedParties" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreementsRelatedParties"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f28161dd-b014-4187-9ac6-0bd3a6cc713c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6250641f-0374-4b04-bbd5-0fc2144ee5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f28161dd-b014-4187-9ac6-0bd3a6cc713c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6250641f-0374-4b04-bbd5-0fc2144ee5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreements" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreements"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de94bd3e-da4f-4492-8ded-9d629af0643c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_2387fa82-8aa7-41d6-ba51-370974f16509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de94bd3e-da4f-4492-8ded-9d629af0643c" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_2387fa82-8aa7-41d6-ba51-370974f16509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bcax-20240930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c14b1d6-c73a-4ca5-ab59-505eddef63a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e7a46f89-50ba-4b0c-9d49-4b3333fac662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c14b1d6-c73a-4ca5-ab59-505eddef63a0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e7a46f89-50ba-4b0c-9d49-4b3333fac662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SubsequentEvents" xlink:type="simple" xlink:href="bcax-20240930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_691a3511-dcbc-4495-a7a3-71e7373e035b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5e36c8f7-667b-4787-bb84-0d565a88064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_691a3511-dcbc-4495-a7a3-71e7373e035b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5e36c8f7-667b-4787-bb84-0d565a88064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_62de6424-ac7f-49a1-8a0e-ff2ddd72b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_62de6424-ac7f-49a1-8a0e-ff2ddd72b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_76c2d661-153d-4fc7-be85-7719872c1ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_76c2d661-153d-4fc7-be85-7719872c1ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a335dc1d-92dd-4b8f-beab-22918d2abdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_UseOfEstimates_a335dc1d-92dd-4b8f-beab-22918d2abdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_9c546f9c-b628-4541-87ca-47243c501a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_9c546f9c-b628-4541-87ca-47243c501a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock_d8bf71fc-b8b5-4b11-b6e7-ad0538f7e4de" xlink:href="bcax-20240930.xsd#bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock_d8bf71fc-b8b5-4b11-b6e7-ad0538f7e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_df3ef51b-da69-4c11-ac62-25604d530779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_df3ef51b-da69-4c11-ac62-25604d530779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_24782df0-73fd-4861-b6e3-0f56cc3639bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_24782df0-73fd-4861-b6e3-0f56cc3639bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_5b1fa640-442f-4547-9704-ed42f4f7e566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_5b1fa640-442f-4547-9704-ed42f4f7e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9e8f0fc-93ee-4743-9daa-f2a1d86e16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9e8f0fc-93ee-4743-9daa-f2a1d86e16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f0527dc2-7c2f-49ba-9364-0cff92f6bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f0527dc2-7c2f-49ba-9364-0cff92f6bad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4f71de52-6ae4-45f0-ae2a-0b072c935fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4f71de52-6ae4-45f0-ae2a-0b072c935fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b373db9f-ee75-46a7-bfbb-065fa505dba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b373db9f-ee75-46a7-bfbb-065fa505dba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_886a51f6-2feb-444b-a996-adf00eb778d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_886a51f6-2feb-444b-a996-adf00eb778d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9edc8691-04dd-451f-8a73-d10c1e94b620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9edc8691-04dd-451f-8a73-d10c1e94b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4c1d2d44-1bf3-4bf7-b44c-f55a0dadb9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4c1d2d44-1bf3-4bf7-b44c-f55a0dadb9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df23f848-3d7f-414f-8bdc-5aa545c4e4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df23f848-3d7f-414f-8bdc-5aa545c4e4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_da7fc5ba-1480-4143-8640-a949a923329d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a312ca8-267e-42be-93b1-48be6a25755f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_da7fc5ba-1480-4143-8640-a949a923329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d83a7f4-11ab-4b1d-be0b-ffb61a630b59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5982e682-9cda-476e-b858-e739c291062d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d83a7f4-11ab-4b1d-be0b-ffb61a630b59" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5982e682-9cda-476e-b858-e739c291062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2008963c-0125-41ac-b78c-857accf1a685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_15d18f0c-43c7-453d-8a96-3700fff39476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2008963c-0125-41ac-b78c-857accf1a685" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_15d18f0c-43c7-453d-8a96-3700fff39476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9099d340-b92b-4108-84f8-b2c98d6e27d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2008963c-0125-41ac-b78c-857accf1a685" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9099d340-b92b-4108-84f8-b2c98d6e27d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ffeca156-be15-4ac9-8a45-a2d70dcf7eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2008963c-0125-41ac-b78c-857accf1a685" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ffeca156-be15-4ac9-8a45-a2d70dcf7eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="bcax-20240930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7c258b32-4249-465c-b22d-5c708c34e87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_44fa4526-fd6c-4e45-b400-c7e5142e54f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c258b32-4249-465c-b22d-5c708c34e87b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_44fa4526-fd6c-4e45-b400-c7e5142e54f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c556f98-57be-4c69-9afa-78c674428601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4ce6556c-3907-48b5-a6e6-d4294a4c4b54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c556f98-57be-4c69-9afa-78c674428601" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4ce6556c-3907-48b5-a6e6-d4294a4c4b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3a64a68e-e1ed-4796-abfd-97127d5810ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c556f98-57be-4c69-9afa-78c674428601" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3a64a68e-e1ed-4796-abfd-97127d5810ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7a0ebf43-dc7f-4d2d-802d-f4aaf4335e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c556f98-57be-4c69-9afa-78c674428601" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7a0ebf43-dc7f-4d2d-802d-f4aaf4335e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_035a863e-da23-4551-b51b-4693797437dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_38b3f5a9-859a-4a45-86e1-6d8dc2c82251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_035a863e-da23-4551-b51b-4693797437dd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_38b3f5a9-859a-4a45-86e1-6d8dc2c82251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d7cbfe-14ff-4f78-b9bc-487b48708c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d7cbfe-14ff-4f78-b9bc-487b48708c84" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e23384cf-d726-45d5-a4b3-71fab42de3a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b3b58f2a-7678-44ad-8ee0-feee76168c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:to="loc_us-gaap_IPOMember_b3b58f2a-7678-44ad-8ee0-feee76168c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0698d9a0-9cc4-498f-865a-c5bb8e2cc977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d123ea81-7a1f-4538-8ec9-1a7f65227e7c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0698d9a0-9cc4-498f-865a-c5bb8e2cc977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1d2bedee-6d6a-4806-bfe9-a259aeb78c01" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2938ce67-cfa6-4cf7-8b29-e8a8bade2922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2938ce67-cfa6-4cf7-8b29-e8a8bade2922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c9b965f7-648d-4f29-89b6-7be07901e2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c9b965f7-648d-4f29-89b6-7be07901e2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2672a430-ce90-433f-b2c0-02446b0bc713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2672a430-ce90-433f-b2c0-02446b0bc713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d746ba4-bc8d-4c77-967c-75c2cd98ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d746ba4-bc8d-4c77-967c-75c2cd98ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3b2d7d8b-51b7-4fad-809c-afa1eaeffe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3b2d7d8b-51b7-4fad-809c-afa1eaeffe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bd2086e6-e7a3-4d73-ae2e-c3bab472c973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bd2086e6-e7a3-4d73-ae2e-c3bab472c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_afc23654-3343-49ee-bc0f-2994d7637200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_afc23654-3343-49ee-bc0f-2994d7637200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9825ee80-0357-41eb-9e60-972443eb6f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9825ee80-0357-41eb-9e60-972443eb6f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_194afa06-7fc1-4a5c-b151-4f6562569f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_194afa06-7fc1-4a5c-b151-4f6562569f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_449e34fb-dac1-42fe-b573-d0913e19b9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_449e34fb-dac1-42fe-b573-d0913e19b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13a9176d-9574-46cb-ba6d-01997f3339e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_5a9a6229-2922-4309-ba73-43c4d6ce7271" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13a9176d-9574-46cb-ba6d-01997f3339e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d43bf69c-822c-46af-ac4e-104a9a429946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f169eafd-3917-4b7c-838e-3bc0bee4e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d43bf69c-822c-46af-ac4e-104a9a429946" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f169eafd-3917-4b7c-838e-3bc0bee4e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_507e018d-48b3-4180-acf0-2ea40fec885d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d43bf69c-822c-46af-ac4e-104a9a429946" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_507e018d-48b3-4180-acf0-2ea40fec885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7988ef10-6fe3-4b9a-a7b0-8136ebd99b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld_94cfcd19-748a-4ee3-a115-abee728f3ee0" xlink:href="bcax-20240930.xsd#bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7988ef10-6fe3-4b9a-a7b0-8136ebd99b26" xlink:to="loc_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld_94cfcd19-748a-4ee3-a115-abee728f3ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_370d1170-e7b4-4fe3-8540-37a9105482bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7988ef10-6fe3-4b9a-a7b0-8136ebd99b26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_370d1170-e7b4-4fe3-8540-37a9105482bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedClinicalTrialAndContractManufacturingExpenses_ef6fe52b-800e-4bf7-9524-ec0f9da46436" xlink:href="bcax-20240930.xsd#bcax_AccruedClinicalTrialAndContractManufacturingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7988ef10-6fe3-4b9a-a7b0-8136ebd99b26" xlink:to="loc_bcax_AccruedClinicalTrialAndContractManufacturingExpenses_ef6fe52b-800e-4bf7-9524-ec0f9da46436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cc8a9b00-9088-4f07-9bff-517c92045d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7988ef10-6fe3-4b9a-a7b0-8136ebd99b26" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cc8a9b00-9088-4f07-9bff-517c92045d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ad0364-c600-43b3-b2c4-881bc7ba1132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ad0364-c600-43b3-b2c4-881bc7ba1132" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f020b15-7102-47ce-8dc0-d8cf7d4b2018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_75c2781f-4298-4fe6-8a0b-83871cd5021f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_us-gaap_StockCompensationPlanMember_75c2781f-4298-4fe6-8a0b-83871cd5021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0859ae71-aace-4564-9120-5071aa4b2fd9" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0859ae71-aace-4564-9120-5071aa4b2fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ba8a8670-797a-44ce-a302-c4b5b16e7bcc" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ee2289b4-9d2a-4da5-8f7f-ae2a858d7c6d" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_ba8a8670-797a-44ce-a302-c4b5b16e7bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_191619b0-3820-41fa-9ba3-1c6356c71c77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_489b13c6-34fa-4239-a3f7-2651e2a765b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd9e1eef-ace7-4f9f-8239-96fd926a317e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_489b13c6-34fa-4239-a3f7-2651e2a765b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c246839d-ae87-459e-8267-2d5cf8142eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c246839d-ae87-459e-8267-2d5cf8142eff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e32114c-98f8-4f8b-a9c5-a1b34a36b504" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0fcd18c3-2cd5-4c4f-8123-8a0d2f72647f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0fcd18c3-2cd5-4c4f-8123-8a0d2f72647f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a3560cc8-5837-458c-92a6-c3203ba5f704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a3560cc8-5837-458c-92a6-c3203ba5f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_36bf1c04-2bfc-4820-a876-829e35e99936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67d48a0b-76ba-4e4c-9a6e-503055cd6723" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_36bf1c04-2bfc-4820-a876-829e35e99936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_53dd7f37-7f76-4a0b-937b-6807a38352f6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c2ba59ec-7e5a-448d-9e5f-047598ab6aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_71151f8d-18b7-43d9-bdc1-087ace98fadb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c2ba59ec-7e5a-448d-9e5f-047598ab6aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8747eaa8-2f7d-4009-a8a5-aeb691ba7cf7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b465751d-6775-4f8e-add8-de427078fdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b465751d-6775-4f8e-add8-de427078fdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_58d9e0c2-e429-43c3-b578-f26560f819c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42b51a2c-555e-45e5-a44e-ca74ee2f1326" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_58d9e0c2-e429-43c3-b578-f26560f819c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5432f00-808e-4a29-8df1-32e51a131327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5432f00-808e-4a29-8df1-32e51a131327" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_db4f156a-08ff-407c-a81e-4df9db84c953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_db4f156a-08ff-407c-a81e-4df9db84c953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a87ca94d-2c32-4612-88bf-a36e706f76b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a87ca94d-2c32-4612-88bf-a36e706f76b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d4fe353-ece4-4a0a-b013-b4ecaed6e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d4fe353-ece4-4a0a-b013-b4ecaed6e74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_074adc6c-eefe-481c-9d40-311adf83bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_074adc6c-eefe-481c-9d40-311adf83bea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b9e06b3a-1b19-4280-af52-09aa42bf3ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c2022476-1a03-4ff4-aad4-8271651ea890" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b9e06b3a-1b19-4280-af52-09aa42bf3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e97a816f-8da9-4437-9203-23e01175cf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityCurrent_019c9bc7-2da0-4ef7-b1a4-fd5df4a3b8ce" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e97a816f-8da9-4437-9203-23e01175cf7b" xlink:to="loc_bcax_FreestandingFinancialInstrumentLiabilityCurrent_019c9bc7-2da0-4ef7-b1a4-fd5df4a3b8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eca3b50f-4c09-483e-8f65-c12f77c5e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eca3b50f-4c09-483e-8f65-c12f77c5e13c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7aeab703-32c2-45d7-9a6d-ef634615ce54" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_aa4c7c79-910b-4bd9-8fdd-4af5df0bb049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_aa4c7c79-910b-4bd9-8fdd-4af5df0bb049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7dbd1a0d-89a6-4a41-9f77-ff560706672f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7dbd1a0d-89a6-4a41-9f77-ff560706672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ab922d1b-b5f4-42b0-93ec-c4243904b653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ab922d1b-b5f4-42b0-93ec-c4243904b653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MeasurementInputProbabilityOfAchievementMember_a63b3cfd-b24c-45c1-9481-e4df7ae7f8b4" xlink:href="bcax-20240930.xsd#bcax_MeasurementInputProbabilityOfAchievementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_598cec8e-eb41-4f73-b634-fe873b13d072" xlink:to="loc_bcax_MeasurementInputProbabilityOfAchievementMember_a63b3cfd-b24c-45c1-9481-e4df7ae7f8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a2e28d4-953d-414d-ae58-88e8a494c44f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_c1035475-bd4f-40d4-b500-ede20350e21c" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_001d410e-498f-45b0-9a65-369d573941cc" xlink:to="loc_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput_c1035475-bd4f-40d4-b500-ede20350e21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_655a6afb-91b5-4998-9e81-1d140be8e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_655a6afb-91b5-4998-9e81-1d140be8e0b9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4840e8eb-f78d-4762-9aae-bb95baacd23d" xlink:to="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_cac7415d-cdd7-49b3-bbbc-33dac91965e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_404d05a5-db3a-4202-89f7-b850c7779efa" xlink:to="loc_us-gaap_NonrelatedPartyMember_cac7415d-cdd7-49b3-bbbc-33dac91965e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3ac25be-9f66-4614-954e-b96e5332dc7d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_be16407b-9928-4abc-bdc7-2ec50cd80811" xlink:href="bcax-20240930.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_be16407b-9928-4abc-bdc7-2ec50cd80811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1679baef-5272-4c72-b14f-e38ec25fd0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1679baef-5272-4c72-b14f-e38ec25fd0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0e97c3ad-5d36-4149-92fd-6b4e2887e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0e97c3ad-5d36-4149-92fd-6b4e2887e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ae2666be-3168-4765-a828-04f422c8b6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ae2666be-3168-4765-a828-04f422c8b6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_08d0da49-bb58-4489-bc3e-4c0cb1d7a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0157f004-0488-4bc1-9e9b-18fe8e0088dd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_08d0da49-bb58-4489-bc3e-4c0cb1d7a3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CommonStockDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b56fa41f-b7cd-4386-a548-1bac17e669bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b56fa41f-b7cd-4386-a548-1bac17e669bc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81796bb5-f629-41b1-9f2c-1b09bd8ae762" xlink:to="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0f540c6d-663a-41b4-894b-4dcff67e78e0" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_0f540c6d-663a-41b4-894b-4dcff67e78e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_2831c6cf-28db-45ba-bee8-8a7c8c383050" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_2831c6cf-28db-45ba-bee8-8a7c8c383050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_577436c0-ef0a-4c4e-a632-0d215a45f309" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a3bc8bf-acef-420c-9411-69d23d545f78" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_577436c0-ef0a-4c4e-a632-0d215a45f309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99c32f99-e71c-41c7-b987-1d2ec87dfb79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16f675fc-0e4d-496c-b826-420c174df919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11e5378a-a3f1-4449-80bc-3203a912c964" xlink:to="loc_us-gaap_RestrictedStockMember_16f675fc-0e4d-496c-b826-420c174df919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_76fb6ec9-c601-419d-9a99-cb3569b4d441" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f6895913-742e-4b23-ab26-d365f6df2912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c733fc2c-04ed-45d8-a7ad-f52d01f88ea1" xlink:to="loc_us-gaap_IPOMember_f6895913-742e-4b23-ab26-d365f6df2912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_101ae848-5358-4028-997e-470c760a3afd" xlink:to="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_43b7d62a-549f-423b-ae4c-4a7aa91d838f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6a25b402-15d2-4152-860b-2da7791ba798" xlink:to="loc_us-gaap_CommonStockMember_43b7d62a-549f-423b-ae4c-4a7aa91d838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_85aff99f-fee7-4cb6-bf71-33e726419434" xlink:to="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2019StockOptionAndGrantPlanMember_0c4c14a6-d0ab-41aa-b753-8dcf336f42f5" xlink:href="bcax-20240930.xsd#bcax_A2019StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ae0c0057-2b30-4b87-a174-e99fd47d0594" xlink:to="loc_bcax_A2019StockOptionAndGrantPlanMember_0c4c14a6-d0ab-41aa-b753-8dcf336f42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8e33721f-b1f8-4f1b-919a-2042ad50fc72" xlink:to="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BioconLimitedMember_35b622e0-0844-4d8b-8000-5a50751db03d" xlink:href="bcax-20240930.xsd#bcax_BioconLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_af09995c-3583-4447-9a59-9f8cd37279ba" xlink:to="loc_bcax_BioconLimitedMember_35b622e0-0844-4d8b-8000-5a50751db03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_046594f3-4498-4ffd-82d0-34a76d810d2c" xlink:to="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bc8ef100-3ad6-4611-8d3c-8df958e84539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bc8ef100-3ad6-4611-8d3c-8df958e84539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9909506d-d794-442e-96ea-cef0f43b70c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9909506d-d794-442e-96ea-cef0f43b70c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_76eb0641-5d03-4c89-aa32-7904eb32227a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesIssued_76eb0641-5d03-4c89-aa32-7904eb32227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bd00cb7f-3ae4-4154-9032-25f382c938fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bd00cb7f-3ae4-4154-9032-25f382c938fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b6564e3-b37e-4697-b68c-516abb3219f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b6564e3-b37e-4697-b68c-516abb3219f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a06ab9e-c453-4932-b493-9427afe6dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a06ab9e-c453-4932-b493-9427afe6dd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3bad3bb4-f56f-4aab-8915-2ac78b9776b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3bad3bb4-f56f-4aab-8915-2ac78b9776b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_deaa148c-8c09-4ffe-b1d6-ea9f09ee6255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_deaa148c-8c09-4ffe-b1d6-ea9f09ee6255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0601db1f-0102-4cd0-88dc-36c9902c19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0601db1f-0102-4cd0-88dc-36c9902c19f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b9f6e5a-e123-488b-9855-e7e860f10931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b9f6e5a-e123-488b-9855-e7e860f10931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a910403d-4055-4d93-8bab-8a19e60e833f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a910403d-4055-4d93-8bab-8a19e60e833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2f8bf01c-5be6-4147-810b-4572855128f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9562756-14c7-4741-b236-2c380756650d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2f8bf01c-5be6-4147-810b-4572855128f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_e61c1bee-c5c9-4109-9f65-702a208cbaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_e61c1bee-c5c9-4109-9f65-702a208cbaaa" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b7256b0f-9765-4695-9812-1565d21392b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BioconLimitedMember_8a610880-4bee-4d40-97b0-6432d9c8a71c" xlink:href="bcax-20240930.xsd#bcax_BioconLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e87220b-3861-4cd6-8bfa-33e98f18678a" xlink:to="loc_bcax_BioconLimitedMember_8a610880-4bee-4d40-97b0-6432d9c8a71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab84f5f3-d0e5-4fe3-9a8a-5e3b55484d57" xlink:to="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_1bfb4b93-364e-490e-8b82-3cfc266d777f" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_1bfb4b93-364e-490e-8b82-3cfc266d777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_a7ee3500-f4a7-4b5c-bf2c-5e20ddb7292e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_a7ee3500-f4a7-4b5c-bf2c-5e20ddb7292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_4edeb847-a307-4548-af5d-6604de797c2f" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember_4edeb847-a307-4548-af5d-6604de797c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bc81139f-2ba9-4dd9-af6c-9187291010a7" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8ad2b2c3-2022-4a0e-a4f5-16dc0e53b1df" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bc81139f-2ba9-4dd9-af6c-9187291010a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ef3cbed8-9e43-4342-b3b3-f96682e8bc2d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsMember_644031f5-b1da-47d5-bdd2-ef78823e1a27" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:to="loc_bcax_TwoInvestorsMember_644031f5-b1da-47d5-bdd2-ef78823e1a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember_487d60cd-2b4e-45fa-b35c-2bebcc820ea0" xlink:href="bcax-20240930.xsd#bcax_TwoInvestorsRelativesOfBoardMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e051f71c-8533-4416-89b2-12d82a644abd" xlink:to="loc_bcax_TwoInvestorsRelativesOfBoardMemberMember_487d60cd-2b4e-45fa-b35c-2bebcc820ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_52fdcfcd-c708-41d2-8d29-34f47eb68321" xlink:to="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_59db5ec9-04dc-4bf5-bac8-8af88833e7a1" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_59db5ec9-04dc-4bf5-bac8-8af88833e7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0e94f852-f416-470e-84ac-7a4acb60b549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0e94f852-f416-470e-84ac-7a4acb60b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_a6b18afb-62b6-49c3-9ec6-49efc9562043" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_a6b18afb-62b6-49c3-9ec6-49efc9562043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_9b3e2521-686e-40db-903b-c307c2b999dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_9b3e2521-686e-40db-903b-c307c2b999dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_f7482dd5-5c9d-453c-93a5-baff2624b2e1" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_f7482dd5-5c9d-453c-93a5-baff2624b2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_e8186308-97ea-476c-a049-3d2b632daebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_e8186308-97ea-476c-a049-3d2b632daebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ef4954db-14bb-484f-8f80-8d86d9f40c21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ef4954db-14bb-484f-8f80-8d86d9f40c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued_ef69d0c0-8ae2-443b-bdc6-57285d502a12" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityNumberOfInvestorsStockIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityNumberOfInvestorsStockIssued_ef69d0c0-8ae2-443b-bdc6-57285d502a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c1ea4207-ffe0-4a5f-870d-8704de3e2102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c1ea4207-ffe0-4a5f-870d-8704de3e2102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue_4dc8465a-364c-4a05-9ed7-a71c23ffced3" xlink:href="bcax-20240930.xsd#bcax_FreestandingFinancialInstrumentLiabilityFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_FreestandingFinancialInstrumentLiabilityFairValue_4dc8465a-364c-4a05-9ed7-a71c23ffced3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_d6b043c1-4148-4650-a0dc-d3db6bc89c2a" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_86d5e20b-6801-4edb-9914-e68f74aca8e1" xlink:to="loc_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption_d6b043c1-4148-4650-a0dc-d3db6bc89c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockConversionRightsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_519947b7-a44f-45ad-8a45-97ef74189ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_839bb8a1-90f9-4e5b-9a6f-a1a03be62619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_519947b7-a44f-45ad-8a45-97ef74189ffa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_839bb8a1-90f9-4e5b-9a6f-a1a03be62619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_91c01a0a-fab0-4e5a-af3f-a1d4f6a6bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_519947b7-a44f-45ad-8a45-97ef74189ffa" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_91c01a0a-fab0-4e5a-af3f-a1d4f6a6bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_7239c03f-427f-4445-8b4e-57ac4e500917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_7239c03f-427f-4445-8b4e-57ac4e500917" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffbc62bc-768c-40a1-890f-54307e6e3a33" xlink:to="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_fb0eab05-0467-45e0-9f92-0fea731fc63e" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_fb0eab05-0467-45e0-9f92-0fea731fc63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bbf013aa-2f3b-4c68-bd0c-73626f30d356" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ef7553d2-e680-42ab-bc8f-d2284f71f0bb" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_bbf013aa-2f3b-4c68-bd0c-73626f30d356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_eaaad0ac-27bb-4c8c-b117-7471f0c94ed8" xlink:to="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityDividendRatePercentage_1e7141ec-78c7-47a9-a372-f6721700495c" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityDividendRatePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d0633924-0402-4ca3-8ce3-e7dff65f5d48" xlink:to="loc_bcax_TemporaryEquityDividendRatePercentage_1e7141ec-78c7-47a9-a372-f6721700495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockVotingRightsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_885a1f42-1ccf-49d7-bf89-131a492b5a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_885a1f42-1ccf-49d7-bf89-131a492b5a63" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67458477-a505-40e1-adb3-ea4e57c11edd" xlink:to="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_b1f16c34-5cff-4a01-b3c0-11708ff2c54b" xlink:href="bcax-20240930.xsd#bcax_SeedSeriesRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeedSeriesRedeemableConvertiblePreferredStockMember_b1f16c34-5cff-4a01-b3c0-11708ff2c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_31493863-b9fb-41f7-afcb-3503110dc9ee" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_31493863-b9fb-41f7-afcb-3503110dc9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_d78f6a7b-fd6e-48d9-bc1a-efecf561f1fa" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca9b057b-87e1-4c72-bc12-bbdd6058b363" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_d78f6a7b-fd6e-48d9-bc1a-efecf561f1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_06d5f9f1-a0be-42bf-beaa-f6fb2ae1c144" xlink:to="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_NumberOfMembersBoardOfDirectors_6acc1467-acbd-48be-90d8-b09e901ec195" xlink:href="bcax-20240930.xsd#bcax_NumberOfMembersBoardOfDirectors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_NumberOfMembersBoardOfDirectors_6acc1467-acbd-48be-90d8-b09e901ec195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_0d2df0fb-709f-42f4-bb27-1729fb87db65" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected_0d2df0fb-709f-42f4-bb27-1729fb87db65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a923d89-d70c-4e61-a8be-df4083657b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a923d89-d70c-4e61-a8be-df4083657b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_4678938c-49f7-4e6c-ad1d-98c9a56d392b" xlink:href="bcax-20240930.xsd#bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_d70eeb47-a006-4f11-a8ce-19d6477c6f09" xlink:to="loc_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected_4678938c-49f7-4e6c-ad1d-98c9a56d392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#RedeemableConvertiblePreferredStockProtectiveProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_5b1fe0eb-75a3-4026-bfcd-82ad9b23eb83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_5b1fe0eb-75a3-4026-bfcd-82ad9b23eb83" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6e379d33-56ba-4232-a486-2b248ffe15fe" xlink:to="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_38615578-466a-44bc-9428-64df9e6aba19" xlink:href="bcax-20240930.xsd#bcax_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:to="loc_bcax_SeriesBRedeemableConvertiblePreferredStockMember_38615578-466a-44bc-9428-64df9e6aba19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_3cebdce5-72a9-4f52-9056-f5ea8e0a3aa3" xlink:href="bcax-20240930.xsd#bcax_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1dc121a-efcf-4899-98f9-9eb9254c56f9" xlink:to="loc_bcax_SeriesCRedeemableConvertiblePreferredStockMember_3cebdce5-72a9-4f52-9056-f5ea8e0a3aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_fcc9832f-dbdb-4cbf-9e34-9e72ea14308b" xlink:to="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_bf6f6619-8153-49e0-84fc-4a3e2600720f" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:to="loc_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage_bf6f6619-8153-49e0-84fc-4a3e2600720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_f7b6f2cd-6f9b-4b71-9f39-31c0633d2aa6" xlink:href="bcax-20240930.xsd#bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f39cc11c-0c21-4e36-a626-7e005a233230" xlink:to="loc_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired_f7b6f2cd-6f9b-4b71-9f39-31c0633d2aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c904a24f-44ac-46cf-b082-426a0a88c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c904a24f-44ac-46cf-b082-426a0a88c1a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:to="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f3d5b505-55b5-4d6a-8ed8-b9d512850e50" xlink:to="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2019StockOptionAndGrantPlanMember_9e66d49e-8bab-4dfa-8435-5a22be22c8dd" xlink:href="bcax-20240930.xsd#bcax_A2019StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:to="loc_bcax_A2019StockOptionAndGrantPlanMember_9e66d49e-8bab-4dfa-8435-5a22be22c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember_f762f28f-f497-4225-a9db-f66703aa0e18" xlink:href="bcax-20240930.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9869f322-fc66-407f-9be4-b194453e7ffc" xlink:to="loc_bcax_A2024StockOptionAndGrantPlanMember_f762f28f-f497-4225-a9db-f66703aa0e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:to="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_beb5576f-3bb7-4858-94e8-b28343d73a34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_039a08ad-d489-4263-bc9d-a6e040713919" xlink:href="bcax-20240930.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_039a08ad-d489-4263-bc9d-a6e040713919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c61de3e4-f9fe-4d2d-85f9-af57c1701bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_RestrictedStockMember_c61de3e4-f9fe-4d2d-85f9-af57c1701bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0af28a30-8b70-4fff-8aae-2963644680fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0af28a30-8b70-4fff-8aae-2963644680fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0f15bb76-1b25-48fb-b792-346ba16d494c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d6a042-03ae-4bc7-a427-901f0df97dab" xlink:to="loc_us-gaap_EmployeeStockMember_0f15bb76-1b25-48fb-b792-346ba16d494c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78869dcc-53d6-4e9a-a264-8ae0045115bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_eb603de1-8f05-4ae2-8371-fa825f03648c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_eb603de1-8f05-4ae2-8371-fa825f03648c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a9aa0753-db72-4edc-8ed1-f10c08c25434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a9aa0753-db72-4edc-8ed1-f10c08c25434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_000ddcf2-28ad-4402-a113-ceed5b3870b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_000ddcf2-28ad-4402-a113-ceed5b3870b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_d285e47c-d464-4b4f-bf9a-3bf1c3d1da09" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_d285e47c-d464-4b4f-bf9a-3bf1c3d1da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_42081bc6-979f-4e89-ab6d-c035b758a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_42081bc6-979f-4e89-ab6d-c035b758a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1b166f25-cee3-4590-840a-f045baa4341e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1b166f25-cee3-4590-840a-f045baa4341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e67e5ce9-9814-4f57-8af7-1f97717d9c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e67e5ce9-9814-4f57-8af7-1f97717d9c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b01a6e51-a9f6-4aaf-ab43-db4173d01a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b01a6e51-a9f6-4aaf-ab43-db4173d01a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0b28d3fc-86ef-4281-8736-d2790046dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0b28d3fc-86ef-4281-8736-d2790046dc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a51b0467-de0e-47be-bddb-2f8165f66d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a51b0467-de0e-47be-bddb-2f8165f66d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96540d9b-5867-4f49-9abd-20baad94c82b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96540d9b-5867-4f49-9abd-20baad94c82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_a282e8fb-1371-4314-8089-fd00cc4a9192" xlink:href="bcax-20240930.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_a282e8fb-1371-4314-8089-fd00cc4a9192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c3e90503-55cc-4d30-8940-bbcc19f42754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d10d6fc-c551-477f-a2ce-85b9e919636c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c3e90503-55cc-4d30-8940-bbcc19f42754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c219262a-bb08-48ed-843e-016b0844e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c219262a-bb08-48ed-843e-016b0844e5dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c2523c8-1092-484a-bed7-f819ec53eb95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4bed86cd-cc45-4b27-9677-4977123b8811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4bed86cd-cc45-4b27-9677-4977123b8811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f541138-fbc8-4bfa-8237-25a434a13a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b40d9761-a78d-40d4-ad1a-6197117f5327" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f541138-fbc8-4bfa-8237-25a434a13a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2fa1ee-cdf4-4134-bd1d-2c06677ec46a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77ff33ee-73d7-4fdf-835b-7797cb85b13e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16c6041c-ac8a-4860-a536-30c7b305a8d4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77ff33ee-73d7-4fdf-835b-7797cb85b13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationRSAAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1596ac43-0572-4a6d-b779-974165719168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1596ac43-0572-4a6d-b779-974165719168" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:to="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d919b44a-4e12-46b0-ad6c-003bda57100d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f0bd7081-1157-4a74-a494-fc4c37408aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_428de47c-414a-43c9-9350-1d1df1ce7d2d" xlink:to="loc_us-gaap_RestrictedStockMember_f0bd7081-1157-4a74-a494-fc4c37408aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e67199d-1e63-48fd-923c-2cf393febba8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cf098a3-e9d4-4ad6-b30a-7a87eb47ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cf098a3-e9d4-4ad6-b30a-7a87eb47ddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_828e5379-8a29-42c6-b1f7-cc2116c14cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_828e5379-8a29-42c6-b1f7-cc2116c14cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66720906-36d9-43eb-8535-3a2d054a6c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66720906-36d9-43eb-8535-3a2d054a6c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_481fd8bc-1ebd-4aa7-a232-7b98fe5ebc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_481fd8bc-1ebd-4aa7-a232-7b98fe5ebc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea88e913-f3e8-4448-8b21-2cc25a0731a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fe1a4cb4-5233-4728-81b0-740305533a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea88e913-f3e8-4448-8b21-2cc25a0731a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69a4ebb8-b094-4756-8263-87ee14a32485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f9a5293-a793-4d3f-9412-ee7bf3079490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f9a5293-a793-4d3f-9412-ee7bf3079490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_864bdf45-978d-406b-9a20-ca709b4e22c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_864bdf45-978d-406b-9a20-ca709b4e22c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2ab3808e-d4a8-4d40-b371-0b4987ebb846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2ab3808e-d4a8-4d40-b371-0b4987ebb846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a2ad1a0d-80eb-4eaa-be84-e23239fa46e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a2ad1a0d-80eb-4eaa-be84-e23239fa46e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3cc26455-94a8-48ca-997e-12866dc7ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2cbd8ad6-b0c2-4ca0-9f81-a7c5d4cbe48d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3cc26455-94a8-48ca-997e-12866dc7ef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd06233-e06c-4065-94c7-f8005764c146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd06233-e06c-4065-94c7-f8005764c146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4424a3fc-8b55-49cf-b71b-ee8133bcbe63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4424a3fc-8b55-49cf-b71b-ee8133bcbe63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92b39aac-2dac-499f-af42-221e696e1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92b39aac-2dac-499f-af42-221e696e1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_33b57894-ed44-4ade-948f-fd6f29d4667c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_33b57894-ed44-4ade-948f-fd6f29d4667c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ef48505a-9096-4a44-a488-037e876c4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ef48505a-9096-4a44-a488-037e876c4cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf4ff4bb-3f87-46c7-873b-a249e8dda5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_632454aa-38c8-4e65-93a2-67e47ccc99ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf4ff4bb-3f87-46c7-873b-a249e8dda5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd06233-e06c-4065-94c7-f8005764c146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_569364f5-1b4a-4bd2-9b5c-5c4c77e2e105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_569364f5-1b4a-4bd2-9b5c-5c4c77e2e105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_877713b0-c02a-47e5-bb6f-39bbe21b89ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_877713b0-c02a-47e5-bb6f-39bbe21b89ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e25675c-8599-4a2f-9565-ea8f1c6a559c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e25675c-8599-4a2f-9565-ea8f1c6a559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1dccd324-dffa-47c0-a28a-060ca522f911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1dccd324-dffa-47c0-a28a-060ca522f911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcd0beb-8241-446b-ba1e-b082bfe61568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e533362-738c-4a14-a8ff-bb7de740c5e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcd0beb-8241-446b-ba1e-b082bfe61568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd06233-e06c-4065-94c7-f8005764c146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7c3c9c8a-27cd-42ed-b687-bdb921de4ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7c3c9c8a-27cd-42ed-b687-bdb921de4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a41c8f36-8bfd-4e0a-87de-3983c7ab46c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a41c8f36-8bfd-4e0a-87de-3983c7ab46c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af69e8e-c7ec-4956-859a-508b29b012a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af69e8e-c7ec-4956-859a-508b29b012a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04377943-ebb7-42da-a499-ea844635e8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04377943-ebb7-42da-a499-ea844635e8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_877b6e4a-fd75-410a-933f-a53e9603e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_877b6e4a-fd75-410a-933f-a53e9603e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_86a1b925-cb7b-4102-b0c8-f4d1973aeb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_86a1b925-cb7b-4102-b0c8-f4d1973aeb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ebff02b8-ee3d-4209-80d6-cebe5e959b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ebff02b8-ee3d-4209-80d6-cebe5e959b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_37bf9388-1431-47b2-8f7e-661a96a67418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48efd252-61c5-49e9-877f-a444df960d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_37bf9388-1431-47b2-8f7e-661a96a67418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreementsRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_19deb78e-382d-4ddb-9a63-1926e2331288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_19deb78e-382d-4ddb-9a63-1926e2331288" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29611a5d-39bb-49cb-b0a3-bd06e451f339" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember_0550c88c-b551-4907-a264-ad0005472765" xlink:href="bcax-20240930.xsd#bcax_MasterServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_MasterServicesAgreementMember_0550c88c-b551-4907-a264-ad0005472765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember_699b5440-e99d-4f04-a2c7-39c6d053a729" xlink:href="bcax-20240930.xsd#bcax_BBLAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_BBLAgreementsMember_699b5440-e99d-4f04-a2c7-39c6d053a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementManufacturingMember_2e70a9f2-13ae-4f0d-a774-1025504d8174" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementManufacturingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementManufacturingMember_2e70a9f2-13ae-4f0d-a774-1025504d8174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementMasterContractServicesMember_e94de7f2-aa5e-4093-b6b0-58bbf4edc327" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementMasterContractServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementMasterContractServicesMember_e94de7f2-aa5e-4093-b6b0-58bbf4edc327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember_e31f7e34-812d-44e8-83c7-3a3fdd896f2a" xlink:href="bcax-20240930.xsd#bcax_SyngeneAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_SyngeneAgreementsMember_e31f7e34-812d-44e8-83c7-3a3fdd896f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BiofusionAgreementMember_b111e87b-e036-462b-ada4-b1749ce66446" xlink:href="bcax-20240930.xsd#bcax_BiofusionAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_BiofusionAgreementMember_b111e87b-e036-462b-ada4-b1749ce66446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PromissoryNoteMember_7196a5b2-5c6c-468b-9eb8-cc2934f97bac" xlink:href="bcax-20240930.xsd#bcax_PromissoryNoteMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e76e1b13-e14b-4114-855c-7f9656770ab5" xlink:to="loc_bcax_PromissoryNoteMember_7196a5b2-5c6c-468b-9eb8-cc2934f97bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb12a301-529a-4095-8f37-7e5cdfa20020" xlink:to="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b8fd0be5-2463-4dbf-8703-224b9aed2362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:to="loc_us-gaap_RelatedPartyMember_b8fd0be5-2463-4dbf-8703-224b9aed2362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_e097bf52-3346-4911-a0aa-01e7c046432a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4d2f4437-bdb9-4657-a003-9edcbe06855d" xlink:to="loc_srt_ChiefFinancialOfficerMember_e097bf52-3346-4911-a0aa-01e7c046432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0cb480a7-a5a9-4652-b543-59734fe76ecc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6cfaab20-4dba-415b-a3b8-abe864bab162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6cfaab20-4dba-415b-a3b8-abe864bab162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2a47f84c-317e-44a1-aaaf-5cfee3052e40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2a47f84c-317e-44a1-aaaf-5cfee3052e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RelatedPartyAgreementTerm_d2a7fc87-5482-4876-8e0b-d9ae7c18978f" xlink:href="bcax-20240930.xsd#bcax_RelatedPartyAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_bcax_RelatedPartyAgreementTerm_d2a7fc87-5482-4876-8e0b-d9ae7c18978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8bbc514b-868f-4cd6-80cb-fb31f0a46f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_LiabilitiesCurrent_8bbc514b-868f-4cd6-80cb-fb31f0a46f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8a564e04-7463-4edb-8eb1-fe55fed013ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_AccountsPayableCurrent_8a564e04-7463-4edb-8eb1-fe55fed013ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2dd66583-f044-48ad-abcf-d040f22f60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2dd66583-f044-48ad-abcf-d040f22f60cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ececfbb6-17d3-4051-8baa-b7fcd29381b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ececfbb6-17d3-4051-8baa-b7fcd29381b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DebtInstrumentCollateralPledgedShares_28f67799-a9e3-40ff-b88d-cac0e714b074" xlink:href="bcax-20240930.xsd#bcax_DebtInstrumentCollateralPledgedShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_bcax_DebtInstrumentCollateralPledgedShares_28f67799-a9e3-40ff-b88d-cac0e714b074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eccf8223-b802-4479-885d-cc38a0e7f8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eccf8223-b802-4479-885d-cc38a0e7f8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83f5f272-3815-4a89-b8eb-e8a83aebf0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26410126-886f-443c-8df2-8b21de328ce7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83f5f272-3815-4a89-b8eb-e8a83aebf0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SignificantAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28389a55-41d4-48f8-a9be-9718d23a2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28389a55-41d4-48f8-a9be-9718d23a2f14" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:to="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_06a201bb-90c0-4385-8cd9-90a034d8e163" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember_f8c21734-e4a3-4bf0-a0ce-9ccff875b236" xlink:href="bcax-20240930.xsd#bcax_IQVIARDSIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_532b8094-886a-4cd9-ab82-170d3fa0ec64" xlink:to="loc_bcax_IQVIARDSIncMember_f8c21734-e4a3-4bf0-a0ce-9ccff875b236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:to="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_5fae5b22-1ad4-4736-9f18-99fc3d7a6571" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember_ebdc33b0-b312-4af7-93b5-b1342176e327" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementMember_ebdc33b0-b312-4af7-93b5-b1342176e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_40ff9c77-1468-4617-ac5e-567da0309b74" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_40ff9c77-1468-4617-ac5e-567da0309b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_91fe4a53-fc43-4d34-8627-e318785c0945" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_91fe4a53-fc43-4d34-8627-e318785c0945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_ecf5a8a8-6fd3-4667-a8d2-0b188a089ed0" xlink:href="bcax-20240930.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b6fbaac7-0bd6-42a1-ac16-6d8f0abd91f3" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_ecf5a8a8-6fd3-4667-a8d2-0b188a089ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5565eb83-d264-43d3-94a5-6bcc1e6f3d77" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_ae47edd1-93e5-49c2-8023-5141ea686d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_OtherCommitment_ae47edd1-93e5-49c2-8023-5141ea686d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_b04b12b2-c8ca-4698-aef5-25d992726a61" xlink:href="bcax-20240930.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_b04b12b2-c8ca-4698-aef5-25d992726a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_49dbad07-00ea-40af-80e0-cd719c86e204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_OperatingExpenses_49dbad07-00ea-40af-80e0-cd719c86e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments_370311c0-8a93-460c-b1aa-252f21b0d271" xlink:href="bcax-20240930.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_bcax_PaymentsForOtherCommitments_370311c0-8a93-460c-b1aa-252f21b0d271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_49c4af8a-23a2-44c6-9833-f7598e8d0946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_AccountsPayableCurrent_49c4af8a-23a2-44c6-9833-f7598e8d0946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b33d8c8-1300-46d8-bee4-046e3e8671b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d351b53-367f-4696-9de5-38b858a0cddd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b33d8c8-1300-46d8-bee4-046e3e8671b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="bcax-20240930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8e5bd49d-b31b-4e8b-a023-d3b226caa132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8e5bd49d-b31b-4e8b-a023-d3b226caa132" xlink:to="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f41d4f2-c48c-4f85-b007-67ef0c85da40" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3a75aded-4b66-4517-8840-4122045404c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_29b01103-5c7f-4048-b6a4-3c7c76b06c65" xlink:to="loc_us-gaap_SubsequentEventMember_3a75aded-4b66-4517-8840-4122045404c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4451c717-a04d-42f0-814e-05d11aafdf72" xlink:to="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LesseeOperatingLeaseAreaOfProperty_4fb17a4c-6072-47c0-933f-023805f62db4" xlink:href="bcax-20240930.xsd#bcax_LesseeOperatingLeaseAreaOfProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:to="loc_bcax_LesseeOperatingLeaseAreaOfProperty_4fb17a4c-6072-47c0-933f-023805f62db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d91b20fe-9889-4d26-942c-a33328826692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2eebe4ad-946b-40a2-808f-ff007bfb47ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d91b20fe-9889-4d26-942c-a33328826692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="bcax-20240930.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@  !)4    &" 8   !ZB:\@    "7!(67,  $SE
M  !,Y0%USO"5    34E$051XVNW8P0D 0 @$L>V_:0]\BW!/(0-I8E)#20
M  !@U/_(5 (   # 5 (   # 5 (   #@R%22)$F2)$F2MDPE29(D29(D??<
4>O(/]HZM)3T     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_3.jpg
<TEXT>
begin 644 image_3.jpg
MB5!.1PT*&@H    -24A$4@  !U,   !&" 8   "9DKVK    "7!(67,  $SE
M  !,Y0%USO"5   ##$E$051XVNS901$ , C ,/R;9@*H@ETBH=_. @
M '",!         "7F0H        0S%0       " 8*8"        !#,5
M    ()BI         ,%,!0        AF*@       $ P4P$       ""F0H
M       0S%0       " 8*8"        !#,5        ()BI         ,%,
M!0        AF*@       $ P4P$  +[Q    ___LV:$! " ,P##^?WH<L$H$
M(CFAMC,   # .T<"        @,U,!0        AF*@       $ P4P$
M  ""F0H        0S%0       " 8*8"        !#,5        ()BI
M     ,%,!0        AF*@       $ P4P$       ""F0H        0S%0
M      " 8*8"        !#,5        ()BI        \)L+  #__^S9H0$
M( S ,/Y_>ARP2@0B.:&V,WS@2         "PF:D         P4P%
M"&8J        0#!3 0       (*9"@       !#,5        (!@I@(
M   $,Q4        @F*D         P4P%        "&8J        0#!3 0
M     (*9"@       !#,5        (!@I@(        $,Q4        @F*D
M , +%P  ___LV3$1 " ,P,#Z-UU&!J* ^Y>0-;L     GQD)         %YF
M*@       $ P4P$       ""F0H        0S%0       " 8*8"
M!#,5        ()BI         ,%,!0        AF*@       $ P4P$
M  ""F0H        0S%0       " 8*8"        !#,5        ()BI
M     &$       #@.@   /__8V 8!:-@%$   )C"#(=$[5&X     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_4.jpg
<TEXT>
begin 644 image_4.jpg
MB5!.1PT*&@H    -24A$4@   A(   #J" 8   #W8ZSB   # %!,5$4
M #,  &8  )D  ,P  /\ *P  *S, *V8 *YD *\P *_\ 50  53, 568 59D
M5<P 5?\ @   @#, @&8 @)D @,P @/\ J@  JC, JF8 JID JLP JO\ U0
MU3, U68 U9D U<P U?\ _P  _S, _V8 _YD _\P __\S   S #,S &8S )DS
M ,PS /\S*P S*S,S*V8S*YDS*\PS*_\S50 S53,S568S59DS5<PS5?\S@  S
M@#,S@&8S@)DS@,PS@/\SJ@ SJC,SJF8SJIDSJLPSJO\SU0 SU3,SU68SU9DS
MU<PSU?\S_P S_S,S_V8S_YDS_\PS__]F  !F #-F &9F )EF ,QF /]F*P!F
M*S-F*V9F*YEF*\QF*_]F50!F53-F569F59EF5<QF5?]F@ !F@#-F@&9F@)EF
M@,QF@/]FJ@!FJC-FJF9FJIEFJLQFJO]FU0!FU3-FU69FU9EFU<QFU?]F_P!F
M_S-F_V9F_YEF_\QF__^9  "9 #.9 &:9 )F9 ,R9 /^9*P"9*S.9*V:9*YF9
M*\R9*_^950"953.956:959F95<R95?^9@ "9@#.9@&:9@)F9@,R9@/^9J@"9
MJC.9JF:9JIF9JLR9JO^9U0"9U3.9U6:9U9F9U<R9U?^9_P"9_S.9_V:9_YF9
M_\R9___,  #, #/, &;, )G, ,S, /_,*P#,*S/,*V;,*YG,*\S,*__,50#,
M53/,56;,59G,5<S,5?_,@ #,@#/,@&;,@)G,@,S,@/_,J@#,JC/,JF;,JIG,
MJLS,JO_,U0#,U3/,U6;,U9G,U<S,U?_,_P#,_S/,_V;,_YG,_\S,____  #_
M #/_ &;_ )G_ ,S_ /__*P#_*S/_*V;_*YG_*\S_*___50#_53/_56;_59G_
M5<S_5?__@ #_@#/_@&;_@)G_@,S_@/__J@#_JC/_JF;_JIG_JLS_JO__U0#_
MU3/_U6;_U9G_U<S_U?___P#__S/__V;__YG__\S___\               #9
M]O(H    !F)+1T0 _P#_ /^@O:>3    "7!(67,   [$   .Q &5*PX;   @
M $E$051XG.V=V96KNA*&"Z\;#>PWD0H.0831=!@H!),*>CMV.KH/@"U$28C)
M=MO_MY;./NT!9*&A5*HA,<80     , :3J^N      #^+A D     + :"!(
M    6 T$"0    "L!H($     %8#00(     JX$@ 0   (#50)      P&H@
M2'P$VI1)8A)O*8TFBH\\UI33:YP5(I?MC#I/GU79+'A.+DT^N5Z^Y7H  ! !
M!(F_S'W!STD%/Z@H3Q**7J@R_N5%P@B80?-MZ6G[J"N28%\% ( C@2#Q1]&_
MB4G.8?&!0YT3FMVE7M?6"L0C$KHQ+V]H>\$(#9QH 0  >P)!X@^BF]SDU8;O
MGQ,*:B:X7?&-2! EZ^\*QFA#*?/R)HT$\]H-H@0 X%@@2/PYM%%G;LD05!M#
MQIAD5"[\0J+.I?^H(JV3R77^DQ B=D6P[2FV:"0X#4>*HPT P+% D/AK-&IJ
M#U'49$R;2$YC4+2)N=:,BEN1:HZI(HB!MY'06S02Z?0I"QQN   .!H+$GX,Y
M!R]D^"NI3.IJ^K*Z8;?Z.IYC(Z%A; D .!@($G\,S2S^NIE?+$3*"!M7S1]O
M>-P_9[TV;LKD$]?3W*C;XWN:<5%D[368.HP^Q]4Q24S>>+PA@OC=9U>[8[+U
ML]OB.3829-E(<&T?=@W6AG-137XCVIC[_>[WUO8S ,!; 4'BK\&HKZG)P\:3
M1$0%8_=PD0EK0.E9S/S&EOU"G)7LGKC,$KK'H>!VX=S]?*\-PHK'8T6?<W*%
M%S^# .%WGU7G!6ZS-%<_NRT.T$@PAI4BU?<ZY:QM3>\:S"[@(A$%T]\J->L*
MK&_3WR_=OKNXGP$ WI'_O;H"-IK(T$U3Y[2F^S-\32+ME+;=JY_]KRA$<"(5
M)(FHG+RNS@DI(B,N+;4%;\@7#;>8W;KG,ZG;39F<%2 <FI*21)OZ,OQ:YW[N
M[IRK0U-24L6XO&HJLY*$J:?U75KO'G5.2%]:$V[;)6VAC"AH^CLWV4APVJJ2
M$E: F-8I_T?4_B=';2:*FB2Y@I8BU=14%]Z:&%6YKTF2[N>7]#, P-OR4D%"
M-=KH6W>.JWNA@5)!=%/]SEMWJME4]2K:?D),!=D"!Z5DO2\Z2_4;6>\/GR?K
M_?>\7IO5TT75INA$"=]RJL\Y)??=HJ#ZVI),%T[*W&+&UDD;5<4OQD2*RG/D
M_9C75)008=VKJ:EE%SMMR@5"Q/U;YYS*BS%UP;6G-F6RY)I#GQ\C.*$J$C8<
M5<2QUYUK2?FO(/-C7TDDLB#C&N:JFR;.A)>(>(/@2DX%9$\_@Q !P-_BZ4<;
MJM&F_%4F^:=,V2A25]U-=BE9$Z@M1%#_;[_@#HMN:KTV>G_XGOV^]=W[^V]X
MO;MN(H1(ZLN,<>6=7I6^]+S_RB\0[@2O&T4EY_E1U(X;JG?)Z>\77X<.2:WM
MZNII#_W+J^#U+W>4(:B^CMUGN1VWUVVV*3W"G5/7F;;8Y+41NG+L,ZE*<H^%
M1,6T;^!X8WJL(:CFCD@\SQ@V$@#\+9XB2)2--OE9F>1?:<I&D[H2W7?GPR)Z
M(^O\W-FYVSO^&XUW_#=GQW^SOC>Z?K] W\1[7F_)_KBHO?$A0D2?]V=\7<83
MO#;ZEUDZBYK:R<(ND]:TY!-_!*N1\+1'U9(Q]=BVHZB3EFN/*W<-3NTNJ#93
MS8V\M(SZGG.;U4;],O<JZFE=9]IBFXU$H,TN;AP0F;2L6_ P/BU2R=17D^9L
M/+CV+20)3LM2R'B['0# VW*H(%$VVB1G952W,[2.*ZA?7,G:D3NOC3021"/-
MQ C[^,#YW/"W_;D![G/VO=U[<)\;ZNW6A3R?N]>'N<?]MT4*"-[X$/.H<T)!
MRWO/V?5X@F<6'!)4<RKL[KVD]@@_FM5(<)_T[&R)2&22710GBYTG#@<;@X-$
M(AG7VHG;[,W?%CP!K=(F&PGN54GMCZ>7I)(5P*::'.[9:5*<H,:TKRA\?0(
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M 6/8^X:H%V#<MMAD(S&M5U"8(;J/M?$W.TW.Z+O<LVL4J9NT^@]_K+'8V!<
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M1* MZHOO]T64*M WHNOAZ1.C9Q/^#;YVCVJSX#-&04%YQQ*MD2A_M;GO>-R
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M)%2CS<3%LQ<F9"$(D2H!$7FU"<IQH^Q*R41R%%2S^3_ 6]&4XV?I$0AK:)<
M^$I80:)L>EL(F]XN0OX@+3#H$*&8%C'?O\QY08"W(,8+8XF1)0#@HY@($N6O
MZBWK]?A8(Q549U!#@S'R8I)VA3 A+[$Q"\#K8;-X/*@6NHX" #Z*B2"AKC1.
MOD6/(PZ)R0(PB$OOAAIQ3"'O[H_H2W^&U"=(]*ZQF!< ^&K^9_]1_JK.2,YU
M]Z0N_#4 08HV"7@3@S^+2&ICJ'YU-0  ;\E((Z&O1+8&XA[0)]7PT@    #
MA+L@H8F,OA%U^0DTT4V02#L["6@C     ,#Q$"0:378VSRY4;9^4"VY=
M &"X"Q**"X--1"*%IP8     >!X:B2N-C"OOGAK01@    # PXG(BF3IA,(F
M$B0R"!(     X#D1$>G)L081I9U. BG" 0   ."C$R2N_5]W8:+[$\<:
M  CQT$@06382G?LG     $"(DR8RDP!4_=$&@E !    (,3I85Q)?8X-U^@2
M     (#GI.TD740T:">$FT8<     ,#A1!DYWAK6$0<     0("3;LA*&PXC
M2P    #$<Z)KKX&X"Q-$]YP;       !3E0PAI4W0J(N     ,QRNFLA[MH(
M(B)X;0    !@GM,H?@01#"X!    $,UIY*UQ$Y80 8T$     ,*<'KDUK.B6
MM_"7      "(^EP;1(18$@    !8S&F<9T,SAI<      #RGL> @D&L#
M -&<IH*#DPD4     ,##:2HPP&L#     '&<[@)#*AR#RY?6"P    !_@(>Q
MY2C")9)W 0   &">T_@HPTK>!0     PPVETI$%D_3]L)      09IRTR]5.
M       $.#UR;- XG@0T$@    "8X71/U,5J)@      _'2Y-B::"&@D
M ##/:90V_$8T,;X$     /!P&L6+2 FY-@     03:>12*D/0&5%M@0
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M?Q]133F^99?Y?GCM(J;C\T83K<6= VP6O/81GDW()P%MQ.=RXC41T$@0[2@
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MCHYYUNGKA8@!5:F1X:_KCFJ]_KQ*13",4]5HLT>8_>BCHF+KG9;CBRM"Y(^
M"F:056VHJ UEM:%"]O_61E:U,<;0MQ192$-$DU)?:B,*,7I-9,+;-NVU9:\3
M^DZP7I5DK\/5M[VV;_/,ZDOM;8?ZLJUON<]C>$Z;ZU98S^AJV,^TU]90-GU=
M%O*PMF^OK:DKOLZRD)O;\YV+9)[U7D46TLA*FKJJ37VI37MMH\90>VF-.RXG
MUZX>_<%W[U>W;7 L;!RGONON,2=N^KTSSXV(WN*Y_+5"\M(:RF0G3-P%"6ED
M]3Z+TC,*MS@1D>$6E+E)8,\.ZELPN?J^N@V-,62N9B)X^4I[6=?'N$6UCA1\
MEPAZG+ 6)83L6-IK:T0VWYXB$V\E2.Y5A$? 7R4X5-*TESAA(;HO7FKO\QGN
MQ;WW<N'OX'$:<^U7"%-QO_=S!?.CRMA&PHYL^67X5'%L(*HGJ26Y<_<AD,Z[
M>6AHZFP&DBR)KEO9K#1\XPQ:(R.Q^E3@G"$E]YR]*>9W/E;J#0=-GN5QR=H\
MD1[_.F+C$:NL)+67EHPQ2?U3)Z(0R9Y&CK*02?M?FW V.OGY/8Y;;)XU3F/&
MP[./=V*/ S]O%!V/E6O#B6SY1<WI-;3T=/2UB\920Q[E1!<-&12^\LQ5-]J4
M21D\>^1876-.T(T0?GU!JWP&<6P628\MQ)XY5M2O,GF6+\^M\H$; +WR-]55
M/1(>]JT5<[]+G7!V-;XX$J^P9UH_3I?7]1V3=86"@XT^AYQ&BSF-_[0].-[+
M&.A(O(:6F>3?FW%9VFM1=PU_[JY)-YHLB*\RM,S/N<G/^:J%-,J0CF.%1D(U
M? ;(NJJ]!G%$1#+R6>[1_IJTR9/<FV1JE@_+CZ-^F:R?,\A"DC$FL=TPGP47
MAZ#\]3S+)QL9;ANGQVPJG^W^&FM(^6[:WK_ B5+=N7P.D]"-OB[7AE==78AE
M'AO#^SX7T 4=U%7#V<()-["/S#KJHP\;O/K[:]76FNN;@9VK-[Y 1C2WX(A(
MM](]=E?Z5V][CA^DD=#DS]KIH[VV].HX )/LH[YLPD](&':OP^9QNO\FY=F!
MJ$+N_6 [ITZ(T,XD]%UQ)-B%B3J!81+#(68 ^#06"W:,[GWKZI$?@(UK\8+G
MM7KGW+-:(\&IBP-MJSSU;'_F??RCVW4';<#6]OPDC80^+UOXVFO[%@&>?'/)
M*]D^3O?_34^WC_A ^Z%WPCG:L.TEOJ?A]^YDOJQ^2W8%MB QEQ^ Z/D:B:V[
M'*+U&@GV#-.S&U>--EQD4%F(X)'&@/V9^E+[=S ;M0%+$D%Y^2"-1'F+7_S>
M18@@BIM+GKF([C-.E]4WQA;L:=E7>[Q:YR\ZPC^21]*N02MA>W!\ ;Y.+PO)
MOA<S"7B/-B(73C<+Z40+PBP8S]9([!%J>+5&@H/=C6M3>BSG914?<7"P^I>%
M3!8G:XMBN1I__SJ\&9')KMY)B+"C6H9XYEC=9YPN%$1FGMW>QPDQWAA>0TM&
M>_RZ_!]_ET=DRSO?Y;7A/<-<&!I[A"^Z9>3.0)VM3I]-H^-QR<6>J9'0-[W8
M"(YCC4;"N]MAA"OUZS&BK22)E*(7GZ']]4U[LTINRJ7BJ>=B/D@CP7I .-15
M_39"!%'\^'[66-UOG"Y<^.>,T7?0 NBF<X].DL3DYWRR^9K "#<B$[S0@[3F
MBSF-<FP,AI??A"]U>)<$:/IZQ,2U97+3-VWLB:;^J2>?83./1J;LW8.0];/(
M!+67EMIK[[M?3>L_L$8C(5+!^NR[NW%]\^_R#\GRMT$;$/+3EX6D]OIHSZ @
M^T$:B?JGYI^SQ2L\,WSHAE^TN>?ES1R\,_N-TWT%GQ@AT5,34_XJD_^["P_W
M=\ISZ=UD>#46*7],^HK\'W^=_U$JNC35=LX-TD3T'8WI31V>BH2N4S?+6'P:
M#=UH$SJ;=P<_.^DP"\;S-!*:=:,DZFP(W+-/7_L2K;>1$(68"DZ.0.BKX[NI
M+573I;3FX-3VP1WF!VDDB#IW9WWFS_C?,%<%_T9*TUWO4P2^/<?IOFV]=*.E
M21MU5K/Q'?(L'Z)7NM_GO^#?1+Z-@/I7<+)_NL<<GX\O<1,1DW5SP2+D5=\%
MU&;Z-A[\?7*N::=^X3,JS_Q@;B\M:T 54O>NM9%@+>-3^WWR'D$<Y1ZX]MQ7
M>6PX6"%BSHCM@S02 [Y%[-T2U/D6.;:>3QB_^X[3_6PD%@F -S+E;VGR9$5P
M-HLEGC3OMM'X*YRF :B^SVO#1:2"G[07G)WY!DQPP#J[3:\*\$4+AKX1N\L1
M'@^(N85O=?AC;J*R)F?E.2HX=)*(- ZT48TR7 O4%_[L?_:\^P,W ;Y%[)TT
M$K[S>9$)OOX'C]_]Q^E^-A*Q8U U71CO)=DXO<<SGK')'D6]4;_Z2YQ&*<3M
MR)9O)O$?@;_[<SP  !^1241!5._L3!2\$<X2(Z$UGANVA;7(A%<%^*H@*MJS
M0-<%/X#G%C[.+3.J'C,:B6=K(XAHE8&63ZCTG:'/&?.%U--_%>\B]D9"D_KU
M]+>?^B4:B?W'Z7[]:LX^I L>E_,!Y.:N[;&96:)1>;9;ZJ?P</\<&%Q OT C
MX=WM9()U%UJR@/O.V7R#UHTC('^6[YZ7YO)82NE9H+V_]:!0LVP;]I.S;W>X
MAS9B3P\!]QCK?H],\,=9-#^AOYNZ?P^\B\";'./X/"-$UNW^7Z&1>)=Q.B$C
M;]\FZNR%NAPS_OH($E1?I@(1]]I K'%KZ!H@S&ERC)'2]^3:\!G;=(:6_.M+
M8':IOD'K>AB\FV0\ZU[%?^>(JO#TD[/R[&1>'3K9Q:NR]2PR,4+B*\*D'XW7
M1N)-0AO[GN.P$7BV1N(MQJGG*"'D#5&>2V_,EX'Z4E-KIEEZ92&#\V7L<<6S
MO&D^D=/]6",E(K*-+C]O4G()N6NY@VO-;L^G2G1QM1%SDK%7H%EQ3A^+3WWK
MM04Y2#L2BB.A;\3:'#SEW'-AVR_U*HF*F/B!&HEWS\3HTRH-"QN;BOY @>\M
MQJGGF(\3_C1ID__+O1XF1(],KD.;NL<><YN$F V@K#R&[2"*TU1P<-**?S"^
M <T.KC79^B)VEUR\@[7:B*,FJ%!@&Y^!TV&Q[7T+=AHX&P[XR._& AN)D'&>
M[]G'J)_?,<_#4;Q#("K?<QS%?N&T#P<)_&\U3CF86"]YDONS+Q>26M..;!_<
MN;F]SD>HC0D_?TALF2_B-!48OL=K@]O!Z:MF!_J:,W;OHF -G$FJ\,A%CU7M
M'J0R]?JC!R(+1D?YBPAO.\*W8-^(2LZ5E_Q&JWNRY![*XYH7TD3%[,R1F.BY
M^.);C&P1GACSY:W&*8,]9^G>'L)'?:FIOM2)FR55D"!1B'N@MIAQ-V>$#)?/
M'9!5;:CH2R;[?VLCJ]H88^B3BRB$(:))X5YO+^VJ]N"N55^ZMFVO[>2]+=<5
MA3CDF7%M-%=7WW<F[7I=UJY<FQ&1D85D7Q_:^I5M$5O_I=_94H^_4M[U=]:7
M.JI>[67Z[$3VV>.4^\WV-7QM=U3;^.:&=^E+GU!.K#U$^AU'&UX734Y*7QE_
MO6:DW6'G4&:3L[[HZ[)U/R!,MF\G$@ISN^C<=2<U;\#FX*U4EMXLA $[CF_5
M-/CZT:L-+?L\#Y/7V?'+&5P?\#S?:9R&/-9\;4?4U;7];VI,N9G W U/C7WX
MZLB62U2,:]7C@EO(FLY*V;Y_Z'R<O^YSC+C6A)IV%\O@9W?.+&CS%-N(A?CR
M?X2>O6M %VS/@UV GXKG6;\R];.^:9,SW@5SG@-'\V[CE!/VU*\BKNV(.B'B
M*#N%D.?/*Y[9'L=$[\9I(D2DWVTCP7YNXP[(W15HTI.!OY=DO/="X@W]&Q"L
MW"14LI#>-HPU$.PMN\VBZ*(_^R\X6\Y30RGK@]^+C7A*%"UH)4EBWEWH\!I#
MOVANTC?_N;[/<R!@F_"QXU0WRK ;G8!1Y9'&CEYMWY-CD>A&FZ1/./;N8V\I
MX\B6]^R?WW&T$3LA;74?G',#79,.V3O@=PPNLR:XD[Z-DU -@7F\@S9BX2M_
M2Z.OFLIS&>T.* M)KJ'6'FQ9Q+R3?:!_30*553+85V+JE__+#5&7Y&A-W(&G
MX=&.OL+?/R1$S'D.>-P>-]=)-<JH7V7>;9SFYY)BUP^1B9?%>'E6(*XN6F?9
M:;+Z=EP3N?.MD9?.N+(SN)3W__\&8\LY(YRAK#6T'-VKXN^UQ;B(O=X&@\OV
M:DQ]J4U=R?Y?WB@J9,#H?F?XK.]:-&/LM,30<.]GMJ3/Q!BCB8PW[@U]U_W.
M\%G?M4)&F[[G(*OP=UY5GF5 .U="QH%UQ#S)_8ZYY[2E3G]JG"XTMEY;UHR]
MH_O.,_OPT85DU5H"A+Q[;\CJ.0_XE<7GM7'( [^:W:_MFVC77(OK\&L&'V5.
M7:[&^*X?4U]?'4+E**MX8_P3;<R$M/3WMZ;U_JXU@JEOLC]*Z-I:?.,S9O'>
M[7D'^FVL,. ;6VOK%+MHOWJ<SHW=V#9HK^WF/NK= !S4]WV>*TOZS5\JCB#Q
M< &%1F+_2<ON7'NX:OHFE"5U;B\MZ^X:*C&_CQLPWC;V[)Q"NZ/@,SMPQ^J;
M:.?NN<;MT[=KY-HZYOG()[H,[U&\"^23!)]0&R\1!+P"W,K=L*!M&Z!GC=.Y
M\1LS3H=K;!W3OF=Y1/_W"?E'STVO+(\X$D,,B4$C\::[E#U+S$+5FO=N!Y\0
M,/>]]MJ:4(?W"5FAA<^MBSM1>J_)J-9#N^?99W:@NM)W_S5'"G,3R]PS73)9
MQ<8]>)<2VG4_0QT^-S<LO9YOH5W4)J:=W>6_TSB=TYS,_7Z[GGLLP$?WIU"?
M$9EX^[5D4]O*2SLYUO@6C<3<.>-?4$$MW>FVIHW:*7BOZSE/CPFN%9I8)AW3
M,_',34Y'/S/?_>=VJ+Z^YMM=N\^(^UV^:[J[K+]VI!'Z;<]XQB$!>^W"L\<Q
M9*Q-UZO'J7WON7IR;=E>QP+37D>5H>>ZY;IN?;EYZ\C^^@[%TDA\G['EG"#Q
M+$.@S;_#(QC(0HZDX/I2FSFUZ+"X+%WXW$G.MX/P:5 >BP,_*(?%<4Z0>,8S
M6W-OK[V)9Y<2>VWOY!6(GAIZ/N]20HOFD38P<SO^M?UKZ7B*;8]W&Z>ND#<G
ME'%U<.>HO?IJ:.Y8TZ?::^O5W#YS/GJ',C6V[/_]!F/+4,?Z"]H(NRS9K; #
MR=G%>H433KW)J/N]=?48G0;K9@WR.4'BE6T=.F]=8NSE3KZA22[&>O\O]NVY
MW[#W_>9VE:'%>=-ORN9_BV\QEI7T:A=?/4[M=EW2)[G?NN=SGA-08Q?^3]!F
M[UFL7!MC@\MO$"2,\4]8?U&27"M,<!-DK'K3]2R(&41+%C]W<@K5ZUDJQ-#1
MD'<GZ%L,G+;B)ONY'=D>*N]W*C%V,,^^WQZ[XC5>*%ZAM1\7L4:WSQZGH]\=
M:1SZC/X:(]B$GG5[F1<XWUW;=T3I;23D^'CC2XXVC.$G^+\L3=:7.MH@*SA@
M0L9N_6+IV\7%[-QB%K\EQEU$SQ/^UAROA";EX7C#MRC$U&GK\WZG,M<W]K2T
MCU&][V5+$EKTN6<3:H>ACW$"PCN,T]B^'U-D(7<=VS'U$<PSF>LK2S0:GU:^
M^FC#&#-1X1UY_OK,4E]J(RLYF4!D(:,7%)] (C+A]?A8TGY! R5/'4.3\3,'
M\>RNQ!7$ ZIB64B_ETSDCFQ6N'ECP\HEOV-)F\S=)R;.P=Y]*J;/SVT&W#KY
M=ORO'*=+QTM,$=3]GCWZ\A[U6=,.GUK&D2TM%]!OT4@8TR].V7=+E-YV.7A
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MAPLHX7@# / ZY(],Y \V- "\.Z>17<0@3$"(     $ $IX?+Y_ 2O#8
M$,=IHHD8! L     @!E.$^V#'2H;     "# :7R487MNO+1>     /@#G!Z&
MED.N#3LH%0    " G]-=^W CFF@G       "G'BA 5X;     )CG86QIVT8@
MUP8     (G@D[;H1V?82&AH)     ,QPTE<G -4@3%Q?62T     _ 5.E)'E
MM:'OQQO01P    !@CI-(!=TU$D/2KIN A00     9CE)HKOP\/B78",!
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0<_Y-M     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_5.jpg
<TEXT>
begin 644 image_5.jpg
MB5!.1PT*&@H    -24A$4@  !"X    %" 8   "*"ZU     "7!(67,  $SE
M  !,Y0%USO"5    /DE$051XVNW8P0D   P",?=?NH5.(24'6<"G23(
MA2Y#     (X+     ,<%    \.:XD"1)DB1)JFP!UJZD/2IXUW\     245.
%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_6.jpg
<TEXT>
begin 644 image_6.jpg
MB5!.1PT*&@H    -24A$4@   D8   #J" 8   !'G(K0   # %!,5$4
M #,  &8  )D  ,P  /\ *P  *S, *V8 *YD *\P *_\ 50  53, 568 59D
M5<P 5?\ @   @#, @&8 @)D @,P @/\ J@  JC, JF8 JID JLP JO\ U0
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M(P    " "BA&       54(P      "J@& $     5$ Q @    "H@&($
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M7Y\&  >C93$RST8BQ[<9M_0W0A0:     +Z=MV)DB*RI?8LJ:Y&I(M$0]0
M  " (_!1C/)&(&A=%ZVR'K%%%P$     OHRW8I2URGY0E=#1D#HC$1P
MCL''8O0TGUIH#3\C#6L1      ["B:C.=-V(1".B6CG2%RA&     #@&)R(B
M4^<L>F^GE3\K4D3(J@H   " @U J1L_JIT[N(CA= P   .!(5!8CHE9BQ^K?
M2.D(    @"-Q,D3V4RRVKI%&I8($BQ$     #L3I73"6J.%?5/X?8?H
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M!    ( #(D>EO;"5!@   (!C(4>E 0     <##DJ#3Y&     #@8B$H#
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MH $ QL#EK]&Q?EN$>KY%%_6V).T-R<JRZ5P]"RLNNY0) ",X?4J -'\-'R,
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M;TY95#_^$^%2.6Z '^;N&-SOVMOOP5<!E-YU;VNHQS,9_)EBWH^0RMDN93+
MGTSVCH6<X'3M_5D.EV+8'?NE/$E$VTK;L2:-/$;'=;HF(M$R,13=(+UDR2WQ
M?^%G^AAQB29K\^?8U/CB-MK#:2WJ?4=4* /Y/PPI6)RRJ.,RLK#[64GAVWK$
MUFPVG,#2D!'33JB+"N(?TETYBXJ_YP+%QY<F^#.U<%J%N9;#/Y$)R>.VE%EZ
M<1S/4-=58ZZUB&C08M2V3@EY[[@L\D?A5/Y/JI=V'*0'::@VC#JKJ'@6[-^N
MM^N@Y<B\C)WC8\0Z%S>4-6GE( T<8J))A^6LN^61WE.YQIFG)3+[S:PK>>9@
MN@%FI>KR*^"N+[2?499G-LLSNT1JATDL6E%\)KG\)RFQG<3LC,L>RH=Y&=91
MMO>Y@-M*)C=6&B,6M\)XC$U_(I.7L>9EK#@^K)R?R[R,C:+(2L$L1$04MW^4
M*BJ,"='WE:DK+<L1?8O>Z'MJ*:[:1;__K^_+5AO>6M-WOHJ[;]5G5^5HKGJQ
MM>[*WZ[OO8_)5$#N5EN6^I:N2_J\ZSRXSZ9W_ZKF+KFH"U\-FZLJ[;H7KL^[
M[G^HYZM[3J&KB4\Z)T<5[K\^-]>[,;HOX5GD/LM57U>Q^]FQUI*.=>]Y6U*V
MW>.-'3M\[T%Z3]F*]'N4R9K/=O$L[)CS*9Z%+9Z%E9Y5'8^K:B\=J^ZG>)3C
M#W=O0ST_>VZD'ZFE2VHIUI__QZG5]V,)1GJ(Q_3A&LR[#]J04D1$-AVX!]PY
M=R=<J6]N8I:4.]=+V?U./6"Z)MTAI<!G,''=&^YE'WK1I?M1#R!SFH\"^U?M
M+R>/,??A_2S>QTT0UEKB)F1QL<),3#Z3$G>>TI@R]YER*1A3)]+>,^M8Z.U5
M)K[CS^QGV+$HE.08\IQ=8V_Z2&W]=T7+*JI[;J3O14,I^EB-CJ88<9/IE,'%
MQW+DHQ0-3>9<']SYCGGP):N)ZSRZWZD'.*=BY!@$I7/PO09)MH/W33C?*1-Q
M[]EB!NT0_89H6QL8!R>(D1.H=%_%SPOOK^L8[ +E45CI69RJM!3/PFEU:;8Y
MBK?KW=VS3*8^0][G\B@L7?S/HQX'ALY_K/5F2#$:E,\&K-E_W1H6H\966GR\
MK;20DZ)+.7)IZ;V'6%!.I0>_^T!+GY,&37$UYWA17(.E],)+<O4=D%WGQ2HA
MGH.N=+YSGJLI,EVS+7'-4YO/2GOT]7'6PX%%WYC[55CWNQAJ\AG[;LQYQGP5
M#5$F ^/37\J$R&\;<&QS+>A<RLC0=ML4!7?.\8;>C:.T1E0:-;)>(\$CT?3D
M9BJ6';(Y)V]U4:SSK^0T>KWTRX_HNW_$@G1=HN.U5 *DD\RRFR-(RIC*.@:^
MR'+7Y9/,K'D^;#2'I].BY)P]-?5"Y6S-'F<+>8*(2'1&]<YD'@CS,FX'U2E]
MYOT<.NJB2/^XG4K90 /!B9C--M^XOV(0PHB0^BS/V'=CB+%.S>9E[/5_5S;W
MURB9##SS:\E$'(-S$^SYSGXS&T61Y9(CJHLB:VWD#!09"( H_A7CQPG!,5Y=
ME#-:S>?=. PM'Z/X\^\C68S$%<Y,DVMAAQWPZA6!KV5AS I?-%L+%AO7^?E\
MOK!]>4G7W;LNSL&S.K9/']+*?<R**Z0SLFO5MA5KD?.Y6VB[8>QYS+D/4V7/
MW3O.RB ]+\VM#Y?UV.LY\K"BN1Q]1]T#1P#"'F7BNJ8I[W3W.EV6M:;E92B0
M0.IGZC@A7;..M1V[BW#4UO$Q.F94FN_6U-26/E+V)6H.+-++4S^PKOUK:1*3
M!A!NSWJLCTVW;VF[2CJ'YHLX-*C[##[Z$F:"EP:I,?O\3E/V1GR+ALYUS:B4
M(4??*9/9&(=KKOD<FWVGF0G&Y_GEVIAMEKG! SX*\MYD8JU[L3-%&?")-NO.
M&SY^55VYS9E[I/.KG_^N3);86MQ[@_.UG>9P.:6EC_3]4G$#@._DX#OPC?%O
M&;.2X*PSKDEGK'-D]QS%%_T^[,P^^EF8Z#0^]"PM]4R%>":'!NVE&Z?P3W6B
MEYZWL8/_D&_2F$7'E-050^^,M[)Q&9:9:&'H*/%[E(FU;F5*792W$C(8,3ER
M<;C4.Q9B<7?T]LEC]':\KBQ&*YO2_[*-R7.R9//=3GB_T,S65;-).2K$AT%2
M"#RV\USG,=JIVO977-)*U)DB8:)R+\F-:%Y$W=K;4S[MKTWKG,Q<)G_7X"YM
M;TRR# @*;OI(K?0WZ3C2-B\W.?I$64E61S$GC>,]D,8<=D&T0YFXGG'OY^HQ
M?'SGPG#E7$'B^+.A+?RM-]*/HJ<4'<UBQ W.?V5>''J!QTSXTO?'?KXYZ' #
MJ<_Y^(2)JEA9^[1L7[XI#EH#P8#B./4^Z+MN*3ES!\Z_;F.?DU!-FDSK9'=C
M9+F$3]?H,'#'<5R+GOI[(2;P,=_S.:>]R\3G^7B//Z3:?3VM'5KL^%B<UK;@
MA'X/CMCZ/D;5EMJA%"/F!5US*Z'9G*'^(\R^UO(OB.NZ7 .5R_3MJX"X^A^4
M]]..&Y#G.LZ/\'L9:EOS*^HV*87$D@.I9#%H3A8^][=X%FQFYA#7,,;2.;0X
M"/$\^5R+TR&XD4?-]3G7<?8H$Q_93&F^BLT2S^84F2[U+G]C:VREM;-?'\GY
M>DJNDR5;U\%/QSI88KLA!63LX#!6@>168+X#C&_RQU"*2(B!>P]Y0:8D]IQ]
M3(_%R)BM97;B";!UZ1,!Y;M5-W5B'F.]GIK;9XS,]B:3$,=K'9OF+U!#/9]C
M[G_H8WUS^UB,#EPKC=T>VO#6AT\;XPC9^I[GEE7M![+V=0V>5V#KS)B:1]V)
M82^FZ[4=L'U]^N9,\B'?WT'?,4^+Z93MX"G7,>4X8X^U-YDTF\O"Z#/NC3G6
MVHJ*3Q0PVG 3,E\?:RMM:Q:C$&U.45SGH'?Y6R?BH:RN2QVW>!:#Z?M5K/Y,
M89Q[;=+UK'7_))E-\BU;0/[B^S3!DNM3!F+N<S2FM,Y4F>U-)G.?JRD*V>J*
MD93V!2'YHQK"]:U?,=:]M;FE'KC*V%N)JII2)!;-W=88O*=$FED[;A+;TWO+
M)DV\J&#/LN^6UY9DMK1,6LW#N;H^?LCK65(QDJS;?^4SN]?6CDH[:*TT3HG8
MBA(P^<8&>!EK)\TM*AWU/<,+'Z:%6OU+;:K/V[L-3&);F^#'RKT;Z1BJ%;:P
MZ9UWMM[JN[.T3%@Y/2HYQ:HEJ[ECWY1\37.:M$T(B]&XUL]C=$#GZ[VO/+MM
M]B2$=K@F.9J'\-E:<ZL.#6U+S>6?N,3QI&-A[!_73G161"]#]"XL:NA(161-
MOFZQS%40BCNRA2 !H++P,??[L85(>]]_&;;8I[HH*AX3"F0"L".DHJT8B[?-
MB5Y45MA^$1%5"M*K5HZ^G^S%5Y3?,^(U"974 2 J*Z!W&5/QO(M4 5U=U+2J
MX0#L#:'2_2)C\8O$1;Z*CS&?A^+TL1!5O*BR'AW&8L3_0;"Z[ )8C, $]+VO
M&!&5"LZ8?@P9F_UF-KDEO;]!*0)'0EI8J 4,#Y)UBHAD!0VPG'K;9F?J;*U]
M-^**^++N>80DRWF+D3KSVR4 $)7/![>RS'[]K:HF-S:)$DKN4(H D' J,5-Q
M+>:Q6S"*TWL;[4Q$U/ W>AW#8O1MF!?O,\5MDP#0);VGO=^9IQ&?J_=G<F.O
MMZN]WJ[LH*_O&DH1.!2N=T9?PH_'+F5K"0O5-W/J*T*U!>D8@BR>Q5^?0E"^
MT0(&UD.=5<0I1]UM,?,RUN3&)K^)C:*H5(B$;>GB45#ZDT(I L?"8<'1/SK\
M^R!LEZF+$H,K ,^IKP =*RI-G5745([2>TK6VFBOVT[2Y*3/L!@!/_2/CKK^
M:.9I*(HB6[?KY4K7VY6RN[S-IF--A2TP*(-#LLAVF8/L*;I0K'H>W\!_;P6H
M&;;_HD-9&-191=9:,B]C]ZH0U8@1:0>ZGV ^Q;\BBJ)H4BH+'6O2=PV?-G!L
M! O.4FX-BA2KC"$B;3PGUI_H?)RMM"9?,9!+$6G?<&U@5:RUT9A!7-\U%<^"
MTD>Z6XLK *$0+3@+*2IBT VBD4=S:EF)WOF,P!Z1PJKA> VFDC[2J'@6O6>H
M\EN@])Y2\2S(6ANE/U"( *@1'9XQQVZ>_^BLB/*LK1P=S '[:Y!>.&RC@1FH
MLXK21THI]9VR 0 \CK0IP8_EBH##8F4\[<S7"-/?-=*+",=K  #8"%BH;IY.
M'J-F1!JL17M##-6/UST/    ZS&G= _HT_8Q(JJL1\<)U_\67&4;%,&4"@
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M,X_1BR95UP9_ 'R,  !@TRSB#.U:_,)B-(F3.E,[V51E,:*7H@S;:?L!*P,
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'14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_7.jpg
<TEXT>
begin 644 image_7.jpg
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M'$Y.3EP2BXB(&L1[2# NV]#N\(P@NV7.=NH[$'UFK<#5]?.!>BX#65\>#_C
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MC^ND@ Q.@),3-(>VH.C0%O2>N1Q]GWD! '#OQL\X]DJPT;%_WO97 ("36Q<
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M7'0'"^>_@IB7Y^+@-[LAESMCUFOSH7!QP>;//D&1IA!_>^<O>&?92IO&:E,
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MDO]%>MI6J!+_:O6Y%1??16E),;IT-1YWF;;$Z+ZKJ_D:O4IW#Q07W4'^^7,
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M<5]L;*S9-DM&CAQIUK<E*I7*YGX!X/SY\V+@VY;^A;$8]O_PPYU)8Q,  "
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M*\LH:!D>'H[,S$PL6+  .W?NM.FYQ<3$V)QY65>PU5J_6JT64Z9,$<LK2P6
MZ],_4!NXG3IUJIB]*^7##S\4;^?DY!@%S9<N78K$Q$0 P*1)D\Q>!Y5*97,@
MO3WQ\O+"RI4KL6#! K-2T*89PHL7+Y9L9\A::6DB(B(B6]@] -Q2@ZR5E960
MR^4 F#U*U%98JCA07_Q,("*BUDJKU:*@H ! ;7E+TXN#0A:/N[N[>+%<:IM
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M,7OV;+-RY!$1$3A^_#C6KU^/N+@XB^T,62LM341$1&2-70/ K2'X*V V<-O
MM5O)7GA!GXBDO%R/H!91>[!__W[Q=D5%!=Y]]UWDYN8B-345+[WTDED9R=C8
M6,R>/1M%145P<W/#[MV[D9R<C!]^^ &??/))O=<U-)22DH*(B C)?98"!$1$
MU#@:C0:OOOHJ?OGE%P# TT\_C3U[]IBUZ]V[-V;.G&GVO= 0G3MW%F^;EG<6
ME)656>TC(B("*I4*R<G)2$Y.QB.//&*U?61DI-EQ>O3H(=DV+2W-:E^&GGWV
M673MVA7%Q<7BMJ>>>@JS9LVR&-BK3_]N;FY8NW8MA@\?#@!8M&B1S8%V6Z6D
MI*!7KUYFV[V]O>UZG-9LV+!AB(J*DBP%+60(CQDSQFH[0]9*2Q,1$1%98O<U
M@*T)#P\W6NNE)1""OPP$MU[,W"1[:&DE/8F(B%JB/GWZ&%T0]_7U%2\RIZ>G
MFUWH[]*E"X*#@\7[P<'!R,_/1WIZ.I*3DQM5+K)7KUXLA4A$9 -[7HN)C8V%
M6JT6[TL%?SMV[(B.'3LB/CY>LH_(R$CQ>T!J(M#JU:O1L6-'C!LW#CX^/GCH
MH8?$?5>O7I7\[#]]^K1XVU*@=MZ\>6(V[=*E2RT\PUHQ,3$VKQ5<GS6%9\R8
M@>CH:.3GYV/:M&G(S<W%SIT[Q6!@8_L':H./0K [-3454Z=.M=C6L+RV0*/1
M8-FR90@/#\?8L6/- M,1$1'\_K5!?'P\IDR9@HR,#*,):Z89PI9*1DOU9TL[
M(B(B(H'=4MYL*4'2H4,'>QW.[BHK*Z%0*!P]#&H !G_)'O@^(B*BUN[[[[]'
M?GZ^T;^F-FS8,#' :ZE$I2&E4FFT'N%//_W4X&-?OW[=[/GFY^<;!2:(B,A^
M-F[<B)R<'/%^4%"061N%0H&>/7MBZ]:M%J\3A8>'B[<S,C*,]N7GYV/NW+F8
M/GTZ%BU:9':<CS[ZR*SZG%JMQNK5J\7[@8&!DL?U\?$1LVE_^.$'R3;-Q=_?
M'XL7+Q;OSYX]&QJ-QF[])R0DB-_/]^[=,SNVL&_CQHUFQ]V\>3.2DY,Q?OQX
M[-V[UVYC:F^42B66+U^.A0L7FKW&AIF_A@%A:^\!PW:MJ0(C$1$1.8[=,H"K
MJZOK;-/2,VR%<L+,!FY]F 7</C%KEXB(FEMY>;FCAV#1E"E3$!(2@I*2$N3E
MY37;<</"PI";FVMS>\,+^3=OWFSP<>?.G2NY7:52-:JT-!$1F5.KU7CSS3=Q
M^_9M<=NE2Y>,VKBYN2$@( #SY\^WFB$Z=>I4\3-\_/CQ2$M+@Z^O+RY=NF24
MF3MY\F0 M0'+V-A8I*:F(CT]'5.F3(%*I8).I\/UZ]>Q=.E2,:"[8L4*BVL.
M \#$B1/%#&1[V;Y]N^3V'CUZ6"V!;5B6.C<W%VO6K)$L[]N0_KV\O)"0D(!)
MDR9)[A?VY>;F8N;,F>+K>?3H4;SYYIMBN["P,+/'9F1DX,R9,Y+]UC=;N:WS
M]_='7%P<EBU;9G9N(F0('SIT"*-'C[;8SM"P8<,0$Q/#4M!$1$1D$[L%@&U9
MB[6U9-A65E9"+I<#N+]6,+5L#/ZV3_9>MU<NE_-OGH@<2JU68]6J50 @61IW
MP8(% &H#:$(6I=0VP:%#A\0+G,+%),-MIOS\_! 5%67QN%(B(R/-+CX:'L-:
MB5_#YVM-8\H$VYMAB<F6Z-BQ8P!JLY\\/3W%^]2^C!HU"D>.'''T,(BHC=!J
MM7CAA1=PX\8-<5NW;MV,@L% ;>GGX.!@,7!KB9>7%W)R<C!FS!@ D Q2QL;&
M&I7-7;5J%4Z=.H7<W%RDIZ=+GLO$QL9BSIPY5H\M9&7:,P!L*<BJ4JGJ7 ,Y
M(2$!!P\>1&YN+A(3$R7+^S:T_^CH:,3&QN+0H4.2^X3@LZ77<__^_9+!=$L3
ML ! K]=;W-=>39X\&=NW;Y<L!;U\^7),FS8-^_;ML]C.U*Q9LR1+2Q,1$1&9
MLDL N"UF7PI!(&8#MQX*A<*FB0C4/LEDLCK;*!0*!H")R*'*RLK$,KJQL;%F
M^X5]*I7*ZC;!S9LWQ?U" -APFY2Y<^<B)R?'Z(*BM?;)R<F(C8W%JE6KQ%*/
MAL>0>AX"P^=KC;4^Z+[SY\^;95S9\OUGJ+2T5+SM[NYNTV.*BHKJ=0S#@$%C
MEHA)2TMCII$%EM:_)*+VJ;&_DS_YY!.S226F5> 4"@5NW;J%I*0DFY8(&SUZ
M-,Z?/X\%"Q88!1^#@X.1D)" B1,G&K57*I7(RLK"^O7KL7'C1J/*$X:/L>78
M_O[^B(^/Q\J5*^MLV]1,,W5GSYYMU\E;*I4*J:FIDON6+U^.D2-'8MFR94:O
M9VQL+%Y[[36N,VLG2J42JU>O1G1T- 8-&F0TJ=$T0U@("(\8,<)B)KMAX-A:
M.R(B(B*[!(!MG>%WZ]8M>QRN60G!7P876SZ6 R9K;+F(;>^,8B*BEJP20/GP
MX=@P<R8 X-JU:SAQX@0R,S,Q9LP8W+ESQ^R"4F1D)**CH_'KK[^BLK(2WWWW
M'4Z<.('4U%0,&C0(\?'Q#1Z/2J7"R)$C)?=Y>WLWN%\R%QP<C-S<7,DU@@U+
M.MJ2=:W5:L4+R[8&ZD^<."'>[M.GCTV/(2*BAG-V;OBEGY,G3QJ591883OYQ
M=75%4% 0WGKKK7I5[/#W]\?.G3NAU6I14%  =W=WJX]7*I6(BXM#7%P<U&HU
MRLK*X.WM;3$ )@34I*Q8L0(K5JPP&X^MU[>L]6VJKGZCHZ/-]MNK?UN.'1T=
M#8U&@\+"0HNOI]08R78^/CY(2$C HD6+L&[=.J-]IIF_MI2"ME9:FHB(J*59
MO7HUYLZ=B\&#!R,C(P-'CQ[%)Y]\ F]O;RQ:M @#!@P  +SWWGOP\/! 7%R<
M^-C]^_<C.3D9!PX<  !LV+#!K/I=4[IX\2*2DI*0EY>'9<N6M;KJ&W:)=MB:
M(=N:RY!5557!Q<7%T<,@*W0Z7:LI,TXM4UE9F:.'0$34+%8#J ;@H=,A[K<+
M2,N7+T=D9*389O/FS6:/\_?W1TQ,#.+BXC!__GR\]]Y[8@;G_/GSH=5J&SRF
MD2-'BA<A3?\QL\&^A/7\TM/3C<I"JM5J'#QXT.9^M%JM4?:4:;:6E),G3XJE
M(R,C(ZVN$4E$1(ZEU6H1'1UM5NIYQ(@11O>[=^^.<>/&-;@J@U*IA+^_?[V"
MQSX^/O#W]^<Y@IUX>7GQ]6QBPM^'Z9K.0D;OPH4+H5:K$1,3@Z*B(HMK/PLF
M3YZ,HJ(B9&1D--F8B8B([&'X\.$H*RO#U*E3<?3H482%A6'__OT8/'BPN,Q6
M1D8&#APX@%Z]>HF/TV@T>/OMM[%@P0+H]7J4E95AR) A%H^C5JNM7I=2J]5B
MO\)M $:3XTTGRI\^?1KCQX_']]]_CT&#!D&M5AM=1]%H--!H-.)CA>-KM5JQ
M+ZU66^?W>E-I= 9P>UHS4PATLRPT$1$1M693 )P'T#\R$IX+%P(C1@!>7I@U
M:Y88G-NX<:/1K$LI/CX^B(N+P_3ITP'4EB!FN<"6[]EGG\6%"Q<  .^__S[6
MK5L'+R\OHV!N2DJ*Y&,# @(0%!2$OGW[0BZ7 P"BHJ+@[NXN&0!.3D[&[MV[
M$1 0(&Z+BHH" +S^^NL6CR'E_/GS1O<MK8D(L#PTM6WY^?DX>O2HF+$?%!2$
M(4.&6/S\U6JUV+MW+XX>/2IN"PH*PK///FL6[,G/S\>9,V=06EJ*<>/&F07D
MA L704%!X@2.NBYF"&V%OJWIT:.'N 2!M7[[]>L'/S\_H_$WM/\.'3J8S>0W
M[,OTLT2KU>+[[[_'B1,G<.W:-0! >'BX62E6C49CTZ2:EOQ9E9B8B"M7KIAM
M/W[\N'C;Q<4%WM[>2$A(:,ZA40/\Z4]_@H^/#]Y^^VU'#Z7=2DI*@J^O+PH*
M"LQ*01MF"%MJ9TBI5-K4CHB(R-&$\^^[=^^B1X\>\/+RPL:-&Y&8F(B"@@*<
M/'D2V[9M0U!0D-'C\O+R$!86)IZK*Y5*#!LV#,>.'</?_O8W5%=7(S P$+&Q
ML7CAA1<P;MPXY.3D8-^^?9@Y<R8\/#R@4"CP7__U7_CZZZ]14E("E4J%-]YX
M X,&#4)86!ANW;J%<^?.P=_?'\[.SN+MM]YZ"P 0$A*"Z.AHJ-5JS)DS!V^^
M^:8X.7+,F#&8,V<.JJNKT:5+%]RX<0-RN1Q+EBQ!5%04'GWT47AZ>L+/SP\;
M-VY$:6EILV8O W8( +NXN#0JVZ,UJJRL%"]XM9?@=VM15575KB8E$!&1?00&
M!B(O+\_1PS 2%14%3T]/NZX#!P#]?OP1 ' %@%_W[D!<'+!L&;!\.91*)6)C
M8Y&:FFJT%IPUAFNX7KY\N<$!8$O!/)5*Q=)V=O;$$T_@].G38K#?5&QL+&;-
MFF7Q\6?.G#$*LL3&QEI=\S$O+\_H[RLX.!@K5ZXT6F>:B.JFU6J1E)1D<>WT
ME)04LXD[APX=PI@Q8RSV:5I"[<R9,^+GL=3GK[ O+2U-# !;FXQAV-:P;TM4
M*I7XV5!76Z"VI+SPO=/0_J.BHM"G3Q^CB@2&?1F6O56KU8B.CC;[CA3^3W)R
M<L3^"PL+;7H.IL>PMYT[=^*IIYZJ]^-V[=J%K5NWFFT?.7*D.)G V=D9OKZ^
M^/333YDY:F<:C0:OOOHJ/OOL,YO6-:Y+1D8&?OSQ1VBU6BQ8L "+%BVR2[]4
M/SX^/MB_?S\6+5J$5:M6&?T?1$='8^_>O=B^?3NBHZ.1EI8F63+:M#];VA$1
M$3G:H4.'D)^?CT<>>00 ,&[<.,3&QN+<N7-8N'"A>'Z]<N5*\=S8P\/#:-D1
MP==??XVDI"0,&S8,+[_\,JY>O8J(B @L7[X<"Q8L0&%A(3IV[(BGGWX:ER]?
M!@!,F# !,3$QV+IU*X8.'0H ^.BCCY"0D(##AP_C^>>?QYDS9W#X\&$\_?33
MXK%\?'R0E96%E2M78LV:->+$=^&<?\6*%5 JE8B*BH*_OS\.'CR(W;MW8^#
M@?#T]$1R<C*RLK(0%A;6[,%?P X!X/86_!4( 49F [<\# "W'Q45%7;OT]W=
MG:6@B=JA@(" %A< -AQ/>'@X,C,S[=)O0'HZ/@7P*X )ITX!JU8!V[<#&1E
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M5!1V[MS9F,.V.,P&;GD:\MZDELE>66^VEE7C1 XB:BE,RU'61:HLCN%ZCP
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M<G)RX.'A@=C86%165HJ/%?HV+#4MW-=JM9@W;QY.G#B!?_SC'U;/#9M"@P/
M#5E+IBY"8/?]]]^O5_"VI*0$Q<7%N'KU*N[<N8,??_P17WWU%1Y__'$$! 3
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M+M$:6B4 U]75==0X9+ICAN9]]]W7I<>7;M2ZX[FYT[AQXX80U 46T]J;:(%
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ME:%4*LW.U6)B8@@,#&3SYLU-SJD,!H/9.8;TV])P?TL"WKJ*_/Q\9L^>W:(
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M-S8V-M34U&!G9\>I4Z<:S3F:.F]Q<7&,'#G29)NP$^PZ% I%B]\O9V?G%C/
MI*SSMF1RV]O;MRA<&/]F" 2"[D-86!@__?13DXXIT#BZ7:?3R0$G*2DI\O?_
M@P\^D+=)OR6K5JT"3&O6-T2J"0;U04_2G$VOUV-K6U_5WMSOG+N[N]D@OJ["
M8#!8[&PP9LP8UJU;QZI5J_#R\J*VMK;=QO'33S_AZ.C(IDV;A.#7!:Q=NY9_
M_O.?#!\^G#-GSG3I6.;/GT]Q<3'EY>5LW+BQ2\<B:!U"#!8(! *!0- 4%@G
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M9"3??/,-K[_^.K_ZU:^Z>DBMXMJU:[(MM*!EK*RLNGH(C<C,S#3[3] U=,=
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MIZ>3D9%QVWT*;I_:VEH6+UX,P/GSYW%R<B(M+<VDS9=??BD_OG3I$OWZ]>/
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M#D$0!$$0A.ZH2=$MT6M4:,R-&S< VJ4L='NZ>O5J1P]! $:/'LV! P<Z>A@
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MR7%K%IOIMGW[]O'IIY^2GIZ.6JUFTJ1)#?:X6KAPH=E$>D)" M.G3\?1T9'
MP$ *"POKO%]P<#!65E9FEYJ]#[L[9V?GCAZ"Q336'UVOUY.7EU?=ORTEA4-+
MEM3YVIMZNS54VN^GGWZ2_O_--]^(]\HNZ,<??VPP(ZH^5555[-V[EP4+%K!G
MSQYT.AV%A86U>E-65%0 U27NL[*R2$A(X-=??V7KUJT$!P>S>O5JOO_^>\Z=
M.T=141%??_UUDXXOD\D("PMCSYX]S1Z[4#^]7E_O MZF:&D)51\?'QP<'$A(
M2&ATVX2$!&F104NT=(Q DTHL[]Z]F^'#A[?X&*T9WZ1)DSAZ]&B+[R^TK<#
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M+7:QM;7%U=65RY<O-^OX*2DI+1J[4+?*RDH4"@4.#@YD9V<W^_XM*:%JTIR
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M![GWWGL[>DB"( B"T"-TYKF7SCRVSF3KUJUD9F9*F<L[=NR0>B";U'?>UZ(
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M&(U&:1]UJ>MV4WG!^/AX#AX\6"OS2*%0D):6AK^_/Z6EI0P?/IP5*U:@4JF
MZ@E)?W]_'!T=R<S,;/9C[@Y,F6*^OKY<N' !*RLK;&QLL+6UY<X[[V3-FC5M
M/@:Y7(ZCHR/CQHW#WMX>C4;3X.]"2Q@,!C0:#8Z.CCSVV&-,FC2I78+^"0D)
MW'7775145#!@P "&#!G"Y<N7F3ES)B=/GNRQ"P\$06A;LV;-DJHZM-4E,#"P
MHQ]FEZ33Z7CLL<=P=G;&V]N;\O)RBQ_#SLX.A4*!G9T=,ID,F4R&G9V=V<_Y
M^?G2N:#I=M-]3;>;KI/+Y2@4"F0R&7*Y')E,QH8-&\PF-VON R _/]_L,ZZM
MLG2+BXMQ<G+"RLJ*J*BH%IW#"H(@"(+0/"M7KN1O?_N;5,UKY<J5_/WO?Y>"
MF.GIZ699K L7+C2K! >0G9V-2J5"I5*Q??MVE$JE6=N'YIP[W'GGG41&1DH+
MTFHRS3OMV;-'JE0"U><N+[SP KMW[P;@'__X!TN6+.'55U^5[KMDR1(^_?13
M-!H-+[WTDG3]YLV;^=.?_@14!X,;DI6599: (9?+42J5Y.?G ]7!\:5+EU)8
M6"C=1Z/14%%1T>3'WQ$LFN+R_^S=>UQ4U?KX\0\JXABF#I"EXR7,41+%>R@H
M5(9B&C3H20C1DV"F@XE'D)122CT(&B6D)F/IR"$+G; ;2%:04 C>,,V<\!:(
MDH*FQ@BH_/[@Q_Y"X@T&N;C>KQ>O%\SLV>O9(^!F/6L]SXT;-XQYNIM49MLK
M#1TZE+R\//;NW5NOXS9&[=JU(S PD.^__[ZA0Q%NH3&O_!",KVW;M@T=@B (
M38!6J\7;VYO P$#"P\-)24G!R<F)/__\DW'CQG'FS!GBXN)8N'!AC;LK*Q\S
M& PL7;I4NC$_<.  04%!;-NV#:U6B\%@(#HZ6EH!677WXBNOO$)45!2!@8%\
M\\TW+%NVC&7+E@$P^^A1.O;OS]JU:QDV;!B???:9]'QQ<3'EY>4L7KR8L+ P
M@H*"B(N+0ZO5DIZ>+MT$;]BP@;BX.(*"@M!JM4!%Z6=G9V>42B69F9ET[]Z]
MQO='I5*1FIJ*M;6UU$=8I5(1'1V-JZLKN;FYQ,?'$Q049/3$8U,P>O1H'GKH
M(<S-S;EQXP:EI:4<.'  "PL+/O[XXWJ=3,W+RV/<N'%LV[:-5JU:,77J5 H+
M"[&PL&#Y\N75_@CZI_CX>$Q,3(B/C[_E,0<.') 60A06%C)]^G0L+2U9LV8-
M)B8FY.3DU,=E 177MF'#!A0*!;FYN926EF(P&# U-<7*RJI6I3 %01#NAEPN
M%PM,&AF#P<!;;[U%[]Z]4:O53)TZE=+24JDZA% [5ZY<8?_^_<3$Q.#L[$SO
MWKUY[[WWI,G?JN6I!4$0!$$P#E]?7T)"0O#S\P.0%@96K5Q:]?_@W-S<F\YA
M9V>'KZ\OOKZ^].O7K\[S#CX^/MC9V3%GSIQJCU<N7NS1HP=ZO;Y:@OCX\>/2
MYV/'CJ5GSY[5XFC3I@VK5JU"I]-A9F8&5"SFTV@T+%JTB#___/..57>Z=>O&
ME2M7JCUVX<(%:0/#HX\^ROKUZYDQ8X:4]%VX<&&COY<W6@EHJ/C&,3,SJY?=
MCR4E)?STTT^,'S]>>LS,S Q?7U]6K%B!4JE\X/KACAHUBOGSYS-X\.!&_XU6
M6W7M]=:<B?>F<:GO!3""(#1M>7EYA(:&TK%C1Y*2DCARY CN[NYTZ]8-.SL[
MDI*2B(R,K%9*YE;<W=TY<N0(+BXNK%FSAO3T=(X=.T:W;MT(#0WEEU]^ 9!*
M"59^KE:KT>ET*)5*O+R\I#(U;[_]MM1G[O"^?3Q47,S9LV<!V+)EB_2'0>4?
M BDI*=RX<0.%0L&@08.DY+).IT.OUZ/5:G%T=,31T9'$Q$3&CQ\O)0N+BHKN
MN)M2)I.A5JMQ<7%!H]%@:6G)Z=.G<7)R(C@XF!4K5O#55U\Q=NQ8UJ]?7VWE
M:7/G[NZ.2J7"P\.#S9LWHU H*"HJXNK5JUA;6_/ZZZ^3F)AHU#$-!@,;-FQ@
MX\:-TJ++K5NW\OSSSV-J:DIQ<3&[=NWB@P\^(#L[&Q\?'Y1*)3UZ])!6['[T
MT4= Q6KCRC*4>KV>DR=/2M\SG3MWQL?'A\+"0E)24OCNN^_X^NNOI3AZ]>K%
MIDV;F#1IDM$7V?GY^=&U:U=I=U?7KEW)R<EATJ1)A(6%$1L;:]3Q&HM_5D^I
M[+WTS\]K<J?GZ^O8IA#CO1Q;V^LQYK'"@^E!;U=D,!@X>O0HQX\?Q\/#@\S,
M3(8.'2JUI!@X<* T]S1DR!#\_?VE%B$C1XX4B[WO05%1$7OV[$&GT[%]^W9"
M0T/)R,A@RI0IY.?GX^GIR;AQXWCUU5<9.G0H0X8,H6_?OLR>/;NA0Q<$01"$
M)J_JW^50<5\S:M0HJ;3QIDV;4*O5O/'&&YPX<8+ERY>S:=.F6Y[OB2>>H&/'
MCOCY^3%ITB0>>N@A]N_?CUJMOJ>XU&HU?GY^V-C8W/2<4JG$RLJ*Q8L7,VG2
M)';OWHU&HV'CQHT =._>G8"  /S\_*0V%@"VMK8 4F(X.3F9'3MVX.+B@L%@
MP,G)Z;:M+MS=W>G:M2OFYN986EJ2D)! 24D)@P8-DI+' P8,(#(RDI4K5S)E
MRA22DY,9,F1(O;;'JBNC)H"A_DK?)B4E86=G=U.25Z%0\,(++Z#1:)@U:Y:4
MX7\05);!CH^/EQI0-S=-O<SCW2R(J&TBMZF_-W>C*26Y'_1)%$$0;BTY.9F0
MD!""@X.QM;4E+"R,(T>.,'SX<!8M6L2F39M8O7KU74\F5O:"<W!P8-&B10P;
M-HS??_\=+R\O%BY<B*>G)U.G3I6.K]I3KC*9=>3($6FW<&!@("DI*0 D:33,
M='# S<V-S9LW$Q04Q,2)$X&*?BP1$1$L7;J41QYYA&^^^88M6[;@[.Q,2DH*
M%A86K%Z]FN#@8#(R,LC(R$"CT:#1:%BV;!ERN9SDY.2[WDVI5"H)#P\G/3V=
M@(  [.SL2$E)D6*N7'GIX^/#].G3&VPRMK2T]+Z-I5 HZ-RY,R^]]!*QL;%<
MOGP9$Q,3]N_?CXV-#4E)2<3$Q$BK>^M*I],1%A;&L&'#.'7JE/3X[-FSV;1I
M$_W[]T<FD^'BXB+UL=ZS9P]ZO9[X^'@T&LU-YXR(B" B(@)?7U\>?_QQA@P9
M(O4NK'3JU"E24U,)#@Y&H]%P^?)EVK5K1WIZ>K6^V<80$Q-#5E86CSSR",>/
M'Z=%BQ;\]==?W+AQ@ZE3ITJ+)@1!$)J3RF3F@^KYYY_'TM)26D3V^NNO,W/F
M3**CHZ4%>7J]'@\/#TI*2K"RLN*//_Y@Y\Z=S)X]FQ]^^*'9+L(WIA]__)&9
M,V<R:]8L#A\^C%*IY-EGG^6WWWXC-S<7A4)!<G(R?I3NM/$  "  241!5'Y^
M+%NV#(5"P=2I4QDR9(A(  N"( A"';FYN6%I:7G3UW*YG/W[]W/^_'E\?'SH
MV;,GWWWW'0\__#!:K98! P9(251+2TM<75TY=.B0]/6:-6M(3$QDY\Z=V-K:
MXNCH*(VQ;=NV6\9C:6F)FYN;]/7JU:NEQ.H_7[=Z]6IV[=I%?'P\MK:V?/;9
M9RB52HJ*BJ1$[^+%B\G,S+SI.BO'*2@H8,B0(4#%1H/UZ]??\KV!BOF6HT>/
M2O-9CHZ.4DGHJL<[.#A(?88KRU(W9D9/  .T;MW:J)-AWW[[+3MW[F3ERI4U
M/O_<<\])??2J?A,]"!P='<G*RB(M+:W:#YO0.(A>P ^.LK*RA@Y!$ 0C,689
M71,3$\:,&<,''WS [MV["0L+P]W=G8*" BY>O$AA8>$]KQ0<-&@0CHZ.! 0$
M,'3H4 (# WG]]=?)RLKBXX\_QLW-#2LK*\Z=.P= ?GX^G3MW)CX^'G=W=Y1*
M)1$1$6@T&I*2DGCSS3>QL[,C*RN+O_OWYZ'(2 )^_96S9\^2D9'!T*%#Z=RY
M,WEY>9P[=PX7%Q>BHZ-9M&@1;[[Y)F?.G,''QP=/3T^@(E'<J5,G'!T=F31I
M$B=/GI06JL7'QS-MVK1[NEX'!P=24U-)3$S$P\.#=]YYA["P,&QL;-!H-,3&
MQC)DR! .'SY\3^<U%E-3T_LZWI(E2UBR9 GSYLUCY<J5=.G2A>O7KW/QXD6<
MG9T)"@JB?__^//744[4>HW('5.O6K>G1HP=Y>7D,'SZ<@H("<G-S^?'''TE/
M3Z=___[57B>7RZ5D,%0D5Z%B]\_Y\^>E/S;O)" @@&>??9:77WZ9\^?/8V]O
M3]NV;2DH*,#.SH[P\'#6K%E#>'AXG9*SO_SR"T%!0?3KUX_"PD),3$RPL+ @
M/S^?Z=.G\^&''[)DR9):G[^Q*R\OO^UC-3U_I]??CV.;0HSW<FQMKZ<NQXH=
MP<*#KG*7RM]__\VH4:/8O7NW-*<DE\LQ& P<.G2(0X<.$145Q?3ITVG;MBWE
MY>7TZM6+T-#0>UJ\]R J*BIBWKQY1$9&TK=O7W;NW$E"0@)OO?46[[SSCM1[
MV,7%A:^__IKWWW^?#S_\D+%CQV)N;M[0X0N"( A"D_?/"G-5OZY:2<W!P:':
M<T5%16S=NI4.'3H@E\NK]0BNI%*I;OEX32K_'JDZCDPF8_+DR36^KNI"\ZKD
M<KDTIZ!0*&I<D">7RVNLKO?/:ZXI/J526>,<PS^/KXRK*2P6KY=EG\9*_EZ^
M?!F-1L.A0X=8OGSY;7?WSIHUB_W[]S^0_8"G3)G"VV^_+96M$QJ7^STQ+ B"
M(-3-D2-'C':NR9,G,WKT:+R\O,C)R:%OW[YD9F82&QM+>'AXK<K$R&0R @,#
MV;5K%P#!P<%\\\TW%!86LF/'#A(2$HB)B2$A(8&$A 0R,S-)2$@@+R^/F3-G
M A6)N?+R<L:,&4-F9J:4J)O\_Y_/S,PD,# 0/S^_:J\/#P\'*B9.R\O+>?OM
MMXF)B4&M5N/CXR,ERQP<'"@O+Z>TM)3(R$AD,AEY>7ED9V<S:-"@6EVS2J6B
ML+"0%BU:4%!00(<.'7!W=Z=3IT[\^NNO]WS.IFK @ '2'R7FYN84%!1@;F[.
MI4N7R,_/9^# @4R8,*%6/7.+BHH("@K"R\L+:VMK3IX\R>3)DTE(2&#Y\N7\
M_???G#ESAN>??_ZFY._MR.5RE$KE/7V_]^_?7_HC\.+%B[S__OLD)"3@ZNK*
MI4N74"@4>'EYL7SY\EKU@\[)R>'99Y]EX,"!_/777QP_?AP+"PL*"@IHW;HU
MHT>/1JE4/E EQ@5!$!X4YN;F>'AX$!(2PN'#A_G?__XGW9?I]7H\/3W)R,B@
ML+ 0M5J-3";#U]<7O5Z/GY\?'3MV9,.&#;<=P\3$1%IL4?EY31_WX]@[?=3V
MV-M9L& !<^;,8<R8,?SZZZ\,&S8,@+???IO<W%P2$Q/Q\_-#K]=C:VM+3$P,
MK[_^.DE)28P8,>*>_TT%01 $03">/GWZ2/-'0M-6;W5_6K=N7>O7'CMVC$\^
M^82%"Q=*-;WOU-_7S,P,M5K-QHT;&VP'2$.QM+3DK;?>8O/FS6+':2,D>L/>
M'\7%Q0T=P@-5@EX0A#LK*BIBRY8M! 8&DI.3PT\__82GIR<)"0EU7B7HY>7%
MFC5K@(KDVK9MVP@+"[OM:Q8N7'C'!-SMXJKL[7HK*I6J6K(L.3D9*RLK::5D
M0D*"-(E:6W*YG(4+%Q(;&TMF9B8=.W9D_OSY !PX<*#6YVUJ@H.#6;]^/7%Q
M<5R_?IW+ER\#<.+$"2Y<N$#W[MT9,6*$U _Z3@P& UJM%@L+"]JT:0-4W%\F
M)26A4JG0Z_6$A(0P?/APCAX]RG__^]]ZN[:J0D-#.7KT*!,F3" D)(0#!PZ@
M4JE(2DJB<^?.0$5RV,+" IU.A\%@N*OSYN3D,&+$")1*)5>O7N7(D2.T:-&"
MHJ(BRLK*^.JKK_#T]&3.G#GU>7F"T&#N90>S(#1'3S[Y)+Z^OKSTTDM2J6>#
MP<#RY<OQ]O8F,##PIH5Z=G9V4IF_T-!0M%KM'=LR5?ZLE9>7W_*CZO/U=>R=
M/FIS[.UHM5H J>V'7J^72C!"Q8Z=F)@8)DV:A+>W-UJM%H/!P+QY\_CEEU](
M34TE*"BH5@N\!$$0!$&HF\I=OXVYKZUP]^HM 5Q:6DK+EBWO^OCSY\_S[;??
MLF3)$C9OWHQ2J63ERI4\]]QS=WT.2TM+%B]>S+IUZQZXG<".CHZT:]>.I*2D
MA@Y%^(?KUZ_?T\^"T'0]Z+VT!$&H8# 8I%*R5:U=N]9H?4LK$ZWIZ>D N+JZ
MHM?KZYP$E1)H=YE(N]UY0D)"" P,!"J2X?[^_HP?/[Y.YZVD5"I)2$A@W[Y]
MTF,#!P[$Q,2$O+P\HXS1F,GE<B(C(]%H-$1'1V,P&/C[[[\Q,S/C\.'#& P&
MNG?O3O_^_8F+B[OMN=+3TW%R<F+7KEU,F3*%@P</$A<7Q\*%"RDN+B8H*$B:
M#(^)B;GO)8XJ>T$'!@8R8\8,@H*"@(H%#7%Q<>CU>J9,F4)B8B).3D[2S\2M
MQ,7%T:M7+ZEOT)X]>S S,^/:M6L8# ;^^]__$A45Q8X=.T1_1Z'9$B6@!6.V
MNVAJMFW;1M>N77%U=962O,G)R3@Y.0&0FII:8]E 1T='=#H=4%&91*?3,6;,
MF ?BON->'#AP@.CH:%:L6"$]IM5JJR6 *[FXN)"4E,2A0X?P]/3DP($#V-K:
M\LDGGV!K:XN-C0W'CAV[G^$+@B (@B T*_6:K;A=,J2DI(1CQXY)2=_HZ&B@
MHJ3@DB5+&#QX<*UVTU4F@3=NW"@UD7Y03)DRY8$M@]W8B<1@XW#]^O5Z/;_8
M[2T(0M4)Q*K:MV_/%U]\8=2QEBQ90D1$! :#02H+79=^I8&!@>3FYD)@(.3F
MDI*2@J6E9:W.5;7?,,"Z=>O8M&F345>0'CAP@)8M6]Y4BOB99YZ1DJ+WPY]_
M_GE?QODG!P<'A@T;QKY]^Y@[=RY0<7]M:FK*L6/'^////[&WM\??WY^77W[Y
MIO>CLHQE6%@88\>.)3L[&W=W=Q(2$K"TM"0Z.IJN7;MB;V]_R\GP^ZFR%[2]
MO3T6%A9$1T=C:6E)0D("[N[N9&=G,W;L6,+"PJ22DE49# ;^_>]_\_+++V-O
M;\^)$R?8O7LWIJ:FE)24<.W:-6;,F,&Q8\<8/7JTT19K"((@-$;&;'?1U)25
ME1$3$X-*I9):'ZQ9LX;8V%@6+EQXRTHE P8,(#\_7TKX*A0*=NS8(?43KDES
M+@%=$X/!P(P9,UB_?KUTSW?@P 'L[.QN>0\HE\L)#P]GR9(ES)@Q@^7+EP,5
MNX?=W-P:1:4O01 $01"$IJI>LU)E9652_]/+ER]S^/!AOOWV6R(C(YDP88(T
M$5J9]'WNN>=J/=%8E:6E)<N7+^?X\>-$1D8^,&61JY;!;FJK)!MJ\O1^*2LK
M:^@0!.H_$?^@_*X1!.%F>KT>=W=W-!H-65E9TN,OOO@B '_]]1???_^]4<>L
M[ 6;F)@(5"3(E$JE5':OKK*RLFJ5L"TJ*F+JU*E2OQB]7D]"0@*3)DTR2EQ5
MX[M^_3H'#QZD8\>.TN.___X[QX\?Q\G)2=JI4Y]^_OGG>A_C5A8N7(B=G1U7
MKEQA[MRYE)65<?WZ=<S,S#A[]BS[]NVCJ*B(N+@X^O;MB\%@H*BH2"IQ:6UM
M34%! 6W:M"$I*0EG9V>BHZ.EW>N%A86H5*HZE>TVIJJ]H $I$>SL[$QJ:BJ/
M//((!04%6%M;X^WM+?4'-A@,//GDDVS<N)%V[=IQY,@1\O/S,3<WY_KUZY25
ME;%X\6)NW+B!G9W=;2?S!4$0A*:MM+04<W-SEB]?CH6%!?;V]GSRR2=W5>'"
MQ\>GVOV<BXL+5E96TOW&RI4KI99D]5W6^5Z.K8\2T#65@=ZP80/N[N[56H*D
MI:7=U3W@@ $#2$U-Y>&''T:I5/+QQQ_3HT</+EVZ=,?7"H(@"((@"#6KEVS(
M^?/G.7;L&&EI:<3&QN+O[\_"A0OY^>>?D<ED3)HTB2^__)* @ "C)7W_J5V[
M=LR:-0MK:VOFSY__P)3EL;2T9.;,F;SWWGN</W^^H<.Y:PTY>7J_B/ZP@B (
MS<^Q8\=0J52XN[O3L6-'3IX\R90I4WCTT4<!^/SSSZ5CZ^-^)S@XF+"P,&FW
MXXP9,Y@Z=6J#]DQ;L& !4+&CPV PX.WMS?KUZXV>1"PI*6'0H$$ 7+AP 8"N
M7;L"</SX<7KTZ,&77W[)T*%#^?KKKXTZ=F.B5JNQL[/CQ(D3K%RYDALW;G#Y
M\F5:MFQ):6DI+5JTX/777^?LV;.T;=N6L6/'<O7J5?KV[<ONW;N)C8UEYLR9
MQ,7%54O\JM7J1MOS1RZ7HU:KJR6"-VS8@)>7%[&QL1P_?IR^??O2JE4K+"PL
M:-NV+7EY>?CY^7'ERA7^^NLO6K1HP=6K5[EV[1HK5ZYDW[Y]S3;Y:V-CT] A
M"((@-!IY>7F\]MIKO/ONNZ2FIM[30B=W=W>BHZ/1:K68F)C@Y^?'XL6+\?#P
MX)EGGN'[[[]GV;)E]7P%C9->KT>KU1(0$,#RY<O1Z_48#(9;EG^NB4PF0ZU6
M$Q$1P;QY\_CXXX_K.6I!$ 1!$(3FK58)X)*2$O+R\LC+RV/OWKVDI:7QR2>?
M$!D9B8N+"Z&AH?SPPP\8# 9L;6U9MFP945%1^/KZXNCHB$*AN"_),#,S,]S<
MW)@[=RXK5JQ@^_;M#\0.O;Y]^S)SYDQ"0T.;5!*XN7L0OO?JT^C1HQLZA+LB
M^CT+PH-EYLR99&9F<OGR908/'DQJ:BKN[NY,G#BQVG']^_?GCS_^,/KXE;U@
MO;V]*2HJXHDGGB J*NJ.?5]OJT,'.'>N5B_5Z_5D9V=+Y?KFS)F#CX]/M9T@
MQG+\^'$>>N@A.G3H(#W6H4,' @,#24A(P-?7E[U[][)GSQ[&CQ]/3DZ.T6-H
M+-1J-;-FS>+33S_E_???ITV;-ER]>I5NW;KAX.# ^^^_+Y6 +BPL1*O5,F'"
M!,+#PTE.3FXRB=]_JBD1G)R<3&!@()Z>GJQ9LT;:T77MVC5B8F)P='2D6[=N
MTGU95%04\^?/9]:L6<TR^0O0NW?OA@Y!$ 2AP>7DY+!LV3)^^^TW)DZ<2&YN
M+J-&C;JG<R@4"BPM+=FZ=2O[]^]'H]&@4"AXZZVW:-^^/;&QL106%MZQ'WUS
M$1<7AXF)"1LV;" H*(BE2Y<BD\D8,F0(04%!1$9&TJ%#AWN^KY@\>3*__/(+
M0X<.1:?3$1(2<M]:>PB"( B"(#0GK6[WY+5KUP!J[('UKW_]"P K*RLL+"SH
MW[\_(T>.)" @H!["K)N>/7NR<N5*=#H=\^?/9]JT:=C:VC;K'9E5D\"+%R^N
MEUU'PKV3R63B#Y=:,C<W;^@0[HJIJ6F]]QH6!*'QF#)E"CJ=CGGSYE6;1*SL
M2VMM;<WQX\<Y>/!@O<7@X." 6JUFP8(%K%Z]FNG3I^/DY(2+B\M=E3.\29\^
M4%!0JU@J)_MD,AG1T=$ ]994.W'B!&9F9K1LV1)S<W.N7+E"OW[]I.==7%S8
MO7LW4Z=.I4V;-DTFJ5E;+BXN//GDDZQ>O9IGGGF&_?OW<_KTZ9L6'LR<.9,1
M(T:P??MVPL+"" X.IKBXN-&4>:Z-RD2PEY<7*2DI>'M[X^SLS/_^]S_^_/-/
M)DZ<R(T;-P#8M6L74#&)/V#  $Z<.$%N;BX*A:(A+Z%!_+.'8WEYN?18U<]K
M<J?GZ^O8IA#CO1Q;V^LQYK&"\" P& Q,GCR9AQYZB">??)*U:]?6^ES_^M>_
M" H*8N# @5+/VM=??QT/#P]L;&R0R^4X.CK66"*Y.2DJ*N+EEU^F5Z]>O//.
M.]C8V#!RY$B2DY-Q<7%ASYX]+%JTB(2$A%J=7Z%0L&'#!EY^^67R\O+(SL[F
ML\\^:]+W*X(@"((@"/?;;1/ K5I5/)V<G%SG@<S,S!IT!Z29F1F>GIZ,'#F2
MI*0D-F[<R$LOO<30H4.;;2*X,@GLY>5%9&0D??OV;>B0'G@B^=NPOOONNWH?
MH[[[# N"T+CX^/C@X^-ST^.5.RJ/'S].QXX=:=^^/9<O7T:OU]<N*7L7<5RZ
M=(DY<^:P>O5J@H.#T6@TA(>'&WVL6TE.3L;*R@H'!P>BHZ/)SLYF]>K5]39>
M0D("#@X.%!868FUM37%Q,8,'#^;LV;/2,3*9C,\^^ZS>8FAL% H%X>'A[-Z]
M&WM[^VK/S9HUBY$C1Z)6JQD^?#C!P<&$AH8VJXE4N5R.2J5"I5*1GIY.1$0$
MV[=O)R8FAI]__IF//OI(.C8O+X]-FS;QS#//-&#$@B (POTP9\X<IDV;QA]_
M_(&7EU>=SC5MVC16K5J%E945'AX>K%FSAB%#AA >'L[X\>/)S\\G)27%.($W
M8F%A8<3$Q/#CCS^R8\<.WG__?0#6K%D#5,PG/OWTT[BYN=5Z#)E,AK>W-P 9
M&1ELV+"AV5;K$ 1!$ 1!J _W+5/16,K?*A0*?'U]6;!@ ;FYN4R8,(%//OF$
MPX</-W1H]:)OW[Y\]-%'K%NWCK2TM(8.1P!:MV[=T"$(]:BQ_*X3!*%A7;ER
M1?K\ZM6K//;88W3HT($]>_;4VYB5O6#GS)G#L&'#.'+D"(F)B?4V7E5%144$
M!P<S9\X<EB]?+B5_ZRNY6-GS.#T]'9E,1GEY.3=NW*!GSY[U,EY3DIZ>CK^_
M/R^\\ )*I9)QX\;QRR^_\,$''S!Y\F3.GS_/EU]^B8.#0[-*_OZ3@X,#"0D)
ME)>7X^OKRX8-&SA]^C03)T[$QL:&*5.F$!P<;)2%KDU5>7EYM8^JC]7T_*V.
MO=.',8]M"C'>C^NIZ[&"\"#1:K7 _U4D:=NV;9W/.6?.'(J*BMBY<R?Y^?D,
M&3*$H4.'HE*I^/###W%R<JKS&(U=1$0$IT^?QM[>GC???).V;=N2F)C(K%FS
M6+AP(6^__39A86%&&R\T-!2M5OO E-<6!$$0!$$PAMON #8V4U-3RLK*[N>0
MMZ10*/#T]$2E4G'HT"&2DY,)" C@7__Z%WWZ]*%'CQZT;]^>=NW:-72H=:90
M*%B\>#&;-V_FM]]^XZ677FHRUU53^7&A@GAO&B=1_ED0F@<;&QN.'#E2J]?:
MVMJBT6CHW[\_!P\>I+R\G-S<7&QL;%BU:M5M=YZ8F)C4:7)>K5:CT^E0J51X
M>GHR;MRX>S^?M37<8P_AK[[ZBCY]^K!Z]6H>?_SQ.B=_[_0^?/KIIPP<.!!3
M4U-^^>473IPX 514VOCGSM<'Q==??\U[[[W']>O7Z=&C!Z6EI7SZZ:?UTG^Y
MJ>K<N3/Q\?$<.'" )4N68&=GQX<??L@;;[S!VV^_S?///]_0(0J"( A&I-?K
MB8Z.)BDI"8!NW;IQ\N3).E=C\?/S(S8VEK_^^HL9,V80%A:&O;T] 0$!>'M[
MX^;FUJP760$4%Q<3%A;&[-FS*2PL9,&"!3S^^.,D)"1@;6V-M;4UPX8-,]IX
M,IF,V-A8O+R\V+)E"T\\\831SBT(@B (@M!<W=<$<%E9&2U;MFQ4"1(S,S,&
M#Q[,X,&#F35K%CDY.>3DY/#;;[]))0-=75UIUZY=M1*"36VW@*6E);-FS>+'
M'W]DX<*%S)T[MTGLDFEJ[_/=JKH8HK:)W.;ZWE0EDMR"(#24WKU[USH!;&EI
M241$!//FS>/X\>.8F9F1EY='NW;M.'/F#+_\\DNU7K55&6-GEDJEPM;65BJ9
M9S 8[FT2LA8[8Z9.G4J?/GU8MFP9*I7JGE__3W=Z'[9NW<ICCSU&=G8VY>7E
MM&G3ALZ=.W/\^/$'8M?-/^7DY.#KZ\O9LV?IUZ\?:K7:*/\.S=6  0-(2$A
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M3D%! ?GY^;1OWUY*-&1F9I*5E45@8" I*2D F)J:$A(20FQL+%]]]14)"0D
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MR[!AP_CG/_]I<ONN7;L8,&! J];S_OOOFUQ_Y957" @(X+'''F/;MFWMKN_
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MVD1"0@)>7EY\_/''S)@Q@S%CQG#PX$'C7,<WJZBH(#(RDO?>>X_R\G(6+%C
M\.'#F3)EBDV,_@4'&P$,O[3$%<*9R,CWUO/P\%"Z!+L-#X00EN(.#SP#O_H"
MTF]J45H4!^XN=6V875S@W>^@LS_T/0&G3L*A.^'!,.B[#_*/0E$OZ%'O<Z[F
M&A1U@2[USOESO15Z7(8K5<!AN*]+W;J[1,*(EV%8%]/;75R@W[M0]?/C?<?
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M6(6$HK9+6G0+83L" P.5+L%F=>KF3<V9$JMOUU;#7Y"3"84I"7^%4(X]A+^
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M1EE9&08.'"C,I/7R\D)@8" " P,Q;=HT///,,R@M+>UQ %Q962G,)-ZY<R>
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MCQX5NQ0B(B)R$#T.@*]=NX;;;KO-*B>_[;;;H%0JK3*6/=+I='!W=^=ZI'U
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M(#,S$Q,F3$!R<G*[P5]%1076K%F#>^ZY!TE)2?#R\D)=71V>>>:93L=.2$A
M8F(B  C[)B<G8]:L61W6D9>79X5G1>:2R62X?OVZV&78/*U6*W8)=LG-S8W!
M.?4I1PA&75Q<.GT>;*].1$1$1$2VBJV@[4=]?3WBX^--MK7WM^CNW;M145$A
MW \*"L+"A0M[O3XB<BR;-FT2)AW.FC4+__=__P>E4@D7%Q<\\L@CF#=O'A0*
M!1Y__'$$!@;"8#! I]-A_?KU:&QL1$9&!A(3$_'XXX]CQHP9 (#ERY?CS)DS
M>/?==X6<:^# @<(YT]+2A'5H-VS8  #XZJNO4%%1@2-'CB X.!@#!P[$U*E3
ML7OW;B'XW;!A U0J%1YYY!&\]]Y[" L+0TU-#5)24K!NW3J,'S\>V=G9^.M?
M_XI#AP[UX:MH_WH< !N3>4MG,/KZ^L+'QP=*I=(I9J6>.'$")TZ<:#><W;=O
M'_S]_?']]]^W>2PA(0%CQXYM=\S6WUQ&:6EI" @(@)^?'T,TLFM2J53L$NR.
M1"*QN5;01/: (2\1$1$1$=DC8ROH@H("L4LA*ZFHJ#"9U6L,4XB(>FK-FC5H
M;&S$WKU[ 0#KUJW#N7/GD)^?CWGSYB$E)06OO_XZHJ*B  #9V=E8NG2I$-X"
MP(P9,X3[2J42,V;,0$U-C9#IJ50J849Q6EJ:R;$ A M84E)2D)B8"+E<CNSL
M;"Q<N-"D8\&1(T<0'1V-W-Q<A(6% 0 &#1J$YY]_'FEI:7C[[;=16EH*C4:#
M@H("H6;J7(\#X//GSW?8RKBG)DR8@-K:6J<(@/W]_5%86-@F *ZOKT=141%F
MSIR)ZNKJ-L>-'3L6X>'A/3I71D8&UJQ9 T]/3[N?#>AHW\B9F9G(S,P4NPQR
M4,W-S6*70&2W0D)4?C'(   @ $E$051"4%Q<+'891$1$1$1$/<)6T$1$U)Z7
M7GH) /"'/_P!A86%>.FEEZ#3Z;!HT2( 0&YN+G)R<H3]9\^>C?CX>),0]\B1
M(TA)20$ C!\_'LG)R29Y7NMVTCVQ>_=N?//--P@*"L+<N7/Q]MMO8^_>O5BP
M8('04GK@P(%X_?77D9Z>CAT[=F#"A G0:#3(S\]WN-RHM_0X %8JE1@Q8H15
M3F[L/3YQXD2KC&?+(B,CL77KUC;KOYXX<0( </OMMUOE/ D)"<C,S,377W^-
MAQYZR.X#X)L9O['Y#>X\8F-CV]W>^G].U(*MGXAZSF PP,7%!<7%Q0R!B8B(
MB(C(+O'S "(BNEEB8B(F39H$;V]O%!86(C8V%CDY.:BMK17V:=VAMZ:F!I,G
M3S89(S@X6%B&U-75%>^^^RXT&HW%W3LC(R,1%14%3T]/?/?==Q@R9 C>??==
MR&0R_/O?_\:CCSX*H"4'&CAP(,:/'P^@)7"^>98Q=:S' 7!=79W5 MLA0X8(
M :BC"PH* H V;: +"POQ]--/X]JU:U8YS[QY\U!65B:T@K[KKKN<YI? @(
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MGGONP<LOOXR:FAK<=]]]>."!!]K<[KKK+M37UV/MVK6(B(C N''C\.VWWP)
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M0O"[W_T.K[_^.B(C(VWN(MFOOOH*2Y<N17AX.(J*BM#<W PW-S<A3/+U]04
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M"&;(1-0[1HP8T:/]8V)BL&'#!L[()R*B;F$ 3!VRAX!5*I4Z['K YNANN]*
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M\<8;^/WO?P\ F#]_/DZ=.H4A0X9@^/#APN^W?_[SGX4VXT1$1$1$1-3"K$1
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M?3&KA!#B/2@(3 CQM)*2$IO7@P/Z Y+&&:66A(2$8-6J5=BS9P^ _L_6 H$
MHT>/QHD3)_#MM]\B,C(2X\:-PY@Q_5\EP\+"$!X>CM.G3R,R,A(??/"!6;N;
M-V^&6"P&T%]>&@!$(A&N7[^.>^^]%S__^<_Q[;??HJFI"=>O7\>>/7M04%"
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MZH=.I\/)DR=Q\N1)7+UZ%5%149@Y<R;BXN),MC-NWQIK$U8((8000HCOL#L
MW-;6AMFS9SOEX.'AX3AQX@3BX^.=TAYQGYLW;WIMH'7,F#%>V2][V+I.E+?^
M#HAW&NS"K2L\_/##9A<H"?%' X/ )24E[$4S"@(30IR)R^6Z_*(\E\M%6EH:
M=N[<B3OOO!, </7J51@,!JL!-#Z?#X/!8')?3DX.,C,S$1D9:?880Z_7H[JZ
M&L>/'T=!00%[?U=7%V;-FH6I4Z?BW__^-U)34TV"*?;@\_D.[^N(@>O;,LN.
M#!9\9#*4&<99LIF9F58#FI]^^BGJZ^OQX8<?(CL[&WP^'U>N7&'/DT.'#J&W
MM]=EP7,^GX_GGW\>5555N/_^^P$ ERY=PM2I4ZWNDY*28G8^<#@<M+2T0"Z7
M6\V,NGCQ(C[]]%/\_>]_Q[IUZP#T3VYL;V]'?'P\QHP9@Q]__!&9F9F#]M>=
MYP(9&;1:+202B=GZWJ6EI<C(R   ;-^^?= )#PJ% A*)!'J]'FO7KH5<+C=Y
M7"J5(C\_?]#UK54JE=5K:R*1""4E)>SYKU0JAYR 8>U]FQ#B.+U>C[:V-I/[
MAEJR@!!""!D.NP/ UZ]?9R\$#->==]Z):]>N.:4MXGZC1HWRRN#C2,H*]9>,
M9^(>@\TZ=P5:>X:,) .#P.7EY10$)H0XC5:K141$A%/7C9/)9(->X&]M;66S
MSBY>O(CN[FZG!\^X7"Y$(A%$(A'>?OMM /W!P)LW;R(D) 3IZ>FX<>,&-FW:
M9'?;&HT&D9&1;ATSAEJMQMUWWPT ^.RSSYQV_($6+ER(A0L7(B<G!P"0FIJ*
MSS__' #PF]_\!A<N7,"?__QGEP<]SY\_SP9>O__^>Y<<+SP\',\\\PR>>>89
M[-Z]&QJ-!O/GST=75Q?FS)F#>?/F8>W:M18G2'CR7"#^;_/FS0@/#\?CCS^.
M:=.FX?///X=:K<;*E2L1&QMK5W#G_???1WM[.Y8N78J0D!!<O7J5#=;&QL9:
MG0"DT^E,@K]2J137KEU#5U<7>\UMSYX]V+!A@]F^KEZ/E!#RD[:V-D1&1IK<
M1W]+""&>IE:KL7__?AP[=@PI*2D0B41FU4,&P^%P3-[+5"H5 -C51DY.#I7(
M=Q&[ \!-34UX^NFGG7)P/I^/RLI*=@8O\2VW;MU"0$  ;MVZY>FNF!D[=JQ7
MKU7L3'U]?5[[>R"$D)&$@L"$$%<;*F/+51R=1-;>WFZV'K"][KCC#I/2J/;R
MQ)A=N7(%$1$1 /K'("@HR.U] /HG[+H[L^CFS9L8-VZ<6X_)F#1ITJ 9DIYZ
M_1#_I=/IL&O7+@ _9?$R$PZ _A+E H$ A86%9A<U<W)R()/)(!*)D)J:"@ H
M*RN#6JV&5"I%86$A]'H]6SV@OK[>:@"XHZ.#O7WJU"EV\HY>KT=B8B+4:C64
M2J7% #!=;"6$$$)&+IU.AYB8&%155>'MM]^&1J-!<W/SL-H<:ID)2V0R&7TF
M<1&[ \ M+2T8/WZ\*_I"?-#MV[<]W06+1EI&K#<'XX=++!:CHJ+"T]T@A!";
M4!"8$.)*5555.'KT***BHA ;&VOW_C*9# D)">CJZD)V=O:@VUZ]>A77KU^'
M1J/!Y<N7'>KOI4N7D)249/=^5Z]>A4:CP;___6^,'CW:H6,S09.JJBKLV+$#
M4JD4DR9-LKL=>\;,F$ZG@T:C<>@"" !V+5%[]?7U0:/1X.;-FV:EI5WEAQ]^
M@$:CP;WWWHO>WEZ,'3O6+<<%^L\QC48#G4Z'*U>N6-R&.1?JZNH@D\G<?BX0
M_Q42$@*#P0"-1F,RZ8-A;?)'=74U.R&AI*2$G;C0T-  C4:#L+ P /T!7$9P
M<+!-?7KWW7<AE4HA$ C Y7)15%0$  Z=\X000@CQ;S4U-2@N+D9*2@J _K+T
M H$ 6[=NQ<F3)Y&0D(!?_.(7>//--]'=W8TGGG@"G9V=>/755]DE)H9R[MPY
MK%Z]&C4U-2@M+<7RY<OQRBNO8->N79!*I5B_?CT X,477X1.I\/2I4NA4"A0
M45$!L5ALLHP%L9_= 6!"C/7U]7EEMJT_E$:V=_W46[=N>>7OPM5X/)[;2QO[
M,AHO0ER/@L"$$&=C_G8G)"1 H]%@RI0I#F5V3I\^'8L6+<+Y\^>'W#8T-!0&
M@P%RN1Q=75V(B(B 5JMURY?OBQ<O0BZ78^;,F;APX8)#;3!!OY24%!PX< "3
M)DUR^9@Q)DZ<"(%  +E<CN^^^PZ!@8%H;V^W^?A145%F:X#:XO;MV^CM[85<
M+K<Y6.0,!H,!;6UMD,OE" @(P+ESY^QNPY'/I^/&C</1HT>AT^F0FIJ*KJZN
M0=N.BXO#GCU[W'HND)%!(!! K]>S6;U _[J["0D)9MOJ]7HV$[>XN-CL/94Y
M-W-R<E!34P, $ J%['K"ED1$1$ H%$*M5D,NET,NET,H%$(L%B,Q,1'SYLVS
MFAW/K#ENS-5KS1-"""'$NV5D9&#*E"DX>_8L@/Y)E__[O_\+M5J-@H("]/3T
MH+:V%MNW;Q^RK5V[=F'+EBV8-V\>TM+2,&'"!-QSSSTP& PH+R_'OGW[  !%
M146HK*QDC[ESYTX(! (*_@X3!8#)L'EKP''LV+$F,V9]C2/KI_;V]OIM)C!Q
M#EI?AA#WH" P(<29F(! 8F(BQ&(Q.T/;7HF)B=B^?3L;5!@,4[I9(I%@]>K5
M&#-FC%U!NJBH*-37U]O5/XU&@X4+%^+''W]$86$A-!J-0X%0 &S9:+%8C)B8
M&(=+(2<F)B(_/Q]-34TV[W/GG7?BP0<?1&%A(3[\\$,T-S<[E E<4U/#SHBW
M175U-0 @/S\? )"7EV?W,1TA$HGP_///0R 0X(,//K [ "P2B7#X\&&[LMJ;
MFYLQ=>I4)"4E8<.&#1:#6 SF=S_<<V'!@@7(RLK"Q8L7[=Z7JAKYO[:V-I,R
MXQ*)Q&+0M;*R$FJU&@"0GIYNM3WCML1B,4)#0ZUNR^5RL7?O7JQ8L8)M6ZU6
ML[>%0B'V[MUK\=Q?MFR9V7WTG9$00@@9&6)B8A 1$0&!0("4E!1HM5HT-#2@
MLK(23S[Y)%L.^L$''P0 W'WWW0X=Y_KUZ^SM&S=NX.K5JV;;,)^;)DR8 *E4
MBKR\//SQCW]TZ'CD)Z/LW2$R,A+7KEUS15^(#W-GF2];^7+P%W"\C#63">PO
MAAH'^G)JGQ]__-'372!DQ# . @/]&19E964VE<@AA!!+&AH:D)N;Z_#^<7%Q
M*"PLM*DT<%!0$)8M6P8.AX/3IT^#S^?;%=!U9-W;]O9VC!X]&C=NW "'PT%D
M9"2BHJ+L;L=8147%L,=L]^[==I53YO%XD,EDX' X2$M+PQUWW&%W,!SH#^#8
MNOZQ5JO%@P\^B/ONNP\\'@\\'@\%!05V'],1P<'!B(R,!(?#P;1IT[!TZ5(T
M-C;:O+] (+!X$6@P%R]>1$!  #[\\$-P.!PL6[8,,V;,&'2?X9X+*2DIJ*BH
M<%MI;>);PL+"\->__A6OO_XZ &#ERI46)["4E94!Z,_^M?;ZUNET4"@4*"XN
MQD,//82\O#S\YC>_&?3X H$ QX\?1UU=G=EK7ZU6(S(R$CJ=SI&G1@@AA! _
MQ>?S<?SX<106%H+#X4 BD2 H* AA86%0*I5H:VN#2J4RV5XBD8#'XZ&PL-!J
MA1+F>R2'P\':M6NQ8\<.\'@\//+((WCFF6<  !P.!Y65E4A-345F9B8X' YV
M[-B!U-14 ,#X\>,Q9\X<UP^"G[,[ S@Z.AH__/"#4]8![NCHP".//#+L=HCG
M>6L6L"]GPXX:9??\#%9O;Z_/E\!F##4.' ['33WQ#[[Z>B#$5U$F,"'$&<1B
ML<7[2TI*$!X>[I)RG2DI*6AK:P.?SX=.IT-24A):6EHP<^9,D[4DP\+"; Y2
M&M/I=.CHZ&#_W][>CI=??AD__O@C/OWT4X2$A#A<<EJOUR,Q,='B8V5E90@*
M"G)IB5,^G\^.'0 L7;H42J42L;&Q)@%M'H_G<$DSC4;#WN[IZ<$[[[R#N^^^
M&U*I%"DI*=#I=%9+OCI;;FXN7GSQ182$A$"E4F'3IDUXYYUW\-O?_I8MQ0WT
MEZEUI$]:K=8D^[RYN1D[=NS '7?<P68E6#M7!CL7<G)R(!*)$!<79W>?"!DH
M)"0$2Y<NQ=*E2W'CQ@W(9#*L7KT:F9F9[#:-C8U0*I4 @/CX^$';8MZC)DR8
M@)4K5^*##S[ A@T;+&;Q&K]&XN+B$!<7A]S<7#0V-N+==]]E ]$G3YXTJR!!
M$ZH)(820D6WAPH4X>O2HR7V#59S*R,@P"?P._"PAD4C,[AM8":>PL!"%A87L
M_W?OWHW=NW>S___3G_YD5R4D8IW= >!QX\;AAQ]^<$KM[4N7+E$-;S_BZO5G
MK;WQI*:FLA,2'GC@ 4R<.!&3)T]&6%B8R_KB#L87=1SA#^L@V\+?GQ\AQ/=1
M$)C8PQ<G-ITZ=8IFY@Z3K;]W9Y\?CK0W6-#"&N-2IK88K-2IO;QAS!B62JTZ
M^W@#+]YXTIX]>UQ^#'O&Q]*V]IZ;CAZ;^">=3H>:FAK4U]=C[=JU[/6M:=.F
M6=S^].G3[.V!?S>9MLZ>/8O$Q$1V8H(MU12V;]_.GLN=G9WLI)PY<^;@Y9=?
M9@/ W=W==CY#0HBK.?MOB4*AH'6\"2$^C:E80I,TG</N '!$1 0N7KS(UOT>
MCHL7+^*!!QX8=CO$.[@CZ[2ZNAHI*2GL^E9 _VQ7 +AY\R:^__Y[G#AQ EJM
M%I]]]AE24U,1%16%&3-F@,_G(S PT&5]<[:OOOIJV&WX0W#4>(T 2V[>O.FF
MGO@/7\Z,)\1741"8V,.5V3C,129G'2,G)\<DPX\XSF P("XN#B=.G,"8,6-@
M,!C0U=6%Q,1$[-V[%Y&1D3 8#.!P.# 8#,C)R4%L;"R"@H*P>/%B $!!00$R
M,C(@D4A05%1D%JRMJJK"R9,G\=133['M ?WG16=G)SHZ.B"3R2"52BUFF>GU
M>K2UM:&]O1V7+EW"Q8L7<>'"!0#]DQ>9S+;!B$0BMNUITZ8A/#P<DR=/QJ1)
MDQS*$"TK*\/!@P=QZ- A& P&]OM(9V<G0D-#+8X9\%,P=J@Q4R@4.'OVK,-C
M9DRCT:"GIP>MK:WH[NYFLU>O7+EBTUK'0J$024E) /K++C_PP ,("@K"O??>
MZW FMK$WWG@#FS=O9O\_G/<))L/[N^^^0W=W-\Z>/<N6>:ZIJ6'7)AU,9F8F
M)DZ<"*!_3>F@H"#,F#$#/![/XEB7E95AT:)%J*BH0'AX.)*2DA :&FKQ7%B]
M>C66+U^.[NYNIYP+0']&MUZOQ]FS9R$0"$PNZOO#]S)BKJ>GASU_@H.#D9N;
M"ZU6RY9Y%HE$)MLSKWGCK& &E\MEVQ*)1)@W;QZ GTI& [ ZR3TY.9D- +_V
MVFO8N'$C^'P^-!H--FW:Q&XW5)ET0@@AA!!/"PD),<D.)L-C=P#XWGOOQ8$#
M!_#88X\-^^#-S<UX\LDGA]T.\1ZC1HUR^Y=;XRSRF3-GLE_4;]Z\":U6"ZU6
MB[_^]:^HK*S$<\\]A]FS9SME H.O\/4L8&_*8O 78\:,H0 P(1Y 06!"R%!^
M_>M?X[///L,]]]R#GIX>'#AP &*QV"S8I=%H4%-3@_S\?'"Y7*Q;MPZG3Y_&
M@@4+D)65A2U;MF#6K%EF ;SR\G*S"DQ,D&K)DB5(2DI"4U.3U?YQMR,!(P
M( !)1$%4N5P(!()! YV6,EE<,:F!F02JT^FP?/ER?/+))P" N^^^&P4%!6;!
MT,;&1F@T&I,Q.WKT*!Y__'$VX'?//?=8'+.!DY;M&3-CS+A9RIC?O7LW]'J]
MV80*5Y=GU6JUX/%XV+=O'YYXX@DV #QERI1AM1L2$H*0D!"[SI7-FS=CPX8-
M#A]ST:)%X//Y" \/!P"\^>:;4"@49N>"2J5">WN[284IH5!H][DPL/^3)T]F
MS\N!AK.\#_%>?#X?F9F9D,OER,O+0UY>'I*3DQ$>'@Z12(3GGGO.9/N:FAH
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MOGT[5JU:A8\^^LCDVN&)$R>@U6HQ:]8L1$5%8>;,F5BW;IW5BE7$NS@4  :
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M)24%[>WM" \/9RL//O/,,XB(B,"E2Y>0E)2$CHX. ,"++[[HR:X3&SD<  :
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M974BM5*IA%*IQ+9MVY"3DS-D6VJU&FJU&A45%3ARY A"0D(<[E='1P<.'#B
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MW.\F !'?P01M)DV:A.CH:)<?CY81< _C(-I0C+?QY0#1G#ESA@R,O?322P"
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M$HF$O< M$HEP]]UWX__^[_\  %]__36*BHJLKFE';#.P*H7!8& SC7;LV $
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MXY&:FHISY\[AP0<?]'1W7,H=I:")ZSA[\L-((Q (4%%1 9U.AY"0$&@T&C8
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MRG0U1Q46R$AE2XEY0MR%P^&8_%BZS]+CD9&1B(B(P.+%BQ$;&XO%BQ=;W!8
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MNBF$$$)Z,4='1T1'1W?XW">??*+T_UV[=K'?,Y,?SYT[A]345-R\>1.!@8$
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M+M>AUX:Y<^?J]/B$$,+@\_FTWF\OH+4 <%?!@M]^^TU;I]&*YN9F-#<WT_K
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M1)$A2H0W-S>SY[6PL- H$YD053Q]^M3032!$KU2=8$*(,4I.3H:_OS\$ @$
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M&C4*T='1D$JE2$Q,U/GY .#APX< E/O:E?KZ>@"&N1:(<9')9+A^_3HL+"S
MX_%@:VNKEY^3_D@JE:*AH0&/'S_&U*E3#=T<G<G*RH*7EY?&?[,(Z8A$(@%
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M#ETVG1!"2"^D<@!86^O>VMG9:>4XAC)X\&!LV;(%H:&A&K^QUX;&QD:8F)C
MQ,3$T$TA;3QY\D2C_2=-FJ2EEFB?8A"XMK96X^,U-S>SDQJTO<8VLY81T1R-
M)2&$$$5<+A<"@0!2J=3032%:-G?N7-37UV/SYLUL2><! P8@-C86 H$ 9\Z<
MP9_^]"?P>#S<N'$# '#__GT [==MM;2T!- :W!LT:!"&#Q^.%2M6X,R9,^#Q
M>#AW[AQ&C1H%9V=G//OLLP@,#,25*U?@Z>F)L+ PI*2D='JCTU@-'#@0HT>/
MQMZ]>S%GSAR8FYOC_OW[2$Q,Q-JU:W'FS!DL6K0(IJ:F2EFQ4Z9,:;>F-A-8
M7[AP(>[=NP=[>WM\\LDG^.BCCW#OWCU()!),G#@1CQX]PNNOOPZA4(AKUZYA
MZ=*E" \/1VIJ*H*#@W76UQ=??!%-34W8NW<OQH\?SP:^KUV[AK5KUV+?OGUL
M2>___O>_['X3)T[LLJ_U]?6PM[?'!Q]\@'?>>8?M*Y.UZ^_O#U]?7UR[=@T;
M-FQ >'@X,C,S==I7TC<PY<O'C!F#LK(RS)DSA];-U!)75U?4U=5!+!;CA1=>
M,'1S#"HS,[-7)\ 0W9#)9!U.GLS.SH90*%1IN0$NEPNA4*CT_H&1GY^OE76%
M"2']ATPF0W)R,I*3DY&>GM[M]E*IM$?+.DHD$J2FIBH=)R4E1>WC$/6I7 ):
MD[(R?8VMK2T^^^PS'#IT"!LV;-!ZP$I=3&8VE84V+DQFJ[;*&UM86+0+]/-X
M/*5_]<G-S0U5554X<.  WGWW7;5_#CP]/57:KK-RZXI_-+K2E]9B)H000HP-
MG\]'0T.#H9M!=&CDR)&PLK+"^O7K$1H:BLN7+R,C(P.1D9&8/W\^8F)BE-[7
MR60RQ,;&HKJZ&F%A8>SCEI:6$(E$^/KKKQ$1$8&(B BL6;.&+>V<F)C(!HN!
MUHG#GW_^N?XZJF4U-34 6@/?B8F)^.FGG_#YYY_CTJ5+.'SX,,Z?/X\%"Q8@
M)24%?GY^['Y2J131T=%L.6?&V+%CL6'#!HA$(H2%A6']^O6(C(QD Z*K5Z]F
MRS _>/  7EY>6BW[K I[>WO<O'D3Y\^?ATPFPZ5+E[!SYTY<O7JUP[Y*)!+$
MQ<7!QL9&Z5I1[.N6+5NP?OUZ1$='@\_G0RZ7*_45 ,:/'X^WWWY;KWTEO5=M
M;2V"@X-17%R,J5.G8O[\^89N4I_RRBNOL+_+ERU;!HE$TJ.RTGW!Q8L7:3U@
MHN32I4M*_W_Z]"FBHJ)ZM,R%JZLK$A(2D)R<K/1X04&!5I;-((3T#U5554A+
M2\/RY<OQ_OOOX_CQXUW^W?[AAQ_PP@LOM)O(V994*E7:IJBH"(<.'8*MK2V<
MG9WQTDLO8=:L64J?#8ANJ!P UE9@L:\$*&?-FH6"@@*</GW:8.L!MZ58%KJO
MC'-OI\T L&+V9=N KZ%NO'IY>:&RLA*'#Q]FR_^I@YE9Y.OK"V=G9PP>/!AY
M>7E*VZ@:Z"7ZH<UKFA!"""'&:?SX\2@N+L:Z=>O0TM*"^_?OP\;&1FF;D) 0
MC!T[METFRY$C1Q ?'P^I5(JFIB8L6+  0&M0<L>.'=B\>3/L[.R0GIZ.J*@H
MI7V=G9WQV6>?X>NOO\:^??MTVTD=6KY\.=S=W3%BQ A45U?CSIT[2F5:W=S<
M\-)++\'9V1D???21TKY[]NQ!;&PL1HT:I?2>_\<??T1>7AY"0T-Q]>I5O/?>
M>^W.6UY>CG7KUJ&XN!CCQX_770<5S)HU"V^]]1:LK*Q04U.#7W[YI5U?%R]>
MC+%CQ[;K:TA("-+3T^'HZ @S,S/V\8[ZVK:_UZY=TWM?2=]P]>I5_.$/?T!=
M71T T/6C99,G3T9N;BY^^>47O/+**R@J*NJW 6" U@,FRIC?.PP3$Q.L7[^^
MQ\=;OGPYSIPYH_38[=NW>WP\0DC_Q,0<QHT;ASMW[B M+0U55568/W\^JJJJ
M4%A8B%&C1N&MM]YB]\G)R<&WWWX+1T='A(6%X1__^ ?R\_,Q;]X\/'SX$!D9
M&1 *A0@,#&3W6;)D"4)#0S%Y\F2\]MIK[+$/'CP( /CBBR_8]_RVMK8(#0U%
M3$P,^QEGQ(@1V+=O'Z12*=:L68.;-V_BTJ5+F#MW+IY__GDD)26Q[=;W1%AC
MIO=W(HH?['J[5:M6(2,CP^C*WC'!W[XTUKV5)H'XKO9E KZ=!7XM+"S X_'
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M^]RY<ST^'B&D?[IV[1I.GSZ-YYY[#O;V]CAQX@16K%@!*RLK'#Y\&$N7+@4
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M=$Q;KR\AA)#.965EX;GGGC-T,P@!T%H*K*ZN#M]]]QWD<GF'V\3&QB(Q,1%
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M8R,X' YJ:VMQ[MPYE)>7H[Z^'MNV;</(D2/A[NZ.M+0T'#MV3"L3:OHJE=8
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M98CI:U14%#NAH&U?UZU;ASMW[N#QX\=X_OGG]=P[W2DI*4%J:BI.G3JEU\^
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M.T)#0PT_>0,:3'E^8_<&9D6O_QD^?#B2DY.Q8<,&G#ES!L[.S@8[L2 ]/1T
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M^>?QZJNO KA=IE8H% YH++%8C.>??Q[Y^?D(#@Y&2DJ*9D4UF49)20D6+%C
ME?]6(# P$%>N7,&N7;NP:=,FK>O"P\,1'1T-B432XVW]_/Q05E:F^=['QP?O
MOOLN2S\3$5&/= J +U^^?'OC8<,L_@Q&(B(RK7'CQN'EEU\VV_WW=19L>WM[
MG^%S6UN;07NR_?O?_]:L)"#;T%^9+:*A*B,C ]'1T>:>!A&1Q=+EY&]+.$'<
MDD\T-0:12*3Y>N/&C3AY\B06+UZ,%U]\4:]Q$Q(2\/;;;^/X\>,X??HTZNKJ
M(!:+!SR.^OGH[WG1=;O^B$2B;JL,!RLH* A965FHK:U%4E(25J]>;9!Q27?'
MCAUC*QLK(10*L7'C1L3%Q4$NEP.XO4BF\VM43T)"0E!65H:8F!@L6[8,RY8M
ML_@^XT1$9#XZ!<"__/(+?OO;WQI[+D1$9&7L[>WAZ.C8Z\&-_LK>VV(_[,$<
MZ"$BLB8*A0+IZ>DH+"PT]U2(B"R6+NV?!AO>=:U",UB6$$";RYMOOHGOO_\>
M*I4*CSWVF-[C/?;88Q")1 @*"L+V[=M15%2$^?/G#W@<]7/;WW.LZW:FY.OK
MBQLW;B E)057KEPQ]W2&+&NMOC54"02" 1U#2$A(8&EU(B+2F4X!<%55%29-
MFF3LN1 1T0"I ]C>&#N ;6MK8V4((J(A9OOV[4A(2.!J R(BLCHRF0QCQXY%
M>'@X7GKI)<R;-Z_?%7>Z&C%B! !@\^;-B(F)&7 995L@D4@P;MPXU-?7X]%'
M'T5Y>3G;19C8V;-G$1P<S!/U;-10?%TA(J+!TRD ELOEF#U[MK'G0D1D=1C
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M_.$/.'+DB,ZA8D_;Q<?'H[*R$@L6+,".'3M05U=GT2UM3"4A(0%+ERY%0$!
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M& L6+,")$R<0%A:&Y.1DQ,?'(SDY&3*9#"$A(0;99XB.CH9$(D%Q<3$.'#@
M %KC9F=G(S0T%&%A8<C.SL:)$R>P9,D21$='XZ&''M)D.>J3T;KNQZG'W[ES
M)Z9,F8)ERY8A)25%ZS[R\O*P>_=N^/KZPL_/#P</'H1 ($!Z>KHFY!ZH]/1T
M'#MV# X.#IH3YQ,2$I"4E(2=.W?"T=$1965E\/3TQ,LOO]SO>,[.SIKG;L*$
M"5K/QT#<T?\F1.;G[.RL^2<0"+2^[^\#=4M+"QH;&S7_5"J5UO=$-/18>O@+
M %*I%%E963K],]=C8/AKF91*)=S=W<W:^[>K<>/&H::F=I+!OP  ( !)1$%4
M!JVMK>:>"NFA<R\[E4IE[ND0$1$-F$PFP]BQ8[%DR1)-6&E)JRC5 7)_0;*N
MVYG2W+ES\=>__A6'#AW"FC5KS#T=B^+KZXN(B BDIJ9VNRXA(0$[=^Z$3"9#
M6%@8Q&(Q,C,S^QQ/U^W(\A04%&A6[:I[:O<E/CY>\W5Q<3$D$@G#7R+JDT@D
M0FAH*+9NW8I%BQ;UNU)4+!9#+I<C.SL;O_WM;WM];TE)28&=G1WL[.PT)9KU
M,7;L6$U+#O6XV=G9\/?W1V9F)OS]_36EIP," C1S]?7U16MK*Z*CH_'((X\@
M.#A8:]SWWW\?&S9LP#???-/K\=+JZFIX>GH"N+U@X=JU:W!R<D)T='2W-A>Z
M4"J5*"HJPK9MV^#DY 3@=CEMN5R.K[_^&BTM+?CWO_^-I*0D?/;99SJ-N6+%
M"J2DI.A=3<ARC@R23>M<1AG0+J7<7QEEH/]5ND1$NK*&\!<  @("++JO$\-?
MRW7ITB5X>'B8>QI:A@T;!G=W=_S\\\]:O?/(<(J+BQ$4%(3Y\^?#SLX.APX=
M0EA8F,'O1[U2)3<WUZ)?HXB(B'I26UL+'Q\?_/SSSUBQ8@4>>. !<T_)9@@$
M DBE4AP\>!">GIZ8-&F2WGWP;$E<7!R"@X.Q?/ER^/KZ:B[O?(+=OGW[D)B8
MB.#@8,R>/5MKNZYT+1E-EB4]/7U V^_?OQ\RF0R-C8T("@KJ<UNI5#KHE6M$
M9#L4"@7^^<]_XI-//D%;6UNO*X#5KEZ]"GM[>U175R,Q,1'??/,-E$IEMTJ#
M4JG48%5# *"NK@Z>GIZHKJ[6JFA27%R,/7OV:,KE1T='HZ*B F*Q& J% M]]
M]QV&#1N&]]]_'ZFIJ9@T:9+6N \__##"PL+Z[)/KZNJ*^OIZ"(5"7+ER17/Y
MLF7+$!P</."*>O7U]1@]>C2$0B$\/3TQ>_9L'#QX$//GST=Q<3'NOOMNA(:&
M0B@4PL?'1Z<Q)T^>C-#04)P\>1)SY\X=T'PZXPI@THF#@T.?JW [A[L]:6YN
MUEIUV]34I/F:)9:)R%2L)?RU= Q_+5=K:ROJZNHLLM3RF#%C<.G2)7-/PV9=
MOGP965E9.''B!"HK*Y&?GV^T^XJ)B4%24A)7 1,1V0#UBHO>_MF:'W_\$<\\
M\PPN7KR(.^^\T^*",U.7@#:T@(  3)TZ%=75U7CII9?PW7??F7M*%D,@$&#W
M[MUX\LDGH50JM:X+"PN#O[\_/OC@ ZWM^MK7$@J%2$U-9646*Z)2J;KU_ 6
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MG)R<V+ES)^W;M\?4U%2:GX.#0X6_@[BX.,:,&4-L;&RE*SAJQMVT:1,M6K3
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MEY<GE37V]O9FR9(E):IZ1$5%\?'''TL]''U\?#AQX@2OO_XZF9F9K%FSAL#
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M*ZD_6576$00H[ /<HT</[.SL>/CP(7?OWB4N+HX6+5K0MFU;+"PL,#,STUE
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M)B9$1$1P[=HUNG3I H"1D1%;MV[E[-FS^/O[DYN;RX0)$[2^KS=OWF3/GCT
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M^_OCZ.B(0J'@[-FS)"0D\.#! WQ]?=FS9P^M6[<F.#BXV%PJRFJL#IE,1D!
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MAS,AL9]'C)7T5:O5)@<8V'*!P,A98U.F3,&:-6L  %%149@S9PZ^_?9;DQ<
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MA."%%UZP^%BQL;$("0G!IY]^BMC86(/%9=[>WLC/ST=V=C9*2DHL/LY$,SC
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M8\^>/08!Y8J*"@H $T((X=BEWK*+B\N$#?X.QC ,%\@3" 1P<7'1NS\Y.1D
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MP]UQ8' PF)66EH:__.4O5OL@<O[\>30T-$S8#_ 3J8=N=W>W7N8#G\^'0"
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MN'W[-G[^\Y^CO+P<*2DI4*E4F#5K%BY?OHS&QD8L6;($"0D)\/7UQ?SY\P&
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M(0H"3P#=W=VHJZN#1J-!1$0$_/W]37ZL;A#8Q\?'XJS5.7/F8-^^?68%_=C
M7E]?'ZY<N8*PL#"\\<8;!N>J;A#XK;?>LB@(_.VWWR(Z.MKD[8UA@[_1T='#
MEGB>/GTZ?OC#'T*E4J&ZNAI^?GY8N'#AB 'YL:ZNKH[[__???V^5?2J52N3F
MYB(L+,QJ 64R/-W?/_;BOBDN7KPX8KE-M5J-<^?.X<Z=.WCUU5>=-FB@5"I1
M6%B(SLY.O=ME,AFWD$0FDP& T=+%UIPWM5J-+[[X @"<>LZ,81@&APX=0G-S
ML][MQN:QO;T=/CX^>O.IU6I16UN+B(@(DX[GS'/#X_%P^/!A+%VZ=,3?$]U%
M&*8:JH2V+CZ?;W#;P8,'H5 H()?+*7-KC!OJ-4?W]6BDUZ;!%85&>ATS=3MS
M7A,)(?81$Q.#H* @/'SXT.)KX,G)R=BV;1N56R>$$#*D40> K5WZF0QOT:)%
MV+]_/[JZNN#IZ<G=?OWZ=00'!\/7UW=4^]<-LHVW8'!*2HK5^@X2Q^ON[M;[
MGK*$B3-9N' A ' 9> 4%!10$'L>N7[^.JU>O8L&"!1;WGM4- @.6]006B\50
MJ51F]23,S\]'7U\? (P8X&.#P+&QL=BQ8X?90>#BXF)LW[[=I&V-,37XJRL@
M( #^_OZX>O4JRLO+,7_^? 0%!5D\!F>E5JO1U-2$S9LWHZ&A 2*1R"HEH&MK
M:[%QXT9(I5*N1R6Q/4NK\D1$1(P8@-N_?S_FSY]OM04"MJ+1:+!UZU:C][$!
M2Y:Y@;K!1IJW_?OW0R02.?V<&=/>WCYDUOC@>61+/5=45.C=;FKPUYFQ_:"7
M+EV*O7OW8M>N7<,&6RW)Q!T\;^:@LL_CPW"O([KWF5K:V=I,V2\%B0FQ+Y%(
MA)*2$A07%Z.PL-#D0'!R<C)24U.Q=NU:NKY ""%D6$Y; IH,+2$A 0J% LN7
M+^=NNW3I$B(C(ZUZG,'!X,&WC3745WI\HRQAXDQ$(A&*BXLAD4@@%HLI"#Q.
ML5F_O;V]B(N+TUN890E/3T]$1$3@XL6+\/3TM&A_J:FI^,<__F%2L*Z@H #_
M^M>_  #+ER\W*;LS)B8&%145R,S,1&QL+"02"<K+RT<\IY5*)50JE<6KTYN:
MFJ!2J8;LISP<5U=7+%FR!"*1")<O7T9+2PO"PL)&_?-R)@*! 'P^'R^^^"**
MBHI&?3&(81CDY^>CI*0$!PX<H*P"![)U2>?Q>K&?2D!;+C$QD?O_>#N?V&"V
M7"ZW^KX3$Q/1T-!@4L]E,CXY^_E/"'%>$HD$$HD$2J425ZY<P:E3IPRV6;QX
M,6;.G(F%"Q>:W8J'$#+^Z;;#&8JCWZLX^OBV8HWG9<VY.7CPH-[WHVJTZ^;F
M1D$U!P@)"<$___E/O=M.G3J%^?/GV^R8NL$U-S<WH^6KG!WUE9YXNKN[]8*_
M?#Z?NTA.B*VQ0>#WWGL/E965D$JE" L+PZ9-FZCG^CAP[]X]E)>78]JT:8B.
MCK9:,-'?WQ]+EBS!F3-GN,Q<<Z2DI*"@H&#8<ZRRLA(\'@]'CQX%,!#\G3IU
M*@H*"M#8V(B=.W>BMK86#,/@Y,F34*O5R,[.QLZ=.W'RY$D$!04A)R<'%145
M6+1H$81"(?[C/_YCV'&5E)18G$&J4JEP[=HUK%JURJ+L:M;TZ=,1&QN+6;-F
MX<R9,VAJ:K)X7\Y&(!! *I6BO;T=5555B(N+0V5EI=G[81@&Q<7%B(N+P]2I
M4U%>7D[!7P<0" 1<II:YF6!:K5;OL8._*BHJD):6QBT<-;:-/;]TGZ/N[1<O
M7C3Y.?_I3W\" !05%>G-@R7S-G@L /#EEU\ZU9R9,X\M+2TFS\&O?O4KF\ZC
M,\Q19&0D]NS9,^(\FC-O[+9%1464R3N!.?K\MO;O"B'$,40B$1(3$Y&7EV?P
ME9J:BL3$1 K^$D*,*BHJ,NGS@B/?7SCZ/8ZS/B]KS4U65A;2TM(,SHU11<1L
M71HX)27%IOL?JT)"0G#\^'%T=74! -K:VN#CXS/J\L^FZNGI&9/!X'OW[CEZ
M",3!>GM[P3",7J:P4"@<]STAB>.P0>#,S$P* H\C]?7UN'CQ(J*BHC!__OQ1
M!26-"0@(0$!  ,Z?/V_V8T4B$>+CXW'\^/$AM]F[=R\6+ER([[[[#I,G3T9*
M2@I.GSZ- P<.8,^>/>CL[,1KK[V&W__^]UBS9@U.GCP)F4R&MK8VG#MW#A*)
M!-]__SV*BXMQ[-@QK%NW#K___>^A4"B,'D^M5B,C(P,OO_RRV<^GJZL+%RY<
M0%14E-6"[//FS<.J5:MPX\8-?//--Q8%VIV5M[<W\O+R<.3($<AD,NS<N=.D
MQ]76UJ*@H !"H1 JE0HG3IR 5"JE:@5.PIR+\CP>3Z\GY."OV-A8R.5RU-34
MV'+(HQ8>'C[B!]RTM#2\^>:;.'+DB-%]F#IG@/Y<Z7X/ &O6K!D3<V:,2"0:
M<1[??/--9&1D#/DWQ]R+%\ZLIJ8&&1D91G\W='_V@8&!)NU/J]72A7A"""&$
M$$*(T[(X &R/H-]XZ3UK;>[N[OBW?_LW+J!Y[=HUQ,3$.&0LNL%@@4  %Q<7
MAXS#%&?/GG7T$(@3TF@T>OV$*4N86!L%@<>/OKX^5%14X/[]^WCNN><P??IT
MFQUKP8(%Z.WMQ?7KU\U^;%I:&C[\\,,ASZ]GGWT6]^[=PZU;M[!ITR:(1"($
M! 2@I:4%GW_^.7Q]?5%75X<#!PX  #[XX ,L6[8,'W_\,:Y<N8*:FAHL7;H4
M(I$(/_G)3_#UUU_#R\MKR OF^_?OQYX]>X;MMVA,7U\?SIT[AR5+EEA]KCT]
M/;%Z]6H(A4*<.G6*ZP_I+(8*2HP4M.#Q>"@H*$!H:"A*2TNQ=>M6H]L"P&NO
MO8:$A 3P>#SLW;L78K$8[>WMD$JE9O^LB'V8LW+8E.U-#=BIU6H4%!2@H*!@
MR(4>CB"7R^'IZ3GL\QCM"FQC^[ 4PS H+"SDJBPXB_W[]X-A&+LM)AXMW7DT
MI]*!-7[V8RW@30@AA!!"")G8+ H \_E\N_2"I0#,T.;/GX\;-VX & @ !P0$
M.'A$ Q_&V9+@SAX,)F0HQK*$W=W=X>'A0><TL1@%@<>^OKX^5%55<26?K9WU
MV]'1@8Z.#NY[5U=7A(6%H;&Q4>]V4XC%8J2FIB(_/]_H_6EI::BLK$1[>SO$
M8C$4"@7>?_]]='9V(CHZ&ILW;\;Z]>L1'Q\/ ,C-S<6%"Q?0V=F)+[[X @</
M'N3*1Q\Z= AGSYY%;6VMT6S1VMI:E)24X(TWWC#K.0# ^?/GX>OKBZ"@(+,?
M:PJV-W!P<# N7[X,E4IED^-8PMR20,! R:?DY&04%A:BHJ("65E9!MOI!KKY
M?#[W=\V6BQG(V,8P#)*2DC!UZE0$! 0@-#04:K7:T</BE)65(2HJRM'#,,FF
M39N@5"JQ8L4*;-RXT6F"Z9&1D:BKJT-86)BCAV*2;=NV<?/(OJ\BA!!"""&$
M$&+(HJN7]@C^ E2R=SBS9LW"UU]_#0"HJZO#2R^]Y. 1Z6,#&BXN+G!S<Z,
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M)X//Y\//SP]U=77<-H/G\>#!@Q (!(B+B\..'3O0TM*"^/AX%!45X?///P<
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M'8V+%R^.=E@VI5:K32ICOF[=NB$#<>R\C31G%R]>'#:K>?_^_9@Z=>J87.S
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M6H000@#8IYQS:6DI]N[=:]9CDI*24%-38W"[7"Z'7"['KEV[] *TN@H+"P$
M"Q8LP(X=.[!UZ]91!<8*"@J,ECDL+2U%:6DIBHJ*()%(+-Z_-5$Y:.N;/GTZ
M_/S\T-C8B/GSYSMZ.$;5U]>#S^<C("# T4,Q&9_/AUJMQO3ITQT]E"%U='1
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M/KUMQ&(Q)!()]R46B[G[=&^/B8F!1J/A[EN]>C7"P\/QS#//0"J58L>.'0"
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M6'9VMMC_=_SX\5 H%% H%+"UM17W.7;L6(>?T\_/#QD9&<C-S<6^??O$,M0
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M-JB;GIZ.__[WOZBIJ4%<7!Q*2DJ0DI*"]/1TR.5R1$1$X/;MVP@/#\<++[R
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MO3U\?7U;G.N\>?/PY)-/MCC7TZ=/HZBHJ-%<<W-S45E9B7GSYJ&\O!QJM1H
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M1D-JM1H*A0(>'A[XY9=?<//F39P\>5*_DVG%O__];PP=.A0'#QYL=JZVMK8
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M" @(@%JMQN+%BU%65H:[=^]BV[9MW3RK[K-KURXL6+  &HT&RY8MP]=??XV
M@  ,&S8,@B @(R,#UZ]?!X F2V;'Q<5AS)@Q>.JIIS!__GS(9#(HE4HL7KP8
MIJ:FD$@D^.M?_]K=TVI2='0T7GKI)0B"@#ESYB W-U><:V1D)/;NW2ONV]1<
M/_WT4XP9,P93IDR!O[\_9#(9LK.SL7CQ8IB9F<'2TE+L*TW=:^K4J=BT:1.\
MO;T-/12B/D^I5"(Z.AK??OMMHVUQ<7&8,&$"PL/#L7KU:HP?/QZ//?88 .#
M@0-0*!18N' A'!T=,7+D2!07%Z.JJ@I3IT[M[FD0$1&1@;$$-)&>L)PS$>D+
M@[]$1-2='!P<L&3)$E175^/JU:M8NG0IWGKK+;S\\LMX[[WW<.K4*<3'QR,T
M-!2YN;G0:#3B?P!04E*"1QYY!(\\\@@^__QSO/[ZZY@Q8P9NW;J%BHH*C!PY
M$O[^_@:>I?[,GCT;8\>.17EY.8J+B^'N[HX-&S9@U:I5F#=O'BHJ*G#JU"D
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MQQ]_;*!9$!%U#T$0L&+%"NS:M:O1>V/#P'!+^S5UOK___>_Z'CH1$1'U4 P
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MV+%CH50J86MKBYT[=XJO :#YN6[9L@5I:6FX>?,F9LR8@94K5R(K*PL[=NR
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M+8U775WMZQ!$1$2D!=%-?W(E&GH#0DMMX5Q65N;K$$1$1.0::E "N+*RDH"
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MN(;'XZ%=NW:^#D-$1$2DQ9@Q8P8Y.3FJ+! 1:0$6+5K$J5.GN/'&&UFX<"$
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M_/W]?1V&B(B(2+-E,!A(2DJB?__^F$PF;P6:B$AKXG X6+9L&2^\\ (S9LS
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MA(>'DYN;R[)ER[COOON\GVTB(JV-6D&+B(C(I2@!?!4I"2PB(M(PHT>/]E[
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M:;5N)C(8#'SSS3<,&C2(@(  3ITZ1=NV;4E)22$E)07XOWG2GWSR23ITZ,#
M@0-9M&@15JN5'3MV\.JKKY*7E\>,&3,P& RDI:7QX8<?<L<==[!APP8L%@LV
MFXV//OH(L]G,PP\_C,%@\-YX,V;,&!8L6,""!0O(R,AH\.=/>'@XRY<OI[2T
ME%&C1M6[;5)2$E555<R?/Y^C1X_6:1U=HZ;=<VYN;JU$=4/.ZZ9-FUBP8 %F
ML]G;7>/\US,R,KS/R\K*" L+8^K4J:Q>O9K P$!FSIS)5U]]Q>3)D[GIIIN8
M.W<NIT^?9MVZ=4R:-(EGGGF&X\>/>RN*ZQ,9&<G9LV>IK*RLM=QL-K-TZ5*>
M>.()7GOMM08?EXC(]4*MH$5$1.1"2@#[0%55E9+ (B(B#>1P.(B+BZ.JJHHO
MO_R2#ATZ4%E9R;!AP]BZ=2O_^9__2=NV;>G6K5NMB]TVFXW^_?M35%1$45$1
M/7OV9.?.G?CY^?'YYY]37E[.WKU[>>NMMQH\-Z.(B#1O+[[X(F?/GJTS9[G#
MX2 _/Q^'PT%V=C9FLYF8F!C"P\-9OWX]145%V&PVC$8CSS[[+)LV;>+MM]\F
M-S>7U:M7\\DGGS!UZE3R\O*\B<Z77GJ)-]YX@R^__)*GGWZ:08,&L7?O7CP>
M#U5553S[[+/T[=O76_$;%!1$>GHZ#H<#J]7*RI4KL5@LEST_\/F)8+?;S9HU
M:_X_>_<?UG2]/G[\B88U)$\.*#- 4YM6J&B"%!IHAJ*>(%!+)# %CRGP$9-)
M0$F&A- !#TQ3P1],4CO$A+1 ) .5#@HIFB7.7XE+*V"B(?-(QO</KKV_+E"Q
M8_GK];BN71=L[Q^OC6UO?=VO^[[)RLKBX,&#%!45F5P3U6HU.W?N9,&"!5)@
MNKVN?&TT&DV;&;:G3IWBQ(D3 +S]]MN\__[[].G3AQT[=C!]^G0>>^PQYLZ=
M"\"($2/HV;,G!04%1$9&\N:;;_+RRR\S?_Y\J17#M30U-:%6JWGCC3=,GD=Z
M>CIN;FYLW[Y=*OTM"()P+Q'!7T$0!$$0KB0"P+>(" (+@B (0ONL6+&"[[__
M'BLK*WKW[LV.'3MH:&C W]^?:=.FL6;-&AP<'"@O+^>++[Z0]CMZ]"@G3YZD
MO+R<B(@(<G-S.7KT*!<O7L3+RXOJZFJJJZM9NG0I__K7OV[A,Q0$01!N!KU>
M3WAX.)F9F:UZ[28E)3%BQ B<G9T)# Q$H]$P:]8LZ7%75U=<75TI+2UE^O3I
MN+N[\^NOO_+EEU\2$A*"0J%@].C1#!DRA D3)E!45,2,&3-P<G(B/#R<W-Q<
M-F[<R*E3IUBT:!&OOOHJ%145C!X]FD6+%DFEFJ&EU4%N;BX:C09_?W\" @+P
M\_.[H?[ 65E9E)65 ="Y<V>.'S^.N[L["H4".SL[U&HUE9657+AP@<Z=.W/^
M_'D6+U[<KG,8:;5:,C(RT&JUQ,;&2CV(C70ZG10,OGCQ(F%A80P8,("GGGJ*
M2Y<N2:]I>GHZY>7E=.O6C1=??)$=.W9P[-@QMF_?3N_>O8F+BR,D)*1=P5\
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MO=,%01 $0;B[B0#P'>S2I4MT[-B1RY<OW^JA"((@",+_1":3X>7EA5*I9.#
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M)(3$Q$3"P\.OVC-5$.Y$24E)5ZV&9&9F1G1T-,.&#</,S*S531 $01 $060
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MN7/GV+]_/] 2D/7S\\/3TY.$A 3L[>U9MFS9__PY-0H/#V?"A DD)24Q<.!
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M,T.E4EWU<V4L QP;&TM$1 2)B8DWM=>X\.?1:K6\^.*+^/KZ$A@8R+???DM
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M]]UW3;8Y=^X<"0D)%!864EA8R+%CQV[1: 7AC]%JM<3$Q.#FYD9)20FAH:$
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M_/(+&S9LH%^_?I24E.#L[,R2)4L(#P\G(B("1T?'/_*C$JD'-4)P?GZ^,%G
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MD7\6H@ L4@M1!!81$1'Y9W/DR!$2$A* ZEB]+EVZ$!45A;>W-ZZNKG3ITH6
M@ !FSIPI1!=+I5*:-&E"UZY=A7I3#1HT(#$Q48PY_3^RL[/YX8<?7KJ^0X<.
MG#Y]FE.G3O'>>^\!</7J5=JU:T=E924 8\:,P=75E7W[]C%X\&!\?'QHV;(E
MK5NWYLB1(S@Y.:D,.DZ=.I5WWWV7A@VK;^GV[=OW)QZAR#^9&O$S.SN;;MVZ
M$1(2@HV-#55559PX<8+ P$"^^>8;H-JA.'OV;(R-C=FS9P_6UM8,'#B0 P<.
M -6#DX&!@5A;6S-UZE3A.R(Q,1$7%Q<F3IQ(MV[=V+QY,P"W;MWBBR^^8.#
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MK[\H!'_[[;=,F3*E5CL+"PN"@X/9NW>OD%(R?_Y\W-S<" H*HF/'CK1MVQ:
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MJ&>G3Y].<G(R6[9LD7*7OO/..WS^^><\^NBCW+AQ X!;MVY165DIY1(V,&#
M #9MVM2DOJK5:G[YY1>C99]^^BD??OAALP?\MVS9@HN+RSUS6[C?\??W)R0D
MQ&B2TY-//DFG3IUP<W.C;]^^R&0R8F)B)%>%T-!0[.WM^?+++VG;MBT'#Q[D
M].G3 "0E)>'HZ,C6K5NY>/$B\^;-JS?U04A(""4E)4#5_6C9LF6<.W>NP5S
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M^@1_+TZ=.E5K,FA.3@Z+%BTB-#04I5(I_7]KB@-)9F8FG3IUNDN]%0@$ H%
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M$"LK*^1R.?;V]OCY^3%FS)A&)[N4E)1(3A@"@4 @$ @>7D0 6/"74E%1(8+
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M8F*S+:OKX\2)$R0G)^/EY852J924]QLW;F3:M&E,FC0):VMK>O;LR2NOO )
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M7GJ&>/[YYQOMSY_AL<<>,RKW[]^?\O+RN]KFWQV%0L&Y<^>:I*2MB9F9F5$
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M,]'K]=*]+B(B@E:M6O'ZZZ]C:VM+>'@X-C8V+%FRA*E3IS)LV#"42B4S9LQ
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MW$E$ %CP0%-96<DCCSQ"147%O>Z*0" 0_"TX?ORX4?GLV;-20.G"A0L<.'
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MF&CB)2#)7-1="P*I9 VS1BLOE.Z"?A53-_6+L!O?<#17T61DP4(FZ>(%22'
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MP2"6T!""AP3"PL*(CH[FR2>?9,V:-0P?/OR><*@*Y5A*2DKHTZ?//2-=+=%
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MQ\2)$S$8#%+$OT03]'H]U=75;-RX\9YR_D*#@3\L+ Q_?W_1T;EDR1(V;-C
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M\<47J:VMQ=/3LTTJ*'*Y'&]O;PX=.@0T.$';BH>'![-GSS:YA@6'<D?P\/#
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MOO@BO7KU8MNV;8P<.9+GGGM./(;1:"0T-!2%0D%04%"="VP&@X'77W]=5$N
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M61\=.G0PD9*OO2U\EY241%Y>'@ %!06W<2:-0X@@E?K)IB$Y.9DV;=J0D)#
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M0ZJJJNC3IP_=NG4C,#"0,6/&L&C1(J!Z\E=04""63TM+XX477J!;MVX,&#"
MGW_^&:/12$1$!%VZ=.'CCS]FY<J5=4[@:B/<WS6]89<O7T['CAT;-( N6;($
MI5)I4J:LK(S(R$A.GCQ)OW[]V+)E"V/'CF7APH6\_?;;'#ERI,YCR>5RTM/3
M30QZ!H.!T-!0IDR90DA("&EI:?SG/_\QDZS.R,BHLYTK5JS WMX>!P<'7GWU
MU3KK2TU-%64\A7,)"0DA)R<'=W=W$\.FA"E")'6/'CT8/WX\N;FY)"0D,'KT
M:#[]]%/BX^-Y]]UW24Q,1*E4$A 0P*9-FXB/C\?'QX>I4Z=R_?IUYL^?3T9&
M!D.&#!%5)P"&#1M6KQ$X*"B(H4.',F/&C :=@X2%%(&=.W<V^ORLK*P8/'@P
MW;IU,Y%6KHN:[X#:VS7_*BLKV;=OG[A=555%7EZ>6;F:QZCK^!86%G3HT$$T
M8IP]>Y:)$R<R=NQ8FC=OSK)ERZBLK"0C(X/*RDI^^NDGID^?3JM6K<1%)JB.
M*&[;MBUGSYYE^?+E3)TZM='71Z*:+5NVX.WM34Y.#M.G3\=@,(C7,2@HB/?>
M>T]4&H#J]VQJ:BJIJ:E865F)AMC:U">IG)24Q,:-&W%Q<<'.SLXDBD3H VK6
MEYR<+/8;R<G)E)65B?+\__[WOSETZ%"=N8F%MF9D9#!]^O1ZS]]@,#!FS!@3
MN6F52L7BQ8OO>/2O0$A("#$Q,2;G(.2=3TQ,)#(RTNP9TV@T#!LV#&]O;Z!Z
M =?2TA*Y7&X6F5W3&2,B(D*4^_[RRR_%U"!2!/"=X?WWW^?4J5/B=G%Q,=NV
M;>.''WX X,DGGV3<N'%UYOBMC[H6R24D)"0D)&Z%V-A8%BU:A(^/#T:C$95*
MA4*A8/3HT8P;-PX_/S]V[]Z-EY>7Z)SGZNI*:6DI.IV.'3MV\,DGGQ :&LJH
M4:/JK2<M+8V8F!@<'1V1R62XNKKBY.2$C8U-O4YH0G_W_OOO\^>??P*P8,$"
MYL^?+^YC,!A8NG0I*2DIO/ONN_CZ^IJLIPGLV[>/-]YX@_#P<&0R&9F9F73H
MT(&V;=OBY^>'JZLK5555M&G31AP_">E-CAT[1MNV;4E-3<75U97=NW?CX.!
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M:6DX.#C<5STYJ50J3.!6K5JE)4584E+"IDV;^.&''R@N+F;(D"'8VMHR<.!
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M(BTM3?@=[]BQ@]C86.1R.8\]]A@U-35\]=57! 8&\NFGGS)__GRV;]].0$
M,3$Q8N!#*]FW;Q]2J934U%1V[]Z-M;4UUM;6)"0D"&-"C?K(<\\]QYPY<["P
ML" J*HHOOOA"JRVU6LW4J5,)#@[6>I[/GS^_V5K7ITZ=HD.'#JQ<N9*@H" .
M'3K$O'GSF#AQ(@<.'&#APH7TZ]>/TM)2 *Y<N4*[=NV8,&&"SO;2TM($J>.F
MT-0HKL^5*U<(#P]O_H(U@5*IQ,C(J)%A+B<GAP,'#C!OWCQ>?OEE]NS90T!
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M(B(B(B(B E965G]V%_X0NG?O_L#[ZNOK_Z[]ZR.12)#)9'^I,H*B UA$Y&^
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M7VZ3MMH*T0$L(O(WXN[=NZ(36$2D!319GYF9F6V2%:)2J>C6K1M[]NSY6SB
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M AXU@>J:_91*)49&1L*RKN,5%A9B;F[>:%M-7S37M>&^FFQD8V/C-@WT%AW
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MZ:Q;MX[L[.P6G\\-LPCKJY"TA%*I%!S,;?5NUM?7Q]#04.LS4U/3)K=W<'!
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MM&5KCG>_2*52I%*I3KEF7?3HT8/@X&!&CQZ-BXL+7EY>6O(U-C8V5%55"09
M&QL;TM+2N'+E"J^__KK@E)!()/CX^%!24B(Z@$5:Y$$G$%*IE,# 0!8N7(B/
MCP\I*2F"LV?W[MWDY^<#\/SSSVO5"&Y(6EH:/CX^9&1D$!X>KK5.([&4D)#
MIDV;6+QX,9LW;R8I*8EERY8U*ST+_ZNQJZ^O+TRRDI.3R<K*:E*.2B*1$!,3
M0TA(B!"T86UMS>S9LX&ZC.#$Q$3:MV\/P)0I4Y@[=RXY.3F,'3N68\>.X>SL
M+/2O-4Y8>WM[?O[Y9[[XX@O6KU_?Z+Q24U,Y=^X<=G9VY.?GX^;FAJ^O+_/F
MS6/\^/&$AX?S]==? [JSF$7J:D/Y^_OCX^/#@@4+Z->O'[:VMO3JU8ONW;O3
ML6-'K3J,<^;,(2,C@XX=.Q(6%L;5JU?)S,P4G)(#!@R@7[]^#!PXL$4GB\:
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M.!V;HKR\G(B(",S,S-B_?[_.9ZM*I6+%BA5\_OGG=.S8$4='1Y1*)<N7+^?
M@0-\__WW^/KZ"A+2.3DY@I/KW^@ /GOV+!D9&?3JU8N77WY9^/SDR9,$!P>3
MGI[.BA4KN''C!N^^^RZ//?88:K6:S,Q,C(R,V+]_/\[.SIP^?9KV[=N3GY_/
MCS_^B*>G)YZ>GF1G9].O7S_Z]^_/J%&C!.=C4RB52K*RLA@V;)CPVW_BB2>(
MCHXF/3V=<>/&D9"0H/-WW-#YDY*2TNKKH*^O#]0YD=LJ&,O8V%A+]<3,S*S%
M6J>>GIYLW+B1I*0DQHT;AZ6E)7Y^?N3EY>D\Y\C(2%Y]]56F39LF&&I4*A42
MB81=NW8)DMR:Z/Y=NW8Q;]X\?'Q\R,O+8]6J53@[.PM._8R,##9MVB2T;VYN
MCKN[.[6UM3@Y.;7!5?G[LWOW;BPM+85 F8,'#Y*?GT_/GCW9LV</,IF,PL)"
M[.WM.7OV++:VMFS:M*F1<4\FDY&=G0W4!:AI BZ:(R0DA$\^^83(R$A!C<+#
MPX.M6[<*V127+EUJTL&[8,$"4E)2FAV+^_O[-Y)/;VV-8DW-N<F3)S-__GST
M]?7Q]/1D\^;-.L>T3DY.&!D9D9*2@EPN;^0 5B@4A(2$L'OW;MS<W$A+2R,J
M*HIOO_V6]/1T.G7JQ#???,.4*5,P-#0D*BJ*=>O6 77O1]$9^-=DZ=*E6K5[
M&P:9#!LV#&-C8]1J-1D9&:UJT]K:NLF:UR(B(B(B(FV!)H.U/OKZ^MRX<4-8
M3D]/Y]*E2Z2FIA(;&\N($2.TYA9JM9JTM#32TM(("PNCMK96*/^B5JO9L&$#
M7EY>G#MWCKY]^PIMGCY]6FACXL2)S)LWCX$#!^H<7SDX.! ;&\N;;[Z)1"(A
M+R^/\/!PDI.3[^M\-?VQM+34.D>52L6<.7.(BHJZ+_MN146%5GF<UF!H:,BU
M:]=(34W54E;2E /116UMK=#_F)@8QHP9TV9C0M$!+"+R#^+NW;MTZM2)V[=O
M_]E=$1'YPS T-*1+ER["2[6JJ@H+"PM.GCS9)NT?/GP8!P<'8=G<W!R #S[X
MH$W:?QCDY>5A;6V-OKX^%RY<T,H(RLK*$O[6&,JZ=>O&[MV[V;U[-[_^^JLP
MV-BY<R= JYU&]8WPOX?ZF4_-R3.O7KV:4:-&<?CP89W&1Y5*16)B(K=NW=*2
M9&E(PV,\[(QCF4PF'*]=NW:\^NJK_/+++WSRR2<L6;*$^?/G-]K'QL8&#P\/
MUJQ90_?NW6G7KAWAX>'8V=GAZNKZ4/LK\N^FI*2$4Z=.X>WM+4C CQX]FDN7
M+K%]^W9*2TL)"@HB,S.3+5NVL'3I4N1R.=[>WDR;-HV1(T<*V;^'#Q]NMKZI
MO[\_(2$A0A9A?'P\9F9FK%JUJL7ZC9Z>GN3DY @.4JB3@3I]^C1JM;K)@):P
ML# L+"P$H[NFCK!"H<#3TY/WWGN/$R=.8&]OS\J5*_GLL\^0R^7X^OKRXX\_
M$A04A*.C(\[.SDT&OWSSS3<\^NBC.B6M-9-IC:STRR^_S(P9,S S,\/#PX/S
MY\\S:]8LC(R,^.VWWWCII9>PMK:FLK*2\/#P%B7G_XDH% JM]UI969D@5QX7
M%T>_?OV(B8GAQHT;R&0RWGGG'9YZZBD6+UY,='0TQXX=8_[\^5175S-SYDSF
MS)G#P($#&3-FC-#FLF7+@#K'E9>75XM&@EV[=J&GI\?DR9.%SXJ*B@3#24%!
M09,3^(R,#*T @N:R;1M26ULKC'?:JM9W;6TM!PX<$)Q:5Z]>;53?5Q>AH:$$
M!P<3$A)"<G(R;FYN9&=G-SKOG)P<EBY=*FP;&QN+5"K%R<F)3ITZ\<,//S!P
MX$#:MV]/4E(2PX8-(SX^7KB_^O?O3UQ<'.O7KR<G)X?''W^<OGW[<O[\>4&J
M>O#@P?_*>Z,Y[MV[1VIJ*M[>WG3OWIUOO_T6)R<G*BLKV;9M&].F36/JU*F$
MA861DY-#0$  <7%Q+%^^G,C(2*WO7_,<V[=O'U.G3FU4PZT^Z>GIF)B88&]O
MS^7+E[EUZQ9CQXYE_?KUQ,3$$!041$9&!MNW;]=YG\7&QO+SSS\WZR13J52\
M_?;;6H[8O+P\4E-36U4[;<J4*;BYN0DUX1P='8F)B6GRF2Z52EFY<J5@4-5D
M 6_=NI68F!B.'CV*FYL;R<G)3)@P@1DS9K!ITR:42B5N;FX<.G2(HJ(B_/W]
M>?;99[548$3^FB@4"O;OW]_L-H<.'6KTV>C1H^G4J1/GSY_7<AYK" T-%26\
M141$1$0>*@U+NT"=3:I'CQXL7;H4J%,]\O'QP=#0D#5KUM"W;U]"0T,Q-C:F
M:]>NA(6%\?SSSVO-R64R&3$Q,5R\>)%1HT;A[.R,2J5B^?+E@KK%HD6+V+%C
M!U W?KIQXT:3P9D^/CZL7KV:L+ P;MZ\B:6E)<G)R<)[LGY :GV'K$9J.3L[
MFXB("&[<N(&[NSOV]O:8FYL3&1G)DT\^R?7KUPD+"VLTWM37U\?&QD;K,S,S
M,^+BXKAPX0*]>_?&TM*RD?.V>_?NPM^:OFG4$S62UU.G3F7PX,&HU6JA%G%@
M8*#6ME"GLA@9&4EV=C:EI:5,G#BQ30,"10>PB,@_C-NW;].Q8T?NW+GS9W=%
M1.0/H;JZFALW;@@OSSMW[O#HHX^V2B:D-61E96G5#M.\A/_*T?G3IT\G)B:&
MRLI*CA\_3F1D).O7KR<_/Y^M6[<*1FZY7,ZF39N(C8UM9#C^YIMOA,RBUF!M
M;=VFY] :A@T;!L#-FS=UKM=$#6HRE1\VFD'B_:)2J80LRENW;C5R .?EY6%J
M:BIDL<V8,0,]/3T 8F)BVLSQ+B*BBY*2$KITZ8)4*F7-FC4\]MACF)B8,&;,
M& X=.D15514%!06</W^>CS[ZB,Z=.P-P[MPY'!T=L;&Q0:U6LWKU:A(2$AI)
MOC9DT:)%3)@P05 BN!\,# SP]/3DP($#@IS2Z=.G!8>R+OKV[<N)$R>8/GTZ
M3S[Y)#-GSB0B(@*%0B'45@P)":%GSY[DY.2P<>-&I%(IERY=8MZ\><R8,8/0
MT%#D<GF33NK"PD+<W=T;&7ES<G)XYYUWZ-RY,VYN;LR;-T_+@1$5%<6<.7-8
MLF0)X>'A9&=GHU*ID$JE6O66_FTT5%I8LF2)4$]]Z-"A?/WUU\AD,G[[[3>F
M3)G"[=NWD<OEE)65L6C1(L+"PCAV[!ACQX[%VMJ:B(@(G74TU6HUB8F)O/32
M2\W6D];\OL^?/X^OKZ_PN;V]/34U-2UF@C7,(FM*.AET1XT?.W8,/S^_5CN
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MJ;^_/QTZ=,#1T9'@X& L+"S8O'DS<7%QQ,7%H5:K\?/SP\O+BZ"@(#9LV,"
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M28F.O979HU58 5Z:^N"38UZZ=(FHJ"AAF4*AP,+"XF_QOBX&@$5$_L$\>/"
MVK5K4U96]J9-$?F'TZ5+%[*RLMZT&0*G3Y]^(6?GZ\;<W)SMV[>S9<L60D-#
M*W5"2Z525JU:Q:)%B]BZ=2L/'S[$P\.#GCU[TJE3)VQM;2DK*V//GCT4%!10
M7%Q,1D8&;[WU%IF9F8P9,T9G>UKYUL6+%^/EY?6Z=O4O@Z.CHS Q??Q<:M:L
M&9:6EIB9F7'BQ D +EVZA+N[.VO7KGTCMHJ(/(\>/7IP[-@QU&HUITZ=8L"
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MNW;MPL'!@8$#!W+DR!%^^^TW+E^^3&!@(/;V]KB[NPO7H).3$U.G3F7@P(&
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M%RAWWOSXXX\X.#A@8F)"3$P,F9F9F)F9<?3H46K7KLV//_Y(MV[=6+UZ=85
MC*A6].=#(I$(%>@3)DS@RI4KQ,;&XN'A@4PF$Q0CFC1I0DQ,#&YN;GS^^>=$
M1T<3&QO+R)$CA23DV-A8IDV;QJA1H_#P\!"J0^;-FT=Q<;&.I/G5JU?9M&E3
MM>?KVE8"04%! (P:-8IFS9K1M6M7^O3I0TI*"I,F36+8L&&8FIIR[MPY+"PL
M*KWF;6QLD,ED>'M[4UA82'1T--V[=V?@P(&H5"INW[Z-CX\/]^[=0RJ5"F-V
MZ- !0T-#?O[Y9VQM;87MJ50J#ATZQ*!!@\3GQAM@UZY=G#U[EHX=.W+ITJ4:
M;4/;V_!QI%(I2Y<N?5'S1$1$1$1$WABOHN^NR.M## "+B(CH\.#! ^K5JT=I
M:>F;-D5$Y(UP]>I5^O3I\Z;->*U(I5(<'!P$1[*QL3$3)T[462<[.QLC(R/D
M<CFM6[>F?OWZKZ2:[4FG\^N0^7U=8VJKR:*CHX5EY\^?IW/GSJ]D/!&1FI"4
ME$2_?OV <MEE8V-C @,#L;:VIGW[]C1HT "I5$K]^O5)2DK"W]\?B43"EU]^
MB9^?'Y&1D82$A%!04("!@0$F)B8L7+B0K5NW5CJ>7"[GN^^^P];6EIT[=W+F
MS!E,3$Q8OGPY4JE4J,;28FQLC).3$^O6K7NJQ-73,#0TQ-G9F1T[=I"6ED;#
MA@V9.W<N]O;V%3* M<D9/__\,[Z^OA@9&3%PX$ :-VXL;&_^_/G,GS^?P8,'
M"_U7X^/C*2DIX<"! V*USQM&&_@-#@[&R<F)%2M6" H75ZY<X=&C1^S;MX_-
MFS>S<>-&.G7JA%PNY[WWWN/==]\E*"A()PEB\N3)U*I5BPD3)KR074JEDI*2
M$I1*)=NV;</=W5U'?OS$B1.</'F2<^?.<>C0(5Q=77%S<V/"A E()!*,C(S8
MLV</5Z]>%0)OST,NEW/CQ@TZ=^[,GCU[A.4JE8KP\'"42B7SY\^G;MVZ?/GE
MESJ)"_'Q\8+RQ\6+%\G-S:57KUXU3I0S,C(B+BZ.L6/'\L,//U!04,#Y\^>)
MCHYFY\Z=S)@Q@[*R,LZ=.\?DR9-9M6H50X8,8?CPX0P9,J1&8XJ\>J12*3_\
M\ /_]W__Q^K5JY')9 P?/IR??_Y92)31]M>%\H3"@0,'$A@8B+&Q,6O6K*D@
M5:ZM#IDY<R9;MVXE.SM;: M0TW8 \^?/Q\?'1SB_S<W-=9(:-F[<B$PFXZNO
MON+2I4OTZ]>/D2-'8FMK6VD2T[1ITXB(B,#!P8'OOON.NW?ODI.3P^K5JW%R
M<B(I*8G!@P?3L&%## T-Z=:M&W_\\0</'SZD??OV7+UZ54BN\/?WY]=??T5?
M7Y\#!PZ(JA&O$8U&@[>W-[FYN0#8V=GIG*\O0K=NW<3Y@(B(B(C(7QHW-[<W
M;8+("R &@$5$1"I06EHJ5@*+_&,Y=NP8HT:->M-FO%'<W=T)"@I"I5*Q>/%B
M[.SL!*=7=:N-JLO?H0<PE%>87+QXD9R<'*Y>O2HL?S((YN_OSW????="8XF(
MO$Q.GSXM_-_3TQ,'!P?L[>U)3DZF5:M6=.C0@9B8&"02"3DY.=C;VW/Y\F6L
MK:UQ<7%A^O3IM&G3AI]^^HGOO_^>E2M7DIN;BXF)"9:6ECK].^_>O<N6+5OH
MV+$CJ:FI5;9QRI0I#!PX$"<GIVK),QD9&3%RY$BZ=>O&PH4+GQE 5JO5! <'
MDYR<S*I5J["QL4&E4I&>GDYA82$#!P[$S<V-%BU:4%I:RNK5JVG8L"%%1444
M%!3\HU0D_HQH*UWM[>UQ<W,C-C96J/@.#@X&REL: (P<.1* Z]>O8V)B@E0J
M1:%0$! 0P,B1(_'Q\6'/GCW<O7N7A(2$%ZK,4R@4>'EYL7;M6N'\6[1H$;Z^
MOD(P:^+$B7S\\<>T;=L69V=G[.WMB8N+P\[.#C\_/YR=G9%*I4BE4HJ+BW%U
M=>7==]]]ZIC)R<E<O7I51[Y6H]&P;MTZ8F-C\?/S(R@H2-@O?7U] @("" T-
M%:Z#^/AXX5J3R^48&!@(B6$UP=S<G(,'#Y*=G8V^OC[AX>&\^^Z[1$1$"-7^
MG3MWYIUWWD&E4M&V;=L:C2/R^OGZZZ]Q<W/#S,R,GW[Z"4M+2W;OWLW@P8.9
M/7LV5Z]>9?[\^?3JU8L^??HP9LP8$A,3<79VUDET>)RV;=OBY>6%6JU&)I.A
M4"B(BXNKMFW:9(9G!>,L+2UUYFK7KEW#U-24_OW[,VC0(.K4^9\+[7%I]*RL
M+)HT:4+W[MT)#0WEX<.'#!X\F-]^^XU[]^[1LV=/]N[=BT0B0:52,7#@0!HT
M:" D?\R8,4-X#A87%PLM5T1>#]]^^ZV.XH V^-NG3Y]JS4^>9-2H4<R;-^^%
M[1,1$1$1$1'Y<_-X0N^?#;$'L(B(2*4\>/" VK5KOVDS1$1>._OV[</$Q.1-
MF_'&.7[\."4E)?C[^XM9ZS6@1X\>0'E%^>-])1]W:M:J58NM6[>BIZ='PX8-
M^>"##UB]>O5KMU5$Y'&>3("Y<>,& )LV;>+0H4-\]-%'C!PYDHB(")8O7\X7
M7WS!N''C*"PL)"XNC@$#!C!QXD0^^N@C^O;M2]>N7;E^_3J/'CUBSYX]N+N[
MX^KJBJFI*7OW[J6DI(3"PL)JV2B52O'S\R,\/+S:^V=A8<&@08.>&OS5:#3$
MQL9B8&" M;4U*2DIPCW0R,@(9V=GH8HR,S.3[[[[CB5+EA 0$,#OO__.HT>/
MQ.#O&T2A4.#DY$1:6AIN;FXHE4I!*C8D)$20FJV,EBU;TJ5+%Y8M6X:CHR,6
M%A9 >9"G9<N6+%VZM,;RQW*Y'#T]/3ITZ$!Z>KK.=AP<',C)R4&A4""7RVG9
MLB4+%BP0OI=*I7AX>+!RY4K6KU^/DY,3&1D90+D$[>'#AW6D<9^D0X<..KVY
MY'(Y??KTX????V?'CATX.SOK/)NBHZ/9MV\?2J6218L6,7#@0)U KX.# X\>
M/>+TZ=-865D)ME07;76GD9$1[N[NR&0RG)R<\/?WY\2)$R0G)Z/1:/CLL\]J
MW/=;Y,WP_OOO\^C1(R(C(_GXXX_9N'$C(2$AO/?>>VS>O!ES<W,<'!R$'G'.
MSL[LV;.'.W?N8&=G]]3C+95*"0\/)RLKJ]K7HC:9H2H5\X\CD4BX=>L65ZY<
M(34U%4M+2]S=W7%W=Z>DI(2S9\_B[NZ.@8$!DR=/YH,//F#0H$$,'CR8??OV
M4:M6+0(# [&PL" L+(R(B B<G9U9L& !APX=PL?'!Z52R=FS9X4QAPP9\LH3
M+D7^AUJM9OKTZ95^EYJ:2K=NW83$E.HR;]Z\/ZTS6$1$1$1$Y'6C4JF(CX]_
MTV8\%[E<KN/'JPJ9F9FOR)H71ZP %A$1>2IE965"$%CLN27R3Z%___[_^+Y;
M\?'QM&S94G!^OT[^+A+00X<.%9Q%UM;6@JRAGY\?1XX<H7[]^FS:M(F\O#SF
MSY]/HT:-2$U-9=RX<=C:VHH]5D3>&%*IE!4K5N#IZ4FW;MWX^NNO^?CCCX7O
M/3P\<')R(CT]G1X]>G#SYDV"@X/Q]/3DWKU[1$5% 3!W[EQNW+A!MV[=,#8V
MYO#APYB:FB*7RUFU:A6%A844%!10ITZ=I\I#/PM'1T=B8V/)R,BH5B"@29,F
MC!DSIM+OY'(Y_O[^?/+))\^LXE4JE8P>/9I+ERXQ??IT_N___D\,^KYAU&HU
MX\>/!\#*RHKT]'242B4^/CY" %^A4)"<G*SSNU:M6E&G3AV^^NHK @("V+ES
M)]>O7T<FD]&@00-R<G)8N7(E/7KTX/;MVW3HT*%:25$*A8)CQXYA:VO[U'/*
MR<D),S,S.G3H@)65%=.G3Z]TO8T;-Y*7ET?]^O49-6H40X8,P=34E)*2DF=6
MF'7LV)$OOOB"A(0$OOWV6XJ+BRDM+:6PL)"TM+0*LKN6EI:T;-D25U=7%BY<
M2$!  "U:M*B0-.'@X,#;;[^-OKX^2Y8L8=BP834.=!@;&S-MVC3>?OMMG6WX
M^_LS;-@PH9?LXU7,(G]^M'*!PX</Q]?7EX"  +*RL@@*"JIPCDNE4N%X+UJT
MZ*G'6R*1L'CQ8C0:3;7FZW%Q<;BYN57[_)%*I41&1C)UZE0R,C+P\/# Q,2$
M6;-FT:Y=.XX>/4I!00%GSY[EZ-&CU*I52^CY.WGR9$Z?/LW)DR?Q\?&AN+@8
M0.@C#^5)'#8V-D1'1Q,0$$!N;BY^?G[5LE'DQ5BT:-$SOS]UZA10_FPI+BX6
M/C\/'Q\?\7XE(B(B(O*G0*/1D)V=K:,&E)V=#:#SK-(N;]>NG= &Y\GYEE*I
MQ-#0$*E4JO/]\[9I;&Q,24F)L WM&$^B4JDH*2FI]!FJ4JDP,# 0?J=2J=#7
MUQ?F5=K?:NU[W.;'[=+:I*^O7ZFB45%1$??OWZ]@YY/;J0IJM9K\_/P*8VFW
M]>3?X<EC\#+0>_0,+Z>OKR\RF4S,N!41$:%V[=IB$%CDA7!P<$ NEU>:T>[D
MY%2C/EZO$A\?'P!,34UIU:H57;MVK;'4X5^)A(0$G)R<A,^AH:%X>7E5^?<O
M*I_\=Y" UM/38^S8L926EE)<7(Q:K<;$Q 0C(R/:MV\OK#=^_'BF3IW*N^^^
M*_R-9\R8049&!K_^^FNUQE2KU0!_JR#4LX[#ZS@O_LEH-!H*"@JJ=<]3*!3(
M9#(:-V[,O'GS2$I*8M*D2>CKZU-24H*!@0$%!05 N;3KU:M7,30T1"Z7USCA
M03MF=9X?$1$1C!HUJL(+H:^O+\7%Q=R\>9-.G3I5NDVU6HVWMS<)"0D,&C1(
MK.SY$Z'M]YN8F$A>7IY.X%=[?!,2$@#HUZ\?^OKZ/'KTB&^^^8:2DA)6KES)
M\>/'Z="A S___#-3IDP!RJM_MV_?#H"SLS-JM;I*]UEMG]^XN#A&C1I5(4E!
MH]$P;]X\3$U-L;:V%LXC/3T]S,S,<'=WUSE/E4HEKJZNI*2D</3H498L6<+-
MFS?Y_???B8J*XO3ITTR9,J6"@LGV[=LI*BKBR)$CK%BQ@MZ]>V-K:RM406JW
M^;@3)3P\G ,'#E!86$A65I9P/P@*"L+,S*S2ZGFY7,Z^??L8-6H4AH:&KV2^
MI)7/MK>WQ\_/[V_UO/NGD)24A(^/#T>/'F7MVK6XNKI6<&RIU6H,# SHTZ</
MMV[=8N# @16.=T9&!L7%Q55.QGC\^JFI(VW+EBU,FS:-^_?OTZQ9,ZY=NP:4
M]S*^=>L6 &^__3:K5JW"V-B8+[[X@KY]^U9Z_3_/5O&Y\OI0*I5\\,$'PC&L
M"E65A3Y[]JQX+$5$1$1$7@MZ>GJL6+&BTGGZ\N7+N7CQ(E >ZX/RI.X1(T:0
ME96%M;4UCHZ.Q,?'DY24A)F9&>?.G2,D) 1?7U]"0D*(CX^G8<.&)"4ET;ES
M9W[ZZ2?6KU]/<G(RSL[.J%0J@H*"Z->OG[#-VK5K<^#  =1J-;5JU<+#PX,Y
M<^;0H$$#G)R<,#4UK?"<G#U[-DV:-.'!@P?T[]\?&QL;-!H-V[9M(S,SD\:-
M&].G3Q]:MV[-QHT;J56K%O7KU\??WY^(B CNW+E#\^;-.7+D"&O6K-&QZ^+%
MB_3HT8/6K5L3%Q>'A84%^?GY%?YFY\^?9]*D29B;FV-K:XN]O3TE)26L7;N6
MIDV;8FAH2&IJJI#XKB4^/AYG9V?D<CE%144X.SNC4"C8L&$#??KTX<B1(_CZ
M^F)@8,",&3/HTZ</=^[<H:2D!%]?7X*"@NC8L2/GSY]'*I4*BHS506,O6\8
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M685WPJ*B(B9.G$A141&.CHXHE4JF3Y].FS9M.'?N' 8&!A@8&+!NW3H>/'A
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MDZQ=NY8I4Z;\HX)^_LGTZ=,'$Q,32DM+\?/S(S4UE7[]^DFU;*NB5JLI*"C
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M7[^.FYL;:K6:PL)"UJQ94V\'N%PN)S$QD9*2$NSL[/#W]Y<<=_#_I.4F3)C
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M-3EN@4#PST*KU=*O7S^Z=^^.L;$Q+5NVI$6+%O?=;WEY.3J=CNCHZ'_,H;!
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MC0T:C4;*_#4V-I8<P/J,60L+"XR-C>G7KQ\Q,3&DIJ;2MV]?WGGG'0X<.,#
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M1UOU8\7'QQ,<''S7=:!4*A7[]^]GQ(@1=.O6C?W[]TL2;SJ=#B<G)S9NW C
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M;FXNQ<7%5WO8@B (@G#3,)E,5%964E%1@9>7%WJ]'D]/3V0R&:M6K6+__OU
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M(H+,S$RQ@$00!$&X965D9+!PX4)T.AVG3IV2ME=65K)JU2J&#Q].5%245;7
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M=N;,F8-,)L-L-I.8F$B7+EVL/I^'#AW*#S_\P*%#AU H%%8!8*V'B\8  "
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M8S*91*_:BQ05%0$0&1G99"E12__'7W_]%;U>#R!EIJQ>O1H7%Q=*2DHX<.
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M7L=?2G5U]569!^S?O_\5?8\1;(F90T$0A%8006"A/;OSSCOIV;,G'3IT8,"
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MB:E3ITH3S6V9$!LX<.!5>A;MCV559$OL[>UQ=G9FPX8-0,/[,WOV;$Z>/$E
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M^"(N+BXX.#@P;]X\%BY<J)ZG;]^^G#]_GO#P<'KUZH7)9&+4J%'5EI:^G20
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MRN3)DTE+2ZOVH:O9;"8D) 1O;V^;GGI"""&$N+]HM=HJ Z[5;:]HZ]:MU0:
M:]I*K;IK:C0:"?[>8A( %D((4:72TE() @LAA!!"""'$33 :C;S^^NL</GSX
MAO;/S,RT>3]DR!!*2DJN&Q VF4P4%Q<S8\8,9L^>7>ESO5Y/0$" E'P60@@A
M1*T,'SZ\KH<@:D$"P$(((:I56EI*@P8-*"LKJ^NA""&$$$(((42]93:;24A(
M("XNKE;GJ5@:NFO7KCS^^.,4%!2P9<N62M?[^NNO&3=NG-J33U$4HJ*B*"HJ
M(C\_7[)HA!!""%$K/CX^=3T$40L/U/4 A!!"U&_6X&^#!@WJ>"1"""&$$$((
M4;]8+!;T>CWMVK6K=?#W6GOV[&'UZM5J\+=KUZX,&S:,KEV[ G#TZ%%FSYZ-
MHBB83";Z]>M'^_;M24A(D."O$$(((<1]3C* A1!"W)"RLC(I"2V$$$(((800
ME =^WWKK+=:N7<OY\^?OR#7W[-G#GCU[U/=>7EX<.G0(G4['F3-G^->__B69
M.D(((800 I  L!!"B)L@?8&%$$(((800]S-%4?CJJZ\8-V[<31_[[+/_C[V[
M#XNJSOL'_AZ!&0>AE-!<Q=+%14E*6H7U 87=B+3K3MPQ<V61O O=UJB-+D$T
M-R.3$-IPU>UNE;H+#6Z7G#3;-"03Q=8?2F+1JE/: Y,](60:1P8&?G]PG;,S
MS)EA!F:8!]ZO?Y3AS,QWX,SAS'E_/Y_O#*C5:MGO=79V8M @^49]+2TM>/_]
M]RUN/W7J%&Z]]59,GCP9=]UU%\-?(B(B(I(P "8B(H>TM;5!J53"8#"X>RA$
M1$1$1$3]YM"A0_C#'_Z *U>N   2$Q.A5"K-UNVU12[$[8NLK"SDY.0  .;,
MF8.$A 1$1T<[]3F(B(B(R#LQ "8B(H<9# 96 A,1$1$1T8"@T^FP<N5*'#UZ
M%#_\\(-T>V5EI=EVC@;"O143$X-GGGD&24E)TFW;MFW#\N7+45559;7*F(B(
MB(@&#@; 1$34*VUM;?#S\X/1:'3W4(B(B(B(B)RNJ:D)Z]:MP\Z=.\V"7VOZ
M(Q 6JWY#0D+,;H^.CL8SSSP#01 8 !,1$0T@I:6E.'WZM+N'T6LJE0J!@8'N
M'D:_N';M&@1!</KCUM348.+$B1:W,P F(J)>,QJ-\//SD_Y/1$1$1$3D"W0Z
M'18N7(@//_RPUX\A%PBKU6I\^NFG.'/FC$./)5?UVYVM[Q$1$9%O2DE)049&
MAKN'06Z4G9V-YN9FB]L9 !,149^(P2^K@8F(B(B(R-LU-34A/S\?A86%3G_L
M[H'P].G3$1H:VF,@G)Z>CG7KUB$L+,SI8R(B(B(BW\0 F(B(G,)H-$*I5,)@
M,+A[*$1$1$1$1'83! %OO_TV3I\^C?7KU_?;\_[K7_\R^UHN$-Z]>S<T&DV_
MC8F(B(B(? ,#8"(B<AJ#P8" @ "TM;6Y>RA$1$1$1$0V"8* O7OW(BLK"PJ%
M C_[V<\P8\8, %T37(.#@_O\^)V=G0[=Y]*E2P@.#L;0H4.Q9<L6AK]$1$34
M*TU-30" D) 0Z/5Z , --]R AH8&L^W&C!D#M5H-H&L)#/%K01"D;<7;=#H=
M(B(B+)Y'$ 2,'CT: /#IIY]B_/CQLN.@_L4 F(B(G*JMK8TA,!$1$1$1>2PQ
M^/WSG_^,JU>OXIMOO@$ -#0TX.Z[[X;!8+!HU]Q?8F)B\/CCCR,N+HXMGXF(
MB*C7#A\^# "(C8V%1J/!MFW;T-+2@M345"0D)   HJ*B4%A8B.W;MZ.DI 1'
MCQ[%YLV; 72=%Z6FIF+:M&EH:&C ^O7K<>NMMUI,;GOFF6<  ,\__SP 8./&
MC9@\>;*T+K$X#DYJZW\,@(F(R.G:VMK8#IJ(B(B(B#R*M>#7U-MOOVWV=6)B
M(I1*)3[[[#.;Z_0Z0U96%G)R<E@A0T1$1$YQZ=(E:#0:%!45(3HZ&CJ=#@D)
M"2@H*)"VJ:^OQ_KUZ[%OWSX<.'! J@8&(&V[=>M6Z'0ZB\=O:FK"D2-'4%M;
MB[5KUR(D) 3!P<&HK*S$J%&C&/JZ&0-@(B)R"8/! #\_/QB-1G</A8B(B(B(
M!C![@E]KNE<"B^OT-C8V6JSAVULQ,3'8MFT;HJ.CG?)X1$1$1 !07EZ.]/1T
MS)PY4[KM\.'#R,[.!@ 4%!0@-S<7,3$QV+ESI\4DM,K*2BQ;M@PM+2W(S<VU
M>/S2TE(\^NBC^/'''U%:6HJ,C SX^_MCZ]:MT&@TN/'&&UW[ LDF!L!$1.0R
M1J,1?GY^[AX&$1$1$1$-4/OV[</CCS_N</!KC5SHVY>VT5NV;,&##SYH5FU#
M1$1$Y P+%R[$]NW;,6G2)"D$GCQY,M+3TZ5MU&HU/O[X8P0&!EK<?\J4*<C*
MRK)8]Q?HFF#WR"./(#(R$N/'CX=>K\>##SX(  @+"\/.G3N1FIJ*9<N6X88;
M;G#1*R1;&  3$9%+L0*8B(B(B(CZVZ%#A[!Z]6I\^>673@E^;>E-V^CDY&04
M%!3(7E E(B(B<H8;;K@!6JT6&HT&.3DYB(J*PO???X_Z^GH Z/$\9-BP81;;
M:+5: ,#5JU>Q9<L6::W?O+P\[-^_7]HN(B("145%>.ZYY[!DR1)GOBRR$P-@
M(B+J-P$! >X> A$1]8(@"! $@6L2$A&11Q,$ 7OV[$%U=35>?_UU?/?==VX9
M1_=*X-MOOQW#A@U#<W,S3ITZA=V[=W--/"(B(G*IJ*@H %W5N%JM%C4U-?#S
M\T-:6IK%MKMW[T9H:*C9;:&AH4A.3K;83C1\^'#\YC>_D;Y.2TO#%U]\87:?
MF3-GPF@T8N3(D4YY3>08NP)@?W_OR(D[.SOQU5=?H;R\' "@4JF@5"HMMFMN
M;I9M2:I2J:!2J5P^3G?K[.Q$0D("?O[SGUM\3Z%00*%0].FQB0@X>?(DMF[=
MBI$C1V+4J%&RQZ/6UE88# :+^UH[=OF"XN)B=P^!B$C6LF7+ '0=@^7:'EV^
M?!D='1T6MZO5:@P>/-CEXW.WSS__''J]'J^\\@HKE8A<I*ZN#O/GST=H:"AN
MO_UVV>/1M6O7( B"Q7T'RK%(5%!0X.XAD(=I:FI"<7$Q5JU:!0"8.G4J)DV:
MA/#P<*>MT]L7ITZ= M#5AK&\O!SAX>%N'A$1$1'Y.M//[F%A80@+"P, V?,0
MN8EI(2$A9FL'6]M.[CE,S9X]V^XQDW/9E>RVM[>[>AQ]IE*IT-K:BO;V=NS;
MM\^ICSU]^G2,&#'"XO:.C@[9(/G<N7-66_QXBK*R,CS\\,.8,V>.6>CM*P%N
M0$! GRL-.SHZ,&C0H%[?WV@THK6UM4]C(._3VMJ*LK(R'#UZ%'J]'GJ]WFF/
MW7W&%2!_'+IZ]6JOUI[J#Z^]]IK%;145%=+_8V)B^G,X1$029T]0B8R,E U*
MK9T_?OOMMQYQ@;HG\?'QV+AQH^R,82+J'4$0\-IKKR$O+P]??/$%OOCB"]36
MUCKEL7WA_%$. V 2U=758=.F37CGG7?,VCR?/'E2=OODY&2TM;6AN;FY7__N
MCA\_'J^]]AIB8V/[[3F)B(B(:&#SCM)>*\2 KZVMS:5!FZL_%+CK N'?_O8W
M5%=7XT]_^I/LS QOUM;6AK:V-G</PR/X^?GUN;*]L[.S3Y7A -#2TM*G^WN#
M\^?/(R\O#QT='?CJJZ^<_OA[]^YU^F,"OGMAD(C(G<Z<.>/R"8%RQ^^VMC;9
M+A+..H9_\\TW6+ER)?;LV8/-FS?[W#DD47_3Z_58NG0IOOCB"WSVV6=.?WR>
M/Y(O$@0!__K7O[!V[5I\_OGG^/KKK^V^K]Q[8OKTZ1@V;!B42B7V[-GCS*%B
MY,B1&#=N' H+"QG^$A$1$5&_\LH 6*E4PF@TR@9\@B#@CCON,/OPJ5:K^U3)
MZ2Z#!@V2K<@=,6*$U0_<<NW VMO;<?WUUUO<WM;6!H/!@)*2$K2VMB(M+8UM
MB'R0T6@<$.&KN^W>O1L[=NQ 5%04KKON.D1%17EU&SZYX\^0(4-DCSW7KEV#
MT6@TN\W:<:>EI<7L<=O;VQ$0$, )&T3D=MW/'Y5*I5>N6QX0$"![_FCM&.[H
M^2/0U0[[_/GSF#Y].EYZZ24D)27U?>!$ U!55142$A)PVVVW8>S8L1@[=BR&
M#!GB[F'U6E_/'P'Y8Z_!8# [5ZRLK+28G.HKG:S(MJ:F)OS?__T?-F[<"(/!
M8%;QVQ?6)M@G)R>CHZ,#C8V-O9J$/V[<..3EY2$Y.1EJM;JOPR0B(B(B<HA7
M!<!JM1J"(,BNF6FZS;OOOFOU^^*'3],+?,Z>X>EM;K_]=CSPP /8M&D39LR8
M 8U&T^N*495*)5NU+.JIK3*#2O(VC8V-V+%C!P @(R-#MAV=:96_Z;''&]K%
M]X=GGGF& 3 1N9VCYX\\AG>MXU-04(#*RDKDY.0@)"3$W4,B\@J"(*"HJ A[
M]NS!GCU[,'_^?-GMY(X]WM(NWM5, ]^^=BHBSZ?3Z;!SYTZL7[^^7Y]7KEHX
M,C(2X\:-@U*IM'HNL&'#!LR;-P^C1HWBWT8B(B+J=SP_'ACLF03K\0&PGY\?
M_/S\8# 89*L3'&5O"RRYP,97VU>EI*1@PH0)>.ZYYZ#5:K%RY4H\]MACO:H&
M=O>:;\'2XP  ( !)1$%4MSVM_=M3*^/6UE;9F>A$<FIK:_'**Z]@T:)%B(N+
M P!\]]UW>.655\RV<[0-:&)BHE3]8=K*TU<GJW1T=+A["$1$-CG20G6@3#;<
MO7LW@H*"L&;-&OSPPP](2DK"7__Z5\R<.=/=0R/R:'5U=5B^?#GFSY^/JJHJ
MJ-5JO/KJJ[C__OLMMG7DV#-]^G2,&#$"@.\??VC@^.BCCY"?GX\#!PY@].C1
MF#U[MM7/^T:C$?[^/5_B<E:'C\[.3D1$1&#<N'$P& Q0*I48-6H4LK*R9)?X
M(B(B(NI/[)#CV^P-^3TV  X("$!'1P>,1J-; CE' AO3#]MB6.,M,[,??OAA
M3)X\&4!7]>[BQ8L1&QN+39LV(3$Q$7/FS.GS^K']R=UK_S* 'ABN7+F"7;MV
M0:_78]VZ=0@-#96^=\\]]^#TZ=,X=>I4KQ_?T8DF8MA@&A9[RS$( /=Y(O(I
M V&R87IZ.C0:#0!@ZM2IR,_/Q]"A0_'TTT\C/CX>F9F9;'5)U(T@"'CII9=0
M4E*";=NV(3HZ6OK>PH4+H=5J^[1>KZ/G?>*$0]/S1V\Y!I'OT^ET>..--[!W
M[UZTMK;BE[_\)?S\_)RRQ,ZU:]=L=I43!00$2.\-6SH[.Q$0$( __>E/7!*!
MB(B(B#R*QP7 *I4*K:VM7M4.U)$/VW(?M-T5U$R<.!%SYLRQN#T\/%RJ!G[V
MV6>1GIZ.L+"P?A^?-_+V -K=X_<&8M7OO'GSL&3)$HL)$L'!P4A)2>E3 .PH
M9U2'N+.5*?<Y(AJ(O'FRX:I5JZ3_AX2$(#<W%X&!@3A^_#C>??==Q,?'6P1<
M1 .93J=#=G8V8F-CI:I?4VJU&@4%!7T*@!WE2-#+Y4S(U01!0&5E)4Z>/(G3
MIT_;?"^(^Z,G=$J*B8E!3DX.YLZ=RXE/1$1$1.1Q/"8 %H-?=[<0=C5'/FB[
M>KVYX<.'XX477L"2)4O,*AB!_U0#U];68N/&C9@W;QYFSY[M5=7  Y&[ UP_
M/S^;^X@W!]"MK:W0:K4X=^X<5JU:97-2Q.3)D[%TZ5*+5M">@-4A1$3>QY,F
M&S[RR"-8N7(E"@H*I$"HJ*@(&S9LP*]^]2O\ZE>_PMUWWRVUN&4U, UD@B"@
MO+P<6[=NQ3///&.U.E"OUZ.PL!#WWGLO7G_]]7X>9<^XG FY2EU='5YZZ25L
MW;K5[OO8LS^*$Z=<V6'CU5=?Q<*%"_DWCHB(B(@\EEL#8+%2L:VMS>>#W][H
M2PM!P/8'[)4K5R(I*0G5U=7(S<W%TJ5+,67*%(OMIDR9@HB(".S:M<MJ6$PD
M,AJ-:&EI<=OSNRJ /G_^O-06??7JU79-A+CGGGM05U>'NKHZ^P;OH9Q1'6)/
M\.#GY\=6T$1$3N#*R8;IZ>G8O'DS*BHJD)J:BHR,#$R8, %[]NQ!5565M%UT
M=#2JJJI05%2$Q8L7FX7%1 .%7J]'1D8&(B(B<.#  82$A,ANI]5JL6#! NS>
MO1MSY\Y%6UM;OU8"NT)OES-Q]/R1O$]=71V"@H)045&!HJ(B_/333_CZZZ^=
M_CSV[#OB1 5QO[-WLOU--]V$4Z=.67U/$Q$1$1%Y"K<$P$JE$D:CT265?H(@
MX,X[[T1@8"!:6EK0V=F)H* @IS^/IQ(_, / _/GS 72%<H(@2/__]MMO\?''
M'V/Z].E(3$S$[;??CN>??QX???014E-3$1049+9(N$JEPB.//((3)TX@)24%
M&S9L0'Q\?/^^,"(GZ&EQ].XMM%M;6[%KURX</7H4.3DY&#]^/#HZ.NQZKN^^
M^PZ#!P]&0D("KK_^^@%W/#(]%MUXXXW2\4@0!"GH-1J-TL]3I5*Y=?( $=&O
M?_UK7'?==6AM;45[>SO4:K79L<R7F;[."1,F8,*$"1;GCU>N7$%U=35T.AV2
MDI(P=>I4///,,UBY<B5V[-@AV])VS9HU.';LF!06LU**!@JM5HO\_/P>JWYS
M<W,!  T-#0@+"X->K\>0(4,P:]8LA(2$2.>/ ^5X9.W\T6 P2&NV&HW& ?&S
M\#6"(.#HT:-8LV8-+ERX@!$C1F#X\.$8.W8L)DV:9+:M6#W>7P8-&H3.SDY$
M1$1(K:4-!@/:V]NESW%??ODESIT[A_7KUV/%BA4,?XF(B(C(*_1K *Q6JR$(
M@O3AS57/<?#@08O;Q<JTCHX.:7V9@>S>>^_%@@4+\.RSSV+*E"G(SL[&D2-'
MD)F9B8<>>LCB0Q@ 1$5%H;2T%#MV[$!U=37^^[__&Z-&C3+;1J["LK6UE95]
MY'7T>CTV;MR(&3-FH*"@ "J52KH0;DMK:RN.'#F"-]]\$__U7_^%O_SE+Q;;
M\'AD[HDGGK [6"<B<I7WWGM/]O;DY&2I.FB@MR_=LV>/69CK[^^/I4N78LZ<
M.=B]>S<T&HW%?6;.G(D#!PX@/S\?6JT66[=NM;F, I$W,PUUM5JMU7V]HJ("
M:]>N14Y.CO2^$2N!MVS9@M+24HO[F)X_\GA$WD 0!'SPP0>HJJK"$T\\@0T;
M-J"XN!A//?64PU7N8DMG4Z;MQ4TY>VWJ6;-FX;[[[L-CCSW&X)>(B(B(O(K+
M V _/S_X^?G!8##8%9ZXBJUU8J9/GXYAPX9!J50.F%93<7%Q4IA[ZM0I+%JT
M"'?>>2<B(R-17%R,#S_\$!J-QJ+5;6AH*#(S,U%=78T___G/5EM']T;WZDN@
MJPW8H$&#S&YCE2"YDFF ^]ACCR$\/-SN^S8V-F+'CAT(#@Y&7EX>+E^^++N=
MK>-18F(BE$KE@#H> 3#K.D!$Y$FL7:06PQBQ4F@@3.:)C(R4PMP77WP1@8&!
MV+=O'QY]]%'DYN9B__[]6+=NG47H%1(2@H*" E145$"CT9B%7D2^PK25L[7]
MNZFI"?GY^=#I=-BY<R<B(B+0U-2$5:M6 >BJ!+;V6:>GS[,C1HQ 6UL;FIN;
M!\SY(WF>IJ8FG#QY$I65E2@L+)2ZA[6TM$@=(!8L6( ??_P1?GY^4*O5%I_W
M[140$"#[&4*LY#4E3KR5>XSN(;+X=WW<N'%8N7(EES @(B(B(J_EL@ X("
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M:_[QCW]@Y\Z=LM</K+EV[1K\_/S0TM*"!0L6("DIB7\;B(B(:$!B #PPV1L
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M("PLS*P26%S_UUX5%16XZZZ[;$Z Z*N>)JV83C!TM-4NN9Y>KT=C8R,N7+B
MX\>/0Z?38>_>O<C*RL)--]V$B(@()"4E.;Q^KRE!$'#NW#E45U>CLK(2%R]>
MQ/SY\Q$?'X]+ERY)^[2XIF]55944#"]<N-#A_;Z[>^ZY!]NW;W=HWTM.3L:*
M%2LP:]8L=H8@(B(B(K+":0&PG&O7KIE]K5*IH% HT-;6YE%MHP%@[]Z]LK?W
MM!::+XB+B\/8L6-17%R,4Z=.R58NRA$#Y(,'#YH%R*M7K\:! P>P<N5*JP&<
M:8#LR'.:\H0 M_NZL:8Z.CIZG,7LZ6MJ>QN]7H^-&S=BQHP9#@6XK:VM.'+D
M2*\"7+&2/C@X&'EY>3WNQXY4A#C*VG$,L#R6>5(5F[O?QT1$O>4KDPL5"@6R
MLK+LWKZYN1ECQX[%BR^^B/S\?!P]>M1F&V=3IF&N1J.1PMSMV[=#J]5"H]%8
M#>"2DI(P=>I4K%JURFI83.0H>P-<<>UJTPD(]E2PRS%M@2X&R;:X<HUR3C#T
M#*9![\6+%_'EEU^BL+ 0R<G)B(B(P+1ITY"2DH+0T%"G7)/0Z_7X][__C<K*
M2FEMX+ESYV+KUJUF^V-34Y-LZ&L:#/>56JU&?'Q\C_O6S3??C,[.3F1F9N*Q
MQQYSRG,3$1$1$?DRI[6 [@U7M(VVU0+:V4P#%4$0W/9AN+<MH+LS#<'ZTOIV
MR9(E4*E44@O>&3-FR%8#=W].5U9.^BJ52F5S;=B>JJ!;6UL];C)&;_1EWVUL
M;)0N=#@Z$4%LA?[DDT\B+BZN-T.WX,J V);N 7%_AA45%150J51H;6UE"V@B
MDGA*"VAG\Y3)A:8MH!4*!<Z=.^?0_0,# Z60H+=5C'*M;^U=0[6WP1N1*7$_
M>N>==ZR>@YFV(!?/&7MJVVR+&"0[<UWK_CI^=>?."8;>V +:M'7SU:M7S2IZ
M38/>H* @C!T[MM=K]LH1 ]^3)T]BSYX]&#5J%!(3$W'[[;?CE[_\I=GSU-75
MX<,//X16JY6J@:=.G6KWFKZ]'=^"!0M04U-C\;V;;[X9-]UT$U:L6(&DI"27
MC8&(B(C(&[$%],#4[RV@>Z-[!:>?GQ\" @(\JFVT+6?.G+$:D)BNM>0MK;14
M*A7NO/-.1$9&2E64UH+;[L+"PK!Z]6H<.7+$K/+WN>>>@U:KQ;///HOT]'2+
MBR.FSUE<7 R=3F?W<Q+<_C[Q\_.S^;OJJ0K::#3V^3683CZPIP+75'5U-7;M
MVM7KJE\ *"TM]8FUK&T=SX#_'--<%5BX>U\F(NHOMHZW[IQ<V)>U$Y.2DGIL
MXRPG+"Q,JOP=,V:,%,*5E96AO+P<<^;,P;9MVQ ='6UQ7]/6T<>/'[<9%A-U
M)]?*68YI6"NN"2Q7"6P/TR!YY\Z=/K%>J:/GCY[>#:$OQ' 7 .KKZP$ 9\^>
MQ0\__""%O$#7Y)NA0X=BXL2)2$E)06!@H$LF NET.M37U^/X\>,X?/BP%/C&
MQ\?CH8<>,CM>RE4#SYHUJU_77 \+"\-MM]T&E4J%HT>/(B8F!AD9&8B,C,3U
MUU_O$^\7(B(B(J+^YM8*8'N(;:.[MY.VIC\K@'LK,3$12J422J72*;.DG54!
M;*HOZZC*5?Y^_/''>/'%%S%OWCS,GCW;:C7P@0,'4%E9Z?!STL!T\.!![-NW
M#\N7+T=L;*SL-G)5T-]__SU>?OEE ,#O?_][ARX8U];68O7JU4ZM^C7EK@K@
MOC)=/TZI5#IT(4O\&Z-2J7#;;;>Q IB( /AN!7!O.7MR8?<*8&?]/+5:+?+S
M\VVNHRI'K]<C(R/#K/)7I],A-345\^?/1V9FIM5*N)*2DA[7;B42V5,]+@@"
MBHJ*4%-3(X5@<I7 ]JJKJ\/RY<N=6O5KRM./7]:8'M<</7]T=05P4U,3&AL;
M 70MVW/AP@7I>\>/'Y?^?_CP89PX<0( I%;Z45%1" H*PHTWWHCAPX>;=4QP
M)C%TKJ^OQ]FS9W'HT"'<>..-*"TM17)RLE3A&QD9:?9YIZFI"6?.G,&I4Z>D
M-7_3TM)DJX'[@R (^."##_#JJZ_BRI4K^.FGG_#FFV_VZQB(B(B(O!4K@ <F
MKZ@ MD?WJC"Q;;3!8/#:UK6V+MCU)AQN;V]WYO  = 4QBQ<O1FQL+#9MVF0S
MN.W.M/)WY<J56+5J%29-FH2\O#SLVK7+9C5P<G(RHJ*BL&G3)OSJ5[]":FJJ
MTU\;>;_&QD:DI*3@OOONPX8-&Q <'&SW>LJ];=M\Y<H5[-JU"U>N7#&K^E4H
M%/#WMWXH[:D-=T='A]<>RTPY8_TX7VE)3D3D"K;."9T]N; O-!H-8F-CD9&1
M@<K*2KLK<\/"PLPJ?\4PMZJJ"D5%18B/C[=:#9R6EH9ITZ8A.SL;-34U6+MV
MK2M>&GFYIJ8FW'###4A/3[=9]2N&M6EI:2@K*S.K^C6M!+:'&"3OV;/'9ZI^
MG:FG8Y7I!,/^[JKUP ,/F/V^IDV;)OU?K-P%T._=!\2U@K5:+=:O7X^LK"Q$
M144A/CX>'1T=Z.SL1$M+B]D^JM?K+0)?L:WS_/GSW;:6>EU=':JKJU%24H+)
MDR=CX<*%F#IU*N;,F8.FIB9V=2 B(B(BZB.[ F"]7M^G)[G^^NL=:LMJBUS;
M:*52B8Z.#I]H(6KK0VUR<K)L^RS3\"D@($!JHZU0*.P.Q:P1P]P=.W98#6[E
MF ;(&S=NE +D]/1TU-;68N/&C5BT:)%L !<>'H[[[KL/Z]>OQ^#!@W'OO??V
MZ36X0D^MC_NJI];)SN"M8=OAPX>1EY>'4:-&8?;LV78?6ZY<N8+BXF( 76V;
M1X\>;7/]9. _OX>:FAILW[X=&HT&O_G-;RQ^]]V/2WTQ=NQ8W'SSS0@("/"*
MUO'V$MO>R7%UM=:V;=L0'Q_OTN<@(G(G>R<7]E?[U>YA;E%1$6;.G-GC_=1J
MM5F8>_+D261F9F+-FC6X^^Z[;5901D1$8/7JU7CPP0<Q:- @FQ7#-/#LV[</
M*U:L   L7+A0]O.,:5@K3C80! '9V=F]:MLL!LGSY\]'5565R_?'Q,1$M+6U
M0:_7X_SY\RY]KOYBZ]C6?8*ELZN@3;LDN(-8@5Q?7X^+%R_B].G3*"XN1DQ,
M#!(2$C!TZ% \]-!#9F,<,F0(2DM+<>G2);/U?@%X1. +=+6FKJBH0$E)"4:-
M&H45*U;@P($#9F%O6EH:#A\^S/7=B8B(B(CZR&8+Z$<??11;MFS!???=U^LG
M\//SPWOOO2>MKVDP&*0*L*JJJEX_+OW';W_[6_SQCW_L<3LQM!3#84<#P-K:
M6KSRRBN8-V\>[KSS3KOO)U9.ZO5Z*4 V74-UR9(E9FNH-C8VXN]__SNNN^XZ
M*=@?/7JTU<<_=>H4/OSP0[O'0YYMUJQ9&#%BA#2KWM3%BQ=Q[MPY3)HT"6JU
M&D:C$2M7K@3PGTI;H]%H414=:L%[   @ $E$050O[KO6)AU8([?ONII<&!H9
M&8EQX\8YW!J/Y(GM^8C(LQ46%B(Y.1D I EP '@<=)(E2Y:@I*0$@&O;0^ET
M.F1G9R,V-M:A4-9:&+=NW3KH=#J+M2D%0<""!0N@4"C@Y^<'?W]_C!\_WNKC
MO_ONN_C@@P_Z_/K(,\R8,0.WW7:;[,3 *U>NX*VWWL+$B1,1%!2$(4.&8/OV
M[6;[HER[\=ZV;18$ 2^]]!)*2DJL5JT[FUSXR?/'ONF/ %ALX?S]]]_CVV^_
ME=8,+BPLE(+>J*@HC!PY$F/'CL68,6.D_5"OUT.CT:"FID9Z/+'*/3DY&;&Q
ML9@Z=2INN>46MP:^0-=8#QTZ!*U6"P#2I%IKX]+I="@N+G9K $]$1$3D+=@"
M>F!R2@OHP8,' P#2T],=>G*E4@FCT2B%BV5E9?CG/_]IUWV[KP,$P.VM[#S=
MB!$C[-K.:#3:K @.# R4*A[E*AJG3)F"B(@([-JU"T5%11;!K37!P<&RE;^9
MF9FHKJY&2DJ*63O>UU]_'55558B,C,3HT:-[K((L+"S$Y,F3[?@)=%4FBQ>0
MN[?F[6NU-#F'&(!.GSX=2J52=J*(:5>"F)@8LY9LIL0 ]ZNOOL)33SV%T:-'
M2Y75/4V $->RGC=O'I8L6>+2BN^>G#ESQJ)B*S(R$N/'CX<@"#Y5*>P*IFO\
M*10*7DPB\B*%A85V;2>>/P+HL=T\=1DY<F2_/$]$1 3*RLIZ;./<G5JM-JO\
M34M+PX,//HB"@@)45%0@-345&1D92$M+ P"L6[<.^_?O!]!5"=G3[SXK*PNU
MM;5]?X'D$10*!=Y__WV[SQ^G39N&C(P,"(* \O)R;-VZU6RB05Y>GMGD WN9
M3GCHCZI?6ZR=/S(4[C^FZPC7U]<#Z%H_N+FY6>I,E)65A:%#AV+BQ(F8.G4J
MQHX=*]M66@R+/__\<WSSS3>HKZ_'YY]_;M8J.20D!,G)R0ZO4>T*8GMG\5BL
MT6CL'E=$1 3/UXF(B(B(G,!I:P '! 1 H5# 8## 8##T^G$<"7KEJD+ZJ[6=
M+[(5@(K!Z>#!@_'PPP_CW7??M0AN>R(&R,7%Q3AQX@26+%F"N+@XE):68L>.
M'3A[]BQ^\8M?2#.#32]:W'///=BW;U^?7V-OVX0S..Y_IL>"^/AX& P&V>/#
MDT\^:;8FK^CCCS_&BR^^:!;@7KMVS>9SJE0JM+>W8]>N73AZ]"B>>NHIW'##
M#<YY04XF=U%O^O3I" T-92A,1 ..(^>/IFM*BI,->?[H6M;"7'O"L>CH:&D=
MX,6+%Z.@H !)24F8.G4J\O/SL6S9,OSZU[\VFRP@_@VT)P@FWV)Z++ 5!C_R
MR",8,V8,_O=__Q<1$1%2"]K>MFTV#9+%]:L]$2<5VJ^PL-#LN"+.KM?K]=+G
MOY:6%ERX< % 5Z>B+[_\4KHO *F*%P"BHJ(0%!0DK1^\>?-FJ_N73J?#F3-G
M</[\>=37U^/PX<,X<>($LK*R<----V'4J%%(3T_'M6O7</+D28P8,0(7+ES
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MVQMKH\OEDMOMUB"[             )A %HLET5/ )#(PEDL-8
M . *4UU=K;*RLD1/ PGD<KG4W=T=U4X*:             "8(E@!#
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MW=VMO7OW1K23 AH             I@@"P              P19 "&@
M     +B"6"R61$\!D\C 6.ZU"9H'            @!&B!C#"-8 '(@4T
M         $P1!( !            8(H@!30            P1;2VMNK"A0N2
MI&7+EJFKJTNG3IW2M&G3E).3(ZO5*DGR^_TZ=>J4)"DM+4T.AT/!8%#-S<V2
MI.3D9&5E99F.:;/9% J%U-+2HLN7+QMMDO3RRR_K1S_ZD20I& SJ].G3QCC]
M!8-!=75U*24E1>WM[:;[Q,-BL1@U<#LZ.E175Z?,S$P5%15)D@*!@!H:&E16
M5F9LO_GFF[5FS1KC?>S;MT]E964*! *JK:W5#3?<H'7KUAGGZDK#"F
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M?YRP_OL./&[XM5F__H'>\'_-]AL+ X/* ^<Y</N5$OP=S#6)G@
M    8&P0  8           " *8(:P            , 5Q&*Q)'H*F$0&QG*I
M 0P           !<8:JKJU565I;H:4QI%HME4B^4=;E<ZN[NCFHG!30
M        3!$$@ $          ("K2"@44C 83/0T#(% (-%3F%((  ,
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M>67(ND/!8-"T9O32I4N'FKZJJZLU9\Z<(??K+WS#'J]=NW9=L2F1A_,W 0
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MWICIGV/5#IX,TM/33=-:%Q<7)V VY@]A      !&Q^_WR^_W3^@B!"0& 6
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M08$77G@AJLVL9O!D8[/9]-133XVH;ZS@=DM+RZ#]0J&0:6KVY.3D$<T#
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M'3AP0&O6K!E6O[OOOEMWW'&'_NW?_BUJVW#&&LZ#!AZ/9T3!ZOKZ^DGSI#@
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MQL$"NU:K=5@!T_['M-ELX[K*MK]XCC51@=^P_G,:[W-QS;B-#
M  "84 2  0           &"*(  ,             %,$ 6
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M>U9^OW_0,1L;&^5RN92;FQLQ7GY^?L1^65E9:FEI42 0B'N^,$< &
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M=FKMVK4$?\? M8F>             (#)R^%PR.%P1+2EIZ=/FO$0B17
M         #!%#+H"^*NOOI+4ET<<            P.107EZN\O+R1$\#">1P
M./3G?_[G4>V#!H!ON^TV55=7C]ND (RO__N__].?_,F?)'H: ##ES9HU2]==
M=UVBIP$       #@*O/YYY]'M5EZ>WM[$S 7             , 8HP8P
M         $P1!( !            8(H@  P             4P0!8
M      "8(@@  P           , 400 8             *8( L
J    ,$40  8           " *>+_ >JJF&]X KV\     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024580864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BICARA THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-2903745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">116 Huntington Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">468-4219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,415,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0002023658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405021137056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 520,758<span></span>
</td>
<td class="nump">$ 230,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">521,514<span></span>
</td>
<td class="nump">231,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset &#8211; operating lease</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">524,173<span></span>
</td>
<td class="nump">233,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current portion</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,481<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability &#8211; net of current portion</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,618<span></span>
</td>
<td class="nump">15,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">367,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 500,000,000 and 365,000,000 shares authorized; 54,424,994 and 711,895 shares issued and 54,409,708 and 640,386 shares outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">709,607<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(200,059)<span></span>
</td>
<td class="num">(153,021)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">509,555<span></span>
</td>
<td class="num">(148,769)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">524,173<span></span>
</td>
<td class="nump">233,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">2,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,410<span></span>
</td>
<td class="nump">8,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,801<span></span>
</td>
<td class="nump">$ 3,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405018753120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">365,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">54,424,994<span></span>
</td>
<td class="nump">711,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405019380512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="nump">$ 43,700<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,764<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">12,016<span></span>
</td>
<td class="nump">6,147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,628<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
<td class="nump">55,752<span></span>
</td>
<td class="nump">26,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,628)<span></span>
</td>
<td class="num">(9,530)<span></span>
</td>
<td class="num">(55,752)<span></span>
</td>
<td class="num">(26,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expenses) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability', window );">Change in fair value of Series B preferred stock tranche rights liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,328)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="num">(13,315)<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="num">(13,343)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(17,481)<span></span>
</td>
<td class="num">(22,845)<span></span>
</td>
<td class="num">(47,037)<span></span>
</td>
<td class="num">(39,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,481)<span></span>
</td>
<td class="num">$ (22,845)<span></span>
</td>
<td class="num">$ (47,038)<span></span>
</td>
<td class="num">$ (39,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, basic (in usd per share)</a></td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (38.23)<span></span>
</td>
<td class="num">$ (11.27)<span></span>
</td>
<td class="num">$ (70.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, diluted (in usd per share)</a></td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (38.23)<span></span>
</td>
<td class="num">$ (11.27)<span></span>
</td>
<td class="num">$ (70.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number common shares outstanding, basic (in shares)</a></td>
<td class="nump">10,901,138<span></span>
</td>
<td class="nump">597,586<span></span>
</td>
<td class="nump">4,174,353<span></span>
</td>
<td class="nump">563,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number common shares outstanding, diluted (in shares)</a></td>
<td class="nump">10,901,138<span></span>
</td>
<td class="nump">597,586<span></span>
</td>
<td class="nump">4,174,353<span></span>
</td>
<td class="nump">563,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">$ 2,271<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 6,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 4,668<span></span>
</td>
<td class="nump">$ 36,336<span></span>
</td>
<td class="nump">$ 13,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405016517920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Seed Series Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Equity</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 37,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (98,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2,231<span></span>
</td>
<td class="num">$ (101,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">(105,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="num">(108,448)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">76,097,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 85,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(98,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="num">(101,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">(137,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
<td class="num">(140,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">367,277<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (98,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="num">(101,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="num">$ (148,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="num">(153,021)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 37,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 37,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">(105,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="num">(108,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,288)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(114,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="num">(117,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,024,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability', window );">Settlement of Series B preferred stock tranche rights liability, upon issuance of milestone shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">76,097,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 85,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,845)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">(137,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
<td class="num">(140,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 367,277<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">$ (148,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="num">(153,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="num">(160,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
<td class="num">(165,529)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">367,277<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">$ (148,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="num">(153,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">393,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">54,409,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 509,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">709,607<span></span>
</td>
<td class="num">(200,059)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,525<span></span>
</td>
<td class="nump">$ 121,148<span></span>
</td>
<td class="nump">$ 164,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="num">(160,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
<td class="num">(165,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,049)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,023,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="num">(174,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="num">(182,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,790,144)<span></span>
</td>
<td class="num">(105,595,101)<span></span>
</td>
<td class="num">(119,599,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (81,525)<span></span>
</td>
<td class="num">$ (121,148)<span></span>
</td>
<td class="num">$ (164,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering cost, expenses and discount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering cost, expenses and discount</a></td>
<td class="nump">332,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">332,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,210,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="nump">367,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">367,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,481)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">54,409,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 509,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 709,607<span></span>
</td>
<td class="num">$ (200,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Settlement Of Liability, Freestanding Financial Instrument Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405019322688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,038)<span></span>
</td>
<td class="num">$ (39,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability', window );">Change in fair value of Series B preferred stock tranche rights liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,216<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(44,719)<span></span>
</td>
<td class="num">(37,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">31<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance on common stock, net of issuance costs</a></td>
<td class="nump">333,479<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability', window );">Proceeds from issuance of preferred stock and preferred stock tranche rights, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">335,006<span></span>
</td>
<td class="nump">77,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">290,318<span></span>
</td>
<td class="nump">40,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">230,440<span></span>
</td>
<td class="nump">4,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">520,758<span></span>
</td>
<td class="nump">44,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities', window );">Settlement of Series B preferred stock tranche rights, upon issuance of milestone shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_VestingOfEarlyExerciseStockOptions', window );">Vesting of early exercise stock options</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument', window );">Fair value recognized upon the issuance of preferred stock tranche rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">728<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">$ (2,374)<span></span>
</td>
<td class="num">$ (11,296)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Upon Issuance Of Freestanding Financial Instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred During Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_SettlementOfFreestandingFinancialInstrumentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Freestanding Financial Instrument Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_SettlementOfFreestandingFinancialInstrumentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_VestingOfEarlyExerciseStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of Early Exercise Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_VestingOfEarlyExerciseStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024358208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business, Organization, and Liquidity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of Business, Organization, and Liquidity</span><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bicara Therapeutics Inc. (&#8220;Bicara&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, Bicara will realize significant revenue from product sales.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reverse Stock Split</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company&#8217;s board of directors approved an amendment to the fourth amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#8217;s common stock and redeemable convertible preferred stock on a 9.2435-to-1 basis (the &#8220;Reverse Stock Split&#8221;) which was effected on September 5, 2024. The par value and authorized number of shares of common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Initial Public Offering ("IPO")</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">On September 13, 2024, the Company closed its IPO, pursuant to which it issued and sold an aggregate of 17,500,000 shares of its common stock at a public offering price of $18.00 per share and the Company issued and sold 2,625,000 additional shares of its common stock to the underwriters of the IPO pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of approximately $332.4&#160;million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8&#160;million. Immediately prior to the closing of the IPO, the Company&#8217;s outstanding redeemable convertible preferred stock automatically converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">33,210,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> shares of common stock. Following the closing of the IPO, no shares of redeemable convertible preferred stock were authorized or outstanding.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In connection with the closing of its IPO, on September 13, 2024, the Company&#8217;s certificate of incorporation was amended and restated to authorize 500,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value of $0.0001 per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically has funded its operations from the issuance of redeemable convertible preferred stock, common stock and through debt financing.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of September&#160;30, 2024, the Company had cash of $520.8 million and an accumulated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $200.1 million.</span></div>The Company expects that its cash and cash equivalents as of September&#160;30, 2024 of $520.8 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022192928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2024, condensed consolidated statements of operations, condensed consolidated statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) and condensed consolidated cash flows for the nine months ended September&#160;30, 2024 and 2023 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements, which were previously filed in Form S-1/A on September 11, 2024.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Emerging Growth Company Status</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our IPO or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in total annual gross revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K), or we issue more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC&#160;480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore classified the Seed Series, Series&#160;B and Series C convertible preferred stock as mezzanine equity. The convertible preferred stock was recorded outside of stockholders&#8217; deficit because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger or consolidation and sale, lease or transfer of all or substantially all of the Company&#8217;s assets, the convertible preferred stock would have become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would have been distributed in accordance with the corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Tranche Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the consolidated financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock issuance as described in Note 6 Redeemable Convertible Preferred Stock to these condensed consolidated financial statements, included tranche rights (&#8220;Series B Tranche Rights&#8221;) to purchasers who participated in the initial Series B Preferred Stock issuance. The Series B Tranche Rights were determined to be a &#8220;freestanding financial instrument&#8221; as defined in the ASC Master Glossary as they are legally detachable and separately exercisable. Management assessed the freestanding financial instrument under </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that such rights should be accounted for as a liability at fair value given they impose an obligation on the Company to issue shares that are contingently redeemable. The Series B Tranche Rights were revalued at each reporting period until settlement, with changes in the fair value recorded in the consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities;</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; defined as inputs other than quoted prices included in Level 1 that are either directly or indirectly observable; and</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s financial assets (which include cash) and liabilities (which include accounts payable) approximate fair value because of the short maturity of these instruments and have been classified as Level 1. The Series B Tranche Rights were classified as Level 3 financial liabilities (Refer to Note 3 Fair value measurement to these unaudited condensed consolidated financial statements for more details).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents are held in standard checking accounts and money market funds at two financial institutions. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company&#8217;s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance&#160;sheet concentrations of credit risk.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with a term of greater than 12 months regardless of classification. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. The incremental borrowing rate is based on the estimated interest rate for borrowing over a term similar to that of the lease payments at commencement of the lease. The operating lease expense for the operating leases is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components of contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this new standard on January 1, 2022 using the required modified retrospective approach and utilizing the effective date as its date of initial application. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption, the Company elected, to apply the &#8216;package of practical expedients&#8217; which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, if any, and (iii) not to reassess initial direct costs for any existing leases. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. During the three months ended September&#160;30, 2024 and 2023, the Company incurred $15.9 million and $6.9 million, respectively, relating to research and development expenses. During the nine months ended September&#160;30, 2024 and 2023, the Company incurred $43.7 million and $20.1 million, respectively, relating to research and development expenses. The Company recorded accrued liabilities of $9.2 million and $9.6 million for clinical trial and contract manufacturing expenses as of September&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company's IPO, the grant date fair value of stock awards granted under its 2019 Stock Option and Grant Plan were determined using the fair market value of the Company&#8217;s common stock on the date of grant, as set forth in the applicable plan document. Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as option-pricing method or OPM and probability weighted expected return method or PWERM. The OPM method allowed for the allocation of the Company's equity value among the various equity capital owners and considered a variety of factors, included the illiquid nature of the common stock, recent transactions involving the Company&#8217;s stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. PWERM involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome which included an IPO scenario or continued operation as a private company scenario. Among other factors were the Company's financial position and historical financial performance, the status of clinical developments, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, of which we have none. Our comprehensive loss equals our net loss for all periods presented.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share was computed using the two-class method required due to the participating securities, such securities did not participate in net losses and therefore did not impact the Company&#8217;s net loss from continuing operations per share calculations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. Outstanding common stock options, unvested restricted stock awards and redeemable convertible preferred shares are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 and 2023, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and restricted stock awards outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999,713</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950,707</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seed Series redeemable convertible preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,848,387</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232,546</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above reflect the common stock equivalents of the noted instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements and Significant Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. As of September&#160;30, 2024, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September&#160;30, 2024</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2023-07,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity report segment information in accordance with&#160;Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its unaudited condensed consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. The standard largely follows the proposed ASU issued in 2023 with several important modifications and clarifications. ASU 2023-09 is effective for public entities for annual periods beginning after December 15, 2024 and for all other business for annual periods beginning after December 15, 2025. Early adoption is permitted, and the Company is evaluating the impact of this guidance on the unaudited condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022418464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value Measurements</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the Series B Tranche Rights at the time of issuance and subsequently remeasured them at each reporting period and prior to settlement. The fair value of the Series B Tranche Rights was determined using a contingent forward model, which considered as inputs the estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, probability of achievement and estimated time to tranche closing. The most significant assumptions in the contingent forward model impacting the fair value of the Series B Tranche Rights are the fair value of the Company&#8217;s Series B Preferred Stock, probability of achievement of certain milestones, and time to the tranche closing as of each measurement date. The Company determined the fair value per share of the underlying Series B Preferred Stock by taking into consideration the most recent sales of its preferred units, results obtained from third-party valuations and additional factors the Company deemed relevant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the Level 3 Series B Tranche Rights for the nine months ended September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:83.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tranche Rights Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value recognized upon the issuance of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,356</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,001)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,997</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company recorded $6.0 million tranche rights liability within accrued expenses and other current liabilities on the balance sheet. The tranche rights liability were settled in September and November 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used in the estimation of the fair value of the Series B Tranche Rights, on the closing dates of Series B financing tranches and as of September 30, 2023:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 2, 2023 <br/>Initial Closing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 8, 2023 Milestone Closing</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred share price</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022109888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Accrued Expenses and Other Current Liabilities</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:67.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,448</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,087&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,053</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022200480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Common Stock</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 500,000,000 shares of Common Stock authorized for issuance, par value $0.0001 per share, of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,424,994 shares issued, net of share repurchased and cancellation, and 54,409,708 shares, net were outstanding as of September&#160;30, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 711,895 shares issued, net of share repurchased and cancellation, and 640,386 shares, net were outstanding as of December&#160;31, 2023. The Company has reserved 5,881,181 shares of Common Stock for issuance to officers, directors, employees and consultants pursuant to the 2019 Stock Option and Grant Plan. As of December&#160;31, 2023, of the 640,386 shares outstanding, 87,404 shares relate to the exercises of stock options, 437,203 shares relate to vesting of RSAs issued under the 2019 Stock Option and Grant Plan, 115,757 shares of Common Stock are held by Biocon Limited and its affiliates (&#8220;Biocon&#8221;) and were awarded by the Company in 2020 and the remaining balance was issued to an investor.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company completed an IPO. As part of the IPO, the Company received net proceeds of $332.4 million after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8&#160;million from the issuance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,125,000 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prior to the IPO, the Company held shares of convertible redeemable preferred shares, which consisted of Series A, Series B and Series C of preferred stock. Each tranche was subject to automatic conversion to common stock per the terms of the initial agreement. Prior to the IPO, there were 81,790,144, 105,595,101 and 119,599,872 shares outstanding in Series A, Series B and Series C tranches of preferred stock, respectively. These shares were converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">33,210,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> shares of common stock upon completion of the IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405023014608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Redeemable Convertible Preferred Stock</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;23, 2020, the Company issued to Biocon 40,000,000 shares of Seed Series Preferred Stock (&#8220;Seed Series&#8221;) with a par value of $0.0001 per share and purchase price of $1.00 per share, in exchange for net proceeds of $40.0 million. On April&#160;26, 2022, the Company authorized for issuance an additional 50,940,144 shares of Seed Series Preferred Stock with par value of $0.0001 per share and price of $1.00 per share. On March&#160;2, 2023, the Company reduced the total number of its authorized Seed Series Preferred Stock to 81,790,144.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In March 2022, as part of the first close of the Company&#8217;s Seed Series extension financing, the Company entered into several SAFEs, pursuant to which the Company received approximately $5.4 million in exchange for its agreement to issue to certain investors shares of its preferred stock upon the occurrence of the Seed Series extension financing at $1.00 per share. On April&#160;26, 2022, the Company issued 5,350,000 shares of Seed Series Preferred Stock with par value of $0.0001 per share and a $1.00 per share price to settle the $5.4 million in SAFEs, of which 4,000,000 shares of Seed Series Preferred Stock were issued to two investors controlled by a board member, who is also a relative of the Chief Executive Officer, and 350,000 shares of Seed Series Preferred Stock held by relatives of the Chief Executive Officer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, as part of the second close of the Company&#8217;s Seed Series extension financing, the Company sold an additional 3,000,000 shares of Seed Series Preferred Stock to the two investors controlled by a board member, who is also a relative of the Chief Executive Officer, referred to above increasing their ownership to 7,000,000 shares of Seed Series Preferred Stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, the Company issued 37,073,162 shares of Series B Preferred Stock at a price of $1.025 per share (the &#8220;Initial Series B Closing&#8221;) for proceeds of $37.8 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was also obligated to sell up to 68,521,939 additional shares (the &#8220;Milestone Shares&#8221;) of Series B Preferred Stock to the same purchasers at the same purchase price as the Initial Series B Closing the Series B Tranche Rights. The sale of Milestone Shares (the &#8220;Milestone Closings&#8221;) was contingent upon the Company&#8217;s achievement of certain milestones. In addition, if elected by a purchaser, the Company was obligated to sell Milestone Shares prior to achievement of the milestones (the &#8220;Voluntary Closings&#8221;). The Series B Tranche Rights are considered a freestanding instrument classified as a liability under ASC 480. The initial fair value of the liability was determined to be $0.6 million. Refer to Note 3 Fair Value Measurements to these unaudited condensed consolidated financial statements for further details. Share issuances pursuant to exercise of the Series B Tranche Rights under such Milestone Closings occurred on September&#160;8 and November&#160;3, 2023 in the amounts of 39,024,386 and 29,497,553, respectively, for net proceeds of $69.9 million. Upon completion of the Milestone Closings, such tranche liabilities of $8.0 million and $6.0 million on September&#160;8, 2023 and November&#160;3, 2023, respectively, were settled to redeemable convertible preferred stock on the unaudited condensed consolidated balance sheets. The Voluntary Closings were not exercised by the purchasers in 2023, and this right has expired.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2023, the Company issued 119,599,872 shares of Series C Preferred Stock at a price of $1.3796 per share in exchange for aggregate net proceeds of $164.6 million. The Company additionally executed various side letters where certain purchasers have the right to tender all owned shares back to the Company for an aggregate purchase price of $1.00 (the &#8220;Put Option&#8221;). The Put Option has no accounting implications as it is considered immaterial.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Seed Series Preferred Stock, Series B Preferred Stock and Series C Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221;. As of December&#160;31, 2023, the Preferred Stock had the following rights, preferences, and privileges:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock had rights to convert the shares of Preferred Stock into shares of Common Stock (the &#8220;Conversion Rights&#8221;) at the applicable original issue price (&#8220;Conversion Price&#8221;) with a conversion ratio (&#8220;Conversion Ratio&#8221;) of 9.2435:1. All outstanding shares of the Preferred Stock were converted automatically into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,210,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock immediately prior to the closing of the sale of shares of Common Stock to the public on September 13, 2024. </span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Liquidation Preference</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B and Series C Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the shareholders of outstanding Series B Preferred Stock and Series C Preferred Stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders and in case of a Deemed Liquidation Event (defined as a merger or consolidation in which the Company is a constituent party, or the sale, lease, transfer, exclusive license or other disposition by the Company of all or substantially all the assets), the holders of the Series B and Series C Preferred Stock shall be entitled to be paid out of the consideration payable to stockholders or out of the available proceeds of the Company, before the Seed Series and common stockholders, an amount per share (the &#8220;Liquidation Amount&#8221;) equal to the greater of: (a) the applicable original issue price, plus any dividends declared but unpaid, or (b) such amount per share amount as would have been payable on the conversion of all Series B Preferred Stock and Series C Preferred Stock (as applicable) into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If the amount to be paid as Liquidation Amount is insufficient, then all Series B and Series C preferred stockholders shall share the assets available for distribution in proportion of their shareholding. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seed Series Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Seed Series preferred stockholders shall have priority over the common stockholders, with a liquidation preference equal to the greater of (a) the Seed Series original issue price, plus any dividends declared but unpaid thereon, or (b) such amount per share as would have been payable on the conversion of all shares of Seed Series Preferred Stock into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, and after the payment of all preferential amounts required to be paid to the holders of the Series B Preferred Stock and Series C Preferred Stock, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Seed Series Preferred Stock the full amount to which they shall be entitled, the holders of shares of Seed Series Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares of Seed Series Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Preferred Stock is not redeemable except in the event of a Deemed Liquidation Event. As redemption by the holders is not within the control of the Company, all the outstanding convertible preferred stock is classified as temporary equity in the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B and Series C Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The holders of then outstanding shares of Series B Preferred Stock and Series C Preferred Stock shall be entitled to receive, only when, as and if declared by the board of directors of the Company, dividends at the rate of eight percent (8%) of the applicable original issue price for each share of Series B Preferred Stock or Series C Preferred Stock, prior and in preference to any declaration or payment of any other dividend on shares of Seed Series Preferred Stock or Common Stock (other than dividends on shares of Common Stock payable in shares of Common Stock) during the same calendar year. The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company unless the holders of the Series B Preferred Stock and Series C Preferred Stock then outstanding first receive a dividend on each outstanding share of Series B Preferred Stock or Series C Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seed Series Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company shall not declare, pay or set aside any dividends on shares of Common Stock unless the holders of the Seed Series Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock have the same voting rights as the holders of the Common Stock, on an as-converted basis. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the board of directors of the Company was comprised of ten members. The election of directors is determined as following:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">The holders of record of the shares of Seed Series Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3) directors of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The holders of record of the shares of Series C Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The holders of record of the shares of common stock, $0.0001 par value per share, of the Company, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The holders of record of the shares of Common Stock and the Preferred Stock, voting together as a single class on an as converted basis, shall be entitled to elect the balance of the total number of directors of the Company.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">Any director elected as above may be removed without cause by, and only by, the affirmative vote of the holders of the class or series of capital stock entitled to elect such director or directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time when shares of Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative vote of at least 65% of the outstanding Preferred Stock holders, including at least one holder of Series C Preferred Stock who does not hold shares of any other class or series of Preferred Stock: 1) liquidate, dissolve or wind-up the business and affairs of the Company, or effect any merger or consolidation or any other Deemed Liquidation Event; 2) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Company in a manner that adversely affects the powers, preferences or rights of the Preferred Stock; 3) create, issue, or reclassify any capital stock unless the same ranks junior to the Preferred Stock with respect to its rights, preferences and privileges; 4) cause or permit any of its subsidiaries to, without approval of the board of directors, sell, issue, sponsor, create or distribute any digital tokens, cryptocurrency or other blockchain-based assets; 5) purchase or redeem or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than as expressed with the Preferred Stock agreements; 6) create, issue, or authorize the issuance of any debt security or create any lien or security interest or incur other indebtedness for borrowed money; 7) create, or hold capital stock in, any subsidiary that is not wholly owned by the Company, or permit any subsidiary to create or issue any shares, or sell, transfer or otherwise dispose of any capital stock; 8) create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation plan; or 9) increase or decrease the authorized number of directors constituting the board of directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional protective provisions for certain classes of shares include the following:</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For so long as at least 52,797,551 shares of Series B Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least 60% of the Series B holders: a) waive or otherwise forego any adjustment in the Series B Conversion Price; b) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series B Preferred Stock with respect to its rights, preferences and privileges; or c) amend, modify, change or waive the liquidation amount applicable to the Series B Preferred Stock. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Preferred Stock</span> - For so long as at least 71,759,924 shares of Series C Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least 60% of the Series C holders: a) waive or otherwise forego any adjustment in the Series C Conversion Price; b) effect the conversion of the Series C Preferred Stock to Common Stock in a Qualified IPO; c) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series C Preferred Stock with respect to its rights, preferences and privileges; or d) amend, modify, change or waive the liquidation amount applicable to the Series C Preferred Stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022982480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Stock-Based Compensation</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option and Grant Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the board of directors adopted, and the Company&#8217;s shareholders approved, the 2019 Stock Option and Grant Plan (the &#8220;2019 Plan&#8221;) under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are awards that are authorized to be issued:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock Options including Incentive Stock Options (&#8220;ISO&#8221;) or Non-Qualified Stock Options (&#8220;NQSO&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted Stock Awards (&#8220;RSA&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unrestricted Stock Awards (&#8220;URSA&#8221;); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted Stock Units (&#8220;RSU&#8221;)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2019 Plan, as amended, the Company is authorized to issue up to 8,856,245 shares of Common Stock. For the period ended September&#160;30, 2024, the Company has issued RSAs, ISOs and NQSOs under the 2019 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2019 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSAs were issued under individual RSA agreements (the &#8220;Award Agreements&#8221;). The Award Agreements dictate vesting terms and once vested, the recipients&#8217; restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided in the respective Award Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In 2024, in connection with the Company's IPO, the board of directors adopted, and the Company's shareholders approved the 2024 Stock Option and Grant Plan (the "2024 Plan") under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2024 Plan, the Company is authorized to issue up to 2,453,616 shares of Common Stock, plus on January 1, and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by 5% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through September&#160;30, 2024, the Company has issued 174,707 ISOs and NQSOs under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of operations as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">398&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,172</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134</span></td></tr></table></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,199</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,252)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchased/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, total unrecognized compensation costs of $0.1 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted average period of 0.1 years. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic <br/>Value (1)<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,850,669</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652,807</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,216)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,494)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992,766</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,789</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,774</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,951</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992,766</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on September&#160;30, 2024 for the options that were in the money. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the nine months ended September&#160;30, 2024 and 2023, was $6.99 and $2.77, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had 7,094,992 unvested stock options outstanding as of September&#160;30, 2024. As of September&#160;30, 2024, total unrecognized compensation costs of $37.0 million related to unvested stock options are expected to be recognized as expense over a weighted average period of 3.3 years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">On September 5, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to 507,383 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 1,014,766 shares of common stock, (ii) 1% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date and no stock-based compensation expense was recognized during the three months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022841040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Income Taxes</span>Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022171968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Significant Agreements &#8211; Related Parties</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Significant Agreements &#8211; Related Parties</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a master services agreement on December 15, 2020 (the &#8220;Master Services Agreement&#8221;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company did not incur any expenses under the Master Services Agreement during the three and nine months ended September&#160;30, 2024 and 2023. As of September&#160;30, 2024 and December&#160;31, 2023, the Company owed $0.0 million and $1.6 million, respectively, which were classified in accrued expenses-related party on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;23, 2019, the Company entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#8220;BBL&#8221;) formerly Biocon Biologics India Limited, which is valid for 5 years unless earlier terminated by one of the parties. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023 and a manufacturing agreement on December 15, 2023 (the &#8220;BBL Agreements&#8221;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended September&#160;30, 2024 and 2023, the Company incurred $0.3 million and $0.7 million research and development expenses, respectively, under the BBL Agreements. For the nine months ended September&#160;30, 2024 and 2023, the Company incurred $1.1 million and $0.7 million research and development expenses, respectively, under the BBL Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $1.1 million and $1.7 million, respectively, which were classified in accrued expenses-related party on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company additionally entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#8220;Syngene&#8221;), on July 17, 2019, as amended on May 18, 2022 and on August 1, 2022, along with a master contract services agreement on July&#160;24, 2020 (the &#8220;Syngene Agreements&#8221;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The manufacturing agreement is valid for 6 years unless earlier terminated by one of the parties, while the master contract services agreement carried a term of 2 years. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $2.0 million and $1.6 million of research and development expenses, respectively, under the Syngene Agreements. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $6.3 million and $5.8 million of research and development expenses, respectively, under the Syngene Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $1.2 million and $2.9 million, respectively, relating to these incurred costs, of which $0.4 million and $1.0 million, respectively, were classified in accounts payable-related party and $0.8 million and $1.9 million, respectively, were classified in accrued expenses-related party on the balance sheets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company entered into a master service agreement with a wholly-owned subsidiary of Biocon, Biofusion Therapeutics Limited (&#8220;Biofusion&#8221;) (the &#8220;Biofusion Agreement&#8221;), which was terminated upon acquisition of Biofusion by Syngene on August 2, 2022. Pursuant to the terms of the Biofusion Agreement, Biofusion provided research and development services. As of December&#160;31, 2022, the Company owed $7.7 million in connection with services provided by Biofusion, which were classified in accrued expenses-related party on the balance sheet, of which $4.1 million were incurred in 2022. The Company paid the full amount on March 21, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a full recourse promissory note (the &#8220;Promissory Note&#8221;) with our Chief Financial Officer (&#8220;CFO&#8221;), pursuant to which the Company loaned $274 thousand, plus interest accruing at rate of 0.86% per annum (or if higher, the applicable federal rate as of the date of the Promissory Note), due by the earliest to occur of (i) December 31, 2025, (ii) the date of certain transfers of the collateral pledged under the Promissory Note, (iii) upon the day prior to the date a change in the Company&#8217;s or the CFO&#8217;s status would cause the loan to be deemed prohibited under applicable law, (iv) upon the date prior to the Company&#8217;s filing of a registration statement for an initial public offering or a change of control, (v) upon acceleration of the Promissory Note in accordance with its terms or (vi) the date three months following the CFO&#8217;s termination of employment with the Company. As part of the Promissory Note, the CFO pledged 616,320 shares of restricted Common Stock as collateral under the terms of a security agreement. There has been immaterial interest income from the Promissory Note. The CFO repaid the full amount in June 2024. As of December&#160;31, 2023, the Company recorded $68 thousand within prepaid expenses and other assets, and $68 thousand within other assets on the balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405023014608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Significant Agreements</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#8220;IQVIA), which was amended in December 2023 to include global clinical trials Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#8220;SOWs&#8221;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $1.8 million, of which $1.0 million was a refundable deposit and $0.8 million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#8220;ATP&#8221;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $0.9 million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of December&#160;31, 2023, the refundable deposit balance was $1.9 million. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $3.5 million and $2.1 million in expenses. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $9.8 million and $5.3 million in expenses, respectively and paid $13.3 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to IQVIA. As of September&#160;30, 2024 and December&#160;31, 2023, the Company had $0.8 million and $1.6 million classified in accounts payable, respectively and $2.4 million and $4.7 million classified in accrued expenses and other current liabilities on the balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022241536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Commitments and Contingencies</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have contingency reserves established for any litigation liabilities as of September&#160;30, 2024, and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024450800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Subsequent Events</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October, 2024, the Company amended its original lease agreement to lease an additional 4,744 square feet of office space (the "Amended Lease") in order to expand the Company's headquarters. The base rent under the Amended Lease is approximately $0.3&#160;million per year. The Amended Lease did not extend the original lease end date under the original lease term.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. (&#8220;Y-Trap&#8221;) naming as defendants us and Biocon LTD. (&#8220;Biocon&#8221;), captioned Y-Trap, Inc. v. Biocon LTD. and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). The complaint alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. We intend to vigorously defend against this litigation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024566592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,481)<span></span>
</td>
<td class="num">$ (17,049)<span></span>
</td>
<td class="num">$ (12,508)<span></span>
</td>
<td class="num">$ (22,845)<span></span>
</td>
<td class="num">$ (9,288)<span></span>
</td>
<td class="num">$ (7,412)<span></span>
</td>
<td class="num">$ (47,038)<span></span>
</td>
<td class="num">$ (39,545)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405025761968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022653840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC&#160;480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore classified the Seed Series, Series&#160;B and Series C convertible preferred stock as mezzanine equity. The convertible preferred stock was recorded outside of stockholders&#8217; deficit because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger or consolidation and sale, lease or transfer of all or substantially all of the Company&#8217;s assets, the convertible preferred stock would have become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would have been distributed in accordance with the corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock', window );">Series B Tranche Rights</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Tranche Rights</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the consolidated financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock issuance as described in Note 6 Redeemable Convertible Preferred Stock to these condensed consolidated financial statements, included tranche rights (&#8220;Series B Tranche Rights&#8221;) to purchasers who participated in the initial Series B Preferred Stock issuance. The Series B Tranche Rights were determined to be a &#8220;freestanding financial instrument&#8221; as defined in the ASC Master Glossary as they are legally detachable and separately exercisable. Management assessed the freestanding financial instrument under </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that such rights should be accounted for as a liability at fair value given they impose an obligation on the Company to issue shares that are contingently redeemable. The Series B Tranche Rights were revalued at each reporting period until settlement, with changes in the fair value recorded in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities;</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; defined as inputs other than quoted prices included in Level 1 that are either directly or indirectly observable; and</span></div><div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions</span></div>The carrying amounts of the Company&#8217;s financial assets (which include cash) and liabilities (which include accounts payable) approximate fair value because of the short maturity of these instruments and have been classified as Level 1. The Series B Tranche Rights were classified as Level 3 financial liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>The Company&#8217;s cash and cash equivalents are held in standard checking accounts and money market funds at two financial institutions. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company&#8217;s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance&#160;sheet concentrations of credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with a term of greater than 12 months regardless of classification. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. The incremental borrowing rate is based on the estimated interest rate for borrowing over a term similar to that of the lease payments at commencement of the lease. The operating lease expense for the operating leases is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components of contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this new standard on January 1, 2022 using the required modified retrospective approach and utilizing the effective date as its date of initial application. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</span></div>Upon adoption, the Company elected, to apply the &#8216;package of practical expedients&#8217; which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, if any, and (iii) not to reassess initial direct costs for any existing leases.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div>The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div>General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company's IPO, the grant date fair value of stock awards granted under its 2019 Stock Option and Grant Plan were determined using the fair market value of the Company&#8217;s common stock on the date of grant, as set forth in the applicable plan document. Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as option-pricing method or OPM and probability weighted expected return method or PWERM. The OPM method allowed for the allocation of the Company's equity value among the various equity capital owners and considered a variety of factors, included the illiquid nature of the common stock, recent transactions involving the Company&#8217;s stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. PWERM involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome which included an IPO scenario or continued operation as a private company scenario. Among other factors were the Company's financial position and historical financial performance, the status of clinical developments, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, of which we have none. Our comprehensive loss equals our net loss for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share was computed using the two-class method required due to the participating securities, such securities did not participate in net losses and therefore did not impact the Company&#8217;s net loss from continuing operations per share calculations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. Outstanding common stock options, unvested restricted stock awards and redeemable convertible preferred shares are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Issued and Not Adopted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements and Significant Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. As of September&#160;30, 2024, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September&#160;30, 2024</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2023-07,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity report segment information in accordance with&#160;Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its unaudited condensed consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. The standard largely follows the proposed ASU issued in 2023 with several important modifications and clarifications. ASU 2023-09 is effective for public entities for annual periods beginning after December 15, 2024 and for all other business for annual periods beginning after December 15, 2025. Early adoption is permitted, and the Company is evaluating the impact of this guidance on the unaudited condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax</a></td>
<td class="text">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Freestanding Financial Instruments, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481288/505-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022240672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 and 2023, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and restricted stock awards outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999,713</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950,707</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seed Series redeemable convertible preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,848,387</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232,546</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405117232816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Financial Assets Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">519,631&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within Cash and cash equivalent</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">230,088&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Level 3 Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the Level 3 Series B Tranche Rights for the nine months ended September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:83.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tranche Rights Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value recognized upon the issuance of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,356</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of preferred stock tranche rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,001)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,997</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used in Estimation of Fair Value</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used in the estimation of the fair value of the Series B Tranche Rights, on the closing dates of Series B financing tranches and as of September 30, 2023:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 2, 2023 <br/>Initial Closing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 8, 2023 Milestone Closing</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred share price</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024334448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:67.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,448</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,087&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,053</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022176288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of operations as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">398&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,172</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSA Award Activity</a></td>
<td class="text"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,199</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,252)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchased/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic <br/>Value (1)<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,850,669</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652,807</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,216)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,494)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992,766</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,789</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,774</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,951</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992,766</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span>The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on September&#160;30, 2024 for the options that were in the money.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022774992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio, common stock and redeemable convertible preferred stock</a></td>
<td class="nump">0.1082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405023282880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity - Initial Public Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance on common stock, net of issuance costs</a></td>
<td class="nump">$ 332.4<span></span>
</td>
<td class="nump">$ 332.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022825984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 520,758<span></span>
</td>
<td class="nump">$ 230,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 200,059<span></span>
</td>
<td class="nump">$ 153,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024510240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>financialInstitution</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld', window );">Number of financial institutions where cash and cash equivalents are held | financialInstitution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 43.7<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_AccruedClinicalTrialAndContractManufacturingExpenses', window );">Accrued clinical trial and contract manufacturing expense</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_AccruedClinicalTrialAndContractManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial And Contract Manufacturing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_AccruedClinicalTrialAndContractManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financial Institutions, Cash And Cash Equivalents Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024329280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Options and restricted stock awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,999,713<span></span>
</td>
<td class="nump">2,950,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,848,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,232,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022641600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 519,631<span></span>
</td>
<td class="nump">$ 230,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within Cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalent</a></td>
<td class="nump">519,631<span></span>
</td>
<td class="nump">230,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">519,631<span></span>
</td>
<td class="nump">230,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds included within Cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalent</a></td>
<td class="nump">519,631<span></span>
</td>
<td class="nump">230,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds included within Cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds included within Cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405012124896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Tranche Rights Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of December 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value recognized upon the issuance of preferred stock tranche rights</a></td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in the fair value of preferred stock tranche rights</a></td>
<td class="nump">13,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of preferred stock tranche rights</a></td>
<td class="num">(8,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of September 30, 2023</a></td>
<td class="nump">$ 5,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022654544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityCurrent', window );">Tranche rights liability</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FreestandingFinancialInstrumentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Freestanding Financial Instrument, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FreestandingFinancialInstrumentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022531824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)<br></strong></div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Preferred share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=bcax_MeasurementInputProbabilityOfAchievementMember', window );">Probability of achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">0.950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Freestanding Financial Instrument, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bcax_MeasurementInputProbabilityOfAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bcax_MeasurementInputProbabilityOfAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022387968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 7,448<span></span>
</td>
<td class="nump">$ 6,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued bonus and payroll related expenses</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 8,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405019507024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">365,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,424,994<span></span>
</td>
<td class="nump">54,424,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,424,994<span></span>
</td>
<td class="nump">711,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance on common stock, net of issuance costs</a></td>
<td class="nump">$ 332.4<span></span>
</td>
<td class="nump">$ 332.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bcax_BioconLimitedMember', window );">Biocon Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember', window );">2019 Stock Option And Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881,181<span></span>
</td>
<td class="nump">5,881,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">1,023,541<span></span>
</td>
<td class="nump">579,975<span></span>
</td>
<td class="nump">575,746<span></span>
</td>
<td class="nump">514,972<span></span>
</td>
<td class="nump">54,409,708<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,386<span></span>
</td>
<td class="nump">504,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,232<span></span>
</td>
<td class="nump">349,962<span></span>
</td>
<td class="nump">4,229<span></span>
</td>
<td class="nump">6,739<span></span>
</td>
<td class="nump">10,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,059<span></span>
</td>
<td class="nump">33,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,210,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="nump">33,210,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | 2019 Stock Option And Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">76,097,548<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcax_BioconLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcax_BioconLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405016206208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2022 </div>
<div>investor </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 23, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>investor </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 14, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 12, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">50,940,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock and preferred stock tranche rights, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityNumberOfInvestorsStockIssued', window );">Number of investors | investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
<td class="nump">81,790,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock | Two Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock | Two Investors, Relatives Of Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,024,386<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,817<span></span>
</td>
<td class="nump">$ 37,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross', window );">Gross proceeds from issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,097,548<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">105,595,101<span></span>
</td>
<td class="nump">37,073,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember', window );">Series B Redeemable Convertible Preferred Stock, Milestone Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,497,553<span></span>
</td>
<td class="nump">39,024,386<span></span>
</td>
<td class="nump">68,521,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FreestandingFinancialInstrumentLiabilityFairValue', window );">Initial fair value of liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.3796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance | $</a></td>
<td class="nump">$ 164,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="nump">119,599,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption', window );">Purchase price for put option (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_BioconLimitedMember', window );">Biocon Limited | Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FreestandingFinancialInstrumentLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Freestanding Financial Instrument Liability, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FreestandingFinancialInstrumentLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityNumberOfInvestorsStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Number of Investors, Stock Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityNumberOfInvestorsStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, New Issues, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share, Put Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bcax_TwoInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bcax_TwoInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bcax_TwoInvestorsRelativesOfBoardMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bcax_TwoInvestorsRelativesOfBoardMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcax_BioconLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcax_BioconLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405016234288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Conversion Rights (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio, common stock and redeemable convertible preferred stock</a></td>
<td class="nump">0.1082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405024308384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Dividends (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityDividendRatePercentage', window );">Dividend rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityDividendRatePercentage', window );">Dividend rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022858576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Voting Rights (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>board_member </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_NumberOfMembersBoardOfDirectors', window );">Number of members on board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember', window );">Seed Series Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Directors Entitled To Be Elected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_NumberOfMembersBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Members, Board Of Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_NumberOfMembersBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Voting Rights, Number Of Directors Entitled To Be Elected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeedSeriesRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405021411040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Protective Provisions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage', window );">Affirmative vote, percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage', window );">Affirmative vote, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired', window );">Minimum amount of shares required for protective provisions (in shares)</a></td>
<td class="nump">52,797,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage', window );">Affirmative vote, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired', window );">Minimum amount of shares required for protective provisions (in shares)</a></td>
<td class="nump">71,759,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Protective Provision, Affirmative Vote, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Protective Provision, Shares Outstanding, Minimum Amount Required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcax_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405012732560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.99<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,094,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation cost, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation cost, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">507,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">1,014,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember', window );">2019 Stock Option And Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,856,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember', window );">2024 Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,453,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage', window );">Percentage of increase in future issuance reserved share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember', window );">2024 Stock Option and Grant Plan | Incentive Stock Options And Non-Qualified Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcax_A2019StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405021454064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">$ 4,216<span></span>
</td>
<td class="nump">$ 1,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">3,172<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405019769328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSA Award Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">47,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(40,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Repurchased/forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">6,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">4.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Repurchased/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405021419072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,850,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,652,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(393,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(117,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">7,992,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">9.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">3.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share)</a></td>
<td class="nump">4.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in usd per share)</a></td>
<td class="nump">$ 6.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average &#8211; Remaining Contractual Life (years), Outstanding</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 133,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share, Exercisable (in shares)</a></td>
<td class="nump">897,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price. Exercisable (in usd per share)</a></td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 16,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share, Exercisable and expected to vest (in shares)</a></td>
<td class="nump">7,992,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable and expected to vest</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405018679600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements &#8211; Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2020</div></th>
<th class="th"><div>Jul. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,085,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,094,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="nump">2,271,000<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="nump">6,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember', window );">Master Services Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember', window );">BBL Agreements | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_RelatedPartyAgreementTerm', window );">Related party agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementManufacturingMember', window );">Syngene Agreement, Manufacturing | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_RelatedPartyAgreementTerm', window );">Related party agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementMasterContractServicesMember', window );">Syngene Agreement, Master Contract Services | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_RelatedPartyAgreementTerm', window );">Related party agreement, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember', window );">Syngene Agreements | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_BiofusionAgreementMember', window );">Biofusion Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_PromissoryNoteMember', window );">Promissory Note | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Promissory note loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_DebtInstrumentCollateralPledgedShares', window );">Number of shares pledged as collateral (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_DebtInstrumentCollateralPledgedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Collateral Pledged, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_DebtInstrumentCollateralPledgedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_RelatedPartyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_RelatedPartyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementMasterContractServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementMasterContractServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_BiofusionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_BiofusionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405022205504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_OtherCommitmentLiabilityRefundableDepositAmount', window );">Refundable deposit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 20,628<span></span>
</td>
<td class="nump">$ 9,530<span></span>
</td>
<td class="nump">$ 55,752<span></span>
</td>
<td class="nump">$ 26,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_PaymentsForOtherCommitments', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement, Refundable Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Services Agreement, Investigator Grant Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement, Additional Refundable Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_OtherCommitmentLiabilityRefundableDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Liability, Refundable Deposit, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_OtherCommitmentLiabilityRefundableDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_PaymentsForOtherCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Other Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_PaymentsForOtherCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementRefundableDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementRefundableDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45405023413536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_LesseeOperatingLeaseAreaOfProperty', window );">Area of property (in square feet) | ft&#178;</a></td>
<td class="nump">4,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Annual base rental expense under lease | $</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_LesseeOperatingLeaseAreaOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_LesseeOperatingLeaseAreaOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR%_N]OM:93^=;0YQ.7%DQ&C7$%N(1%W[Q)1"Y*^%57[9YVJ[L.WF:X<(BCK
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MVYO%[$%<7,UN9W?S)7"NE\L'!YRM9O?+NX?KY</-?'9[#OX /YP%./MR#KX
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M;"]W;W)K<VAE971S+W-H965T-BYX;6RU6MMNVS@0_17"6RRZ0%U+I&39V<1
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M-VUVW3799>?@1^=P@J;M:@<PA)1L<G X&64B3[]>7][B#R.2XQ5(L0+OIKX
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M&D L><?H22N8?!/]L/&D*)*5Q(A<""]R"\CC6PS='Y6#93$.V[_ISH(?H<R
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MIDX+W%<;U;>05(OL2BGI@PI.)P4#8TL[E_ZDH5S R01\\7!E/Y8)-PT #8R
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MD)A3ZS5KQ[V1CCY*I8/@MON>;F:$DHZFA;I#C\Y6&%%9P.^UK>6>C633_@C
MZDP0+"FZN@-UGNM4WW@]##<B'//Y#CF@MWE ,VUSGQI+S4/H _GBA!H,YQ(D
MN^-2A*F*#L(J:482@$!]T:'9-UR-PB>=Q42FI+68J@7Y8%?^!#<^""O&5 G?
MQYYHOF$!0>9'$!3B%@O7/5 TUL\&\:X7_9Z0HD_$_8_%_D8P#?7F?6H($ZS3
MLVEDSWTI45Z+)ZQV(+\@ F\%')^%TZ'41H[I1"YR<YM[Y=MH,=O&FKB.P-K;
MJXI.1=*VD)KX+IP>#_Q;V=I@DP5VKG_3#3B'GU%R&5*2#*"("W?DV 3=4+7
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MLO=+A('^!ALKC\DQ:'[S;;@9 ;L[&2PD&7NY/X9;T^4."Q'^7NO#0-(P$#)
MIK2BP9>%#$6<1O1G',4I?-V+Q:UH6*\#Z7[^Y%*'WE4]L6X'EMYV\P70OU#4
M/%LDJP5[T;6]5F _<+\@&J@4>X,'6G@SR'6%+CQJOXGWKX WUG-3562R9]BW
M&NJ7AZ]\_9*K8^D=5B$L?=)0H ID$?K-@V021CZEAB>,0O,?M]"UFRT[>("$
MLSYX3D_2*8(/O%*([=QH<42C]IVW)%:]?1G?*_\L^:?>);RO*!OX27W%WGZ6
MN..70Z(?GTQ%GFY@X9B#QAVG'V!'\\[W6?/K+;S>DZ&&+N",0H /-.&.#>K&
MCJ]B[P2$KLSRP#P(0^88/C*R<#Y!6].)(M8(LA\@$^3'.:+&B(PM%:H%AN3)
M19\R.U:LPU?]I>%-1SW)E>P(:;K1O@>1KJ[Q@OF@$-*L/F!@FQYRA]\QWJMQ
M]JXOM<9%P8UYRD1X[Q%9^#5<+R&&_?OE=?M>F:W06AI]5,%Q/U\?R#U>R7VV
M6YX7^_)#66&=GF6B3$<, <C1J_[1AM#T+_FZP#A0@$T?Y^L)?X,5XZ$;CE\D
M-UG3U1!X7S==;U*U?*EU^#9<"7[!-V''Q_D^\0\*KXW"HP8S>/5@?/QJCPL?
M_D-K:[H7>VK;UB[ISX56$ KA _#[S +"DP\X0;@H_<W_ U!+ P04    " !&
M@&Q9WPJ>6L(%  !-#P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U7
MVV[;.!#]%<*]H 5<6Y;MU$D3 TG:H@NTBZ#I=A\6^T!)8XN()*HD9=?[]7N&
MNOC2.$T7^V)+)&<XY\R9H7B^UN;.ID1.?,^SPE[T4N?*L^'0QBGET@YT205F
M%MKDTN'5+(>V-"03;Y1GPS (3H:Y5$5O?N[';LS\7%<N4P7=&&&K/)=F<T69
M7E_T1KUVX+-:IHX'AO/S4B[IEMP?Y8W!V[#SDJB<"JMT(0PM+GJ7H[.K":_W
M"[XJ6MN=9\%((JWO^.6WY*(7<$"44>S8@\3?BJXIR]@1POC6^.QU6[+A[G/K
M_;W'#BR1M'2MLS]5XM*+WJPG$EK(*G.?]?H#-7BF["_6F?6_8EVO'4]Z(JZL
MTWECC AR5=3_\GO#PX[!+#AB$#8&H8^[WLA'^58Z.3\W>BT,KX8W?O!0O36"
M4P4GY=89S"K8N?E[J8SX*K.*Q">2MC($QIT]'SHXYR7#N'%T53L*CS@Z%9]T
MX5(KWA4))?OV0P3511:VD5V%#SJ\I7(@QD%?A$$X><#?N$,Z]O[&/T?Z5MDX
MTPS6BK\N(^L,Q/'W?9AKEY/[77+!G-E2QG310T58,BOJS9\_&9T$;QX(>-(%
M/'G(^Z^DYC\Y$E]2$@N=H2Y5L11.1AGX\$ *)U115[POG0CE+!R67^N\E,7F
M^9-9.'K]QHJ%*F01*YD):2W!ITNE$ZE<D8B("I'7^R4"HPL.8^7#D%;HA4"&
M'>41F2[-0A:)>$MQ,SKRHV/Q0A5PK"N+:?OR#"ML;%3I8_M(*\K$J/D/F__Q
M@?-+']T9:Y0VJ!]SAWZWJ. .0..L@F11>"[%1M?2ICZ.F!_H6Z40,S/R5$Q'
MI_V3\0A/GH#PS=Y3._M%._#QV-6/P;+'R/\#)00KP6QV)+AVMH7RR-5;@0BR
M3D$]B(5ELY-ZY)U';LDHJ.U*?#$0$ ;\<6!9)SP-8[]465MAGCP*6T46(  @
MVP@6<:,M&.1L2#).,5YJXUC0);;0B;<L\62$TP+4N<S+?U#+_]&!K:'9A!P9
M-&'L65G>0HH830]/3"KJ92U-(G*=4-87ZU0A',Q;E9 O 4Y06?DBH1V"'HCA
M!D<4&3:^=3J^:^K&XV2#NCH3>.E[.Z/LW:N%(<)&B!1;".,G2Z,C&:E,N0T[
M@+V"M)@&3\].LIAW\.0:\-PF :\F*]=P:-6R4 L52[9%=G(O78;F0SC&AU#0
M1>SS\HN",'3$XK 7'6/M0?AXC<DX?+W@=$7_<Z@JV_>L=%RP'O?YV$U$OFVI
M/A6#O3K8D<P!"LA3V)3A-7A0PF2R#;L_*H!H@SY]QTN08=VIJQ:":W-DT"\0
MC97<T+F*G._KC:>JP'L?BRR^7# ?,7K6H=$Y?"B3O"JE 56=Q*SG0R:)XC=T
MA 52J8W=30.0@H,$;C-:R:Z^]H\7X<\(",.A+[4?@BW^.)40CE?2C\G>MO7[
M9;+@^L9K 2@@P7^)$'^)_'C*_'B>'/CZJ%JQ7,FL[CZ>QL.#*=SI@N^W$8-]
MC1KYAZDNF[1T?0QNMIFP/J>MMDR]^\DD%->>BK:F]MGXB?EHW!]/3X"Z;72/
ML'DQZP?!Z.4!W'N(P['5/SU]C3/H_@7]/44P$893\/1D$'!Y95ZE^WMG'=G-
MH27CV%0PHN^X>%BJM:?AU^![&!B J+5A)30$1TWH_DNXUM[QC= :FY,@88ZW
M.'BKW_6J?F% ARK>[7C>365K'SLMG4$VJGUTF^NW.-H&PYVD(;DQ:#ZUN)1J
MTZ8JCZ0"'PC2H#V%3>JV*V;-R*>VWXGK9M-MMZD;$XY-4/I4C ;!R/_!ZAW2
M$ONC GW-5]*&I+$O13"8B@!PVB.(3QXQ'83/VAIY!O]'^_#I=! \$Z,@P-]]
MW\[#G2M.3F;I+W(6#; J7'W;Z4:[N^)E?47:+J\OFN!EJ9"_C!8P#0:OI[U:
M(^V+TZ6_,$7:X?KE'U/<=\GP LPOM';M"V_0W:#G_P)02P,$%     @ 1H!L
M6<F_%TBM @  +08  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK55=
M;YLP%/TK5ZR:-BDJA)"$9DFDI.VT2:L6M?MXF/;@P"58-3:S3=/^^UT;PC*I
MS5-?L*\YY]QS;7R9[Y6^-R6BA<=*2+,(2FOK61B:K,2*F7-5HZ0WA=(5LQ3J
M76AJC2SWI$J$<11-PHIQ&2SG?FVCEW/56,$E;C28IJJ8?EJC4/M%, P."[=\
M5UJW$"[G-=OA'=KO]493%/8J.:]0&JXD:"P6P6HX6R<.[P$_..[-T1Q<)5NE
M[EWP.5\$D3.$ C/K%!@-#WB)0C@ALO&GTPSZE(YX/#^H?_2U4RU;9O!2B9\\
MM^4B2 /(L6"-L+=J_PF[>L9.+U/"^"?L6VPR#2!KC%551R8'%9?MR!Z[?3@B
MI-$+A+@CQ-YWF\B[O&*6+>=:[4$[-*FYB2_5L\D<E^Y0[JRFMYQX=KG*,MU@
M#M>/=,P&#3"9PU=;HH;+1FN4%KYPMN6"6XYF'EK*Z9AAUNFO6_WX!?T+N%'2
ME@:N98[Y__R0O/:&XX/A=7Q2\ [K<QA% XBC.#FA-^HW8.3U1B_H;=@3VXJN
M<+\;3!CXM=H:J^F3^?U<R:UB\KRBNT8S4[,,%P'=$X/Z 8/EVS?#2?3AA-^D
M]YN<4G^% WM-?3C \1BN/#SKX.((GBFZSL82015 *"B4H+[ Y0[><4DKJC&D
M8-[/@ [:8K4E(7?:5YAUP7#0)W6[RW16^J0Y/E"+J2N7LG=S!M-!DJ0T3@;1
M:-PSMTHVK=>:/6GR0%J"V>-"AH,TFM)SFL0]K=:J0.,:$A-0H$=%*:'2I,>T
MQ4]2N(CAF[($/(-A-$B&$4W2030>/?<5A$=7N$*]\XW*[5<C;7N;^]6^%Z[:
M%O /WC;2&Z9W7!H06! U.I^. ]!M<VH#JVK?$+;*4GOQTY+Z.6H'H/>%4O80
MN 3]'V+Y%U!+ P04    " !&@&Q9)+J5H.$$  !N"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6RE5FUOXC@0_BL66ZWN) N2$ JT@ 3=WEZE6RUJ
M[^7#Z3Z89""^.G'6=DJY7W\S3DCA"MU*]Z$E=F8>/S/S>#*3K3:/-@-P[#E7
MA9UV,N?*JU[/)AGDPG9U"06^66N3"X=+L^G9TH!(O5.N>E$07/9R(8O.;.+W
MEF8VT953LH"E8;;*<V%V"U!Z.^V$G?W&O=QDCC9ZLTDI-O  [K=R:7#5:U%2
MF4-AI2Z8@?6T,P^O%C'9>X/?)6SMP3.C2%9:/]+B+IUV B($"A)'" )_GN &
ME"(@I/&MP>RT1Y+CX?,>_2<?.\:R$A9NM/I#IBZ;=D8=EL):5,K=Z^W/T,0S
M(+Q$*^O_LVUM&Z)Q4EFG\\89&>2RJ'_%<Y.' X=1<,8A:APBS[L^R+/\))R8
M38S>,D/6B$8//E3OC>1D045Y< ;?2O1SLQN=YYB<!Z>3QTG/(2+M]Y+&>U%[
M1V>\Q^R++EQFV6V10GKLWT,F+9UH3V<1O0GX &67]0/.HB"*W\#KM^'U/5[_
M#-[MMTJZ'?MSOK+.H +^.A5C#1&?AJ!;<65+D<"T@[*W8)Z@,_OX(;P,KM\@
M&+<$X[?0OYO_]WNS7S-@N%&*8L<R8=D@"'A0_S&;">3.])H=N8C*9=K(?R!E
M>+^9M+8210*<E<*P)Z$J8!=!%P%"5H*I43BA;#.99&P0\SB*^7@<[P\@!$@Y
M*["=H)G?Q;M;5B9!2GB,*%*6T!E*";J6W.\04##FPV#4 -4(6T!O["36H9$L
M-DSX$% D#O(5$MHKQ8,,PY"/QH/_2>4R#GA_=/D>'I\@:6B$GD:_^ZH&C6 P
M0CX:A3P<A>=*<9A_YC2^7\L$##)(I<$6IND1\E+I':"[)Z\+B\U'%,XR#(M\
M';DZ)!$%X;A!_EK6_0\]/ALR62I1=-G\= R^O(1PG(C#\#D;#;%>;=$-8 )A
M?S(\@TFDK4.TGH'V#)!_W!_R*.B_=GP"ZRBQZ'+_,-\7CU785LR[XN$L# =\
M.!B>E3J6, .5LM6.+:3&W+%?9"Y=(P2).128<B61D64_?/PPBJ+@NK;TB_#Z
M1V_IQ2"VPF#'(S!W4')94 X#;T?[!NB[2(&MA/*5W8HV. Q;%.A"L6O397?%
M@;))U?P(.\%?!35?=K?\ZBN(]]3M"X9[QQXH&Y D/M)P:70"D/K$7/3[43?&
MSXE2/I-KAR=B.%7BB^"SOC72+U)I$UVAQ#@QR)$[E=)'J/$P0T(%0Y;PC),"
MU;T4.[%2\)_D(#?MA"++BVC<';7'KXW.O6$K?Z08!3R,!@>]J\N61N(=:53V
M*EA?VY?:8]6>P#A)/ RD@(6@1^S@R!8WVOM==S*Z2M)2<GU_,1)1YGS_M/#A
M-HL;,CG (75UV:U %/S$%#@U^2+;:O4W7EM?Y0J_XMABDH:5'VAP/ZGU6=^1
MLA$ZEB*W^Y*B=IP4BHF-P0B@<&>R@(KTLL06,QQCYF+43A@,^& \X"$V;Z(?
MAF-<C_EH&)VXTR3=[\7=A&=/)(!3IRO!CUAJY_N@A?TQGEI3$'20!;+O]WD4
M!DCF\JAH!PFI2GQL1$\)>U%Y]]1WMW<P ^5@-G[2L\QKMQZ'VMUVF)S7,]2+
M>3V)?A%F(U'C"M;H&G2'@PXS]717+YPN_42UT@XKZQ\S'(C!D &^7VOM]@LZ
MH!VQ9_\"4$L#!!0    ( $: ;%EQ0R?J<!   -8X   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;,U;;7/;-A+^*Q@W[=@SC*Q7V[*3S#AO<[FYM)DD
MS7VXN0\0"5FX4 0#@))UO_YV%P )BI(LIVGG/K2Q26*Q[_OL GZV5OJK60AA
MV?TR+\SSDX6UY?7YN4D78LE-3Y6B@#=SI9?<PJ_Z[MR46O",%BWS\V&_?W&^
MY+(X>?&,GGW0+YZIRN:R$!\T,]5RR?7FI<C5^OG)X"0\^"CO%A8?G+]X5O([
M\4G8W\L/&GX[KZED<BD*(U7!M)@_/[D=7+\<X_?TP1<IUB;ZF:$D,Z6^XB_O
MLN<G?61(Y"*U2('#/ROQ2N0Y$@(VOGF:)_66N##^.5!_2[*#+#-NQ"N5_U-F
M=O'\Y.J$96+.J]Q^5.N_"2_/!.FE*C?T?[9VWXZF)RRMC%5+OQ@X6,K"_<OO
MO1ZB!5?]/0N&?L&0^'8;$9>ON>4OGFFU9AJ_!FKX XE*JX$Y6:!1/ED-;R6L
MLR\^BDR F6>Y8*]4L1+:2OSY ^A&:"TR]LFJ].NS<PM[X8KSU--]Z>@.]]"=
MLO>JL O#WA29R-KKSX''FM%A8/3E\"#!3Z+LL5$_8</^<'R WJ@6?$3T1GOH
M?1;+4FGP0_;F6R7MAKV6)LV5J;1@_[J=&:O!8?Z]2W!'=[R;+@;1M2EY*IZ?
M0)08H5?BY,4O/PTN^C<'N![77(\/4?\#YOH1=-EO!7LM4K&<"<V&([(%6,0N
M<-6RY,6&26,J^-PJ]E*J%,)NW$_Z??J/F04'C3 U9Y\$DA1:PJ_;>YS^\M/5
M<-B_B;ZA)X.;,X@-NV"<E5RS%<\K@;2>]'M ?,!*X(EV8+S(6%GI= '1RDHM
M4_?= +YKODJ8+)BXAX^*.\$@N[$"4F"I50K[$I-/QD 98B[/(7WT4/9;():S
MX04)/FP+SBN[4%K^%YA&8J@'7J3(#.-9)C$%\9Q-^LD4-#(8CX_4!DE\C+Q[
MQ"2^WW-0!AL2VZ,VV[!3E:+!X)E5%E@L*C(OD)+6Q&(=8A/L?35(+J<D6H^]
MJ_<D/7&#(EBDB?O,I3:68;")\,BS@X8>7-Z8UE[BWOHB,)<%Z%06=VT91&$%
MLB(+8,,(\%X0X]/MVS<F03] 0UCD<+V0P%);^E1 4<@8+\'R]Q*RO,@W[,FD
M-PZ&[[@):>5.0[@(1Y9<'G]((6R@#,**E8#$K4UD8UQ5UDHSI+2J!/+(CDK3
M"IX7::V/!^1GW.XT]"$']9$Y24:3QX3CL0[(MQGR+DDFL1:2"3*SK5EO):#J
MC#-^9+)8@^&CG&/7*M(^I!^K59[#NQD$*)LIKC.VI/25P(9H.L9SH^"=%CE'
M?% [Y$**.7MS+]**'O\VGX,TL QE?9P&%R(G!L(6YH$]*'S^7H$?[HP>(T"N
M[ >&CU' 7SM-C1YI!E0])I _7_WUQK EGREX)8L4T*C!J("5$C+7NA#:+&2)
MWUP^3I*'TJ5WM1&0O1PE@XMABRQ1?-G1#@0K;R?HX22*DU/<P!>]=P68 +-7
MH/4*S RBU140,U"K2(TN>U=-D?H<\;KF7KUJELL[R&R9"\8\A\R#/UY<)9/A
M()F.IK'MO4 Q5^]ECC8M("_1RYJ;0U)[GS!\*>IJ#%X!RN@\]LH!?O'5/AWX
MQ.@??M;@R_" V@CC)#<\)Q5O\[M'&$\W@A?<>2T\Q-Q>Y^?M\.(IN.?*%0#8
M+N3]9:!L*(2#3@%IS!FU(2$2:G6TG0NW[]JJ(PPH"YP _;_-!I)J6&C)_$7E
M56$1[&[+[!2W1ZL,W1,48F1&!9:S.=0]8R$'HCUD 2BYHNW3G!LCYQ(_@F4L
MEWPF<X35%>!_S6X_O6+CJ[[;37H#S[F,R@JRVRQ#760"ZCKT/$X9,X&5YZ+Q
M]8_H;_CF5V4%&[&W2.X+D7L/"0& /+)FO"."EU4%K\ D0 XS*"1%]Q/D/YF1
MRGV"Q""P\, MQXB;5QI(:.2(RQS,2Z:H09YIP0QQ+W0J353+=RO7:<94D&NZ
M/ADP0<; !Z'WL0YT7U']^17R'OWJ(/@(*RGNQ)>J0I9AX]$T@3XI&5U=T(KA
M-!E/+Y/)9(0IU)2"FN%\D^Q&OA?3WK11].\8!RDX:2ZHD_9R=9E.G#36RQFL
M*5U^?'+5P&EBZLE%]* MII=KE[#; A $<!"#_$0WK4P:M3+;X,N']H,^,>,Y
MX7AJL7V>Z8:3XZ)0MK8^A3KN$.4^,).3 .6R"RA_&EV!P6M85TK@KM?JL2X.
MU*#!8)I,IM/DZG)'$7KU<!$:74XOHBJT#7/Y'6!<S$1=[QA<C.,XC&M.4T<
MO@@JW\#!BD/*J@ .0QYAX$06E;%>H,I"[HRTM. K!Q:=<C!\!84*$*7BG@5Y
M9[RI,X$#XKV(V-_7"<;Y\4-EV6\E,M[.B\USLE&!.3?%&*/T!P$A4XYO#68]
M:1'01.E2+K&?T)!/0I;=BSN2 ^BAR Y8E1)TGH=P:.,C5T^#C.VE7M >NR6C
MUBXW&L0^U\&RW+6*<]A3K5$+9"1LM.A+[&%,$CK2%62(.V&N_4R!0*A/?JB/
M!0!/-+C/)[OV<M2IN7*Q[,!#[>[;:UP+6+\&IUAB8G&#A4@9'89J#.#Q"32$
M:%S,'-#^WDE$1J[1<VYTVB7T 5]LCRK2YKU&5]FU\".^B#'5M#<<CR;7 S .
MNGQEZY+;B+9+8Y2$O**P$E=6@0>"&!B-I)K1*!D.^I S+O9I"9Q69-+UP372
MP,U2C\)"&^*QUAXR?E%9 9Y)V\E]X!+YN,?^(;]5F&:=]H+_-*%PT/6?(L;"
M/0 ".0"$X;^J4S.VZD7S:][LE; ,3 EO7#738"NG78#%[88J:=PM<M;8(-\7
MMF0HX%J&H@7@IN0R0]*!!0!4PIHMAAA? 0 AM\1$!W)8+6=.$!Q%P (J;X%;
MY *R:\H='.$0YP!KLI;FWY#^3C,Q)ZA%^&TI]!T.@714#'W+WIVB8!M'WX$\
M%=+"=A5TA[[C/26!M \\)(0-S!R1+U2;O#+8W(&'8.'%[Y6#6=*4X&RTHZ^B
M82\4 F,"@=,,K8!($EP5'S9:.W.&VTHPQ_D56!MHS1ZT3TCT3C$EWY!5,/W$
M!D"9(IO6UHL+:LOA9@(,*SI#(&0Y=0$6TT^HUA'LV]-1QI:^I0_K3".^59#5
M?*1"N<1B!?Q<LU-^=DP2A*0/%J2PRR#7 WK*$+1#+X#:!*\$=(5:(T\XG9TY
M=-CAUC\ OUNK*L]<_9\)T2C58[4HEWHW^+[H.T47KT4[<YGQX21(W.]+(TDK
MB>B]<0:=X3S"ZK%O 5==8V%P09]5X?Q#PGIR[*(M?$O8+9P;_-!YM5-XE%T.
MI!,$95J52D>87^HF&8*LO8-#H:<=T'.0-S([*1O[/P#]VAM]A]/[XAH9(\(?
M^_RZ=NN8I3_BUTA,"[3]8?_^#L<^;NSVESLN341H9GB(Y,&2>F@/!QSYW'K;
M@YK"< .5$DQ,PX/0ZVJPMM3M+.U-OR_]/R99)#^N%M>%)8YG_!+$W.;WR+$K
M(O$JSZ-D4E?G3;>0=8KB<;O$J0.J'0B,8-*'1R1S&[<<G5F\L9JFOC:MD\7%
M#@&#-4Y5R,@N?&01EM6H]%$3>5BQ=#Y-_MQFTOE<X"6*6/)NR#]AZQ!A?F_"
M=N2&P!Y:!R=5F5BZ-O+S#M@N#4T.HL$%8". RV&LTP#< ]%Y:XB WV;6]BB_
M [(MZY2#P_D._ @X*L:XA\8HV/&V9G^V/E<7[ES=;[@]1WE=9]9CX7ZW92SV
M]$;?!PMV C]_0@@IO@"W7\.>="!#N'H>%06G;W?$ 1QDD))2.@795G!347RG
MJ7%( 5_1_1$L&RG!\:N?S^J(>J 7Q0 3/'C@007 E_LSG2L8OF6(ZBF.$C#8
M25@>,GR<G#&M>^3NI,,X.2X6@5*[2W>$[ * ;:.K%KG6]U$NV/W%&<LJ'8X/
MZ-@!^F$@RC7;"*[;\ROG Q@KWK0)96=L-P1"5!Q@M7%!B[-&$104;IWV\\^4
ME]+2;)GD;M>2JLB%,3^L;'6CPQVZ>W>&3!);BIRG$TK?ZTBM(Q[R;N24?K-R
M22D4FQ;SM)E4S$"SD!-^59%B&[141QEYG4/*Q%N8*(1K08?Q*!W?#&Y^I+U;
MGGC(A =K>">- 4LM<Q' -')9Y?"14)7)-\VK8TWY?V2E+XH&J(\9!?J1,/&W
M<LO];)#O5'ELF>2 ,'NFGRPY+I_[(\,EI$X<^>-+4(4[X_:'!?4%Q!89V3K>
MXJ:9J%XSV=O6":Q2CI&C04XT8,'Q2.$'.T:4G*Q-"2K97?2(988G.Z>#LYKI
M;='E8_C<G4;^.)-VH06P.3K;;R+Y>$9W%,<_79NKHYF,6^*DN8Y3W]&)[KAM
MHX\_6XKCA6BE3G<>UHG[)(2Z57>"RJKC%Q[E(I18']IL*[0?\)H&D'K.MB^_
M[7.G'EN!.]U23? Z"&?[R!Q=25E""9EA2[-4>+D,83<. 5->8?^R<6TN <J9
M'S%SZ ?QCC'6YI6R-5=;6>U!5-$5U7<VP5RZ$:P'ZH:M7,\%/ZZDH:.L6TLE
MCZH  MX#QRU46IIBLW6OJ*FM#D"&ZW_UV5%0##Y=:VDQ=^)8E6"EWJD4J%HX
M2;;L8O)S(!B7NT[E"",C68#G9_[NG".!SNS>'SPYQ9M*F1*NA<+OCP5\6X2N
M&01.F)F(,#%9B3 N>8JW<M Q(4 +1!)N&(*W)+IM!+K=?(X&1A;VC>L)S@<.
M]_6.-VQX!GTNE'-L_ZRCHT4I<,I2X!S)NT;-!#:#<SSZ)).\*R#"L><+6[[<
MY'S=3<,%GBOPHG#H'AC/<.A%F8@D<76\5&NR5W2>2/RX8K\;']PPR/\I#?H2
MUQDE3@;?FFY(CG:D1&C-0Z#BJV'_J8KHR&OG7<BH[<<1SX[SSZWCSQLV/O.Q
MC] (:[X-\4!#HFH&.%-R<ANKDCHLZ%(JI/0@=1>-)'1%J);9E&A]G7A=L'CP
M$G#L'>G JJ^B,/CAI@31W.W337,",\M!WG3!9?$4_^8A\U.=&S8Y:P[42<4X
ML_#M(.WG4& +-./S)?\:'L8C(^RF7:K01S1)46OH;DS (N,3[$Z#U?=T@?.+
M72Y27V^FY?6E;1_9F9A9O&]9N9&T#GK%=[D4A0MW_UK2+61CW<$C//3L0F0#
M&9%12&.K/E-:@Y-G#.J?V-RPRX8Q>$L)IJT%&;04'&7C BA,=6 )!)&[&=$^
M+DNV/"ZFH"(O<=.$QA*NX2#7"@=VM6_0$,Z=T-6*:O%[PZX:B7BF2ISKNO3B
M *_?-$HQ?E1TBEF-?GR:R^*KR,X(6X.G^AD_5.P;7#H]"]<^A7<Z]S.5TN;&
M^JYJ'LXI;1@)=*,*RGMS';)L:F39U$BT8[BZ0DE&Q -55VM$N]I=[V^FG[*W
MJ&_%<H7UR30E:C),+NG>UN"H\=9?5HY;E;A?5^*:,U]VKQG'6Y5R)=KN@T><
M=XX+GOVG,I8F27Y2V-S[W+I;<<-FK5!I!R^]<%4J:7P:M_57*C'9BGS>7-FO
M-;I5+9+O+!=[[?*]=0.=K"[-2Y41;_Z.%H(&4BSN'!^$A>/49FCX 'N]O=!G
MUQ\LG4=_:T:P _^B#L,*-G5_=E8_K?]H[];]K5KSN?N+O_=<WTD(IES,86F_
M=SDY<6H)OUA5TE^NS92U:DD_+@0'Q\(/X/U<06SZ7W"#^D\97_P/4$L#!!0
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M#$$'#+]\0-@I69V2?V9REK%R0<!VYB.BAC;"3M1]5?LQ0%SGH8SR&766^NX
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M__3#_'1V\03H90-Z^93W%\C:2_IGOV\$N]-9P?,=PT!A\$SF3C,.JEI<,PJ
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MUW?D&-KE)SH0SFI47<=CPNV5/2@0*3O*A&>!%GCXGN]J+8E\\#JB%>["0FF
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M:N^%HY789RE<6P*-#+I$# 5LF?5KW#E4*07JIDJDM+5I]CJDJ2"59@&H@7R
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M%S?0][6UH7N)#OI;^^)O4$L#!!0    ( $: ;%G7'3P[* ,  /\&   9
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MTO/ 3-N&_U 8Q('?[[RGTT$23/^\[5=02P,$%     @ 1H!L679!,7!]!
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MBO:!EGU;.>$D5X?Z,^&B15##6+2ZB$J!N+XAA!\F,D#=/ =_ 5!+ P04
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M$+F_.PMR!U:_!C^);ZC6P:<O1IE("S)5>_"M:V9RN]2MTO,Y.#\Z1R#3-4B
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MX49E#6@]D=(T'S9!>X6?_ =02P,$%     @ 1H!L6:]8_\*_ @  $P8  !D
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M_15"#8H$R%H77Y/:!A)+BP;8-$:"M ]%'VAI;!.11"])V=G]^E(7RY8C,Q+
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MLM@7?%A@YP;M$G!]J93=#EQSZ/X%Z5]02P,$%     @ 1H!L6=A@7-C' P
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ML>HR7GV.J&XDVY8G^G=,2I:5EQO *7!MH-ZO&),/-_HC0?-1:/$O4$L#!!0
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MFK[1+&]'AR<FM:#_HF'_1:/^B\:]-V,BW(SM:5!IIL$W J_#XD[O)'>YVCR
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M&GN)<IAB]P;2".!^(M#5>F(,-/U@^ M02P,$%     @ 1H!L62+YGYE^!@
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MRIS4W_BQ"<2!@>09-O : Z]O$)PP\!L#_Z4G!(U!\-(31HV!=MVN?=>!B[#
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M\L XR29"-.><I)M<R4A)M7'^A]Q2CN26I*AI]/?OBHEN)4W$/UW:+CHPZ.Y
MML)<B1T)Z;6AEA!!^2,U9C__A(?FKUW"@H0YD# 7$N9!PGQ(6  $:XAU4(EU
MH*//[NEZGZ[(0TS5(KMC(E(J3=@^E5VRTZ(NE1TDS(&$N9 PKX -<UB6NSW.
M\,0TI[W'0SE!>@R 8 TYV96<;*V</C%)8J22V6PB2S>(?E=YK:"="[3=NC.6
M.;3&S5NS:+>:V/VC^^>T&]GVR+::K=P.AT,UYS=;>=H!7CI/0,("(%@CL,,J
ML$-M8&___'([1_?.$MVF(?H7?21"JK5KH=JI?"U6ZU<JN<K]T5(YCD(JZ@2N
M*_9:9Y?.)) P!Q+F0L(\2)@/"0N 8 UACBIACEX[VQI!BA42YD#"7$B8!PGS
M(6$!$*PAUG$EUK%^%DTC&:G9<D=^%!(]F6II.9=J#A+F0,)<2)@'"?,A8<&X
MG02.#Y+ AI8FE98F8*E60;(/_/?MXR1T,6FG1_BXD=,F3<;'C=QV(Y6R'37R
MM*.[-%J0L  (UH@J-NL:F*F-ZSR?$]04$765I6[TUI?.#* TIZ0=!A[W6Y%W
MRV:'2ANW1.2!=LT'I050M*9$#LJD6"^1,,PT(K)U)'MT[]0);L6B=8\7>C\7
MA_\,ERZH2Z_#I6IZ_'@-ZC. HC6#;]7!M_XO^'Q/5]5\G^>Y+,]MPSWG65H1
M1^0ABE6JT;T:E X:,_V@K0UM-R[6QCD^75"?7H?/P:@M#DB? 12M*8ZZ](RU
MQ<*7/*:_1P>U0*>H!7:J![3X#$IS0&DN*,T#I?F@M "*UE1M78/&@]=^AL>@
MM6M0F@-*<T%I'BC-!Z4%4+2F:NM2-];7NL]_F->#+A8?),T!I;F@- ^4YH/2
M@I+6R#S-4\_TN"ZSXY?5V;O6[=OTD0H9;8AD'/D\^WKBKM!DIQA!:^^@- >4
MYH+2/%":#TH+H&A-T=8E>/SJ-7@,6H0'I3F@-!>4YH'2?%!: $5KJK:NQ6.H
M8KP>=+'X0,OQH#07E.:!TGQ06H#;-?F3)7E<U^2QOBC_HN?O^6H59=_0JG9G
M/HI#EKT7H#0'E.:"TCQ0F@]*"Z!HS8]0Z[</EOG:2[D%^@8#E.: TEQ0F@=*
M\T%I 12MJ=KZA8BE?R%R_E*N!UTL/M#W)Z T%Y3F@=+\DM;XJN^X,!] N2PT
MU3O8EI!0OLFWJ B4OT@KONVNKE;;8.;YYH^CZS?X:H$[KCOXRBTVN=3X8L_-
M1\(W42I03-?*E?EA9!N(%]M8BA/)=OFFB <F)4ORPRTE*\JS!NKW-6/R^21S
M4&TFFOT'4$L#!!0    ( $: ;%G"\D!N1 (  -T$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0X+GAM;(U4;4_;,!#^*Z<,32!M39J&@E@:B9=-( T-4;%]
MF/;!32^MA6,'^]*"Q(_?V2E1APK:E_C.=_?<\S@^YVMC[]T2D>"Q5MI-HB51
M<Q+'KEQB+=S -*@Y4AE;"V+7+F+76!3S4%2K.$V2<5P+J:,B#WLWMLA-2TIJ
MO+'@VKH6]ND,E5E/HF'TLG$K%TOR&W&1-V*!4Z2[YL:R%_<H<UFC=M)HL%A-
MHM/AR5GF\T/"3XEKMV6#5S(SYMX[5_-)E'A"J+ DCR!X6>$Y*N6!F,;#!C/J
M6_K";?L%_5O0SEIFPN&Y4;_DG):3Z#B".5:B571KUI>XT7/H\4JC7/C"NLL=
M<\>R=63J33'[M=3=*AXWY[!5D([?*$@W!6G@W34*+"\$B2*W9@W69S.:-X+4
M4,WDI/8_94J6HY+KJ)BV,X</+6J"KRO^.MB_0!)2N0/X#*^CL =2P[54BD_4
MY3$Q X\3EYMN9UVW](UN/TH:P&CX"=(DS>!N>@'[>P=0T<</PZ/C+__BQ:RD
MEY/V<M+08/2?<N#W=\Z *\+:_=G%MX/+=L/YB3AQC2AQ$O&5=VA7&!5,=IR\
M1W;4DQV]AUZ<\A2!J:"Q/&.6GF"?#]<]M,(B5/Q##^#YC;/IN'?HAP'=#]^J
MR(ZR+(]7.SAE/:?L?4Y:MT*%B\XSIXEM?.07@-U6S]&"0A]ZAKU=C#KL8;)%
M*1F,7C&*MVZK'_QK81=2.T:NN"H9'+$BVPU3YY!IP@6>&>)Q".:2WQ^T/H'C
ME3'TXOB9Z%^TXB]02P,$%     @ 1H!L6:]6T0%F P  E1<   T   !X;"]S
M='EL97,N>&ULW5A1;]HP$/XK4;I.K30UA*R!K("T(56:M$V5VH>]588X8,EQ
M,L=TL%\_GQU"H#Y$^[#"@B#V?;GOOK//B<.@4BM.[^>4*F^9<U$-_;E2Y:<@
MJ*9SFI/JJBBIT$A6R)PHW96SH"HE)6D%3CD/NIU.'.2$"7\T$(O\-E>5-RT6
M0@W]L-/8/'OZFFIK_-'W+-^X2.G0?[QX_VM1J)MWGCV??3@[ZSQ>WNS:+PQP
MZ0=.TNL#2*\Z^D"9#8K1QX?1[R/'J'O;U%M*#U#6/TC9'F$8<>+4U1*%./8Z
M2$);^6#.X8'SN'<:,?*N0]EY(^L<<XO<"9VW$[+.0;T$1H.L$)N5$/G6H-E)
M3KTGPH?^F' VD0R\,I(SOK+F+ABF!2^DI_02U.%"L%1_+!S:'JS.FB=GHI F
MMHU@?R?UY3O N@<"&>>-P*YO#:-!292B4MSJCKG8&)]!7MU^6)5:X4R25=B]
M]C<.YJ2#3 J94KFY(_AKTVC :09R))O-X:R*,@!0J2+7C92162&(T;#VJ!N:
M=DHYOX=;U\]LBWN9M>;-E*%HFEI0W;0TM@/\;3;+W:;MO8K7*]E3H;XL=#K"
M]*%"Z9VD&5N:_C)K!&#L(<Y.RI*O/G,V$SFUR1\<<#0@:S]O7DCV1T>#4IEJ
M Y6^]T2E8M.VY;<DY0-=JG4Y+3-<<_<$-?_;<9Y1027A;=&Z]H]YE%^M..J]
ME61S5]D5[-18;T>.7>3U*8B,3T'D2=1D__A%1LGQ:ZPWL4<NLO=F=_:7B Q/
M063W%$1&1RDRJ#>^K=WUUMZZL7KP#C/T?\ ;$=\$]28+QA43=6_.TI2*9UML
M3:_(A--M?GU]2C.RX.JA 8?^IOV=IFR1)\U5=S 0]56;]C=(+XR;%R@=BXF4
M+FDZKKMR-C%-3S=TU/H AUWDUAQN!/.QF!L!#(N#*<!\K!<6YW_*IX_F8S%,
M6]^)]%&?/NICO5S(V'RP.&Z?1!_N3),DBN(8&]'QV*E@C(U;',/7S89I P\L
M#D1ZV5CCLXU7R/XZP.9T7X5@F>*5B&6*CS4@[G$#CR1QSS86!SRP6<!J!^*[
MXT!-N7VB"&85TX:M8!Q)$@R!6G37:!PCHQ/#QST_V"J)HB1Q(X"Y%401AL!J
MQ!%, 6C D"@RS\&=YU&P?DX%FS_B1W\!4$L#!!0    ( $: ;%F7BKL<P
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 1H!L63D?HBON    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M1H!L69E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !&@&Q9S@/+H?H%  ")(   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M1H!L62J/4FG_!@  ;"0  !@              ("!/0X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $: ;%FX0;P!C@0  /@8   8
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M965T.2YX;6Q02P$"% ,4    " !&@&Q9R;\72*T"   M!@  &0
M    @(&8:0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M $: ;%DDNI6@X00  &X+   9              " @7QL  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 1H!L67%#)^IP$   UC@  !D
M             ("!E'$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !&@&Q9:Y;@0K *  !W(0  &0              @($[@@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $: ;%F%63T?]P$
M )($   9              " @2*-  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 1H!L6:ZU:OA""   ]QH  !D              ("!
M4(\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !&@&Q9
MC_X26=L$  #!"P  &0              @(')EP  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( $: ;%G7'3P[* ,  /\&   9
M      " @=N<  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 1H!L679!,7!]!   MPD  !D              ("!.J   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !&@&Q9:+MY&]\"  !("P
M&0              @('NI   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( $: ;%D >H^K0P(  (H&   9              " @02H  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 1H!L6;+H+*RP
M&   @TX  !D              ("!?JH  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !&@&Q9$*4S:S,#  #L!@  &0
M@(%EPP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $:
M;%G;$UIH; 0  ,X+   9              " @<_&  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 1H!L6:]8_\*_ @  $P8  !D
M         ("!<LL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !&@&Q9AJ>M.#8$  #4"@  &0              @(%HS@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $: ;%F8R_AE=@(  # %
M   9              " @=72  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 1H!L62>P!QT.!0  %!X  !D              ("!@M4
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !&@&Q9N2_7
M-I4"   7!@  &0              @(''V@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( $: ;%G88%S8QP,  *$.   9
M  " @9/=  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M1H!L63&'QDUA P  P0T  !D              ("!D>$  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !&@&Q93'=<- H$   @&@  &0
M            @($IY0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( $: ;%EYTO@(TP(  $P'   9              " @6KI  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 1H!L65)ES.(1 @
M,@0  !D              ("!=.P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !&@&Q9$@H).$,#  "O#@  &0              @(&\
M[@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $: ;%G"
MV4:&]0(  *P)   9              " @3;R  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 1H!L64N++()?#0  \;X  !D
M     ("!8O4  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $: ;%E0&6:@\ (  !L*   9              "
M@9(= 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 1H!L
M62+YGYE^!@  NBP  !D              ("!N2 ! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " !&@&Q9AF\U%9L#  #C$   &0
M        @(%N)P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( $: ;%G;,(Z3(P,  )\*   9              " @4 K 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 1H!L68XX-CU2!   ?A
M !D              ("!FBX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " !&@&Q9"R,J>W8*  #1@@  &0              @($C,P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $: ;%FA0!:-
M]@4  %@T   9              " @= ] 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ 1H!L6<+R0&Y$ @  W00  !D
M ("!_4,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !&
M@&Q9KU;1 68#  "5%P  #0              @ %X1@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( $: ;%F7BKL<P    !,"   +              "  0E*
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $: ;%D*M#S2&00  %L@   /
M          "  ?)* 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !&@&Q9
MDBR@EK@!  #G'   &@              @ $X3P$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !&@&Q9C$_JC[H!  #N'   $P
M        @ $H40$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .  X #\/
(   34P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business, Organization, and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity</Role>
      <ShortName>Description of Business, Organization, and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Significant Agreements ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsRelatedParties</Role>
      <ShortName>Significant Agreements ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails</Role>
      <ShortName>Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Description of Business, Organization, and Liquidity - Initial Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails</Role>
      <ShortName>Description of Business, Organization, and Liquidity - Initial Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Description of Business, Organization, and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Organization, and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/CommonStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Redeemable Convertible Preferred Stock - Conversion Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Conversion Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Redeemable Convertible Preferred Stock - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Redeemable Convertible Preferred Stock - Voting Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Voting Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Redeemable Convertible Preferred Stock - Protective Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Protective Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stock-Based Compensation - RSA Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSA Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Significant Agreements ??? Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails</Role>
      <ShortName>Significant Agreements ??? Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SignificantAgreementsRelatedParties</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SignificantAgreementsRelatedParties</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bcax-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="bcax-20240930.htm">bcax-20240930.htm</File>
    <File>bcax-20240930.xsd</File>
    <File>bcax-20240930_cal.xml</File>
    <File>bcax-20240930_def.xml</File>
    <File>bcax-20240930_lab.xml</File>
    <File>bcax-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="550">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcax-20240930.htm": {
   "nsprefix": "bcax",
   "nsuri": "http://www.bicara.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "bcax-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "bcax-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bcax-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcax-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcax-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcax-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 198,
   "keyCustom": 35,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 23,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 2
   },
   "contextCount": 220,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 470,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 550,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.bicara.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity",
     "longName": "9952156 - Disclosure - Description of Business, Organization, and Liquidity",
     "shortName": "Description of Business, Organization, and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bicara.com/role/FairValueMeasurements",
     "longName": "9952158 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952159 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bicara.com/role/CommonStock",
     "longName": "9952160 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStock",
     "longName": "9952161 - Disclosure - Redeemable Convertible Preferred Stock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bcax:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bcax:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bicara.com/role/StockBasedCompensation",
     "longName": "9952162 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bicara.com/role/IncomeTaxes",
     "longName": "9952163 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bicara.com/role/SignificantAgreementsRelatedParties",
     "longName": "9952164 - Disclosure - Significant Agreements \u2013 Related Parties",
     "shortName": "Significant Agreements \u2013 Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bicara.com/role/SignificantAgreements",
     "longName": "9952165 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bicara.com/role/CommitmentsandContingencies",
     "longName": "9952166 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bicara.com/role/SubsequentEvents",
     "longName": "9952167 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bicara.com/role/StockBasedCompensationTables",
     "longName": "9954475 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails",
     "longName": "9954476 - Disclosure - Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)",
     "shortName": "Description of Business, Organization, and Liquidity - Reverse Stock Split (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails",
     "longName": "9954477 - Disclosure - Description of Business, Organization, and Liquidity - Initial Public Offering (Details)",
     "shortName": "Description of Business, Organization, and Liquidity - Initial Public Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails",
     "longName": "9954478 - Disclosure - Description of Business, Organization, and Liquidity - Additional Information (Details)",
     "shortName": "Description of Business, Organization, and Liquidity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcax:NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld",
      "unitRef": "financialinstitution",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "bcax:AccruedClinicalTrialAndContractManufacturingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails",
     "longName": "9954481 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails",
     "longName": "9954482 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)",
     "shortName": "Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954483 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "bcax:FreestandingFinancialInstrumentLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "bcax:FreestandingFinancialInstrumentLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails",
     "longName": "9954484 - Disclosure - Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)",
     "shortName": "Fair Value Measurements - Assumptions Used in Estimation of Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954485 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcax:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcax:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bicara.com/role/CommonStockDetails",
     "longName": "9954486 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "9954487 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails",
     "longName": "9954488 - Disclosure - Redeemable Convertible Preferred Stock - Conversion Rights (Details)",
     "shortName": "Redeemable Convertible Preferred Stock - Conversion Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
     "longName": "9954489 - Disclosure - Redeemable Convertible Preferred Stock - Dividends (Details)",
     "shortName": "Redeemable Convertible Preferred Stock - Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "bcax:TemporaryEquityDividendRatePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "bcax:TemporaryEquityDividendRatePercentage",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "bcax:TemporaryEquityDividendRatePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "bcax:TemporaryEquityDividendRatePercentage",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails",
     "longName": "9954490 - Disclosure - Redeemable Convertible Preferred Stock - Voting Rights (Details)",
     "shortName": "Redeemable Convertible Preferred Stock - Voting Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "bcax:NumberOfMembersBoardOfDirectors",
      "unitRef": "board_member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "bcax:NumberOfMembersBoardOfDirectors",
      "unitRef": "board_member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
     "longName": "9954491 - Disclosure - Redeemable Convertible Preferred Stock - Protective Provisions (Details)",
     "shortName": "Redeemable Convertible Preferred Stock - Protective Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-163",
      "name": "bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954492 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails",
     "longName": "9954493 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
     "longName": "9954494 - Disclosure - Stock-Based Compensation - RSA Award Activity (Details)",
     "shortName": "Stock-Based Compensation - RSA Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-178",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails",
     "longName": "9954495 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails",
     "longName": "9954496 - Disclosure - Significant Agreements \u2013 Related Parties (Details)",
     "shortName": "Significant Agreements \u2013 Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-186",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ResearchAndDevelopmentExpense",
       "us-gaap:ResearchAndDevelopmentExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bicara.com/role/SignificantAgreementsDetails",
     "longName": "9954497 - Disclosure - Significant Agreements (Details)",
     "shortName": "Significant Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "bcax:OtherCommitmentLiabilityRefundableDepositAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "bcax:OtherCommitmentLiabilityRefundableDepositAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bicara.com/role/SubsequentEventsDetails",
     "longName": "9954498 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-220",
      "name": "bcax:LesseeOperatingLeaseAreaOfProperty",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-220",
      "name": "bcax:LesseeOperatingLeaseAreaOfProperty",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "bcax_A2019StockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "A2019StockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Stock Option And Grant Plan",
        "label": "2019 Stock Option And Grant Plan [Member]",
        "documentation": "2019 Stock Option And Grant Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_A2024StockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "A2024StockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stock Option and Grant Plan",
        "label": "2024 Stock Option and Grant Plan [Member]",
        "documentation": "2024 Stock Option and Grant Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r502"
     ]
    },
    "bcax_AccruedClinicalTrialAndContractManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "AccruedClinicalTrialAndContractManufacturingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial and contract manufacturing expense",
        "label": "Accrued Clinical Trial And Contract Manufacturing Expenses",
        "documentation": "Accrued Clinical Trial And Contract Manufacturing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "bcax_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r502",
      "r672"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r611",
      "r612",
      "r613",
      "r614",
      "r658",
      "r673"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r212"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r532",
      "r542",
      "r574"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r525",
      "r535",
      "r545",
      "r577"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r570",
      "r578",
      "r582",
      "r590"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r254"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r81",
      "r98",
      "r113",
      "r144",
      "r148",
      "r158",
      "r159",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r286",
      "r288",
      "r321",
      "r361",
      "r426",
      "r483",
      "r484",
      "r502",
      "r513",
      "r627",
      "r628",
      "r667"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r102",
      "r113",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r286",
      "r288",
      "r321",
      "r502",
      "r627",
      "r628",
      "r667"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r496"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "bcax_BBLAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "BBLAgreementsMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBL Agreements",
        "label": "BBL Agreements [Member]",
        "documentation": "BBL Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "bcax_BioconLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "BioconLimitedMember",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biocon Limited",
        "label": "Biocon Limited [Member]",
        "documentation": "Biocon Limited"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_BiofusionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "BiofusionAgreementMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biofusion Agreement",
        "label": "Biofusion Agreement [Member]",
        "documentation": "Biofusion Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r473"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds included within cash and cash equivalent",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r61",
      "r111"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r61"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Financial Officer",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r99",
      "r100",
      "r101",
      "r113",
      "r135",
      "r136",
      "r138",
      "r140",
      "r146",
      "r147",
      "r163",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r187",
      "r188",
      "r191",
      "r194",
      "r201",
      "r321",
      "r385",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r414",
      "r435",
      "r457",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r601",
      "r607",
      "r615"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r146",
      "r187",
      "r188",
      "r189",
      "r191",
      "r194",
      "r199",
      "r201",
      "r385",
      "r386",
      "r387",
      "r388",
      "r488",
      "r601",
      "r607"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r76",
      "r363",
      "r413"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r170",
      "r171",
      "r471",
      "r625",
      "r626"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Equity",
        "verboseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r611",
      "r612",
      "r614",
      "r658",
      "r671",
      "r673"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r414"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r414",
      "r432",
      "r673",
      "r674"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 500,000,000 and 365,000,000 shares authorized; 54,424,994 and 711,895 shares issued and 54,409,708 and 640,386 shares outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r365",
      "r502"
     ]
    },
    "bcax_CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of directors entitled to be elected, common stock",
        "label": "Common Stock, Voting Rights, Number Of Directors Entitled To Be Elected",
        "documentation": "Common Stock, Voting Rights, Number Of Directors Entitled To Be Elected"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r86"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r477"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r183",
      "r189",
      "r346",
      "r354",
      "r360",
      "r474",
      "r476"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_DebtInstrumentCollateralPledgedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "DebtInstrumentCollateralPledgedShares",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares pledged as collateral (in shares)",
        "label": "Debt Instrument, Collateral Pledged, Shares",
        "documentation": "Debt Instrument, Collateral Pledged, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note loan amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r329",
      "r330",
      "r486",
      "r487",
      "r500"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r182"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r20"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r214",
      "r245",
      "r246",
      "r248",
      "r492"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per share, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r133",
      "r135",
      "r138",
      "r139",
      "r140",
      "r143",
      "r281",
      "r284",
      "r298",
      "r299",
      "r357",
      "r374",
      "r478"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per share, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r135",
      "r138",
      "r139",
      "r140",
      "r143",
      "r281",
      "r284",
      "r298",
      "r299",
      "r357",
      "r374",
      "r478"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r142"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus and payroll related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation cost, period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r92",
      "r106",
      "r107",
      "r108",
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r132",
      "r145",
      "r164",
      "r165",
      "r166",
      "r202",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r331",
      "r332",
      "r339",
      "r373",
      "r378",
      "r379",
      "r380",
      "r394",
      "r457"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r532",
      "r542",
      "r574"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r519",
      "r529",
      "r539",
      "r571"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "bcax_FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of Series B preferred stock tranche rights liability",
        "terseLabel": "Change in fair value of Series B preferred stock tranche rights liability",
        "label": "Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability",
        "documentation": "Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails",
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r314",
      "r496"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails",
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r314",
      "r496"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Estimation of Fair Value",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r498"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r313",
      "r314",
      "r316",
      "r351",
      "r352",
      "r353",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r496",
      "r498"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r356",
      "r496",
      "r499"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r203",
      "r208",
      "r302",
      "r314",
      "r351",
      "r489",
      "r490",
      "r491",
      "r496"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r203",
      "r208",
      "r302",
      "r303",
      "r314",
      "r352",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r496"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r302",
      "r303",
      "r304",
      "r305",
      "r314",
      "r353",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r496",
      "r498"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Rights Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Fair Value of Level 3 Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r310",
      "r315"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in the fair value of preferred stock tranche rights",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r315"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value recognized upon the issuance of preferred stock tranche rights",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r315"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlement of preferred stock tranche rights",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r315"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsChangesinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance as of December 31, 2022",
        "periodEndLabel": "Balance as of September 30, 2023",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r315"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r313",
      "r314",
      "r316",
      "r351",
      "r352",
      "r353",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r496",
      "r498"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r578"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r578"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r578"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r578"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r578"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "bcax_FreestandingFinancialInstrumentLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "FreestandingFinancialInstrumentLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche rights liability",
        "label": "Freestanding Financial Instrument, Liability, Current",
        "documentation": "Freestanding Financial Instrument, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_FreestandingFinancialInstrumentLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "FreestandingFinancialInstrumentLiabilityFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial fair value of liability",
        "label": "Freestanding Financial Instrument Liability, Fair Value",
        "documentation": "Freestanding Financial Instrument Liability, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_FreestandingFinancialInstrumentLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "FreestandingFinancialInstrumentLiabilityMeasurementInput",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Freestanding Financial Instrument, Liability, Measurement Input",
        "documentation": "Freestanding Financial Instrument, Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r437"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_IQVIARDSIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "IQVIARDSIncMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IQVIA RDS Inc",
        "label": "IQVIA RDS Inc [Member]",
        "documentation": "IQVIA RDS Inc"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "IncentiveStockOptionsAndNonQualifiedStockOptionsMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Options And Non-Qualified Stock Options",
        "label": "Incentive Stock Options And Non-Qualified Stock Options [Member]",
        "documentation": "Incentive Stock Options And Non-Qualified Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r78",
      "r80",
      "r358",
      "r371",
      "r480",
      "r483",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r307",
      "r310",
      "r315",
      "r376",
      "r377",
      "r442",
      "r472",
      "r497",
      "r670"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r307",
      "r310",
      "r315",
      "r376",
      "r377",
      "r442",
      "r472",
      "r497",
      "r670"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r273",
      "r275",
      "r276",
      "r277",
      "r390",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r89",
      "r131",
      "r132",
      "r144",
      "r150",
      "r159",
      "r261",
      "r262",
      "r274",
      "r375",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r259",
      "r260",
      "r266",
      "r267",
      "r268",
      "r270",
      "r384"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r605"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r570",
      "r578",
      "r582",
      "r590"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r594"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r594"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r594"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r149",
      "r159",
      "r483",
      "r604"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "bcax_LesseeOperatingLeaseAreaOfProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "LesseeOperatingLeaseAreaOfProperty",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of property (in square feet)",
        "label": "Lessee, Operating Lease, Area Of Property",
        "documentation": "Lessee, Operating Lease, Area Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual base rental expense under lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r38",
      "r39",
      "r40",
      "r42",
      "r43",
      "r44",
      "r45",
      "r113",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r287",
      "r288",
      "r289",
      "r321",
      "r412",
      "r479",
      "r513",
      "r627",
      "r667",
      "r668"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r77",
      "r368",
      "r502",
      "r608",
      "r624",
      "r664"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r95",
      "r113",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r287",
      "r288",
      "r289",
      "r321",
      "r502",
      "r627",
      "r667",
      "r668"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_LiabilityUponIssuanceOfFreestandingFinancialInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "LiabilityUponIssuanceOfFreestandingFinancialInstrument",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value recognized upon the issuance of preferred stock tranche rights",
        "label": "Liability Upon Issuance Of Freestanding Financial Instrument",
        "documentation": "Liability Upon Issuance Of Freestanding Financial Instrument"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement, Additional Refundable Deposit",
        "label": "Master Clinical Contract Services Agreement, Additional Refundable Deposit [Member]",
        "documentation": "Master Clinical Contract Services Agreement, Additional Refundable Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MasterClinicalContractServicesAgreementMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement",
        "label": "Master Clinical Contract Services Agreement [Member]",
        "documentation": "Master Clinical Contract Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementRefundableDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MasterClinicalContractServicesAgreementRefundableDepositMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement, Refundable Deposit",
        "label": "Master Clinical Contract Services Agreement, Refundable Deposit [Member]",
        "documentation": "Master Clinical Contract Services Agreement, Refundable Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MasterClinicalServicesAgreementInvestigatorGrantPaymentMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Services Agreement, Investigator Grant Payment",
        "label": "Master Clinical Services Agreement, Investigator Grant Payment [Member]",
        "documentation": "Master Clinical Services Agreement, Investigator Grant Payment"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MasterServicesAgreementMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Services Agreement",
        "label": "Master Services Agreement [Member]",
        "documentation": "Master Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ]
    },
    "bcax_MeasurementInputProbabilityOfAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "MeasurementInputProbabilityOfAchievementMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of achievement",
        "label": "Measurement Input, Probability of Achievement [Member]",
        "documentation": "Measurement Input, Probability of Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred share price",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r498"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsAssumptionsUsedinEstimationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r498"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds included within Cash and cash equivalent",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business, Organization, and Liquidity",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r63",
      "r79",
      "r93",
      "r103",
      "r104",
      "r108",
      "r113",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r137",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r281",
      "r284",
      "r299",
      "r321",
      "r372",
      "r434",
      "r455",
      "r456",
      "r511",
      "r627"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Pronouncements Issued and Not Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536",
      "r546",
      "r570",
      "r578"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expenses) income",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610"
     ]
    },
    "bcax_NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions where cash and cash equivalents are held",
        "label": "Number Of Financial Institutions, Cash And Cash Equivalents Held",
        "documentation": "Number Of Financial Institutions, Cash And Cash Equivalents Held"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_NumberOfMembersBoardOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "NumberOfMembersBoardOfDirectors",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of members on board of directors",
        "label": "Number Of Members, Board Of Directors",
        "documentation": "Number Of Members, Board Of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r618"
     ]
    },
    "bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs included in accounts payable and accrued expenses",
        "label": "Offering Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "Offering Costs Incurred During Noncash or Partial Noncash Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r480",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability \u2013 current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability \u2013 net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset \u2013 operating lease",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment amount",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_OtherCommitmentLiabilityRefundableDepositAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "OtherCommitmentLiabilityRefundableDepositAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable deposit amount",
        "label": "Other Commitment, Liability, Refundable Deposit, Amount",
        "documentation": "Other Commitment, Liability, Refundable Deposit, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r524",
      "r534",
      "r544",
      "r576"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r537",
      "r547",
      "r579"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r537",
      "r547",
      "r579"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_PaymentsForOtherCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "PaymentsForOtherCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount paid",
        "label": "Payments For Other Commitments",
        "documentation": "Payments For Other Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r187"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r414"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r187"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r414",
      "r432",
      "r673",
      "r674"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r364",
      "r502"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance on common stock, net of issuance costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance on common stock, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of preferred stock and preferred stock tranche rights, net",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "bcax_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of preferred stock and preferred stock tranche rights, net",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability",
        "documentation": "Proceeds from Issuance of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9"
     ]
    },
    "bcax_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note",
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r338",
      "r359",
      "r370",
      "r502"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r519",
      "r529",
      "r539",
      "r571"
     ]
    },
    "bcax_RelatedPartyAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "RelatedPartyAgreementTerm",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party agreement, term",
        "label": "Related Party Agreement, Term",
        "documentation": "Related Party Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r209",
      "r343",
      "r344",
      "r362",
      "r369",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433",
      "r464"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r343",
      "r344",
      "r345",
      "r346",
      "r362",
      "r369",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433",
      "r464"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r666"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r209",
      "r343",
      "r344",
      "r362",
      "r369",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433",
      "r464",
      "r666"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements \u2013 Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r391",
      "r392",
      "r393",
      "r440",
      "r441",
      "r442",
      "r461",
      "r463"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r183",
      "r189",
      "r346",
      "r354",
      "r360",
      "r475",
      "r476"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r472",
      "r483",
      "r669"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r520",
      "r530",
      "r540",
      "r572"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r521",
      "r531",
      "r541",
      "r573"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r538",
      "r548",
      "r580"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsFinancialAssetsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r71",
      "r367",
      "r381",
      "r382",
      "r389",
      "r415",
      "r502"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r132",
      "r164",
      "r165",
      "r166",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r290",
      "r292",
      "r293",
      "r295",
      "r297",
      "r331",
      "r332",
      "r378",
      "r380",
      "r394",
      "r673"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r501"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r213",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSA Award Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r67",
      "r69",
      "r70",
      "r71",
      "r99",
      "r100",
      "r101",
      "r146",
      "r187",
      "r188",
      "r189",
      "r191",
      "r194",
      "r199",
      "r201",
      "r385",
      "r386",
      "r387",
      "r388",
      "r488",
      "r601",
      "r607"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "bcax_SeedSeriesRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SeedSeriesRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seed Series Redeemable Convertible Preferred Stock",
        "label": "Seed Series Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Seed Series Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r481",
      "r482",
      "r485"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "bcax_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Redeemable Convertible Preferred Stock",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Redeemable Convertible Preferred Stock, Milestone Shares",
        "label": "Series B Redeemable Convertible Preferred Stock, Milestone Shares [Member]",
        "documentation": "Series B Redeemable Convertible Preferred Stock, Milestone Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SeriesCRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Redeemable Convertible Preferred Stock",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series C Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SettlementOfFreestandingFinancialInstrumentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SettlementOfFreestandingFinancialInstrumentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of Series B preferred stock tranche rights, upon issuance of milestone shares",
        "label": "Settlement Of Freestanding Financial Instrument Liabilities",
        "documentation": "Settlement Of Freestanding Financial Instrument Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of increase in future issuance reserved share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchased/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased/forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in usd per share)",
        "periodEndLabel": "Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock (in shares)",
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
      "http://www.bicara.com/role/StockBasedCompensationStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r213",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares allowable under the plan (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price. Exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in usd per share)",
        "periodEndLabel": "Ending Balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share, Exercisable and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationRSAAwardActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r218",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested stock options outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Exercisable and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r99",
      "r100",
      "r101",
      "r113",
      "r135",
      "r136",
      "r138",
      "r140",
      "r146",
      "r147",
      "r163",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r187",
      "r188",
      "r191",
      "r194",
      "r201",
      "r321",
      "r385",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r414",
      "r435",
      "r457",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r601",
      "r607",
      "r615"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r52",
      "r53",
      "r92",
      "r106",
      "r107",
      "r108",
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r132",
      "r145",
      "r164",
      "r165",
      "r166",
      "r202",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r331",
      "r332",
      "r339",
      "r373",
      "r378",
      "r379",
      "r380",
      "r394",
      "r457"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r145",
      "r332",
      "r355",
      "r383",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r506"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r145",
      "r162",
      "r332",
      "r355",
      "r383",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r506"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r523",
      "r533",
      "r543",
      "r575"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options and restricted stock awards outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r49",
      "r52",
      "r71",
      "r185"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering cost, expenses and discount (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r385",
      "r457",
      "r466"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r224"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r52",
      "r53",
      "r71"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering cost, expenses and discount",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r394",
      "r457",
      "r466",
      "r512"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r52",
      "r53",
      "r71"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r65",
      "r416",
      "r432",
      "r458",
      "r459",
      "r502",
      "r513",
      "r608",
      "r624",
      "r664",
      "r673"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r112",
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r202",
      "r296",
      "r460",
      "r462",
      "r470"
     ]
    },
    "bcax_StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Tranche Rights",
        "label": "Stockholders' Equity Note, Freestanding Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Stockholders' Equity Note, Freestanding Financial Instruments, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r46",
      "r47"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityReverseStockSplitDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockConversionRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split ratio, common stock and redeemable convertible preferred stock",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SyngeneAgreementManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SyngeneAgreementManufacturingMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syngene Agreement, Manufacturing",
        "label": "Syngene Agreement, Manufacturing [Member]",
        "documentation": "Syngene Agreement, Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SyngeneAgreementMasterContractServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SyngeneAgreementMasterContractServicesMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syngene Agreement, Master Contract Services",
        "label": "Syngene Agreement, Master Contract Services [Member]",
        "documentation": "Syngene Agreement, Master Contract Services"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SyngeneAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "SyngeneAgreementsMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syngene Agreements",
        "label": "Syngene Agreements [Member]",
        "documentation": "Syngene Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, by Class of Stock [Table]",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r21"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total redeemable convertible preferred stock",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r253",
      "r366"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity Disclosure [Text Block]",
        "documentation": "Temporary Equity Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityDividendRatePercentage",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Temporary Equity, Dividend Rate, Percentage",
        "documentation": "Temporary Equity, Dividend Rate, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockDividendsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity [Line Items]",
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityNumberOfInvestorsStockIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityNumberOfInvestorsStockIssued",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of investors",
        "label": "Temporary Equity, Number of Investors, Stock Issued",
        "documentation": "Temporary Equity, Number of Investors, Stock Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, par value (in usd per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r21"
     ]
    },
    "bcax_TemporaryEquityProtectiveProvisionAffirmativeVotePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityProtectiveProvisionAffirmativeVotePercentage",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affirmative vote, percentage",
        "label": "Temporary Equity, Protective Provision, Affirmative Vote, Percentage",
        "documentation": "Temporary Equity, Protective Provision, Affirmative Vote, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockProtectiveProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum amount of shares required for protective provisions (in shares)",
        "label": "Temporary Equity, Protective Provision, Shares Outstanding, Minimum Amount Required",
        "documentation": "Temporary Equity, Protective Provision, Shares Outstanding, Minimum Amount Required"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of Series B preferred stock tranche rights liability, upon issuance of milestone shares",
        "label": "Temporary Equity, Settlement Of Liability, Freestanding Financial Instrument Liability",
        "documentation": "Temporary Equity, Settlement Of Liability, Freestanding Financial Instrument Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, authorized (in shares)",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "bcax_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering (in shares)",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, shares issued (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/CommonStockDetails",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityInitialPublicOfferingDetails",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "bcax_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount",
        "terseLabel": "Net proceeds from issuance",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues, Gross",
        "documentation": "Temporary Equity, Stock Issued During Period, Value, New Issues, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in usd per share)",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share",
        "documentation": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price for put option (in usd per share)",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share, Put Option",
        "documentation": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share, Put Option"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityValueConversionOfConvertibleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of directors entitled to be elected, preferred stock",
        "label": "Temporary Equity, Voting Rights, Number Of Directors Entitled To Be Elected",
        "documentation": "Temporary Equity, Voting Rights, Number Of Directors Entitled To Be Elected"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r665"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bicara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "bcax_TwoInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TwoInvestorsMember",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Investors",
        "label": "Two Investors [Member]",
        "documentation": "Two Investors"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_TwoInvestorsRelativesOfBoardMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "TwoInvestorsRelativesOfBoardMemberMember",
     "presentation": [
      "http://www.bicara.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Investors, Relatives Of Board Member",
        "label": "Two Investors, Relatives Of Board Member [Member]",
        "documentation": "Two Investors, Relatives Of Board Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r84",
      "r85",
      "r87",
      "r88"
     ]
    },
    "bcax_VestingOfEarlyExerciseStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20240930",
     "localname": "VestingOfEarlyExerciseStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of early exercise stock options",
        "label": "Vesting of Early Exercise Stock Options",
        "documentation": "Vesting of Early Exercise Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r140"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0002023658-24-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0002023658-24-000002-xbrl.zip
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MBXR^6K9N&Y8^>1B-+*.X.6V[">;1=::6YSGN^[WC'V';;T)6R$4:"F<1$KT
M_"\)"TH!V82%7*1/<1;QSPL@EB/9E3*S0<T'?XQ)B.G4\JFIOE:B>SNQ;,O0
M)ZN)BJSJ?>=**%4Y <#+G2'B5WKW]?_V]W[WZ6[0MXUCZX9&4;I!9C8P>3BZ
MG\@HL$WL%GQ'9HYG<?RGX)_9:&-F_*_A/1S9:+WHON.&S3/U=\[^Z>AG-H)X
M./MW3=-"G:Q/SE40%!E0D)F-)EZVWF<AT2TS&VODM%%V9EMF-A#)::/L5+;,
M;."1TT;9N6N9V:#D9=/&D9+5,K-A18[N(T01%6:CB(-@Z)$_ KBI]PK_6>]N
MMG+!D3E,EO8 ^4?K[<8EGA.X0(;AGV.BFW0]IO7:^0S_H9BP)%4SM?JP/C*,
MEB8UVVUSJ+65IFEJ\JBEUAO_PO#?XA[/?Y\ 1J:6?34FULO8O]'J,__33\OT
MQS>R)/V_M>7K=/<%+ATZON],;V3YNH%7SW1PO.V7JPD9^3=*ZUJ%8[CN*WUB
MO=@W_PX\P.%[>,BR$:4W5](UW D/]V:ZW?D\=#_"JL+?X>+6E[CT:I7>[*.'
M'U\P=%P R)7A3";ZS",W\8]/IN7-)OH[ !OXFES1FSXM/PZ_@DX7 ZZ/5DU7
M&YY>@.-:"D'B ^!],WYS=/H:3GU</]YN7;>E]%/2M4R/?Z3/<^.3$2:B;S0%
M^!($S:\UM;;RL0MH"*83(##^)-'_Q3BYD009'A._XR/]^!3H)M"%DW&(&Z$F
M/@]+<-R;/\DMN2DW/XV +J]&^M2:O-_\^1E8SA/NR4_AR9GJ]I]%3[>]*P\H
M>11>Z%G_(3=R"T!,__P9?ET3%DGQ$7VMK"!D?]SWGWMWPN"Y^]P;+%,$@ZL=
M]&Y_//6?^[V!T+V_$WK_>_M;]_XO/>'VX?OW_F#0?[@O\1.T3)_P#]T; YWX
MCBT*=]>WUX(BU;4V\\O^UZ;_;5QYQ/"^,[MI+,NG4DGHZ\/3=^$SR'/;L>^#
M*3S$$"*Q_T1&=(-*3;!U5)LFL6[N'".81EJL1B7^""[H@%+Y&]4*BZ=TSAZ'
MA2];RK3L#]]U]W?AP2:_[%IGK":EZB@KY;JE-;?JJLQJ3[MNU]4L:F^3CHM5
MF#)[0R4FT'^O)669>]'H6 .',TLGCD@Y+A''/^ =^!YO;[)0501S;A[^6P"V
M/W$G[T]DYKA^31@Y[E3WP8A[\V]&UALQKWPWF+.Y4NN\;>1QWRP9BD6Q&(7E
MWWYTGYY[3]_^*3SU'A^>GH7''T^#']W[9^'Y00"E^PR:59!5X>%)D.L?S%^$
MAZ_"\V\](:&/Y[JX>_N,I^6VJBU!:[L]M&9M?DK('O4D^B.;-/KJN +XL\(?
M,3$)H0\A$#"TS3TTRR.]O1=&>I9ITH0C5U-XQ!AONS+U]ZMWHKM7Q(YI5 6;
MB,S\T!=3)5% EV>5:(6,<K,,J&=3V@]/&3^AL?P)#:X(N")(,>:PG(QFKC=K
M@I$^\>:J0*MUG M1!<]/W?M!GPK\DG7!Z3R'?)+?GU-/+/I'KC,5D@:UX#O"
M?C8V,U]+X[4>1O:$D07BTPZHCLG.;#T:H/L*]][36V->JF/<4;[2%*4I7YP+
MQ8P;G!>/3^2%#KZS?8R=Q[ALU#I?^K?=IRY*@*?N8^_'<_]V(/3O;Z\90JV2
MS<WLO>F&3S]<<$:"._]@0?<$;T8,.J1:L&S!\CW!&%/S+ZM+>AK4'YF&$]^R
M&H&NEV!HM95K69'SVED:V$ MI1!#JWG=D(LQV8I[$OT\K4#C;Y>E$J)D:]9"
MRD[\1S=O\LH]G%WH@HU()Q;2$88TC^B^WSKFLK<&*S(PM^^3F>N\XG,6;EJS
MUKDC$_VG[I+M<C&#,3E/,!1R&<<R8OE9?^M'F<]P-N6RR=*J=5KU*Z4MJ4VM
MG@&!Q7)8Z NDFQ1*F! \/=RU5;A3C_<#Y1 !#&4'<_["OP/7\DR+;MP!I9HU
M?GO-TC=920E /\U]T6WK/_3O7ZK!OE4BH?[UT_7@6HA&H+F5I)EE82+<.]=I
MA)(_"WT<(LI[&3<@<JB6KFFZQ/.B?[[!\^18K;1K'5EN"+^!/1%FA(7NZYI]
M(.1VN=??J,PSEU*M,P@L$-%-25T/$^_WHEOX^> ^.S_GY@YN>?OB>/!%J^\0
M]WT)52P/[B.85B"0LUM>N/OJN^YYNC$./.+['K>_V&621Z 9??+_6;/0N(XP
MJ-8ZD@*,<E3#*P17&6'8-0U"(?@A @F&(AY=('EKID^$WALQ M]Z)4*XV=K[
M)4<4^NB$RQP,@9($)*5?JA]\SLY1*(Z[+M&7>$BK=1IR<Y6#KK(_]9L#&'T<
M._9*-!<W+FF-UI6FR&V&0GX["80"=1'4_)\_M11XE2?X9$)F^)E1P%L4@/<F
M 9*\ -Z[#C R"2OU,NE?-0 9X5J^!4\,@YC$):8P"UPOP&BF[PAP!;5+9>7#
M\!>4,)C6Z!K^3?9$<572JFKS6FLW"@FM*?)U4RHF2D=7M?U1.U19!&\:?\74
MHN=,+'->C!J=13I</YE;@L^-CS*$^+/E3VA GH ))Q@3L.4RZ+S+ 8^K4]DT
M>)\.G<F'3 9!)N"XX4O.&7;W4:J'4A9Y,\:Z_0(';.'GV((C"^&Y;C[L9,S8
M*E\"T:>+(<OLAD6DK=YE94A9?6Y8-,(<-*!CX#O&[Z(PTUWA59\$1/AOJ@HV
M9X]WDC['3D;L1.(EE"YSU#3!O;_M_F\I\+\ N92?>7J1\ IS\ZNA$11M*U&1
M%DH_S]3_$/XR<8;@66*--?&W8G2'X(L-/;B=;'8?][NJ[%?O7;9:D@O0MTV,
M/1-A^"X88V+\+DRQAO[GF-"T#)K[B?J&#_(OPECW:)V/*>B3"9S$LCCT'_X(
M+/0>P&D8DN@">.;<@5 Q(1*6@45N1,+[B*D270L\C65@@DDGX]!+9RXQ"+5>
M9$6@9:Z>\ &>!_0K> %H8&_L8)%%7&;ECW5_=>T_]>55TEHE>G/T#;^(@FZ;
MP@<E_,8A< &<'_X;O@"OIY?"3;B*Z#ETCRI=!%VD[OE"6Q),_=V[+J20EDJP
MD@CCG_"H^",ROC]WE6;ZFYV<KRWTL__G3W)#^I3\;]X(Y6W@NK3A&1(5:D1?
M]P-O+D_;($_7*D2W03I-B=P"?0Q=:].GRAD_M=W4&I_VIM1*2"SD9&#BJ>7[
MP/9D LSL.G0+^>1=(*#+WX4^JG5L&?E*A#O=UP6L1%P5:(MG),,C3P%<J4EU
ME%E/Y"68A%F\P=6S\ &II_E)4%3E.KK"'UNT'&R&Y6#'%F_A@N=2BWB_5%\F
MY2_)F6,6$1MQYGS7CD2E'(N\R(;DNW?*U@!KE)K<"4^[QP&[W;C8_Q5PO'%O
M?$38TN(6?0AF?^!OOF6I;%'6KN7D;OK(LXB.;HI1;]X['_YW["Y>]D*NAB[1
M?[_21_" &WWR$XP(-"KWZ 2P<<]_<1O\M\B'J*5 )90#B&-=F,"G$$$W#% .
M+O81IN+216,P]:@ LN(J]80W!:T";W%CU0\2:@I >!?1]H7'@<&(8'L17ESG
MIS^.3U^#*4SHVDPRLFQ*H32=A[D&!3YSPPKI:?E3?-GF"^(K-B\POA(-X-J&
M9=:PHIEJ/%D97BFQ&9^TW?=7,57)$BAUT.;;6T9D+L"];M:+R3>H((E:]6)2
M%\5^7[L"F\L*C<A\2^=5=K: ':ZBZ7<ZQ9<35 G-W0M#<%4+$(]2IU@)"MUG
M^YU["P3]XKCO*9%A>A$E=2.Z:!$D5F0,:J181>SNA"V(2U9C*!<I# >;S,JS
M0W=>IJ*0^1)X\"#/V]E%1$G0T^[LRH7+XE(6626N[*5[<1?/DS%<_D+!<AO[
MMCMX4\W!FY7+ 8ZV!">PK#$UIF*-TF+M-,(.ZM]V:( \\,+ !F D['J3TA+!
M<>F[)N_X\I\6O!I>*]CP;0[JE%?+H^9$-#L*?2LGW <A8(=.4W=-3\!R?LO<
M5+RH?M!_*39<<4!$O* 8:6ZR?UOT,@D;">WL9:)L;692%>+.'Q'TQF0RB>E?
M^ !43>-RX9;^]0 8$-(9Y%9XOC=3UN-H&:#<IB42Z1;MM<S)]=WJJ[".7VDI
MA?WEQ% W?@>-%-CF582"$?W?IU-12)>&XN^=U[!U6BOLG":N*[]Y2[>O;CB
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MA!08/U'WE; H6QB[:&G]*</H#0FHI_OT+/0_?]0[*[L;LX?*JH"PM"C:&OC
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M97"VRJ#!E0'?[76X,FC'V[WX?J\ST0: T8?GWWI/>V_VXGJ@[+7D1+=:YWJ
M):'"@.C(JP=PYC??TG5&:@ 1^HV\Z)/0&Z!#5;@[<+9J -'-U0!;0H4!T9%;
M#=1C-=#E>N \] !@%-,"PE?=\!V7JX#S50%UK@)8DR<,2(W<*J#%JY/.2P,
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MPG@9X9SL-:VUB1.B #LE\LC&"JVYA#,0,ROW?RM#TM17152_$TQM3($HJ-V
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M>G<"_!H\?.O?=9_AC\$S_/.]=_\\$!Z^"@^/\%7/?;B @<_)*;,^_+#UP+1
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M(Q?HLT3 C5I':XJ2NAZHX 1\<02<V51GB8*;M8[:%NMLB^#+*J:-K?RX%8O
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M*BUNT8>P *#&C;=$T(WNQ V9$3@[GX?NQ\[&!:[?=WS$R'(F)F\N+SKY7_P
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M<H7E-V#_[_HD(#F1G]#U"D6^W#HX&\I.+] \]Q\C!E]!J<6%/ <7!Q<'U[F
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M"BYL>D*(H!O8[D2W,:HLV(X/KZ/SK6V3V&$S%)O2NXXM1$>6K=L&CKGV?#A
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M-CUJ\W%-:A2W*'7KHPXMB4XU -H'E52'S'""HNJ=W![N7(8CPG>X;.P)/9#
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M'?HB".F-OO5?K4:[T[/&,D.!%Q_!U$KCPB.B2!42VD7?'V">36<XX/L@$W^
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M%;@WV$C$"4/$9F8:JV*D/-M')/- ZCOGWZ5R718$TG*R+6&V:SQ+K84\-^4
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M+2_>\F6*&P)M>Q6AXK.9K8HMFQ9 [!F\$!3KE8\.[_HFX.WV*T&89'9N_1Z
MTWE\$B.["6QCI-!?I/5P<B;]DJ),L@;%&&Y1-,M0AJG2-JD_9>"#B@S4$XT6
MR@]:V/L@JJ\YX[RZ*G@JHN#1B]"+4AU96-A$JLN)</?9*>FS$_I8U7(C0H);
ME?)UYY7P]5<@+W$S[%@G<W#GQ^6IK67[KXJ%@'6TN8][I/F&R'Y)G''GXX?@
MG-HY*&]>MQIQT[!_.O**,8/*M+25@M.VIFH.8@S)PNND.%OHF>-RIJGZO&PB
M4N2TI+="U?* 1*<"&3U&AG;+VU2SW JFR]2$:]>>WP>P-B;IEG.GF$O2D:&G
MRR:T5$N3.53SE#Y!RC25W]/A?^46FY^-,D$A8\2[&NQ^;?PYFW92\)2$4*5<
MTQ:#4-(#P\UAXIOG)/-J\D*7/*+TQ%'TNMZ<6#Q#0WD%9AR-PJ&!',C74QG0
M]CZGKX)@/DTE.G+(3/\$F3E!9NH"F>E7[21R.YD)-YF+Z^DE/% )I718^6<I
M K^ !/Q(&IW1\=-5BZ[ ENL>W63@C7&!M :4(.+EE8-62=%@"IDT&[HJNIO6
M3=HYO4 -I2<1F7HHIV$+5*MR^HO5T=:C4\Z.Y![WNXU^;[#V'F__^VZSO^D;
M!;=>40!=LV?XU/[6OA5!6[U&J]4^'$&W7U1G&VE=1MB<]'W2Q[8[S+4/&^4^
MUE[^Q _F39_5R[/P7'<NGMVK*!N7;HA +4UBMY8GL,]/;;DP*2A)CA8; ,=Q
MSJC<,L>[ZW9_'7IUJER'O+TSF4Z;T\GJMBW\;V]UXA'.]5G=/JO3PP<;2&E?
MRP0C^^#%_KEAIFS#69L(5#L)\=05EWY_NSO2:0P&DE]6K@N!"VO%+J6M#MBB
MS773:&;Z'317W9PG.C>7-(DI,Y$$IY&<NT%\+M]:,)*DW3N[&-BCT<@>X.SB
ME2X)!^#P$[^4\TNOAOP"WGO;'O6:]J"9;^3R--TA?>7CU!VW@EQK:IRP.7Y+
M&F6GV[5"I"/0']56O!5;O.I;WS_TK9]Z/X5[CDB8H@L_X%&0K?;[_:B'$SM4
M8X=!#97 \.QB: ^[0[LSW+<2.&H'0@^)W$X#G!R(75GB5=_X8;T4P&C/"N#$
M#M78850_!=!IH@)H=]IVKYOOK5=% 1Q>/KVN3Q7E7X^PE=VE'",M(=V<M7/&
MP;WN*)VK7,V,EI58?3_@SM-Z+N73&BQ2]YUO IO1P9U9CW;MO)I^:KSM(YR7
M:*+)<>I:N:3E+:YM=VM,"%8,H88$ZV%^BE05QP!WVF<7<'WS/4G3&71RA8WB
MSA8S3TR-#^.BL:.;M7!^B-"FQ@H?Z3.?59M%ZYI:%L(?N2(W*D06&@!" OYG
M>K<S[E]54BV3<!EPFRI5Z(XS_T04).%D8T/V2O<0N..2(?!X"</ AW_RF+]H
MPY6L+5!W[05,-VME=TMY";.DV?PDTL [QBFGV1H0; [/@P"=='-JU%Y:#<+0
MSRA)&[-\N;S]@%6JLH6H_ 8L*J9'C /7PXJ3RW5]>[-%'FH$,-8-Q5S@B[\V
MAQ3*ZAL/:WOG6&L3\>@-'@6(M66".@H_>21@30ZRHBHIY^0K/CMDZ*] XDLY
M!7)M5^57A$HW"'.K6>G/)94=OKF\_?,MH;&P[*B\MKZ&1=!2'UK:9++>? ^6
M(.';P^;;=];5 NO ) ?$@?P8F7KJFY^\:#(/L'U,X8#A%S\X-2#%:->(Q2^^
MA2(":T]I2TI]9R:_Y'OY\-EJ"ME6CGYR]"C\TI7/(P&"=6E>1+6SA.@#6GI,
M6[D !KW)I[F:IFK9? )IT^=X!C2]F\$F9@Y-.D^_$J$5GL29N>WJP=FV]GJ5
MTHJ'!2;,T013UU-7:021AT:1]2@<1-X+N+T^P?X0=JP;IUNMGNJ9SJV549@N
M= V0+#>O]"B0\&389(?%DF5CJR8OX?PQ'?;*,T7CU;%%L#?9AV3^J/N9R%H
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MQBTZP("#7>S1LANV9;I^].K2]?UJZ7JJLELQ--8EZ=&=74W2CT8U3M)_2_T
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MY> 4\\9A')Q^Z^3@/)^#\W2L]Q90N1.6[PE8ODXYEN\$RSO!\@[76YLA545
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MMZ[ V7?4=]5)>A&ZY:"<,.Z]W@X<-3,9'M,,U)<?P9*;<\/M[ME%KJ2$,\/
M^7,1@8QPPKF'HH9BXL1(8^0B#1];LN4%4D(GBI _UQX$_.B1*@<&F&("WK15
M+I,[X"RK-5!"Q+'^2H TP+R9SUU/XH!,FG;ZP9S9D?G@D#_(:;]2?B@PESH9
M<PE.V3!%U8%OL(NR7[+IYW0%,M<;)<OE'(-@>-/Y1O^%3^3(&#P)C"<WF7#J
MY .80Z$CT0U)[%$H"B5 F1&5-XTPW;&$;2Y5)IN<0D1'B$F"1ST-@X45P[VE
M/>%_S3!?_!"DQ_]%P@'7Y0!*T6Z9\5PJ>E9-&(]:ZX7Q!L6>%\@]U!<%">K=
M]<6HO><ETB#3/*K, ,J4<()2#JM:)34KLOR:'N\N6,9]G&YGSZ0;H+I=,P-V
MA]/M[GF)P\.=[@;\V3.:>*/>'FVHT?X/M;^_Y76P"<B: SV9>.7!#L<P+O9O
MV-T^^G?"IWE5(O0=?E'.NI.?4@K?)AP0V*#25$'S$_0IL >)1?CC'\ZC,CK:
MC,Y(K1O^+7QC'L"BY5)E\&0BBUY*@CF&W=LMB.:HS50V4?)?3"FS3U,EVF2F
M[,LHH2?#H] ,C@P62@FLUZ IG<K(S8?!D:4R]JMBT0_V9=%W6F<7_?U8]"2
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M9"1"74R3D21U].](DH+DF(DY2PU.1M)GT;D%PW1NM&*84N\>*6;6IS*DIUQ
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M(F*K?11$Q*'L]:+;<9C'\2R(ZJ5ECX1P#KAD$V]9NY*>5OL8J%<S]-UQ),C
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M,A&0G3'<1P6:B8"4%O*I<D#+P@R>6#4D1!G)_<=,S)K#FH.=SX0$Q9L3)J=
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M&6R>>]E:&N-AAN;<B\JL25.>-VS#9DG 05M!A!0<^A(BHL@ Y*(@C2_""A]
M6/B$Q#/>.V6AQ+)JQO:V7B.JS@)AU2E'OAL;*N-8A\6O3+51NWBB,YE%FG%I
ME.B=CW@CIE9KG_QFI]VTPLOUTKP8@0\$)S3L# E-1?C)G.68X[V(;NEAO)>)
MN=<O_@?3W+=<//.FE].9=:,[+J1F(K7&00!@1A'1LMRO0F"!J9VH2?O=(2'A
M$A)Z1 <(S2-C"]=,FDD8[A.JMT_-5<:=0FV=0K'IB-B6DY"@FBD;DKWZ_V3(
MAE."!3A%4<A/O*^GT4X5CDI<'JA=_$Y)RZ+24AOP7YMZR\)EDT9",S9IZH5&
MZ$R@9'[Q<*K8EA]R>.]B/?_^._^O^]N823O1V5EA\L47%NIS<>;=V22[^4_I
M"IW<O3G8?5??>*,+?[EHAR?YI\J.8#>WWQ2*U=@3NF!'?HAG.M.NL#Y0F2M(
M@0!X_=O'=_'46Y(.DO4@G6:KH%.@@SBJ6G4V.?]]D8\I/$HL/;469*N]"?3?
M*VA):@"14=:9+%/IF54I-2$_X&&WBK1(*6X1]4EG45K&Q'LM$(%QTA]>M'(=
M,399Z:H_^! GT5Z(!*U;[P\!X2I,].EL+)V*J[XP[\2JC)N(ICYB)<TR]8>
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M_U\+Y?^QJ?P/VE[$1P'R\=>6]J(R)WDA*CHC$0!Y?UH(!^NYAN)S'_?KP6O
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M+$W,TL3#$,S2A%]J93H.9FEB76!=V P(LS1]A:JP9P?.ZU>%"I#7Q=+TBJB
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MB;N(%/G_-F[9=OS8QG>P0\8.G__R%@J^LRUW]E5T'2RF@>X#J6]%;=*!H/.
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M4XIZAR2B_I1%:5E>ZFZYZBA?]($S.&Q?GLRX+&<$V+BL73Q6<Y6:?*9HL]V
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MYF>BB G;RL9O6Q&2$@C#,9&WS+2@21NE_.;BDZQ\\AMDI8B(;%1"0L.-9FL
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MY"?0K3\QT+G:CA*HZ_33)>SB,B.+5FPGC05I76)M':;IKX8NN+5^H',^6<V
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ME, 2C"C.1-ZXTL)Q!U=,I;8#QH;U)I@Q9;08<TAAS%(!N1 ;%TV=FY9UK\K
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MH[9UU  S?*9Y^J[>L]_CX)Y)A3?SC,AHZFTKV@$SZR<;:#59,#Q^:'ZUQM[
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MU8S[%;M_V8.*33TRC' />'6I^%9H)0X;HO4/4>=?,L51,TY6$W(K%M:W9'O
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M#(_N0)/M3GNG<3C(3)/ T@"+EW:<8G@^#@Y!0<?PI])9%\"_,SA<1F=U:8]
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MAM&E!V&,&D-V&=]AI^"^?FH.61?S[=QRZ$*S@PB-EW,W]+WA;9R[KF5S>S!
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M2\$;= 9*9#0W(YJO"(IF(=MIV-W[+V<CSPP@])9";9>=M%F3<K7X!TC\C$[
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ML5@AB:8,J@[EA!N@EGM9XL=<8G]&2W %U,V!^(=CPHHO2$)O;JO.:]4B@T&
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M5\%<6]GYHS6-)%QW*CSUX#5*\G[IBGB(^D.0XBG?Z^E5B1RB-+/*(FI@Y(1
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M@=,4%9@C!H^#U\VZ&17]#*AY<A$NA?M/J7#_MTOA_H&%>RQ[I"N=)X='II[
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M'3R4_::+7)+K:L$*<!Q1/&3@O&W)I0C.DZVX(8T"*TB*$%+:D9=*CF!G&IG
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M3WA&3%F'G:ZY:&Z'TW!38?GO /*FAC^6EZM37+@#<4Z0 &B/HBV15V9$*Q;
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MF8LC3$EB$F@L7!LE=FFDP*9H)W\@<O?=@2K-MU*$\&<+ZGQ++E1C>NYUNHP
MRTR9DS@Z<^P!FJ$P LY*Y&CC#BQAIXG$6LB&T*OVAZ5&/=_4R)&M^@CGB(1C
MW&[V]^>%YO=@L%PNS9.3P6<X.5Y4HN"#B#1D)$6\K3H!"J;$79S1;S=<*UI6
MQU:I% 5L'XN;992(K;;'1:*#8TNR44D\9QIHS^9)P!RK@V[U9$'GKSIIR,1W
M"NP@P4+XQU@[M30' -7?:^Z65A718DJ[((BJ61**]WO!<#@S#6!$2Y2CH?!.
MC5!X';,<7"B9X6+^=]RCTJ0Q1U_!)CO=$>ZX25XXHI<%)K(91_-R^3H,*K_8
MOR+E3G 'BI/+Z2/ZNW.;V F+I[9 7CA8QV#TPJ6E=YV1D^D/8I,_K7<46]T'
M<T:DV5NEVCVWPN4]U_@8Z3C%#HG3Z";\04= :&1J!H6MN_*NA]/%V7-=YCK;
MPJIAT::FXKC+%,[MA13*XO(KL]P1L4GL+(6*Q#-SOE%R%R7[!"5LQR@C>*'2
MJYEGW)2>9*SO^I2CD$%?PK$J_JE6J0X&LXY<9:.\0G_HT;P^-;$G%Q"/XAFB
MZT,FQOG'(9YKWT#B]YR.J.6U&#>T/PRBFR>)9KJ2BQ/W-W. Q=RA2P3"WN!-
MM;YB@KQ6U-2KHU5YLG:+^_L84Y61+ RYBLVA%^>GX<2OYR_SWR">Y5WC8%*)
M'D.;@*IJ,ZGD_S+7"N89M$2]M!Y&#Y>P9"3+6VO>^F!$JO!8HD7FX^+,BU Z
M6=.U,/D[IQNE(*F\,[MAGN S!5DOI'SEG#B7YYB*&(R9_6A-;)O2K3*YJY-\
M9!&MZ*GX>&2:"+6VW2*D"%%<5TH5<MQ[,.>45673)V-T<I3I47.).==RG)XR
M:D*T5M/Q_>',DBI=M.DN158,B5O]'OJM2'K HNH7S$@?W(^6Y:/#^2[4+N=+
MH/_YF91 /WY ZWVO$"FM;BB5B])2/OG&!D2CU*8B;YW:;%TF:DX<ILTJQ@O
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M3>]V=1A0+  [XD_=0/I.](=W-^'X&,B0"L_<'AO)O/73#ZO+1,3,DY,Q_P6
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M]$K?]*5..9+;><:J2&FMEO"4U 'I84.MTW)>EGT==L5K'$5&7:2!K&YU8RJ
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MXETQ29A;PTV)\B E9%P'B,'W/Z <R2<1T4==5Z6!FB-$!8'"(/Q62XKOH5
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MY1G"(,.1A@](=KYIFV<.F%Z*;MDDW"C$AU65/\@P5:2 N:O[95<"@T$7UOI
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MA?'QC50])^<0MW%C98XU*W(J3X &KH1_Z;U:AI^@C)1@P3./6-3XXZ?K8.Q
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MD!A.85(X H6"+_"&"_+E;WP+1 Y>ROB)C5Z%A;Y:_#2SM!8H(.HXCB(J=I)
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MDK#V:K$  <!E\1Y[\:+DLAI8[NJC$S1%:$6N^$2J.:PY*_F9* #WWM*"D[[
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M]=>V!)108CU))HPJ43=MOZ?B6K84U7:NR.'0HJ;KY;S'1.++JTZ:GB_7=E8
MI5)'Y<ZK+6VI-^4 -@H%R53AT\H],:FCB,\S#E1& 'C?UY'8>F6!(!TVSY(1
M%==LU.1$,9M/+$-]UGOR'2JJ<GVVX.>G^0?%50:C>F;_0CZ!T3LC&A.!IR(C
MJ81))/!E@=#=32LZ.0F$U5<+(ER41H8D=MB+0O-FOP,"A4!>X.%S6M.[#TQT
M\,%9YA%2\"D=]?W9@:X]U2V?95U$OC@56\4U.R"P:E8++F*1G$:E14;SO&+'
MD):".=O@.[5=Z2&,\'HD A?AY.$!6$971^WH35F2)7ZM-V'<VC)$*A>: ,Z3
M(TVG*G1]8A#@%-(N [?SC!5,# @FN/?]QB-<0!^19KK__\C;[@5=._X HAD@
MW (#OF5U4Q(Q?7CVO[@Y'<VZS^@Y!#PF%";^P15ULO?\*T]7V&ZH+5$FLT>J
M/'Y=3>8*0(*V$0V;^!R*IZ\6O]Y4Q#&*<0+X/K R-?/R5PUU2!5N8/+T$!H8
M7^=-M6OMIS=MMVO]G_6'L,VZ(_/0*GB=B4F1U/%""GQNB"^7^C]MGNQ2)]@>
M8^$J'3,3Z%'K%7,Z4^*'5+Y+_.75XC5/H[LSW5OHDFA'CD)HG>6MFL2*'I7I
MUMQQ+OQGZ/O):BOTHI\9A26XZWZ$8H!)]BQ/9[[!KY ^U6='VNNF)9;(<R-,
MMT@R0-YJ^[;MXKC*X4$C^B,?=J%3B&=NVM82+7\>J:PH93+$^?70;:NJS.LV
MG)-"3C:<!G7SU ^]K;2'VAQ6X$').Z3;0TO5L.]W)J"V&B+K"O=4I*_# I09
MLT">^8D&9.#'3_I&XPNBD%&-^]]S7PZ.N$ANVQP% *\P7+O$<(4ZI+NC"4X;
MO/[P$NHS=H4GB!))QSW?X]'@EH>AK2D8,0J6?NI4T"P'3ZJA3+WLP&UK'"N\
MQ>CV3P6 $K8?:L-E$3<.F:?U_'?PP_N1ORW[?\VV/GHE&7D_Y^N(:]??T$N;
M@N&4LB[W[$*["9Q<':8M9=3IQ"^/CA?",0UV]UZKUZX]'BK/?Y;R(Q&^--Q+
MPA+4&OVXN23HZ' .B1RX"U[\T\*+__7)X\4?&."_]-=,OE=X83*U$HZ)N)*T
MQ\4B!R-?]><]Q_6;<E4E#"^(C<(?]<'Z;,O.I;14T8:R6,LE]?:4(VY(:VW]
M8]](L?/PYR[8=D+UV_21,7W9-,&<X9]&I__%WS#[W_S\XN7S(LF,C*935184
M2N1YV..RB A4.!TL!(O[QY;6Z)@(&[9%QR06"I0]*T=*9*G<J X@(RPS?^[J
M9<1>)AU<7W[%Q$50E6^;9WOJ.1Y8(S+AA5'N2W#V U)-S$\\/)'B<.GE-(I$
M:H-3J90M'1/0,B6OFQ[M'G:S8SAJD-Y+-N3D2Q["W4>74CAV_(93A8&9=XB/
MM1F>2'6F!/MN[+XK7##WNQ!A.EXAIY#&8[0UL$GF 7I1CLF8%G=Z?2YTCUPM
MOCUTG* -*_SE5\_HJ8XV*V&54A8L[M%DD'XXFMMM#!-,^G3\NF)QPC?IO(,]
M%V$R@ZSJ<%C^[DA2NRI"YZ>O0M?_2(0#&Q#'A!\0&=]9<,V=I;B3KA8O1'*<
M=P[GFDG\=%OM%/111E>)QEC(WR@YBW\>3? V,MN#H$H&2O:W.1"2GC ^A:P!
M_9R:P\&CBUW,&SE8#">#TTE+$>C-3!-:)<B,Y$?6;TJ0Q#F!;7D'EJN62!#?
M6NJ/4C3[EHH_G*T5?BCD.=K]$-^&.;0H]($S7AH7_PC-H,MFI3]+#(9'@V<W
M4O1EKJT_\G7R:Z2)MNCS9*^P]0D+NX!K]7!)7-G@4X,&7AH<K/X&*S>W9[)G
M_FHQ4EB'%$]7]V^T^Y-ZO=UN6VE@+/1DU"!\T+@6'=72W[DR5K%!5"$*:S">
MW &J0"$,*$Q=,HW953=K:BV@?&D6*+I'/K #@Y/6JF)QA6?*&0_O._5MVT2A
MIR&<(+H,U[Z/&97RMX-H RF73WQ>>&U A&)N09+ZD"NMA\.@NANT4YKY&T<D
M5,B5T+VB0P9G2&RN1:X\. /V#7JCTFV>.8^G&H,XJ(,PJ%A_<PZE9RBZJ\E=
M$69:I*?FKL59LIPS-D@8BVA[D7T1"@K=AU$&9S7RXA0CO*=MBE3M2SYQI*43
MPC%F >$L%M<W,2_7W,GFL:'[N#BT)YUO#4Z54SZ(UB. "APF+"MA3A(W!['V
M']E>_KV\Z_W&8OB=L),-$_I@IJD<4PQOJ^8:_O%:CR(GEU0G++DOF173-@5[
MY[TW(0KQ1F3M"EQ7BY_$/SH0ZZ,D=K!-1ZET&$<XK:+T*32&$_.;.)'MW-,C
M.:<J+\ 8Z-8!JH9WH&"A,S:21/".QF0=OL'#JIS1!)0Z?RSY1NHK\UFNL5I\
M6N5T4@9-? 1_./%1RA;+A_[(6_J7-KD4I  J+IUYSP01C3>*WR#.Q(YI..<6
M9KC/(E!1K2D;^&F.O5KYQ,@<[ZM.DX&LRL3.W&>^6@],T?QD&4W?2S"3X<QT
M$I]OOJY9XCPIQEM<1%Q=BX0Z-<'#X,,?9(03P,!38V']R!MAADCWM*1"9F32
M5CA=ST*$X4L@=)#M( 7K+6J*IQ/[N8';=47]<]?<&97&BYD'22QJ&VY,Y#_F
M0D*2JI]9@*R&#[<]8\JZ61F#8%S#RC?I=F=E1KB'GJ8Z1OGA^PL_%*]D-QOU
MQ;O0;OJK2(FVC[KGMZ2'R$P(Z;#0Y$;L=<UMNX5S"FQ=;$ ;\7TF*DV]\R8H
MN<3)#J\B4,CP$@4"UTGN]$V)5UUJE\IXU(X)*WLM>7),F]TVRHJI5%3+XXFU
MRAJFE_2@L,O3F9IU)(NL-AC6>USU35W_):FJ5KAQ,PSI!$'B>0L'U@\% P1%
M*-1UE=:^7L7#S6R_"*5OJ#@WOO![BU4<N><3U7S[U:O",^];EKK?[1=WV.;5
M3/*[1PFXDT@$EBXY>9&H0]3I<QPB(4PQR!VV&Y)U3A\WOH?9B=%6C]>26JVI
M-10C0<^N@43&-^O?)_SQ[@W8B8R28;[^C'LA;%RR'B1]ABG3=EM^^8/^@)["
M]PBRC6 %6S#QP8F6$,K1:JXV+A:C3B)/(&8+;S.,F?#=FVB6E<-JJ(H:1%&?
MY1+9M%]  3J=R,*U^&OX% 5/PL@KUEX>=:,&>[HE8":G2;<Z %>!GT]_Z..)
M*_W#PA4O)>_S)>__O)2\'TBBS<::LRGA5+913KW7DUQW:Q95K$22FU H:W)A
M2%P#J<=_CT)<8T<[ <UD2:?8YN+.R(7([N :T%C!Q4_L:OV!&KZXXAB9/RGO
M=%UE8IS":":;%A"KKD;2":*GV_^?O2]M<N.XLOTKB(EY$58$R"?1^RAB(FC*
MLC5A6QI1?OI< !+=)1:JX%H:@G_]RWONDC>K"D WI:;8)/1%[&Z@EEQNWN7<
M<T(W=H]M2N4 6)64C4MH;5>0F",>PPS/>?\,6:+7<'Z4EE;FNM#6Q;Y8H^H9
M2O@'1=4P[ADKDM9B7 >,L$"E,N'M3UP-2Z@,J?U%+O$4^..^CIX.M>(@D\CS
MELU4_K:H"XL/JN*I,5@I W<_4_GHRB3VOK<&TA(M:V?XPH]4PX445$LS"VFC
MIN*2QN5%016_N]*\PF@)NJ:N0W7MTWTWC>\NA9.F%1G^.(T%HF^V7#8S.&@M
MKUA9<2!SRJDWP3H8KPV[[VX^XU;;#Q8SYAX2Z9R%5G4@;$<N9\\F.I5KY!S6
M1;5VRI%M<RP0Q@G>Y6RO]O,G70&XU!DL6/(D)BN'M^#NW/!+\1V2%]HD-/9T
MEE-7QSL(>4N Q=-'AZ,I_PTJA6&*-9?DP5M7>Y >G/%V-0Q]*Z_W_9OPAY9\
MMMMG8-ICRI<8:)2=D+^,)X GKMUAL-L0]RAOJ-*GN!DO ==1<REE36D<1?<J
M@3LE3ZJ$XT^L)=U0/OFZVT/[\;-V>T.DV79!1R'GUT6)<3X8K $:J6LD_>J.
MNNR4T(VZTV?I%:%-B[Q+M'@E(TORR(7-X[9I"0@C8A:2[(?*1?X0G X+DQSB
M')&O?GBY>%.3 &4T+2+VTOAEV9G<R/?H1:R;GIH?)5K2+%N1CFO&C@[=W//9
ME9?<*2*KU[YKH$LZJJ7Y& T@AO!2DH ?ALT-M_Y!-&S1(7(,.U2E\;K[EH#0
MSQ=?#BU%6L0[N_3T2G-CYX='>=(*S8?.+))9 53644(_EEG CG$0^&63[_KI
MDR@.Z5Z[?<Q9K? 2=#BISHAEK5?!(94 N /T)]J(8]8/&J-@?\F^#[L],O_T
MR',CQP@-K+U,Z?F8FJX3%&U&4N*$*6*SQ1'V')=#.FS8@ZB+&RZ8Y"0/+,ET
M:EB?N+U[>%YL)-467;6F9<A2N<,_)0@CU%C\9[,C5%\<YU0') S)LW73M@.S
MCE>S>*JY D:B(!S5%]B\2"-)2ZQ.<5;3<DC?4WTRLK) 2J]ET=V537[K+LP^
MF*W >#M;#NK //'%<*E^-3_U&G2[)3 _<#D #B#A/_,E7KKB;UP0W_IOL89L
M?/5FU^77@RA-P?-I2PT[MJ56A;3H_+K*NMC%&.,6W[606SLNO@CD-),AL!/E
M:_)W86Z_E'+4RPY4$:_XW>U%=.W//L;L.F>B&>;Q$Z#[;;FB<ZCJFYL@YXAP
M]786,2U9/@JRJN.B%/EH4I1*9*"$+$843?N2$/OPZJUH)9TNH6W+ON%?^.FB
M(\PPL^B?X>*2P/':<$N":'?^;0$/7H3=*GZRP0X%B<"X&#RR!68?5C$."7$V
M:-!FEX[.Q"O^\N(;RAB4M)VEW^FS/_[^]QBF+U]]\Q+TN<6.O *1]L9%-LV.
MJ#O6"[U=%PT-)>\SANO/_H!/OWH>G9S/?O?[SQ<O/OULZ5=.031*+[5?2"P-
MF2S\; 6]R8OIF9SPDV6=:JW6=FUI*G($YFQG&Y*4+BUK4G6HC@KNX/645,P2
MV7,\F*OF&%CLC!>)YEZ@K)#>1C/#HD+/)>A_(W DC[+L\,^&4!K\KU;8I?$3
MI^>JHTK)\D]+,A<M ?@(O,RU%0:50R1]$2IV<>Z*BG'2\6OEOM1B*78%",+X
M;LQ:2Q*$3<LP;IIX7G%R_'?Z!2?IUD >':_Z)H3]8M4T;W2;QH'>*%A\O29%
M\R##NBW*%I)MVTKUZN.PU9WJU,KQ%2^P;]I$J\X9?LI89IR_GI.K.T;CM#-4
M-7<F8($@:R\&QHX\JKD&\H7*0BF/Y,;8%=:M$^.$<"-=#G=9TO_ABR!30A.0
M:#P,0-56&4#AW_"M&5VU)H4MQ I5V-PD)9Q\:1_3*:P#.&LS-Z%;TRZBM  A
MG,2&*@* 6@@*SDBMX]7Y9#*O .)^DN^M-9E$"[&,QI&C MRXZ03Z#,-."Y?/
M-EIH91Q+Y);#BNK=^$[Q(U0VHQ/;B;VE6BI<=AM/7CIM,6PR.>3D3<;G(Z?"
M#[KW5*YU]?>KKO[[:UW]P:WDAZ#D$YZ=S[<A@E"KOJ'J;308?&;XWKTY8$VH
M[\J6]R]55H6[/.G*G/+E@[6'@7?0>29L)^AD43/!3[(F>6O@AZ!QG&JH69QX
MJ17Q8XH:1D2,?JJ[T5P7K3!W75H?C,[ ]_+%(4"DI9_*>MB%%E'"VZV2L2?,
M7C7];/2Q1X^"U:;QV_B/"@X04F4QA"'*]*4CC)*D>[2&C*ZZ+?Y=M!MZ5%T[
M?+5#$9V"CADP7<>#HFE=9BI= 6=-5>QV A.3Z_G7(58RRHCQAUWGEWUZ<DON
M/$.H$=S-\( .$A'G/:EZV_$W4Q=2A\6/ D??,R/P/.412:@<+6C\]IJ.@M^>
M6M-:S4]I3[J_+@"N:'NYD_ZK4]].0FBX#FW>R7"[ 7969>*<"6^[7&Y3[(H;
MC;[H3XX#7%BF6(87.2?)2G$P1?/ GV&;Y#-;\TS_[ P1V/F,+_0A&Z.7%?'_
MW#"057UO6:9NY*%XP9I^B?'[T+1O0F*)1A-:=/<ELVHBQ@TK(Q#&A+OS.L&W
M:TE3C1=/FC6 :J&ER5WR\<J;W>ANY:'Y.3V.9I@Y% LIR$CR#5H6L"*N.](^
MY+60=3%F<Y+%#Y@_]*N@USMW.J:,XF]UP"!8I=Z*R>5.9HRHG[ALU2R$HEW?
M+C/P&W>&CG1>A3OY^>)+ 5Y,T<DGLIYL;D['6:*8GKE*D@;1A-"'O)BD3+3D
M88Q#M!?/@_OV[?"4B%LG>M1LE>NKR)&9>4M+*E#%'9YW?G.KT='\8KXA'*,Q
MFM[AQM]JJ4I>)]X@KAD^LF&,V#\YJRWS5L<BT3&&=AH@+]!O9=#-@IY%4V)6
MY[*!2_PIQQ,RJLEQR;N;!TNRKF^Y50VL> G%P(W]E";<*F\&L/<7IW(FXJ!3
MP&5/1_N'"35D^[&35#(]PGB2W]((?0C;\YX2V.33?E7W\6@/G)GZ!FLZ#LV3
M'H2'(DAR%#GWU?-)N$&37,A3?.H]5,9(H!M\3T!::OU3DNTG/8P78,?^9#5U
M9D8<=([LO#G7\\Q$#[Z@&8W@KM.LKZW+O:Y+'M@Y*D\?SSVXFW>YV(7H$V\Z
MIK*T6GH,4O?1(]T>E0$_V=*,03>[%#XIEXLO,O2E@,+FF83\@^O7$ TJZ4V2
MEF"< @]4(61-\X:<2B+@L"*8(IR4]:VM2N?VV )N4U/RTJ9HR><+0/GF,SMR
M#DFIGYLI/NG4-:\N-W%XOK)YF-"'OJT$N7G4S:1[2?-E;K!* O<0911.->)<
MEMEQ5"G:BQI= X0["&BH+)0^VH4U8QVMI;L#,^ S2KH/.]VY'+N5=Y*;.@3K
MGIMQV85!K5,RM2 -QEYK*&L@5OAF2W7GL 19FW%9T -2L%\M:K"QD9%%QWM7
MMLKW.Z%[HW(5BA$-@T-9*K1EF!F]'X#30)O1KZIJU$1Z .['#:6X/<GN\7J.
MSG]TTV((>H:6B-.]]Q^KY72PD-)3Y]9FGE\<[^=,0EE3+D?BI(TE!^-N;-E3
M]4&2])N.HB17(4N=T[0PFF91":>7]&U-%QTWW.P^Y*U*6RAQ^B1NQQRJ\TVR
MEM\1#H),FN H,,7_?/W-=U_S?BKY8$,U'X7.T-*VQYD$P"_Q)Z0C4R%AJ*+P
MPH<2/('[:#U@@PQU22>J5&NI4,KT5'FV6"%NNG3K1K](?.IMM3E0U@0\A,>1
M<I#Z[3O"MS$5:C0S^\ "]R3?9^2D%-Y457-@$:/OM*I)-5"* +)71Q9(_"T]
MH[R#5=;T=*;H:WR.PMPCVL!Z_<FT4#KW)+W =#4KN4!'63.!!,<E66Z&8F0S
MHMGB&'C!+0+Z<# ]-#A#+9@4;O%PKM'H?/6;Z4PS^_/%RS65Y^,EE!*][+J!
MHJ ES\22@ /EAAOF:J!@3;$OW_F",)#8[1ZV7;* SFQI7G!LO"Q?Z$)^]<;X
M?<5?H&5]&_]);7LZ5#[=+>N;;+,-LU):R,[0D9MQ!&%":7PRB@PY$V:)1+!)
M[6;UT>X"JQY7*%\-%V:I'5[T1&EB4 9L"/:VD'_TBHAV?G")X5%&G=P(/<3S
M4<_.2SV-4VY+7W85P&I K[H14Z>[<L[Y9+166-_65$DY+AG.TU32XJ21@4)<
M/?!7P=#,*,/9WG%SA1\^0WLQ;DMOF7DXQ$BCQ0SU<+RPV= ][&R>'LU47"O:
MMCFP)5(#B)UOZT$T&'^AV?6-U% SR!]U:G48-<P>#YNILX0&5R#$?_SW[_[P
MM( 03\752N:_ /WGXM@, D>KM%*:$<;&=1?NX"V!FX6")Z^<R3W>*?4P9PRI
M36P5 AT+0[T!F8F(D^D5PX]EUW,N6BB=Z)P%VE&OZ#A4['<P:61*K9I5V!:>
M/DC2%M$'WHQ:/V&5EX8Q$R.->$V^R<\M7^>ZW"S=EC UC,QWR9Q'OEB=I(MZ
MYN/M)%$,J)ZP5Q*>ZYDSO43IV_7/V(ME7BOY JZ+(A__TF/"ZOB.*.=J*7H3
M@'#4"(43W1378+0E4M'AAY_-9[AC=*=2<AQM:*I51$"JSNQI1TD\*0ZKHNV]
M+?=, 7X@(&#\*8G7\3A[<YO.TSX=2G(N\,G*AP?47FP5;99<'1AJ>QC!.P^U
MZ"YSQ#QT\ZZ#.P]^RNDRLS=D,ZZ"CM/&"JCY0MDS&%G'-YW/_/H,*U;5I73]
MH:[HC&9_F3CU;?.PM\6:@:.O_:K[Q'0*:NXXZT=TGK8[9/!Y+XR>K%1>>S$A
M.1?81T4H\LW,W(\%*D'=-L_!!Y#\<4](FDH*\(,J;8A6PA\6N_@4MRKGL"TK
MA4V7GG2-(UV8>Y[C55@7%!8SCCF5%5V2"U> A!G9#S(J5 [D<O)-O,!M25E-
MSEIFN;&7'=86%^ILI6LKP2B;8SLK_DYZ EC&00'5S)UEV1BW[D'CP.M1C3/#
M[$X<!5VB82="R<GMD##;<A7/0L?M^ &Z ,YUZJBLLX.P:>?NB>'0>ELFZWF>
MS'*4@-312P\B.8>MM13F)C?/)/CG'"] %[FEU$&:-PD8#?QCT7=!\F^%?[E)
M>$?3?*@9X AS.4&2.&%GSTXMQE #E:9EL-(]AVZ:PE6TU=G%(<@8*DO(-&%%
M9)D>+*'I!_7UY"_.A'N^?(=V]Z*XIY* 2W\@SJ11D:9T VAALJJ69334#?),
M,9;XV%B=LDJ\*J%(;2;Q@5K?B]E"2V3Y#AO;-7.$Y7NB)+?06QI51Z4#J13Y
M*HT/SZ>-K2HV9VTPV&9Q%Y3<9I\AR'!/W@P/B5+GS/%TA<[D'$_F&L_6M.83
MCAA:@Q2,:&+YA8KUFY05:@<E[7"0V2T\W*UL<R;Z.?TD3SR]_O"F6Y,=0:W+
MUR\OC-1\@4=4U!I6(>54MY:V9FRU*_S+877YOFPS>?/-59<.0>IVMJ0_,O/V
MI;A\5H94NCG;!>:@U+.$$57EMAE]\QYS;"*QVA;(R<=1@?,^BVID1C+68C((
MAO1"1 -K@091QXF0D353@F/'\5*1)<4U!9=9\HF0V<,J*F]AY;9A Y@PW#.T
M=DZ.%^\_VX9-SNG$A,LDNO;0C6A-C*LK>AN91&P@58P?.1<6(3]Q&WD>R.U+
M/\[9Q"#HX:TK&>DJG"H_1]+9IX>F],MFVX1?LD_+=^8(;YR2%H'YR.?V>7TK
MJK%,IK8B]J).1<5 ZK8=2Z&X+N[T0/<9C;.I?KS1C*]+4M9R*J@&.B<L"<]A
M4GI%GVT5!CS;0]/;*?R,69\O%E>L9_WQIMH%B/< _+AS,XDDHDG?''U&>2BS
M],Z*/"QG\R%OV(<7O=_"1%^H?']SJ;P-&3%^H..SU?&9_)/$.DO+:Q)4H$X'
M)ON\.61(2VU8R5;,I2.2$+_CRK6X7.O;ALY$&@*5D9\],29TXX9)LB/'5,E9
MO[Z?#R T >EYRR>G*EK&N2-])GA8<K!,!'W @YN*FO^(S.NVN)-.+V\LFI3>
MOX2K\S9'&^PF7/8*"N)42E+>@C %D.6!>)PU:: S#/0K_IFN_?,MUZR!D#E!
MPCI&K%1>>(BO<0(&X3,Y2$HF<@.LA% +J(;H-%V36'S*Z";L&&:7H .Y#WK)
M#=3E.)L(?;YX/6#+=(-$@L@,QA5I#()*PD]KON>#4(^UP(WUN[)+E%RE$VC,
MR0(NAXR91DN6O4VSRDB&.'Y#U5%3IV%)>098NU(%$[780J40MB5<XY$#1LQ4
MEE/*=IA,EMX[A?VCC*#?)'/5!K^^$N$+R!Q4/M7]VG$[: -D-]K3?"]D1B3=
MAV=C*%/=J%V1KS?YUSU1I'Z-MBB45EPYCTE+>*9QX91@PY%850Q(YC$M+%4'
MZF9';IE3@CG [:8$T\^M5K@&@28 OLP/08Y(J5A='G]D&ZT93J@EG?9F.3'@
M<#RXLXH5^#A"/KMSBI:*J\ZG%^^]K"U-DA*,Q:BWTV!+!J%)S8'S=]5DT17$
M< [$\,>G!6)XUSY<7A&(MIT+R^#QD:XG?[AA)U,"M6HZCMZ+V5,B#^ 2ZM(S
M*7"/15)YG(5#NOS5*ECZE1*L'<N^'L'H0T!@.9CDZ5@/^FUX&U*)8(1/5[<
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M+(7T/6>2[G'<2KMXWA@^+0T!$*MU)>.@Y;1\MTP('2:?54CQ!WQ:;1. LDE
M=L[R^_A)/?B1BDPZ$<PW.3E=L^U0\+IQDK"32BM+DM.\3GD;I/@$;%:\V 6D
M/T*%6U&&5F)3LZQ! N5E&W$."'8B;_T7N-ZBCYM.GW0ZF1]4U&9PMXE>8!="
MKWPP':E=0&V:J*4GLJ^3LL42O[*C!^ II5.@O]9QR"OZ1[.Z(^YS#A6)"";
M)BG_DW[QT)*IK(4U=Z\Y]())\*-A9>Q)M-^IHSKO;AV-1^TG04"K" #IRI.!
M*1)<C4HI9.,L8@;XQ#NROB=?VUL*TT*![5H-<7< *2=)&I\#LA '[<7LRQ))
M).>?XEF%#S+FY098"^)/(Y0?J+:7BPT4TOUS+%50B8)T(*JAUMBSZ\)RO'9'
MAMI)I2^.%EE-5 ^8>UE'25O5=5VQRSP:4WV4Z4KN\L,V>H4SM%-V\7\-1'%.
M+Y*MJ],@[UY[HNLF.:T\*M("M,2Z4IYR#=>SKD/0=+(^U0&9P,G HK6H</9
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MH>LUP^&(?]MP5U(-?8M2^EP!3X=-1YJRO$"II=YF=@UX7!0_2IU*MTV+5C/
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M5L8L7E9LY.RS>QH]Z9.F3<;NM2^.]+$I988X66C;0*\_)Q_.0-.8V$N45RG
M%)I7TQ=Y?1'=EI2^#M'$BP/L>W(MW^^.[@1&GDBVX.0779C4)\\A_SFHLFI
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MG,?W(-W&3:<UWSR&JC<<M),2'G?;C:,TC3P<+8DJ/Y._%Y=]+3F>TJ^BK%9
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MB8\YB>FDC)>O0YL.Z;SD'9]6['V:4[2'72?M%S6CFSLD$6+03.[&1(W98U3
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M'R0B^BHQ^N9J9#SWMJ.J$553& )*$I*TAMO0._>=ED5%IG7 \4$YB-X4&?D
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MGA[0%V=BTF)MOD:3_]Q#.CPPKL3S54A4.*Q95Y&0(W^:J:\9O/ B5EAK@#3
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M+SZ?MG;90==)9S'7[B[[Q#@B7"NG2T&[Q6G[=6>_O\#F+:=0^2-Z.HF3^ J
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M9*;PKDZ"99-OP-1Y$3_R&IUC_ P3 "5K]/$DI=RN_L,OU=HA"="GMQD&+5\
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MW23J)?E8/ ?8OJFUB!C>U8#\[?.PF_=&5Q*#IA&OB%L<?A]/U'^GH!Z/ ^M
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M'@OTBE4J+0 9L_6(!0AX5,KI)B60?915#,LK%Q>7J;&O>7D%O(T^5:EP;0;
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M>./#I'WJ "ZS9F@./[[Y/U!+ P04    " !&@&Q9\3:>UT0/  "0@P  %0
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MR(JY[N+]\B/X&?SVRW\!4$L#!!0    ( $: ;%F4-Y&A'50  +C" P 5
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M[3[)]'!9+]%\W[,H1M0C:R1 ((\*%).&_"O%(403%'H>56@=4][\+*K)B4K
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MN03&C'?9!U:KGU4_U15P1@=(.D:'(B5O6Q_XK@1S<OIO(_;.F\)%!40_S#L
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MO$]2%.\!+4^T;)'#%;VSP+/ Y&PNT;:^./,3@%/S'!XNW0ZJ7K0\"^2LWFQ
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M)=#<A$CDY;YT-"0V WEBK.F@F0[GY'.HBQ7NQ46M/TZ;W7"<%ZAO1)*F+__
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MD.;'YSSP):;O-'GZY)U2$[N@K)6-V-;'<];6R/,1V]DDO1_[R0^W+2HOOT-
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M8H%,F,: 46B0 W.2C@N27O;7FSG+Y20QQVDMIQ^#6PUOU]_$4C"I@?N.QX#
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M"6:(%7&,\XS&<0IJ\C$*S;%\];"]%K@W@.[]WL$'>O'CG-.30VO\@,GE!:P
M"ZH6B98$=QS6K(*L1?:A8.N]Y"@[K9X8#?W^AZA868OZS'W\YO<W5<G$(B !
MIFF(42I]6'D2YQ&B492@I/!Q0)(L3)G=%#2KZ#M611M8,Z2:V=U5S5#CJ]TK
MH >@D3163V2-;?/"MC2-IH9MGO):TF;,"7.R)7,E?ME%_G5E=SG9&' *EQLL
M#!J%7(=^D \RMZ]7O$T$4Z,F^Y* -*9^R#."_"R11T\<YH@&-$$D#1A.TRBD
M,=%N&S(-S_%9H>#WW1K[B@&)0I]"JI  --O0X-VX@G? $9A&GF*&20L2#:X
M&I+8Y8Y9>Q+C3P;6KT2?U-'N)1K+S-?+1)^FO<XF@-<,=-[0+;B^JT2KD6]%
M];#(1.831E.4ICB7JBY6_KE2>E$F\IB(A#(M_WP<S$R.^6/KC9(-Y"M/KO4
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ML& ^@6+(!#WA-"0-)HN?-.B!U[X<8VZKG&6P\KP5*L<D'16=G'AD9M]N_PY
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MC&4PM07@ELEH AC; %<\SMAG=LECXZ.#7>\8,6#T@@>VXGQ7/$:4[EWRF*T
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M8#V@2FC6+3"K')IM*V#E1=8X-UIR=#F4^<J0K'%DKS3)WJHS>Q.;RYNCY*9
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M*9G0_&"_U,R-#TY).&]Z</:$YMWM%E?L7UN^%9]>12.@MJ:2N%$8ARF(,&$
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M>HG2NX@Y7FJ^.Y=>$HZN5_J?4),3RO+E%\[+U<,/OBEMD@;+$I11+P2^[R8
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MN8E'LC3Q0ZD#40FJ93EL<:AM9W2$A9K5+,=!.:/9.%_4!+?+DF,$]N%9\[G
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MY^0RN9;FF_0 O.I<D\L,&)MG,O"FGC9HVC,_HC_Z9JS2P*>!ZR% W+K0+/%
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MT^EIHS_-7(7/DH:()>XIFA^H&0)<X[&;'%[_HN'CW9Z/'70,VAH:3#!E8:B
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M4B<>4+EYX_J6G[&D!O#A[>@O=2\SY/N$NJX+7)RD  :1#U"(&>"BC>,TS:+
M5[/$=;"P+.<M/*<&Z'1PF=H:3H71DF:Y;?:IJ09]SDUH*:=!N?%F<RHX7*D-
MG0:;+C>HTUE,34UA@OXX+5/_=2VB$-_RIQ^;ZNM6),/=9Q_SDA'^5:D^<3]@
MLV+T<?V!?5HQ,7!R"0-&:>@AX'LH!C"-"<!QAH";LM!S_= / R2CK4P@8UEI
M-2B(4YGND'!8BX4(M6/FL :1A5[O%B,;,JS5YF:SHBMRUAZCP<UID%LX[1;<
M9\X>06>'H1C#\X$Y+9(S<IRN29T-7ML,[X;S1UB]JQV0/HA,LJPYC\2*]2'C
MIH%;'S1&8,QRWICDQN[8,;JFGI$L^LO5[>6:2MV;@G8RK=J>R_2^^,9$RI5H
MH%+0KVO1<:/YIQC06'WA7N+=ACU72T1A3!GDSB\+,( ># 'V2,H]8"HJ[!+F
MITHSTXUB9_L:?=^I;^$TZ+:.\A[A79-Q*D8Q[G&NG^IB70\:Y0ZG0-RI,5>T
MQ\WNJ9R=?K6=4COBKK))RJ:_%68:<@G,XC:KJV"%K:<NA!T@>LK],)>M'I2Y
MOUUH71C1M:0Z2ZRJ#L,=/,HB%Z$,A)"[&##BGU*8N@ E44I<DB#*E!+8)^+S
MI[BAG,IS.74[(R<-WUQ:":,:8H<A%3D5FUF5HB'6G:I!4\MJQ%1^0167_EO^
MYYR(-DVB3P79M/V=JINGDM5?Q1M*<X$16GUCV;:@(I3SD;VLJWPWD2J(2  I
M2@#),BI"P0' (>,F+:$TBAC&<4JE@RNFL+*L!!LTG1V>S@[1W;"KRMFCRBVH
M/;+. 5NG15<A!&!LQR2B+]?8!S45:FX+QJN:+>Z%0ESF&GNB%Z"903S4XC.F
M63<8J#$&;+Z(C6G^'(5NC"^N=MI1EB_KB- ;A\"_M-4M_WA?/JY_+Y8>8G&8
M\!.+NB@ , TA2)(D!:&XQ$2$N@F4,MT'8%@^B1JH3@MVX0C G"V. "VGSX;X
M,WQ2&*):3>]K$2RM+21(&L@!XF\WEB__<#!XA]:<1<0EB-H)K,RCFK.G^&*,
M?>&N/6L3] [>7)BFF>]'"'@D3KD'G<4@\7P?8#_-H.<F)$Z4)B@,P+(LC@U,
MQ0E+ YR1\W,-T:LFB W0A=. M9ML*T&@J5%, Y#FG<DT3O+9<":)5R;/@>Q-
MQ.UV\;TAF_PU;V_]#]]DZ&<T\"(?>)[/W40Q;2[) G[41FZ:>%D<)S30'!>I
MB9+M0%F+X&&>8MM$:8>-]F1)W2V04R;S,M9HW.S0''V'6)MP9*D$P!BGS$^]
MU$7H6L,Q)S)P8(;FU)4UFY&OZN\/H_WP/_TA/C*N%>,TB%S1HCP) 20) DF0
M,(#3C(8L"V&$I#*3U,#.<D6 :RD]&C7!&O"*#<[E."FGW,SSQ[ "^S3"(O46
MZDH4FVJQ+@=TWA;L2HPX:]&N]K9FM03;W!5<8MB7=54M_22E 8H#D!%1[1BB
M&& O#(&+DC3F7A'%U%<99'"TNI(*4)]GP&$Y*PY&L>[AB/X@=.,X\Q* H,MU
M(TH2@$D: .*'Q"-I@E.,E0I%M.G72,,T0+^<1M.F2DUQ"8(:.,Y/ M)?K,\
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MB,\<^W7!OC$B;H7?[@KZ%3TSV6R'_K<MRYP (9]4<(' 85DS0YN:D+7PG!W
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M5&"8,*TXQ(4E9XM##)/4C4.,//G>FA-]%2TSJPVCNYQ^B%(_<5, W8P &)(
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M<O[U6YB=3<@G<DE[#R2' DH:"0%# >XI-#:*1Y9] SS<N?ANN.@^S7BX8/O
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M]O;3_WGU^LW;EV\_7>>^T5.K0VEZCO=93>76?KK+ _.K6,+"A4&PF7-0F=S
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M>.8HG!9.*5^\\ZW'V=U-R;A5$>W!TT#>':#F_LEM-D913 C@E>*UU%] M,5
M$CR%:)(.;K#YF7O-07RVF2TMW..#Q-T!;NZ8A)1E9LPP#G7C@(J,@>-,539D
M++0): .T=G!^F#F(3U+OXW,0GR+KL<M2]YG&1](RLAZ[*01/;ISS%#]$"44$
MD4T..K'_/G,0GZ3L0^<@/D7RXR/KB3/Y7,J6%SJ2>6*U1:-.X(62@$BG-C(E
MLWPTN_USS$$\ %,#RKP/0#UA)I^1&FV(!9*O3^9<G?Z7*? ,3'+A2Q%,[U89
M_\//03P04 /)O -/Z8XK3D8A1\I20?;&UE)I1P$(_:%3+(PA%ZZYI[1G&X[A
M'X0U]*GW$W '$'D[2PL,2WR%F_^^G=V8)/-A?G+R9K[X/2SR1#*N+5,)F*KS
M8ZR4X+TKD(O4='3+1#)K7YZ[,WV=..![8N%VS>XPBND =(].P2H*1> Y0WTH
M1((K%AQ:0?PDJ:UDB:N!IV[N6:TR%+B&0\-3!Y0]135[0^T;'<QS.GG#8C4$
MX%Z&Q>*,F#GZ.C^=K8Y6J\4TGJ[J:?!I_GZMCPFY#,ZGY"A>)D]"A>3KP_ ,
M.3";+)WW+K3.?S^9R'$]^[$@V5AYHV-T[8G>W';5Y]PT:7]UNB!FWV\66^_&
MW_#W]8^6$\N,<4$9D*F0XRNU D>^"SB6F3 FDILO=@H!]EI^7"]N</@]DUXZ
M/([O9G+]%OB21\^MMH'. 6M+(!X-\2B< >X-SR%8K\S01_0N=([[@G"T8[NY
M"O>&*<73<=XB07*315RM3K95:!=ORW=^@YXLSR8&#G7"#B@3&'DQ64(D@7O-
M44<;][*<AU U[IO#<0SJLVEQ[/S>G8[U)M^T) T?ERNYIX^8:->NIK1'DV?<
M.5E \\HB\P)\"ADX+RR0'R.R3GL!=;?UQWW=. XD!]!,9^!;GP./<ZB9*>0W
M1RC*D1MM:P%*T0YB\B;II!RZW6["]EI^W >3HT!O +UTZ%[>'B 4K15U_]2\
M&"A56_![LNHEJ6@5F7876O<1;Y+M&>SE93_9GJ>HYL!(^O4LCY3K24G$B,:
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MV@%:Z9/PG)F;;?<.=T*;<_$S5+\_!=.W'-9Q<=&G[;YS<L/^IOJACQMJSL2
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MS>GJ=(%UFX19PHF)1AN%$J*LEU[&6XC&)=#<A$@;A?LRH..T&Y'C)OL'1=P
M6NH AFO6-I;XU6EM ?U^/05WP^65[.7R]1^X2-,E&6P9&+'B$1(YC* \[;%(
M?X)79*D+FIQUZ]9 3Z=RW'QA>R .K*<>D/A8]>U]Q;>;&^#+[N++=5^23U_"
M;"N2_\ EN:MO9QN1360,6<:HH&A30(40P7FN081D7?36FMC\@?4S\39N2F0
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M^9?O*;_$&'OO(D4T)5AXFJ5L"&$H/8K>6*8DMKE+)+)MOO* \@CP/SH$2N>
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M]\_^?9Z QM_>EP:M=3$_5NU_FX['GZ:S](\N8R"&.\M10QD(1U*%%($S$<P
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MG:NJ+I2_^;3Y&S !@R'Y3>M_AUB*.4<%;\!Y6MI,Y0S26@9$J!)I\'>(-/>
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MB^GEYP!"A%_L( [@<<D\[8QBO;'7T(A[6TKYTGL&3@A#(-YLD+/2)D[0-*U
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M9_-Y6#SZA<&YJ"AE0 B&8()+#;QK@"3'E &BH@JY,T<MMM4*9OJD8#:44"K
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M(YQU#E0AEN_!W<Y&BU&8GUU=G=V9T?C@_H8=ZY;K$^\CL)V\.8WKX//I>.2
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MW;I_E']SQGDX-'YCL8R_??+>6IQ\4%['1F'(8CXEIF@J:(:R8F*AV8\%5]A
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M+?H$ "&I.I*6\%Q3=_&E!Q[-$S[OBLS%WG7J : W(JL'TAB9=D'2O:DE8XB
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M&O9_ %F5"6H,5 IJU-+6$ N2&Q):6V],0V8\82IKXN^E6KG.84BMA-B'?)9
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M22&X#'S9]AL5ZNL1ID9*2U":FX.I-#^Q>JZHTJ/Z2LU99Q7V(6B\>!MHN$Z
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M.L54E]??MB3_1WUQK2)3T>+Z-9.]+7\XY-JTU#2E+$TI2$(Z *T#T*HHS#H
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M+3(P,C0P.3,P+GAS9%!+ 0(4 Q0    ( $: ;%GQ-I[71 \  )"#   5
M          "  =_B @!B8V%X+3(P,C0P.3,P7V-A;"YX;6Q02P$"% ,4
M" !&@&Q9E#>1H1U4  "XP@, %0              @ %6\@( 8F-A>"TR,#(T
M,#DS,%]D968N>&UL4$L! A0#%     @ 1H!L668#/A73QP  HS(( !4
M         ( !ID8# &)C87@M,C R-# Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M $: ;%G=T6<3&G\  (XA!@ 5              "  :P.! !B8V%X+3(P,C0P
M.3,P7W!R92YX;6Q02P$"% ,4    " !&@&Q9P1+3SID'  #%)@  #@
M        @ 'YC00 97AH:6)I=#,Q,2YH=&U02P$"% ,4    " !&@&Q9_/\_
M>(\'  ![)@  #@              @ &^E00 97AH:6)I=#,Q,BYH=&U02P$"
M% ,4    " !&@&Q91,WM+.P$  #''0  #@              @ %YG00 97AH
M:6)I=#,R,2YH=&U02P$"% ,4    " !&@&Q9!LZ1N!LX  !)\P( $@
M        @ &1H@0 ;&5A<V5A9W)E96UE;G0N:'1M4$L%!@     *  H ?@(
' -S:!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>bcax-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcax="http://www.bicara.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bcax-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-11-08</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-13</startDate>
            <endDate>2024-09-13</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-13</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-13</startDate>
            <endDate>2024-09-13</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-09-13</startDate>
            <endDate>2024-09-13</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-13</startDate>
            <endDate>2024-09-13</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-09-14</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-09-13</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bcax:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bcax:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcax:BioconLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:BioconLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:BioconLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsRelativesOfBoardMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcax:TwoInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeedSeriesRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMilestoneSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-06</startDate>
            <endDate>2023-12-06</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-06</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcax:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2019StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcax:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementMasterContractServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-24</startDate>
            <endDate>2020-07-24</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BiofusionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BiofusionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementRefundableDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>bcax:financialInstitution</measure>
    </unit>
    <unit id="segment">
        <measure>bcax:segment</measure>
    </unit>
    <unit id="investor">
        <measure>bcax:investor</measure>
    </unit>
    <unit id="board_member">
        <measure>bcax:board_member</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0002023658</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-103"
      decimals="INF"
      id="f-401"
      unitRef="number">0.1082</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-103"
      decimals="INF"
      id="f-552"
      unitRef="number">0.1082</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-42271</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BICARA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">85-2903745</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">116 Huntington Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 703</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">468-4219</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">BCAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-26" unitRef="shares">54415619</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">520758000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">230440000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">756000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">633000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">521514000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">231073000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">202000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">414000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">613000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">2115000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">2094000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">524173000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">233982000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">1531000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-47" unitRef="usd">2142000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-48" unitRef="usd">431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-49" unitRef="usd">1044000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">10410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-51" unitRef="usd">8053000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-52" unitRef="usd">1801000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-53" unitRef="usd">3561000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">308000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">285000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">14481000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">15085000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">137000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">17000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">14618000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">15474000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-65" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-67"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-10" decimals="INF" id="f-68" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-10" decimals="INF" id="f-69" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-10" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-9" decimals="INF" id="f-71" unitRef="shares">81790144</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-72" unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-9" decimals="INF" id="f-73" unitRef="shares">81790144</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-10" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-9" decimals="-3" id="f-75" unitRef="usd">81790000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-10" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-77" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-11" decimals="INF" id="f-80" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-11" decimals="INF" id="f-81" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-11" decimals="INF" id="f-82" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-12" decimals="INF" id="f-83" unitRef="shares">105595101</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-12" decimals="INF" id="f-84" unitRef="shares">105595101</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-12" decimals="INF" id="f-85" unitRef="shares">105595101</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-11" decimals="-3" id="f-86" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-12" decimals="-3" id="f-87" unitRef="usd">108235000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-11" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-12" decimals="-3" id="f-89" unitRef="usd">121148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-14"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-13" decimals="INF" id="f-92" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-13" decimals="INF" id="f-93" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-13" decimals="INF" id="f-94" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-14" decimals="INF" id="f-95" unitRef="shares">119599872</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-14" decimals="INF" id="f-96" unitRef="shares">119599872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-14" decimals="INF" id="f-97" unitRef="shares">119599872</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-13" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-14" decimals="-3" id="f-99" unitRef="usd">165000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-13" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-14" decimals="-3" id="f-101" unitRef="usd">164604000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-3" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">367277000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-104"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-105"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-106" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-107" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-108" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-109" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-110" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-111" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-112" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-114"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-115"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-116" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-117" unitRef="shares">365000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-118" unitRef="shares">54424994</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-119" unitRef="shares">711895</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-120" unitRef="shares">54409708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-121" unitRef="shares">640386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-122" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-123" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-124" unitRef="usd">709607000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-125" unitRef="usd">4250000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-126" unitRef="usd">-200059000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">-153021000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-128" unitRef="usd">509555000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-129" unitRef="usd">-148769000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-130" unitRef="usd">524173000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-131" unitRef="usd">233982000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-132" unitRef="usd">2310000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-133" unitRef="usd">2271000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-134" unitRef="usd">7400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-18" decimals="-3" id="f-135" unitRef="usd">6511000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-19" decimals="-3" id="f-136" unitRef="usd">13554000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-20" decimals="-3" id="f-137" unitRef="usd">4668000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-21" decimals="-3" id="f-138" unitRef="usd">36336000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-22" decimals="-3" id="f-139" unitRef="usd">13544000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-23" decimals="-3" id="f-140" unitRef="usd">4764000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-24" decimals="-3" id="f-141" unitRef="usd">2591000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">12016000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-25" decimals="-3" id="f-143" unitRef="usd">6147000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-23" decimals="-3" id="f-144" unitRef="usd">20628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-24" decimals="-3" id="f-145" unitRef="usd">9530000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">55752000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-25" decimals="-3" id="f-147" unitRef="usd">26202000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-23" decimals="-3" id="f-148" unitRef="usd">-20628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-24" decimals="-3" id="f-149" unitRef="usd">-9530000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-55752000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-25" decimals="-3" id="f-151" unitRef="usd">-26202000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-23" decimals="-3" id="f-152" unitRef="usd">3147000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-24" decimals="-3" id="f-153" unitRef="usd">13000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">8715000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-25" decimals="-3" id="f-155" unitRef="usd">13000</us-gaap:InvestmentIncomeInterest>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-23" decimals="-3" id="f-156" unitRef="usd">0</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-24" decimals="-3" id="f-157" unitRef="usd">13328000</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">0</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-25" decimals="-3" id="f-159" unitRef="usd">13356000</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-23" decimals="-3" id="f-160" unitRef="usd">3147000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-24" decimals="-3" id="f-161" unitRef="usd">-13315000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">8715000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-25" decimals="-3" id="f-163" unitRef="usd">-13343000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-164" unitRef="usd">-17481000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-165" unitRef="usd">-22845000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-47037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-167" unitRef="usd">-39545000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-168" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-24" decimals="-3" id="f-169" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-172" unitRef="usd">-17481000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-3" id="f-173" unitRef="usd">-22845000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">-47038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-175" unitRef="usd">-39545000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-24"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">-38.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-24"
      decimals="2"
      id="f-179"
      unitRef="usdPerShare">-38.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-180"
      unitRef="usdPerShare">-11.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-181"
      unitRef="usdPerShare">-11.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-182"
      unitRef="usdPerShare">-70.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-183"
      unitRef="usdPerShare">-70.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="0" id="f-184" unitRef="shares">10901138</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="0" id="f-185" unitRef="shares">10901138</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-24" decimals="0" id="f-186" unitRef="shares">597586</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-24" decimals="0" id="f-187" unitRef="shares">597586</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-188" unitRef="shares">4174353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-189" unitRef="shares">4174353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-190" unitRef="shares">563483</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-191" unitRef="shares">563483</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-192"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-26" decimals="-3" id="f-193" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-194"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-27" decimals="-3" id="f-195" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-196"
      unitRef="shares">504544</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-197" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-198" unitRef="usd">2231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-199" unitRef="usd">-101036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-200" unitRef="usd">-98803000</us-gaap:StockholdersEquity>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-32"
      decimals="INF"
      id="f-201"
      unitRef="shares">37073162</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-202" unitRef="usd">37185000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-33"
      decimals="INF"
      id="f-203"
      unitRef="shares">10428</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-204" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-35" decimals="-3" id="f-205" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-206" unitRef="usd">264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-207" unitRef="usd">264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-208" unitRef="usd">-7412000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-209" unitRef="usd">-7412000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-210"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-37" decimals="-3" id="f-211" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-212"
      unitRef="shares">37073162</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-38" decimals="-3" id="f-213" unitRef="usd">37185000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-214"
      unitRef="shares">514972</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-215" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-216" unitRef="usd">2538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-217" unitRef="usd">-108448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-218" unitRef="usd">-105908000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-43"
      decimals="INF"
      id="f-219"
      unitRef="shares">6739</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="-3" id="f-220" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-45" decimals="-3" id="f-221" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-43"
      decimals="INF"
      id="f-222"
      unitRef="shares">54035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-44" decimals="-3" id="f-223" unitRef="usd">352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-3" id="f-224" unitRef="usd">352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-225" unitRef="usd">-9288000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-226" unitRef="usd">-9288000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-227"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-47" decimals="-3" id="f-228" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-229"
      unitRef="shares">37073162</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-48" decimals="-3" id="f-230" unitRef="usd">37185000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-49"
      decimals="INF"
      id="f-231"
      unitRef="shares">575746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-232" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-233" unitRef="usd">2917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-234" unitRef="usd">-117736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-235" unitRef="usd">-114817000</us-gaap:StockholdersEquity>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-53"
      decimals="INF"
      id="f-236"
      unitRef="shares">39024386</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-53" decimals="-3" id="f-237" unitRef="usd">39817000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <bcax:TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability contextRef="c-53" decimals="-3" id="f-238" unitRef="usd">8001000</bcax:TemporaryEquitySettlementOfLiabilityFreestandingFinancialInstrumentLiability>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-54"
      decimals="INF"
      id="f-239"
      unitRef="shares">4229</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-55" decimals="-3" id="f-240" unitRef="usd">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-24" decimals="-3" id="f-241" unitRef="usd">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-55" decimals="-3" id="f-242" unitRef="usd">519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-243" unitRef="usd">519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-3" id="f-244" unitRef="usd">-22845000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-3" id="f-245" unitRef="usd">-22845000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-246"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-57" decimals="-3" id="f-247" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-58"
      decimals="INF"
      id="f-248"
      unitRef="shares">76097548</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-58" decimals="-3" id="f-249" unitRef="usd">85003000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-59"
      decimals="INF"
      id="f-250"
      unitRef="shares">579975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-3" id="f-251" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-252" unitRef="usd">3468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-253" unitRef="usd">-140581000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-254" unitRef="usd">-137111000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-255" unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-256" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-257"
      unitRef="shares">105595101</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-12" decimals="-3" id="f-258" unitRef="usd">121148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-259"
      unitRef="shares">119599872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-14" decimals="-3" id="f-260" unitRef="usd">164604000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-261"
      unitRef="shares">640386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-262" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-263" unitRef="usd">4250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-264" unitRef="usd">-153021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-265" unitRef="usd">-148769000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-66" decimals="-3" id="f-266" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-67" decimals="-3" id="f-267" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-268" unitRef="usd">1147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-67" decimals="-3" id="f-269" unitRef="usd">1147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-270" unitRef="usd">-12508000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-67" decimals="-3" id="f-271" unitRef="usd">-12508000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-69"
      decimals="INF"
      id="f-272"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-69" decimals="-3" id="f-273" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-70"
      decimals="INF"
      id="f-274"
      unitRef="shares">105595101</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-70" decimals="-3" id="f-275" unitRef="usd">121148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-71"
      decimals="INF"
      id="f-276"
      unitRef="shares">119599872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-71" decimals="-3" id="f-277" unitRef="usd">164604000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-278"
      unitRef="shares">640386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-279" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-280" unitRef="usd">5447000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-3" id="f-281" unitRef="usd">-165529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-75" decimals="-3" id="f-282" unitRef="usd">-160080000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-76"
      decimals="INF"
      id="f-283"
      unitRef="shares">349962</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-77" decimals="-3" id="f-284" unitRef="usd">1315000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-78" decimals="-3" id="f-285" unitRef="usd">1315000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-76"
      decimals="INF"
      id="f-286"
      unitRef="shares">33193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-77" decimals="-3" id="f-287" unitRef="usd">1038000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-78" decimals="-3" id="f-288" unitRef="usd">1038000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-79" decimals="-3" id="f-289" unitRef="usd">-17049000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-78" decimals="-3" id="f-290" unitRef="usd">-17049000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-80"
      decimals="INF"
      id="f-291"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-80" decimals="-3" id="f-292" unitRef="usd">81525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-81"
      decimals="INF"
      id="f-293"
      unitRef="shares">105595101</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-81" decimals="-3" id="f-294" unitRef="usd">121148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-82"
      decimals="INF"
      id="f-295"
      unitRef="shares">119599872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-82" decimals="-3" id="f-296" unitRef="usd">164604000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-83"
      decimals="INF"
      id="f-297"
      unitRef="shares">1023541</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-83" decimals="-3" id="f-298" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-84" decimals="-3" id="f-299" unitRef="usd">7800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-85" decimals="-3" id="f-300" unitRef="usd">-182578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-86" decimals="-3" id="f-301" unitRef="usd">-174776000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-87"
      decimals="INF"
      id="f-302"
      unitRef="shares">20125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-87" decimals="-3" id="f-303" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-88" decimals="-3" id="f-304" unitRef="usd">332427000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-305" unitRef="usd">332429000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bcax:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="c-89"
      decimals="INF"
      id="f-306"
      unitRef="shares">-81790144</bcax:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <bcax:TemporaryEquityValueConversionOfConvertibleSecurities contextRef="c-89" decimals="-3" id="f-307" unitRef="usd">-81525000</bcax:TemporaryEquityValueConversionOfConvertibleSecurities>
    <bcax:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="c-90"
      decimals="INF"
      id="f-308"
      unitRef="shares">-105595101</bcax:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <bcax:TemporaryEquityValueConversionOfConvertibleSecurities contextRef="c-90" decimals="-3" id="f-309" unitRef="usd">-121148000</bcax:TemporaryEquityValueConversionOfConvertibleSecurities>
    <bcax:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="c-91"
      decimals="INF"
      id="f-310"
      unitRef="shares">-119599872</bcax:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <bcax:TemporaryEquityValueConversionOfConvertibleSecurities contextRef="c-91" decimals="-3" id="f-311" unitRef="usd">-164604000</bcax:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-87"
      decimals="INF"
      id="f-312"
      unitRef="shares">33210876</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-87" decimals="-3" id="f-313" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-88" decimals="-3" id="f-314" unitRef="usd">367150000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-23" decimals="-3" id="f-315" unitRef="usd">367153000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-87"
      decimals="INF"
      id="f-316"
      unitRef="shares">43232</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-88" decimals="-3" id="f-317" unitRef="usd">199000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-318" unitRef="usd">199000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-87"
      decimals="INF"
      id="f-319"
      unitRef="shares">7059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-88" decimals="-3" id="f-320" unitRef="usd">2031000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-321" unitRef="usd">2031000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-92" decimals="-3" id="f-322" unitRef="usd">-17481000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-323" unitRef="usd">-17481000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-324"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-10" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-326"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-11" decimals="-3" id="f-327" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-328"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-13" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-93"
      decimals="INF"
      id="f-330"
      unitRef="shares">54409708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-93" decimals="-3" id="f-331" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-94" decimals="-3" id="f-332" unitRef="usd">709607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-95" decimals="-3" id="f-333" unitRef="usd">-200059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-334" unitRef="usd">509555000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">-47038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-336" unitRef="usd">-39545000</us-gaap:NetIncomeLoss>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">0</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-25" decimals="-3" id="f-338" unitRef="usd">13356000</bcax:FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">4216000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-25" decimals="-3" id="f-340" unitRef="usd">1134000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">41000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-3" id="f-342" unitRef="usd">5000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">199000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-25" decimals="-3" id="f-344" unitRef="usd">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">280000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-25" decimals="-3" id="f-346" unitRef="usd">855000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-21" decimals="-3" id="f-347" unitRef="usd">728000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-22" decimals="-3" id="f-348" unitRef="usd">-410000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-17" decimals="-3" id="f-349" unitRef="usd">-2374000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-18" decimals="-3" id="f-350" unitRef="usd">-11296000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">-211000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-25" decimals="-3" id="f-352" unitRef="usd">-7000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-44719000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-25" decimals="-3" id="f-354" unitRef="usd">-37592000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-25" decimals="-3" id="f-356" unitRef="usd">150000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">62000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-25" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">31000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-25" decimals="-3" id="f-360" unitRef="usd">-150000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">333479000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-25" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">0</bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability>
    <bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability contextRef="c-25" decimals="-3" id="f-364" unitRef="usd">77645000</bcax:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">1527000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-25" decimals="-3" id="f-366" unitRef="usd">149000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">335006000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-25" decimals="-3" id="f-368" unitRef="usd">77794000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">290318000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-25" decimals="-3" id="f-370" unitRef="usd">40052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">230440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-372" unitRef="usd">4158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-373" unitRef="usd">520758000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-62" decimals="-3" id="f-374" unitRef="usd">44210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bcax:SettlementOfFreestandingFinancialInstrumentLiabilities contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">0</bcax:SettlementOfFreestandingFinancialInstrumentLiabilities>
    <bcax:SettlementOfFreestandingFinancialInstrumentLiabilities contextRef="c-25" decimals="-3" id="f-376" unitRef="usd">8001000</bcax:SettlementOfFreestandingFinancialInstrumentLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-25" decimals="-3" id="f-378" unitRef="usd">703000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <bcax:VestingOfEarlyExerciseStockOptions contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">51000</bcax:VestingOfEarlyExerciseStockOptions>
    <bcax:VestingOfEarlyExerciseStockOptions contextRef="c-25" decimals="-3" id="f-380" unitRef="usd">51000</bcax:VestingOfEarlyExerciseStockOptions>
    <bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">1052000</bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-25" decimals="-3" id="f-382" unitRef="usd">0</bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">0</bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument>
    <bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument contextRef="c-25" decimals="-3" id="f-384" unitRef="usd">642000</bcax:LiabilityUponIssuanceOfFreestandingFinancialInstrument>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-385">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"&gt;Description of Business, Organization, and Liquidity&lt;/span&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Bicara Therapeutics Inc. (&#x201c;Bicara&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, Bicara will realize significant revenue from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In September 2024, the Company&#x2019;s board of directors approved an amendment to the fourth amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#x2019;s common stock and redeemable convertible preferred stock on a 9.2435-to-1 basis (the &#x201c;Reverse Stock Split&#x201d;) which was effected on September 5, 2024. The par value and authorized number of shares of common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Initial Public Offering ("IPO")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;On September 13, 2024, the Company closed its IPO, pursuant to which it issued and sold an aggregate of 17,500,000 shares of its common stock at a public offering price of $18.00 per share and the Company issued and sold 2,625,000 additional shares of its common stock to the underwriters of the IPO pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of approximately $332.4&#160;million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8&#160;million. Immediately prior to the closing of the IPO, the Company&#x2019;s outstanding redeemable convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;33,210,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt; shares of common stock. Following the closing of the IPO, no shares of redeemable convertible preferred stock were authorized or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In connection with the closing of its IPO, on September 13, 2024, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 500,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically has funded its operations from the issuance of redeemable convertible preferred stock, common stock and through debt financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of September&#160;30, 2024, the Company had cash of $520.8 million and an accumulated &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deficit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $200.1 million.&lt;/span&gt;&lt;/div&gt;The Company expects that its cash and cash equivalents as of September&#160;30, 2024 of $520.8 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-96"
      decimals="INF"
      id="f-386"
      unitRef="shares">17500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-97"
      decimals="2"
      id="f-387"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-98"
      decimals="INF"
      id="f-388"
      unitRef="shares">2625000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-99" decimals="-5" id="f-389" unitRef="usd">332400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-99" decimals="-5" id="f-390" unitRef="usd">29800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-100"
      decimals="INF"
      id="f-391"
      unitRef="shares">33210876</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-101"
      decimals="INF"
      id="f-392"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-101"
      decimals="INF"
      id="f-393"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-102"
      decimals="INF"
      id="f-394"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-102"
      decimals="INF"
      id="f-395"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-102"
      decimals="INF"
      id="f-396"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-102"
      decimals="INF"
      id="f-397"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-398" unitRef="usd">520800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-399" unitRef="usd">-200100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-400" unitRef="usd">520800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-402">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#x2019;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of September&#160;30, 2024, condensed consolidated statements of operations, condensed consolidated statements of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) and condensed consolidated cash flows for the nine months ended September&#160;30, 2024 and 2023 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements, which were previously filed in Form S-1/A on September 11, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;We are an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our IPO or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in total annual gross revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K), or we issue more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC&#160;480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and therefore classified the Seed Series, Series&#160;B and Series C convertible preferred stock as mezzanine equity. The convertible preferred stock was recorded outside of stockholders&#x2019; deficit because, in the event of certain deemed liquidation events considered not solely within the Company&#x2019;s control, such as a merger or consolidation and sale, lease or transfer of all or substantially all of the Company&#x2019;s assets, the convertible preferred stock would have become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would have been distributed in accordance with the corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Tranche Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the consolidated financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Preferred Stock issuance as described in Note 6 Redeemable Convertible Preferred Stock to these condensed consolidated financial statements, included tranche rights (&#x201c;Series B Tranche Rights&#x201d;) to purchasers who participated in the initial Series B Preferred Stock issuance. The Series B Tranche Rights were determined to be a &#x201c;freestanding financial instrument&#x201d; as defined in the ASC Master Glossary as they are legally detachable and separately exercisable. Management assessed the freestanding financial instrument under &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 480&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determined that such rights should be accounted for as a liability at fair value given they impose an obligation on the Company to issue shares that are contingently redeemable. The Series B Tranche Rights were revalued at each reporting period until settlement, with changes in the fair value recorded in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; defined as inputs other than quoted prices included in Level 1 that are either directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s financial assets (which include cash) and liabilities (which include accounts payable) approximate fair value because of the short maturity of these instruments and have been classified as Level 1. The Series B Tranche Rights were classified as Level 3 financial liabilities (Refer to Note 3 Fair value measurement to these unaudited condensed consolidated financial statements for more details).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents are held in standard checking accounts and money market funds at two financial institutions. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company&#x2019;s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance&#160;sheet concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with a term of greater than 12 months regardless of classification. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. The incremental borrowing rate is based on the estimated interest rate for borrowing over a term similar to that of the lease payments at commencement of the lease. The operating lease expense for the operating leases is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components of contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this new standard on January 1, 2022 using the required modified retrospective approach and utilizing the effective date as its date of initial application. The adoption of this standard did not have an impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon adoption, the Company elected, to apply the &#x2018;package of practical expedients&#x2019; which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, if any, and (iii) not to reassess initial direct costs for any existing leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 730&#x201d;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#x2019;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. During the three months ended September&#160;30, 2024 and 2023, the Company incurred $15.9 million and $6.9 million, respectively, relating to research and development expenses. During the nine months ended September&#160;30, 2024 and 2023, the Company incurred $43.7 million and $20.1 million, respectively, relating to research and development expenses. The Company recorded accrued liabilities of $9.2 million and $9.6 million for clinical trial and contract manufacturing expenses as of September&#160;30, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company&#x2019;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company's IPO, the grant date fair value of stock awards granted under its 2019 Stock Option and Grant Plan were determined using the fair market value of the Company&#x2019;s common stock on the date of grant, as set forth in the applicable plan document. Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such as option-pricing method or OPM and probability weighted expected return method or PWERM. The OPM method allowed for the allocation of the Company's equity value among the various equity capital owners and considered a variety of factors, included the illiquid nature of the common stock, recent transactions involving the Company&#x2019;s stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. PWERM involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome which included an IPO scenario or continued operation as a private company scenario. Among other factors were the Company's financial position and historical financial performance, the status of clinical developments, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term:&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss consists of net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, of which we have none. Our comprehensive loss equals our net loss for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share was computed using the two-class method required due to the participating securities, such securities did not participate in net losses and therefore did not impact the Company&#x2019;s net loss from continuing operations per share calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. Outstanding common stock options, unvested restricted stock awards and redeemable convertible preferred shares are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024 and 2023, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options and restricted stock awards outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,999,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950,707&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Seed Series redeemable convertible preferred stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,848,387&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232,546&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements and Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. As of September&#160;30, 2024, the Company has not identified any new standards that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update (ASU) 2023-07,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that an entity report segment information in accordance with&#160;Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its unaudited condensed consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2023-09&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. The standard largely follows the proposed ASU issued in 2023 with several important modifications and clarifications. ASU 2023-09 is effective for public entities for annual periods beginning after December 15, 2024 and for all other business for annual periods beginning after December 15, 2025. Early adoption is permitted, and the Company is evaluating the impact of this guidance on the unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#x2019;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-405">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="c-1" id="f-406">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC&#160;480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and therefore classified the Seed Series, Series&#160;B and Series C convertible preferred stock as mezzanine equity. The convertible preferred stock was recorded outside of stockholders&#x2019; deficit because, in the event of certain deemed liquidation events considered not solely within the Company&#x2019;s control, such as a merger or consolidation and sale, lease or transfer of all or substantially all of the Company&#x2019;s assets, the convertible preferred stock would have become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would have been distributed in accordance with the corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <bcax:StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Tranche Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the consolidated financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Preferred Stock issuance as described in Note 6 Redeemable Convertible Preferred Stock to these condensed consolidated financial statements, included tranche rights (&#x201c;Series B Tranche Rights&#x201d;) to purchasers who participated in the initial Series B Preferred Stock issuance. The Series B Tranche Rights were determined to be a &#x201c;freestanding financial instrument&#x201d; as defined in the ASC Master Glossary as they are legally detachable and separately exercisable. Management assessed the freestanding financial instrument under &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 480&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determined that such rights should be accounted for as a liability at fair value given they impose an obligation on the Company to issue shares that are contingently redeemable. The Series B Tranche Rights were revalued at each reporting period until settlement, with changes in the fair value recorded in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</bcax:StockholdersEquityNoteFreestandingFinancialInstrumentsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; defined as inputs other than quoted prices included in Level 1 that are either directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:76.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions&lt;/span&gt;&lt;/div&gt;The carrying amounts of the Company&#x2019;s financial assets (which include cash) and liabilities (which include accounts payable) approximate fair value because of the short maturity of these instruments and have been classified as Level 1. The Series B Tranche Rights were classified as Level 3 financial liabilities</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-409">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s cash and cash equivalents are held in standard checking accounts and money market funds at two financial institutions. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bcax:NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld
      contextRef="c-3"
      decimals="INF"
      id="f-410"
      unitRef="financialinstitution">2</bcax:NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-411">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company&#x2019;s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance&#160;sheet concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with a term of greater than 12 months regardless of classification. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. The incremental borrowing rate is based on the estimated interest rate for borrowing over a term similar to that of the lease payments at commencement of the lease. The operating lease expense for the operating leases is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components of contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this new standard on January 1, 2022 using the required modified retrospective approach and utilizing the effective date as its date of initial application. The adoption of this standard did not have an impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;Upon adoption, the Company elected, to apply the &#x2018;package of practical expedients&#x2019; which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, if any, and (iii) not to reassess initial direct costs for any existing leases.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-413">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 730&#x201d;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#x2019;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-23" decimals="-5" id="f-414" unitRef="usd">15900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-24" decimals="-5" id="f-415" unitRef="usd">6900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-416" unitRef="usd">43700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-25" decimals="-5" id="f-417" unitRef="usd">20100000</us-gaap:ResearchAndDevelopmentExpense>
    <bcax:AccruedClinicalTrialAndContractManufacturingExpenses contextRef="c-3" decimals="-5" id="f-418" unitRef="usd">9200000</bcax:AccruedClinicalTrialAndContractManufacturingExpenses>
    <bcax:AccruedClinicalTrialAndContractManufacturingExpenses contextRef="c-4" decimals="-5" id="f-419" unitRef="usd">9600000</bcax:AccruedClinicalTrialAndContractManufacturingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expense&lt;/span&gt;&lt;/div&gt;General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-421">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company&#x2019;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company's IPO, the grant date fair value of stock awards granted under its 2019 Stock Option and Grant Plan were determined using the fair market value of the Company&#x2019;s common stock on the date of grant, as set forth in the applicable plan document. Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such as option-pricing method or OPM and probability weighted expected return method or PWERM. The OPM method allowed for the allocation of the Company's equity value among the various equity capital owners and considered a variety of factors, included the illiquid nature of the common stock, recent transactions involving the Company&#x2019;s stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. PWERM involved the estimation of future potential outcomes for the Company, as well as values and probabilities associated with each respective potential outcome which included an IPO scenario or continued operation as a private company scenario. Among other factors were the Company's financial position and historical financial performance, the status of clinical developments, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term:&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss consists of net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, of which we have none. Our comprehensive loss equals our net loss for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share was computed using the two-class method required due to the participating securities, such securities did not participate in net losses and therefore did not impact the Company&#x2019;s net loss from continuing operations per share calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. Outstanding common stock options, unvested restricted stock awards and redeemable convertible preferred shares are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024 and 2023, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options and restricted stock awards outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,999,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950,707&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Seed Series redeemable convertible preferred stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,848,387&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232,546&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-104" decimals="0" id="f-425" unitRef="shares">7999713</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-105" decimals="0" id="f-426" unitRef="shares">2950707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-106" decimals="0" id="f-427" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-107" decimals="0" id="f-428" unitRef="shares">8848387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-108" decimals="0" id="f-429" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-109" decimals="0" id="f-430" unitRef="shares">8232546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-432"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-433">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements and Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. As of September&#160;30, 2024, the Company has not identified any new standards that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update (ASU) 2023-07,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that an entity report segment information in accordance with&#160;Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its unaudited condensed consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2023-09&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. The standard largely follows the proposed ASU issued in 2023 with several important modifications and clarifications. ASU 2023-09 is effective for public entities for annual periods beginning after December 15, 2024 and for all other business for annual periods beginning after December 15, 2025. Early adoption is permitted, and the Company is evaluating the impact of this guidance on the unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-434">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Fair Value Measurements&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets that have been measured at fair value as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within Cash and cash equivalent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within Cash and cash equivalent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of the Series B Tranche Rights at the time of issuance and subsequently remeasured them at each reporting period and prior to settlement. The fair value of the Series B Tranche Rights was determined using a contingent forward model, which considered as inputs the estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, probability of achievement and estimated time to tranche closing. The most significant assumptions in the contingent forward model impacting the fair value of the Series B Tranche Rights are the fair value of the Company&#x2019;s Series B Preferred Stock, probability of achievement of certain milestones, and time to the tranche closing as of each measurement date. The Company determined the fair value per share of the underlying Series B Preferred Stock by taking into consideration the most recent sales of its preferred units, results obtained from third-party valuations and additional factors the Company deemed relevant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the Level 3 Series B Tranche Rights for the nine months ended September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.191%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tranche Rights Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value recognized upon the issuance of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,001)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,997&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company recorded $6.0 million tranche rights liability within accrued expenses and other current liabilities on the balance sheet. The tranche rights liability were settled in September and November 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used in the estimation of the fair value of the Series B Tranche Rights, on the closing dates of Series B financing tranches and as of September 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.892%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.399%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 2, 2023 &lt;br/&gt;Initial Closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 8, 2023 Milestone Closing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets that have been measured at fair value as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within Cash and cash equivalent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;519,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within Cash and cash equivalent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;230,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-436" unitRef="usd">519631000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-439" unitRef="usd">519631000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-440" unitRef="usd">519631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-443" unitRef="usd">519631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-444" unitRef="usd">230088000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-118" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-447" unitRef="usd">230088000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-448" unitRef="usd">230088000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">230088000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the Level 3 Series B Tranche Rights for the nine months ended September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.191%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tranche Rights Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value recognized upon the issuance of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of preferred stock tranche rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,001)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,997&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-31" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-25" decimals="-3" id="f-454" unitRef="usd">642000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-25" decimals="-3" id="f-455" unitRef="usd">13356000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-25" decimals="-3" id="f-456" unitRef="usd">8001000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-62" decimals="-3" id="f-457" unitRef="usd">5997000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bcax:FreestandingFinancialInstrumentLiabilityCurrent contextRef="c-62" decimals="-3" id="f-458" unitRef="usd">6000000.0</bcax:FreestandingFinancialInstrumentLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-459">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used in the estimation of the fair value of the Series B Tranche Rights, on the closing dates of Series B financing tranches and as of September 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.892%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.399%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 2, 2023 &lt;br/&gt;Initial Closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 8, 2023 Milestone Closing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-124" decimals="2" id="f-460" unitRef="number">1.01</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-125" decimals="2" id="f-461" unitRef="number">1.23</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-126" decimals="2" id="f-462" unitRef="number">0.5</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-127" decimals="2" id="f-463" unitRef="number">0</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-128" decimals="3" id="f-464" unitRef="number">0.052</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-129" decimals="3" id="f-465" unitRef="number">0</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-130" decimals="3" id="f-466" unitRef="number">0.950</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput contextRef="c-131" decimals="3" id="f-467" unitRef="number">1.000</bcax:FreestandingFinancialInstrumentLiabilityMeasurementInput>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-468">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,448&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus and payroll related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,053&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-469">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,448&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus and payroll related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,053&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bcax:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-470" unitRef="usd">7448000</bcax:AccruedResearchAndDevelopmentExpenseCurrent>
    <bcax:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-471" unitRef="usd">6035000</bcax:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-472" unitRef="usd">1807000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-473" unitRef="usd">1742000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-474" unitRef="usd">1087000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">184000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-476" unitRef="usd">68000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-477" unitRef="usd">92000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-478" unitRef="usd">10410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-479" unitRef="usd">8053000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-480">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Common Stock&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 500,000,000 shares of Common Stock authorized for issuance, par value $0.0001 per share, of which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,424,994 shares issued, net of share repurchased and cancellation, and 54,409,708 shares, net were outstanding as of September&#160;30, 2024 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 711,895 shares issued, net of share repurchased and cancellation, and 640,386 shares, net were outstanding as of December&#160;31, 2023. The Company has reserved 5,881,181 shares of Common Stock for issuance to officers, directors, employees and consultants pursuant to the 2019 Stock Option and Grant Plan. As of December&#160;31, 2023, of the 640,386 shares outstanding, 87,404 shares relate to the exercises of stock options, 437,203 shares relate to vesting of RSAs issued under the 2019 Stock Option and Grant Plan, 115,757 shares of Common Stock are held by Biocon Limited and its affiliates (&#x201c;Biocon&#x201d;) and were awarded by the Company in 2020 and the remaining balance was issued to an investor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In September 2024, the Company completed an IPO. As part of the IPO, the Company received net proceeds of $332.4 million after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8&#160;million from the issuance of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,125,000 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Prior to the IPO, the Company held shares of convertible redeemable preferred shares, which consisted of Series A, Series B and Series C of preferred stock. Each tranche was subject to automatic conversion to common stock per the terms of the initial agreement. Prior to the IPO, there were 81,790,144, 105,595,101 and 119,599,872 shares outstanding in Series A, Series B and Series C tranches of preferred stock, respectively. These shares were converted into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;33,210,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt; shares of common stock upon completion of the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-481" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-482"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-483" unitRef="shares">54424994</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-484" unitRef="shares">54409708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-485" unitRef="shares">711895</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-486" unitRef="shares">640386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-132"
      decimals="INF"
      id="f-487"
      unitRef="shares">5881181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-488" unitRef="shares">640386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-133"
      decimals="INF"
      id="f-489"
      unitRef="shares">87404</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-134"
      decimals="INF"
      id="f-490"
      unitRef="shares">437203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-135"
      decimals="INF"
      id="f-491"
      unitRef="shares">115757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-103" decimals="-5" id="f-492" unitRef="usd">332400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-99" decimals="-5" id="f-493" unitRef="usd">29800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-103"
      decimals="INF"
      id="f-494"
      unitRef="shares">20125000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-136"
      decimals="INF"
      id="f-495"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-137"
      decimals="INF"
      id="f-496"
      unitRef="shares">105595101</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-138"
      decimals="INF"
      id="f-497"
      unitRef="shares">119599872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-100"
      decimals="INF"
      id="f-498"
      unitRef="shares">33210876</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <bcax:TemporaryEquityDisclosureTextBlock contextRef="c-1" id="f-499">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;23, 2020, the Company issued to Biocon 40,000,000 shares of Seed Series Preferred Stock (&#x201c;Seed Series&#x201d;) with a par value of $0.0001 per share and purchase price of $1.00 per share, in exchange for net proceeds of $40.0 million. On April&#160;26, 2022, the Company authorized for issuance an additional 50,940,144 shares of Seed Series Preferred Stock with par value of $0.0001 per share and price of $1.00 per share. On March&#160;2, 2023, the Company reduced the total number of its authorized Seed Series Preferred Stock to 81,790,144.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In March 2022, as part of the first close of the Company&#x2019;s Seed Series extension financing, the Company entered into several SAFEs, pursuant to which the Company received approximately $5.4 million in exchange for its agreement to issue to certain investors shares of its preferred stock upon the occurrence of the Seed Series extension financing at $1.00 per share. On April&#160;26, 2022, the Company issued 5,350,000 shares of Seed Series Preferred Stock with par value of $0.0001 per share and a $1.00 per share price to settle the $5.4 million in SAFEs, of which 4,000,000 shares of Seed Series Preferred Stock were issued to two investors controlled by a board member, who is also a relative of the Chief Executive Officer, and 350,000 shares of Seed Series Preferred Stock held by relatives of the Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, as part of the second close of the Company&#x2019;s Seed Series extension financing, the Company sold an additional 3,000,000 shares of Seed Series Preferred Stock to the two investors controlled by a board member, who is also a relative of the Chief Executive Officer, referred to above increasing their ownership to 7,000,000 shares of Seed Series Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;2, 2023, the Company issued 37,073,162 shares of Series B Preferred Stock at a price of $1.025 per share (the &#x201c;Initial Series B Closing&#x201d;) for proceeds of $37.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was also obligated to sell up to 68,521,939 additional shares (the &#x201c;Milestone Shares&#x201d;) of Series B Preferred Stock to the same purchasers at the same purchase price as the Initial Series B Closing the Series B Tranche Rights. The sale of Milestone Shares (the &#x201c;Milestone Closings&#x201d;) was contingent upon the Company&#x2019;s achievement of certain milestones. In addition, if elected by a purchaser, the Company was obligated to sell Milestone Shares prior to achievement of the milestones (the &#x201c;Voluntary Closings&#x201d;). The Series B Tranche Rights are considered a freestanding instrument classified as a liability under ASC 480. The initial fair value of the liability was determined to be $0.6 million. Refer to Note 3 Fair Value Measurements to these unaudited condensed consolidated financial statements for further details. Share issuances pursuant to exercise of the Series B Tranche Rights under such Milestone Closings occurred on September&#160;8 and November&#160;3, 2023 in the amounts of 39,024,386 and 29,497,553, respectively, for net proceeds of $69.9 million. Upon completion of the Milestone Closings, such tranche liabilities of $8.0 million and $6.0 million on September&#160;8, 2023 and November&#160;3, 2023, respectively, were settled to redeemable convertible preferred stock on the unaudited condensed consolidated balance sheets. The Voluntary Closings were not exercised by the purchasers in 2023, and this right has expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;6, 2023, the Company issued 119,599,872 shares of Series C Preferred Stock at a price of $1.3796 per share in exchange for aggregate net proceeds of $164.6 million. The Company additionally executed various side letters where certain purchasers have the right to tender all owned shares back to the Company for an aggregate purchase price of $1.00 (the &#x201c;Put Option&#x201d;). The Put Option has no accounting implications as it is considered immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Seed Series Preferred Stock, Series B Preferred Stock and Series C Preferred Stock are collectively referred to as the &#x201c;Preferred Stock&#x201d;. As of December&#160;31, 2023, the Preferred Stock had the following rights, preferences, and privileges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the Preferred Stock had rights to convert the shares of Preferred Stock into shares of Common Stock (the &#x201c;Conversion Rights&#x201d;) at the applicable original issue price (&#x201c;Conversion Price&#x201d;) with a conversion ratio (&#x201c;Conversion Ratio&#x201d;) of 9.2435:1. All outstanding shares of the Preferred Stock were converted automatically into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,210,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Common Stock immediately prior to the closing of the sale of shares of Common Stock to the public on September 13, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Liquidation Preference&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B and Series C Preferred Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the shareholders of outstanding Series B Preferred Stock and Series C Preferred Stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders and in case of a Deemed Liquidation Event (defined as a merger or consolidation in which the Company is a constituent party, or the sale, lease, transfer, exclusive license or other disposition by the Company of all or substantially all the assets), the holders of the Series B and Series C Preferred Stock shall be entitled to be paid out of the consideration payable to stockholders or out of the available proceeds of the Company, before the Seed Series and common stockholders, an amount per share (the &#x201c;Liquidation Amount&#x201d;) equal to the greater of: (a) the applicable original issue price, plus any dividends declared but unpaid, or (b) such amount per share amount as would have been payable on the conversion of all Series B Preferred Stock and Series C Preferred Stock (as applicable) into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If the amount to be paid as Liquidation Amount is insufficient, then all Series B and Series C preferred stockholders shall share the assets available for distribution in proportion of their shareholding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Seed Series Preferred Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Seed Series preferred stockholders shall have priority over the common stockholders, with a liquidation preference equal to the greater of (a) the Seed Series original issue price, plus any dividends declared but unpaid thereon, or (b) such amount per share as would have been payable on the conversion of all shares of Seed Series Preferred Stock into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, and after the payment of all preferential amounts required to be paid to the holders of the Series B Preferred Stock and Series C Preferred Stock, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Seed Series Preferred Stock the full amount to which they shall be entitled, the holders of shares of Seed Series Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares of Seed Series Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Preferred Stock is not redeemable except in the event of a Deemed Liquidation Event. As redemption by the holders is not within the control of the Company, all the outstanding convertible preferred stock is classified as temporary equity in the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B and Series C Preferred Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The holders of then outstanding shares of Series B Preferred Stock and Series C Preferred Stock shall be entitled to receive, only when, as and if declared by the board of directors of the Company, dividends at the rate of eight percent (8%) of the applicable original issue price for each share of Series B Preferred Stock or Series C Preferred Stock, prior and in preference to any declaration or payment of any other dividend on shares of Seed Series Preferred Stock or Common Stock (other than dividends on shares of Common Stock payable in shares of Common Stock) during the same calendar year. The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company unless the holders of the Series B Preferred Stock and Series C Preferred Stock then outstanding first receive a dividend on each outstanding share of Series B Preferred Stock or Series C Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Seed Series Preferred Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; The Company shall not declare, pay or set aside any dividends on shares of Common Stock unless the holders of the Seed Series Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock at the same rate and same time on an as-converted basis. No dividends have been declared or paid as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voting Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the Preferred Stock have the same voting rights as the holders of the Common Stock, on an as-converted basis. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the board of directors of the Company was comprised of ten members. The election of directors is determined as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;The holders of record of the shares of Seed Series Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3) directors of the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The holders of record of the shares of Series C Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The holders of record of the shares of common stock, $0.0001 par value per share, of the Company, exclusively and as a separate class, shall be entitled to elect one (1) director of the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The holders of record of the shares of Common Stock and the Preferred Stock, voting together as a single class on an as converted basis, shall be entitled to elect the balance of the total number of directors of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vi.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;Any director elected as above may be removed without cause by, and only by, the affirmative vote of the holders of the class or series of capital stock entitled to elect such director or directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Protective Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At any time when shares of Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative vote of at least 65% of the outstanding Preferred Stock holders, including at least one holder of Series C Preferred Stock who does not hold shares of any other class or series of Preferred Stock: 1) liquidate, dissolve or wind-up the business and affairs of the Company, or effect any merger or consolidation or any other Deemed Liquidation Event; 2) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Company in a manner that adversely affects the powers, preferences or rights of the Preferred Stock; 3) create, issue, or reclassify any capital stock unless the same ranks junior to the Preferred Stock with respect to its rights, preferences and privileges; 4) cause or permit any of its subsidiaries to, without approval of the board of directors, sell, issue, sponsor, create or distribute any digital tokens, cryptocurrency or other blockchain-based assets; 5) purchase or redeem or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than as expressed with the Preferred Stock agreements; 6) create, issue, or authorize the issuance of any debt security or create any lien or security interest or incur other indebtedness for borrowed money; 7) create, or hold capital stock in, any subsidiary that is not wholly owned by the Company, or permit any subsidiary to create or issue any shares, or sell, transfer or otherwise dispose of any capital stock; 8) create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation plan; or 9) increase or decrease the authorized number of directors constituting the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional protective provisions for certain classes of shares include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - For so long as at least 52,797,551 shares of Series B Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least 60% of the Series B holders: a) waive or otherwise forego any adjustment in the Series B Conversion Price; b) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series B Preferred Stock with respect to its rights, preferences and privileges; or c) amend, modify, change or waive the liquidation amount applicable to the Series B Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series C Preferred Stock&lt;/span&gt; - For so long as at least 71,759,924 shares of Series C Preferred Stock are outstanding, the Company shall not do any of the following without the written consent or affirmative of at least 60% of the Series C holders: a) waive or otherwise forego any adjustment in the Series C Conversion Price; b) effect the conversion of the Series C Preferred Stock to Common Stock in a Qualified IPO; c) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Series C Preferred Stock with respect to its rights, preferences and privileges; or d) amend, modify, change or waive the liquidation amount applicable to the Series C Preferred Stock.</bcax:TemporaryEquityDisclosureTextBlock>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-139"
      decimals="INF"
      id="f-500"
      unitRef="shares">40000000</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-140"
      decimals="INF"
      id="f-501"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-140"
      decimals="INF"
      id="f-502"
      unitRef="usdPerShare">1.00</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-139" decimals="-5" id="f-503" unitRef="usd">40000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-141"
      decimals="INF"
      id="f-504"
      unitRef="shares">50940144</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-142"
      decimals="INF"
      id="f-505"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-141"
      decimals="INF"
      id="f-506"
      unitRef="usdPerShare">1.00</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-143"
      decimals="INF"
      id="f-507"
      unitRef="shares">81790144</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="c-144" decimals="-5" id="f-508" unitRef="usd">5400000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-145"
      decimals="INF"
      id="f-509"
      unitRef="usdPerShare">1.00</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-146"
      decimals="INF"
      id="f-510"
      unitRef="shares">5350000</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-141"
      decimals="INF"
      id="f-511"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-141"
      decimals="INF"
      id="f-512"
      unitRef="usdPerShare">1.00</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="c-144" decimals="-5" id="f-513" unitRef="usd">5400000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-147"
      decimals="INF"
      id="f-514"
      unitRef="shares">4000000</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityNumberOfInvestorsStockIssued
      contextRef="c-146"
      decimals="INF"
      id="f-515"
      unitRef="investor">2</bcax:TemporaryEquityNumberOfInvestorsStockIssued>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-148"
      decimals="INF"
      id="f-516"
      unitRef="shares">350000</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-149"
      decimals="INF"
      id="f-517"
      unitRef="shares">3000000</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityNumberOfInvestorsStockIssued
      contextRef="c-150"
      decimals="INF"
      id="f-518"
      unitRef="investor">2</bcax:TemporaryEquityNumberOfInvestorsStockIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-151"
      decimals="INF"
      id="f-519"
      unitRef="shares">7000000</us-gaap:TemporaryEquitySharesOutstanding>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-152"
      decimals="INF"
      id="f-520"
      unitRef="shares">37073162</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-153"
      decimals="INF"
      id="f-521"
      unitRef="usdPerShare">1.025</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross contextRef="c-152" decimals="-5" id="f-522" unitRef="usd">37800000</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-154"
      decimals="INF"
      id="f-523"
      unitRef="shares">68521939</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:FreestandingFinancialInstrumentLiabilityFairValue contextRef="c-155" decimals="-5" id="f-524" unitRef="usd">600000</bcax:FreestandingFinancialInstrumentLiabilityFairValue>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-156"
      decimals="INF"
      id="f-525"
      unitRef="shares">39024386</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-157"
      decimals="INF"
      id="f-526"
      unitRef="shares">29497553</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-158" decimals="-5" id="f-527" unitRef="usd">69900000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-159" decimals="-5" id="f-528" unitRef="usd">8000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-160" decimals="-5" id="f-529" unitRef="usd">6000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-161"
      decimals="INF"
      id="f-530"
      unitRef="shares">119599872</bcax:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="c-162"
      decimals="INF"
      id="f-531"
      unitRef="usdPerShare">1.3796</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-161" decimals="-5" id="f-532" unitRef="usd">164600000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption
      contextRef="c-162"
      decimals="INF"
      id="f-533"
      unitRef="usdPerShare">1.00</bcax:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerSharePutOption>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-100"
      decimals="INF"
      id="f-534"
      unitRef="shares">33210876</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <bcax:TemporaryEquityDividendRatePercentage contextRef="c-13" decimals="2" id="f-535" unitRef="number">0.08</bcax:TemporaryEquityDividendRatePercentage>
    <bcax:TemporaryEquityDividendRatePercentage contextRef="c-11" decimals="2" id="f-536" unitRef="number">0.08</bcax:TemporaryEquityDividendRatePercentage>
    <bcax:NumberOfMembersBoardOfDirectors
      contextRef="c-4"
      decimals="INF"
      id="f-537"
      unitRef="board_member">10</bcax:NumberOfMembersBoardOfDirectors>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-9"
      decimals="INF"
      id="f-538"
      unitRef="board_member">1</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-9"
      decimals="INF"
      id="f-539"
      unitRef="board_member">1</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-12"
      decimals="INF"
      id="f-540"
      unitRef="board_member">3</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-12"
      decimals="INF"
      id="f-541"
      unitRef="board_member">3</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-14"
      decimals="INF"
      id="f-542"
      unitRef="board_member">1</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-14"
      decimals="INF"
      id="f-543"
      unitRef="board_member">1</bcax:TemporaryEquityVotingRightsNumberOfDirectorsEntitledToBeElected>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-544"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-4"
      decimals="INF"
      id="f-545"
      unitRef="board_member">1</bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected
      contextRef="c-4"
      decimals="INF"
      id="f-546"
      unitRef="board_member">1</bcax:CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected>
    <bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage contextRef="c-163" decimals="2" id="f-547" unitRef="number">0.65</bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage>
    <bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired
      contextRef="c-12"
      decimals="INF"
      id="f-548"
      unitRef="shares">52797551</bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired>
    <bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage contextRef="c-164" decimals="2" id="f-549" unitRef="number">0.60</bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage>
    <bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired
      contextRef="c-14"
      decimals="INF"
      id="f-550"
      unitRef="shares">71759924</bcax:TemporaryEquityProtectiveProvisionSharesOutstandingMinimumAmountRequired>
    <bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage contextRef="c-165" decimals="2" id="f-551" unitRef="number">0.60</bcax:TemporaryEquityProtectiveProvisionAffirmativeVotePercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-553">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Stock-Based Compensation&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option and Grant Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the board of directors adopted, and the Company&#x2019;s shareholders approved, the 2019 Stock Option and Grant Plan (the &#x201c;2019 Plan&#x201d;) under which the Company may grant equity-based incentive awards to the Company&#x2019;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are awards that are authorized to be issued:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Stock Options including Incentive Stock Options (&#x201c;ISO&#x201d;) or Non-Qualified Stock Options (&#x201c;NQSO&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Restricted Stock Awards (&#x201c;RSA&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unrestricted Stock Awards (&#x201c;URSA&#x201d;); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2019 Plan, as amended, the Company is authorized to issue up to 8,856,245 shares of Common Stock. For the period ended September&#160;30, 2024, the Company has issued RSAs, ISOs and NQSOs under the 2019 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2019 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSAs were issued under individual RSA agreements (the &#x201c;Award Agreements&#x201d;). The Award Agreements dictate vesting terms and once vested, the recipients&#x2019; restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided in the respective Award Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In 2024, in connection with the Company's IPO, the board of directors adopted, and the Company's shareholders approved the 2024 Stock Option and Grant Plan (the "2024 Plan") under which the Company may grant equity-based incentive awards to the Company&#x2019;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgement, initiative, and efforts the Company largely depends for the successful conduct of its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2024 Plan, the Company is authorized to issue up to 2,453,616 shares of Common Stock, plus on January 1, and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by 5% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through September&#160;30, 2024, the Company has issued 174,707 ISOs and NQSOs under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense for non-employees and employees in its statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,172&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSA award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,252)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchased/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, total unrecognized compensation costs of $0.1 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted average period of 0.1 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of options award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &#x2013;&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic &lt;br/&gt;Value (1)&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,850,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652,807&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393,216)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,494)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,789&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897,774&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,951&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and expected to vest as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#x2019;s common stock on September&#160;30, 2024 for the options that were in the money. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of options granted during the nine months ended September&#160;30, 2024 and 2023, was $6.99 and $2.77, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had 7,094,992 unvested stock options outstanding as of September&#160;30, 2024. As of September&#160;30, 2024, total unrecognized compensation costs of $37.0 million related to unvested stock options are expected to be recognized as expense over a weighted average period of 3.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;On September 5, 2024, the Company&#x2019;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to 507,383 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 1,014,766 shares of common stock, (ii) 1% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date and no stock-based compensation expense was recognized during the three months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-132"
      decimals="INF"
      id="f-554"
      unitRef="shares">8856245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-166" id="f-555">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-166" id="f-556">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-167"
      decimals="INF"
      id="f-557"
      unitRef="shares">2453616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage
      contextRef="c-168"
      decimals="INF"
      id="f-558"
      unitRef="number">0.05</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-169"
      decimals="INF"
      id="f-559"
      unitRef="shares">174707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-168" id="f-560">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-168" id="f-561">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-562">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense for non-employees and employees in its statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,172&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="-3" id="f-563" unitRef="usd">1469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-3" id="f-564" unitRef="usd">398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="-3" id="f-565" unitRef="usd">562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-3" id="f-566" unitRef="usd">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-23" decimals="-3" id="f-567" unitRef="usd">2031000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-24" decimals="-3" id="f-568" unitRef="usd">519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-569" unitRef="usd">3172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-3" id="f-570" unitRef="usd">924000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-571" unitRef="usd">1044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-3" id="f-572" unitRef="usd">210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-573" unitRef="usd">4216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-3" id="f-574" unitRef="usd">1134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSA award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,252)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchased/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-178"
      decimals="INF"
      id="f-576"
      unitRef="shares">47199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-178"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">4.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-179"
      decimals="INF"
      id="f-578"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-179"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-179"
      decimals="INF"
      id="f-580"
      unitRef="shares">40252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-179"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">4.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-179"
      decimals="INF"
      id="f-582"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-179"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-180"
      decimals="INF"
      id="f-584"
      unitRef="shares">6947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">4.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-180" decimals="-5" id="f-586" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-179" id="f-587">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of options award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &#x2013;&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic &lt;br/&gt;Value (1)&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,850,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652,807&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393,216)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,494)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,789&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897,774&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,951&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and expected to vest as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#x2019;s common stock on September&#160;30, 2024 for the options that were in the money.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-589" unitRef="shares">4850669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-590"
      unitRef="usdPerShare">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-591" unitRef="shares">3652807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">9.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-593" unitRef="shares">393216</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-594"
      unitRef="usdPerShare">3.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-595" unitRef="shares">117494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-596"
      unitRef="usdPerShare">4.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-597" unitRef="shares">7992766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">6.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-599">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-600" unitRef="usd">133789000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-601" unitRef="shares">897774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-603">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-604" unitRef="usd">16951000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-605" unitRef="shares">7992766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-606">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-607"
      unitRef="usdPerShare">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-25"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-3" decimals="INF" id="f-609" unitRef="shares">7094992</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-610" unitRef="usd">37000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-181" id="f-611">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-182"
      decimals="INF"
      id="f-612"
      unitRef="shares">507383</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-182"
      decimals="INF"
      id="f-613"
      unitRef="shares">1014766</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-183" decimals="2" id="f-614" unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-615">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Income Taxes&lt;/span&gt;Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-616">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-617">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Significant Agreements &#x2013; Related Parties&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a master services agreement on December 15, 2020 (the &#x201c;Master Services Agreement&#x201d;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company did not incur any expenses under the Master Services Agreement during the three and nine months ended September&#160;30, 2024 and 2023. As of September&#160;30, 2024 and December&#160;31, 2023, the Company owed $0.0 million and $1.6 million, respectively, which were classified in accrued expenses-related party on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;23, 2019, the Company entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#x201c;BBL&#x201d;) formerly Biocon Biologics India Limited, which is valid for 5 years unless earlier terminated by one of the parties. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023 and a manufacturing agreement on December 15, 2023 (the &#x201c;BBL Agreements&#x201d;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended September&#160;30, 2024 and 2023, the Company incurred $0.3 million and $0.7 million research and development expenses, respectively, under the BBL Agreements. For the nine months ended September&#160;30, 2024 and 2023, the Company incurred $1.1 million and $0.7 million research and development expenses, respectively, under the BBL Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $1.1 million and $1.7 million, respectively, which were classified in accrued expenses-related party on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company additionally entered into a manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#x201c;Syngene&#x201d;), on July 17, 2019, as amended on May 18, 2022 and on August 1, 2022, along with a master contract services agreement on July&#160;24, 2020 (the &#x201c;Syngene Agreements&#x201d;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The manufacturing agreement is valid for 6 years unless earlier terminated by one of the parties, while the master contract services agreement carried a term of 2 years. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $2.0 million and $1.6 million of research and development expenses, respectively, under the Syngene Agreements. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $6.3 million and $5.8 million of research and development expenses, respectively, under the Syngene Agreements. As of September&#160;30, 2024, and December&#160;31, 2023, the Company owed $1.2 million and $2.9 million, respectively, relating to these incurred costs, of which $0.4 million and $1.0 million, respectively, were classified in accounts payable-related party and $0.8 million and $1.9 million, respectively, were classified in accrued expenses-related party on the balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, the Company entered into a master service agreement with a wholly-owned subsidiary of Biocon, Biofusion Therapeutics Limited (&#x201c;Biofusion&#x201d;) (the &#x201c;Biofusion Agreement&#x201d;), which was terminated upon acquisition of Biofusion by Syngene on August 2, 2022. Pursuant to the terms of the Biofusion Agreement, Biofusion provided research and development services. As of December&#160;31, 2022, the Company owed $7.7 million in connection with services provided by Biofusion, which were classified in accrued expenses-related party on the balance sheet, of which $4.1 million were incurred in 2022. The Company paid the full amount on March 21, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a full recourse promissory note (the &#x201c;Promissory Note&#x201d;) with our Chief Financial Officer (&#x201c;CFO&#x201d;), pursuant to which the Company loaned $274 thousand, plus interest accruing at rate of 0.86% per annum (or if higher, the applicable federal rate as of the date of the Promissory Note), due by the earliest to occur of (i) December 31, 2025, (ii) the date of certain transfers of the collateral pledged under the Promissory Note, (iii) upon the day prior to the date a change in the Company&#x2019;s or the CFO&#x2019;s status would cause the loan to be deemed prohibited under applicable law, (iv) upon the date prior to the Company&#x2019;s filing of a registration statement for an initial public offering or a change of control, (v) upon acceleration of the Promissory Note in accordance with its terms or (vi) the date three months following the CFO&#x2019;s termination of employment with the Company. As part of the Promissory Note, the CFO pledged 616,320 shares of restricted Common Stock as collateral under the terms of a security agreement. There has been immaterial interest income from the Promissory Note. The CFO repaid the full amount in June 2024. As of December&#160;31, 2023, the Company recorded $68 thousand within prepaid expenses and other assets, and $68 thousand within other assets on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-184" decimals="INF" id="f-618" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-185" decimals="INF" id="f-619" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-186" decimals="INF" id="f-620" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-187" decimals="INF" id="f-621" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-188" decimals="-3" id="f-622" unitRef="usd">0.0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-189" decimals="-5" id="f-623" unitRef="usd">1600000</us-gaap:AccruedLiabilitiesCurrent>
    <bcax:RelatedPartyAgreementTerm contextRef="c-190" id="f-624">P5Y</bcax:RelatedPartyAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-191" decimals="-5" id="f-625" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-192" decimals="-5" id="f-626" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-193" decimals="-5" id="f-627" unitRef="usd">1100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-194" decimals="-5" id="f-628" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-195" decimals="-5" id="f-629" unitRef="usd">1100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-196" decimals="-5" id="f-630" unitRef="usd">1700000</us-gaap:AccruedLiabilitiesCurrent>
    <bcax:RelatedPartyAgreementTerm contextRef="c-197" id="f-631">P6Y</bcax:RelatedPartyAgreementTerm>
    <bcax:RelatedPartyAgreementTerm contextRef="c-198" id="f-632">P2Y</bcax:RelatedPartyAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-199" decimals="-5" id="f-633" unitRef="usd">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-200" decimals="-5" id="f-634" unitRef="usd">1600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-201" decimals="-5" id="f-635" unitRef="usd">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-202" decimals="-5" id="f-636" unitRef="usd">5800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent contextRef="c-203" decimals="-5" id="f-637" unitRef="usd">1200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-204" decimals="-5" id="f-638" unitRef="usd">2900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-203" decimals="-5" id="f-639" unitRef="usd">400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-204" decimals="-5" id="f-640" unitRef="usd">1000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-203" decimals="-5" id="f-641" unitRef="usd">800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-204" decimals="-5" id="f-642" unitRef="usd">1900000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-205" decimals="-5" id="f-643" unitRef="usd">7700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-206" decimals="-5" id="f-644" unitRef="usd">4100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-207" decimals="-3" id="f-645" unitRef="usd">274000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-207" decimals="4" id="f-646" unitRef="number">0.0086</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bcax:DebtInstrumentCollateralPledgedShares
      contextRef="c-208"
      decimals="INF"
      id="f-647"
      unitRef="shares">616320</bcax:DebtInstrumentCollateralPledgedShares>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-209" decimals="-3" id="f-648" unitRef="usd">68000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-209" decimals="-3" id="f-649" unitRef="usd">68000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-650">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Significant Agreements&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#x201c;IQVIA), which was amended in December 2023 to include global clinical trials Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#x201c;SOWs&#x201d;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $1.8 million, of which $1.0 million was a refundable deposit and $0.8 million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#x201c;ATP&#x201d;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $0.9 million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of December&#160;31, 2023, the refundable deposit balance was $1.9 million. For the three months ended September&#160;30, 2024 and 2023 the Company incurred $3.5 million and $2.1 million in expenses. For the nine months ended September&#160;30, 2024 and 2023 the Company incurred $9.8 million and $5.3 million in expenses, respectively and paid $13.3 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, to IQVIA. As of September&#160;30, 2024 and December&#160;31, 2023, the Company had $0.8 million and $1.6 million classified in accounts payable, respectively and $2.4 million and $4.7 million classified in accrued expenses and other current liabilities on the balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OtherCommitment contextRef="c-210" decimals="-5" id="f-651" unitRef="usd">1800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-211" decimals="-5" id="f-652" unitRef="usd">1000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-212" decimals="-5" id="f-653" unitRef="usd">800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-213" decimals="-3" id="f-654" unitRef="usd">900000</us-gaap:OtherCommitment>
    <bcax:OtherCommitmentLiabilityRefundableDepositAmount contextRef="c-4" decimals="-5" id="f-655" unitRef="usd">1900000</bcax:OtherCommitmentLiabilityRefundableDepositAmount>
    <us-gaap:OperatingExpenses contextRef="c-214" decimals="-5" id="f-656" unitRef="usd">3500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-215" decimals="-5" id="f-657" unitRef="usd">2100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-216" decimals="-5" id="f-658" unitRef="usd">9800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-217" decimals="-5" id="f-659" unitRef="usd">5300000</us-gaap:OperatingExpenses>
    <bcax:PaymentsForOtherCommitments contextRef="c-216" decimals="-5" id="f-660" unitRef="usd">13300000</bcax:PaymentsForOtherCommitments>
    <bcax:PaymentsForOtherCommitments contextRef="c-217" decimals="-5" id="f-661" unitRef="usd">8800000</bcax:PaymentsForOtherCommitments>
    <us-gaap:AccountsPayableCurrent contextRef="c-218" decimals="-5" id="f-662" unitRef="usd">800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-219" decimals="-5" id="f-663" unitRef="usd">1600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-218" decimals="-5" id="f-664" unitRef="usd">2400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-219" decimals="-5" id="f-665" unitRef="usd">4700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-666">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Commitments and Contingencies&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have contingency reserves established for any litigation liabilities as of September&#160;30, 2024, and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-667">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Subsequent Events&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October, 2024, the Company amended its original lease agreement to lease an additional 4,744 square feet of office space (the "Amended Lease") in order to expand the Company's headquarters. The base rent under the Amended Lease is approximately $0.3&#160;million per year. The Amended Lease did not extend the original lease end date under the original lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. (&#x201c;Y-Trap&#x201d;) naming as defendants us and Biocon LTD. (&#x201c;Biocon&#x201d;), captioned Y-Trap, Inc. v. Biocon LTD. and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). The complaint alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#x2019;s fees, and other equitable and injunctive relief. We intend to vigorously defend against this litigation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <bcax:LesseeOperatingLeaseAreaOfProperty contextRef="c-220" decimals="INF" id="f-668" unitRef="sqft">4744</bcax:LesseeOperatingLeaseAreaOfProperty>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-220" decimals="-5" id="f-669" unitRef="usd">300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-23" id="f-670">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-23" id="f-671">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-23" id="f-672">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-23" id="f-673">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
